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Abstract
The Australian elapids are some of the most deadly snakes in the world. Their
venoms contains a cocktail of chemicals including peptides and proteins with a broad
range of biological activities including pre- and post- synaptic neurotoxins, anti- and
pro- coagulants, cardiotoxins, cytotoxins, hemorrhagic toxins and myotoxins. To
date, however, a systematic approach aimed at the annotation and characterization of
all components of all Australian snake venoms has not been undertaken. Therefore,
the overall aim of our “Venomics” group is to isolate and evaluate a large number of
venom proteins from Australian snakes with a view to finding biologically active
molecules that could ultimately have application in a therapeutic setting. A key
component of the overall effort is the understanding of structure-function
relationships for many of these molecules. This thesis focuses on the structure
determination and analysis of two proteins, textilinin-1 from the Australian Common
Brown snake, Pseudonaja textilis, and ACII-4 a phospholipase from the King Brown
snake, Pseudechis australis.
Textilinin-1 is a small protein of 59 amino acids. A BLAST analysis showed this
molecule has a sequence identity of 45% to the well known Kunitz inhibitor,
aprotinin (bovine pancreatic trypsin inhibitor). The most interesting property of
textilinin-1 is that it has potent anti-fibrinolytic activity, most likely because it is a
nM inhibitor of plasmin. For this reason, textilinin-1 is being considered as an
alternative to aprotinin in surgery as an anti-bleeding agent. In this study, I
determined the three-dimensional structure of recombinant textilinin-1 as the free
inhibitor to 1.63 Å resolution, and its structure in complex with trypsin and
microplasmin (the catalytic domain of plasmin) to 1.64 Å and 2.78 Å resolution,
respectively. An unusual feature of the structure of free textilinin-1 is that its
canonical loop, the region which predominantly interacts with and inhibits the
protease, can adopt multiple conformations. In one snapshot taken from the crystal
structure this loop is inverted such that the critical protease binding residue Val18
becomes partially buried. In complex with trypsin or microplasmin, textilinin-1 binds
such that its P1 residue, Arg17, inserts into the specificity pocket. In these complexes
the catalytic serine hydroxyl oxygen of the protease is in closer-than-van der Waals
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contact with the carbonyl carbon of the scissile peptide bond of textilinin-1. In the
microplasmin complex, His603 adopts an altered non-catalytically competent
position such that its side-chain has swiveled around its Ȥ1 bond and out of its
classical catalytic triad location. To compensate, a water molecule is observed
bridging the serine and aspartate side-chains. The reason for this appears to be due to
the close approach of Val18 from textilinin-1 forcing the histidine to move. An
interesting observation from the trypsin-textilinin-1 complex when compared to the
structure of trypsin in complex with aprotinin is that the relative docking angles of
these two inhibitors differs by ~25°. The reason for this difference is the variations in
the sequences of the two inhibitors. At the P1' and P3' sites, two bulkier amino acids,
valine and phenylalanine are observed in textilinin-1 as compared to alanine and
isoleucine which are present in aprotinin. As a result the textilinin-1 molecule is
unable to dock into trypsin in the same orientation as aprotinin.
ACII-4 has a number of important biological activities including its ability to
increase prothrombin time in citrated plasma and to inhibit the conversion of
prothrombin to thrombin. ACII-4 has also been shown to inhibit platelet aggregation
by collagen, arachionic acid and ADP, and inhibit the conversion of factor X to
factor Xa. As a first step to understanding structure-function relationships of this
molecule its X-ray crystal structure has been determined to 1.56 Å resolution. ACII-4
has a characteristic PLA2 fold stabilized by seven disulfide bonds. In the crystal
structure, a Ca2+ ion is observed bound to the polypeptide, coordinated to seven
ligands Tyr28O, Gly30O, Gly32O, the side-chain oxygens of Asp49, and two water
molecules. The active site consisting of the catalytic triad of His48, Asp92, and a
water molecule are visible in the structure. A polyethylene glycol molecule from the
crystallization buffer is positioned in the active site where the fatty acid substrate
would be found. The side-chain of Trp31 is situated in the opening to the active site
and forms a hydrophobic contact with a second polyethylene glycol molecule. Two
possible dimer formations of ACII-4 can be deduced from the crystal lattice contacts.
One is a hydrophilic interface with a buried surface of 1141 Å2 and the other is a
hydrophobic interface with a buried surface of 686 Å2. The implications of the
structures determined in this thesis for the functions of textilinin-1 and ACII-4 as
venom components and as potential pharmaceuticals are discussed.
ix
Abbreviations
Į Twinning fraction or phase angle
ı Standard deviation
ĭ Phi, main-chain dihedral angle
Ȥ Chi, side-chain dihedral angle
Ȍ Psi, main-chain dihedral angle
Å Ångström, the unit denoting 10-10 metre
B Thermal parameter
CD Circular dichroism
Da Dalton
DLS Dynamic light scattering
DNA Deoxyribonucleic acid
ESI Electrospray ionization mass spectrometry
F, F Structure factor; complex number and absolute value
Fcalc , Fc Calculated structure factor
FFT Fast Fourier transform
Fobs , Fo Observed structure factor
h, k, l Miller indices
I Intensity of X-ray diffraction beam
k1, k-1, k2 , k-2 Rate constants
kDa kiloDalton
Ki Dissociation constant for inhibitor binding
LLG Log-likelihood gain
MAD Multiple anomalous dispersion
MALDI-TOF Matrix-assisted laser desorption ionization-time of flight
MIR Multiple isomorphous replacement
MR Molecular replacement
Mw Molecular weight
NMR Nuclear magnetic resonance
PDB Protein databank, Brookhaven PDB
PEG Polyethylene glycol
PLA2 Phospholipase A2
xRfactor Residual index
Rfree Residual index
rmsd Root mean square deviation
rTxln-1 Recombinant textilinin-1
SAK Staphylokinase
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
STK Streptokinase
t1/2 Half-life
VM Matthews coefficient
xi
Table of Contents
Statement of Originality.............................................................................................. iii
Acknowledgements..................................................................................................... iv
Publications by the Candidate relevant to the Thesis ................................................. vi
Abstract...................................................................................................................... vii
Abbreviations.............................................................................................................. ix
Table of Contents........................................................................................................ xi
Table of Figures ....................................................................................................... xvii
List of Tables .......................................................................................................... xxvi
Chapter 1...................................................................................................................... 1
Introduction.................................................................................................................. 1
1.1 Background.................................................................................................. 1
1.2 Australian snake venoms and their components.......................................... 1
1.3 Blood clotting .............................................................................................. 3
1.4 Serine proteases ........................................................................................... 4
1.5 Mechanism of inhibition of serine proteases ............................................... 9
1.6 The properies of plasmin and its role in blood clotting ............................... 9
1.7 Aprotinin in therapeutic use to regulate blood loss ................................... 13
1.8 The properties of textilinin-1 ..................................................................... 14
1.8.1 Textilinin-1's mechanism of inhibition.................................................. 16
1.9 Phospholipases........................................................................................... 17
1.10 The properties of ACII-4 ........................................................................... 21
1.11 Aim and synopsis of this thesis.................................................................. 21
Chapter 2.................................................................................................................... 23
Preparation of Proteins for Crystallization ................................................................ 23
2.1 Introduction................................................................................................ 23
2.2 Materials and methods ............................................................................... 24
xii
2.3 Cloning, expression and purification of recombinant textilinin-1..............25
2.4 Preparation of free recombinant textilinin-1 for crystallization experiments
....................................................................................................................26
2.4.1 Concentration and SDS-PAGE of rTxln-1 .............................................26
2.4.2 Mass spectral analysis of rTxln-1...........................................................27
2.5 Preparation of the recombinant textilinin-1-trypsin complex for
crystallization experiments .........................................................................29
2.5.1 Mass spectrometry analysis, SDS-PAGE and activity assay of bovine
trypsin .....................................................................................................29
2.5.2 Mass spectrometry analysis of the rTxln-1-trypsin complex .................32
2.5.3 Purification by gel filtration ...................................................................32
2.5.4 Superdex 200 column .............................................................................33
2.5.5 Mass spectral analysis of Superdex 200 fractions..................................35
2.5.6 Activity assay of the rTxln-1-trypsin complex.......................................35
2.5.7 Superdex 75 column ...............................................................................36
2.5.8 Concentration of rTxln-1-trypsin complex.............................................37
2.5.9 Additional samples of rTxln-1-tryspin for crystallization......................37
2.6 Cloning, expression and purification of human microplasminogen...........37
2.6.1 Extraction of plasmid .............................................................................37
2.6.2 Expression and isolation of human microplasminogen..........................38
2.6.3 Gel filtration of refolded human microplasminogen ..............................41
2.6.4 Preparation of rTxln-1-microplasmin complex ......................................42
2.7 Purification and characterization of native ACII-4 ....................................44
2.8 Preparation of ACII-4 for crystallization experiments ...............................46
2.8.1 Concentration of ACII-4.........................................................................46
2.9 Discussion...................................................................................................46
2.10 Summary.....................................................................................................47
Chapter 3 ....................................................................................................................48
Crystallization of proteins ..........................................................................................48
3.1 Introduction ................................................................................................48
3.2 Methods and Materials ...............................................................................50
3.3 Crystallization experiments with free recombinant textilinin-1 .................51
3.3.1 Cryoprotection of free rTxln-1 crystals ..................................................54
xiii
3.3.2 Data collection and processing of free rTxln-1 crystals ........................ 54
3.3.3 Space group determination of free rTxln-1 crystals .............................. 55
3.4 Crystallization experiments with recombinant textilinin-1-trypsin ........... 56
3.4.1 Cryoprotection of the rTxln-1-trypsin crystals ...................................... 57
3.4.2 Data collection for the best rTxln-1-trypsin crystals ............................. 58
3.4.3 Space group determination of the rTxln-1-trypsin complex crystals .... 58
3.5 Crystallization experiments for the recombinant textilinin-1- microplasmin
complex...................................................................................................... 59
3.5.1 Data collection and processing of the rTxln-1-microplasmin crystals .. 60
3.6 Crystallization experiments with ACII-4................................................... 62
3.6.1 Data collection of ACII-4 crystals ......................................................... 62
3.7 Discussion.................................................................................................. 64
3.8 Summary.................................................................................................... 66
Chapter 4.................................................................................................................... 67
Crystal structure of free recombinant textilinin-1...................................................... 67
4.1 Introduction................................................................................................ 67
4.2 Introduction to solving the phase problem of the rTxln-1 crystal ............. 69
4.3 Phase determination of free rTxln-1 .......................................................... 70
4.4 Initial model building of the rTxln-1 crystal structure .............................. 72
4.5 Refinement of model of free rTxln-1......................................................... 73
4.6 Refinement statistics and quality of free rTxln-1 structure ....................... 73
4.7 Crystal structure of free rTxln-1 ................................................................ 77
4.8 Crystal contacts.......................................................................................... 87
4.9 Comparison between textilinin-1 and aprotinin......................................... 96
4.10 Comparison between textilinin-1 and proteins with highest amino acid
sequence identity...................................................................................... 106
4.11 Comparison between the six amino acid sequences of textilinin-1 to 6.. 113
4.12 Summary.................................................................................................. 115
Chapter 5.................................................................................................................. 116
Crystal structure of the rTxln-1-trypsin complex .................................................... 116
5.1 Introduction.............................................................................................. 116
5.2 Phase determination, model building and refinement of rTxln-1-trypsin 118
5.3 Refinement of the rTxln-1-trypsin complex crystal structure ................. 119
xiv
5.4 Refinement statistics and quality of rTxln-1-trypsin complex crystal
structure ....................................................................................................120
5.5 Crystal structure of the rTxln-1-trypsin complex .....................................125
5.6 The interface between rTxln-1 and trypsin...............................................126
5.7 Crystal contacts.........................................................................................130
5.8 Comparison between rTxln-1 in the trypsin complex and free rTxln-1 ...133
5.9 Comparison of the rTxln-1 trypsin complexes with an aprotinin trypsin
complex ....................................................................................................137
5.10 Summary...................................................................................................145
Chapter 6 ..................................................................................................................146
Crystal structure of the rTxln-1 recombinant human microplasmin complex..........146
6.1 Phase determination of rTxln-1-microplasmin complex ..........................148
6.2 Refinement of the rTxln-1-microplasmin crystal structure ......................148
6.3 Refinement statistics and quality of rTxln-1-microplasmin crystal structure
..................................................................................................................150
6.4 Crystal structure of the rTxln-1 microplasmin complex ..........................155
6.5 The interface between rTxln-1 and microplasmin....................................157
6.6 Crystal contacts.........................................................................................167
6.7 Comparison between rTxln-1-microplasmin and existing
microplasminogen and microplasmin structures ......................................174
6.8 Comparison between rTxln-1 in the microplasmin complex, in the trypsin
complex and free rTxln-1 .........................................................................185
6.9 Comparison between the rTxln-1-microplasmin complex, the rTxln-1-
trypsin complex and an aprotinin-trypsin complex ..................................188
6.10 Discussion of rTxln-1 dimer.....................................................................198
6.11 Summary...................................................................................................200
Chapter 7 ..................................................................................................................202
Crystal structure of native ACII-4 from Australian King Brown snake (Pseudechis
australis) venom.......................................................................................................202
7.1 Introduction to hemihedral crystal twinning ............................................203
7.2 Phase determination of free ACII-4..........................................................204
7.3 Refinement of model of PLA2 crystal structure .......................................209
7.4 Refinement statistics and quality of ACII-4 crystal structure ..................210
xv
7.5 Crystal structure of free ACII-4............................................................... 214
7.6 The calcium ion in the structure of ACII-4.............................................. 216
7.7 Active site ................................................................................................ 221
7.8 Comparison of ACII-4 with other PLA2 molecules................................. 229
7.9 Crystal contacts and electrostatic surface ................................................ 237
7.10 Dimerization of ACII-4 ........................................................................... 242
7.11 Pharmacological activities ....................................................................... 247
7.12 Summary.................................................................................................. 256
Chapter 8.................................................................................................................. 257
Conclusions and Future Directions.......................................................................... 257
8.1 How can we modify the potency and selectivity of textilinin-1 .............. 259
8.2 Further investigations with ACII-4 and other Australian snake
phospholipases ......................................................................................... 261
Appendix A.............................................................................................................. 263
Common and latin names of Australian venomous snakes ..................................... 263
Appendix B.............................................................................................................. 264
Laboratory methods ................................................................................................. 264
B.1 Analytical ultracentrifugation .................................................................. 264
Appendix C.............................................................................................................. 266
Crystallization of protein ......................................................................................... 266
C.1 Introduction.............................................................................................. 266
C.2 The process of crystal growth.................................................................. 266
C.3 Crystallization methods ........................................................................... 267
C.4 Preparation for crystallization, screening, optimizing ............................. 269
Appendix D.............................................................................................................. 270
Molecular replacement and model refinement ........................................................ 270
D.1 Introduction.............................................................................................. 270
D.2 Structure factors and the phase problem.................................................. 270
D.3 Solving the phase problem....................................................................... 271
xvi
D.4 The Patterson function..............................................................................272
D.5 Molecular replacement .............................................................................272
D.6 Model refinement .....................................................................................274
D.7 Reliability indices .....................................................................................276
Appendix E...............................................................................................................279
Computer programs ..................................................................................................279
E.1 Introduction ..............................................................................................279
E.2 AMoRe .....................................................................................................279
E.3 EPMR .......................................................................................................280
E.4 PHASER...................................................................................................281
E.5 ARP/wARP...............................................................................................282
E.6 COOT .......................................................................................................284
E.7 REFMAC..................................................................................................286
E.8 MrBUMP..................................................................................................286
References ................................................................................................................288
xvii
Table of Figures
Figure 1-1 Blood coagulation and fibrinolysis pathways. .......................................... 4
Figure 1-2 Nomenclature for the description of protease subsites. ............................ 6
Figure 1-3 The catalytic mechanism of the serine proteases. ..................................... 8
Figure 1-4 Enzymes and pathways involved in fibrinolysis..................................... 10
Figure 1-5 Domain structure of plasminogen.. ......................................................... 11
Figure 1-6 Human microplasmin aligned with bovine trypsin. ................................ 13
Figure 1-7 Txln-1 aligned with aprotinin. ................................................................ 14
Figure 1-8 Sequences of Txln-1 to 6. ....................................................................... 15
Figure 1-9 Phospholipid hydrolysis by phospholipase A2........................................ 18
Figure 1-10 The catalytic mechanism of PLA2 ........................................................ 20
Figure 1-11 Sequence alignment of PA11, PA3 and PA15...................................... 21
Figure 2-1 Non-reduced 4-20% gradient SDS-PAGE of purified rTxln-1................ 26
Figure 2-2 MALDI-TOF mass spectrum of rTxln-1. ............................................... 28
Figure 2-3 Sedimentation equilibrium experiments of rTxln-1 performed in the
analytical ultracentrifuge. .............................................................................. 29
Figure 2-4 MALDI-TOF mass spectrum of trypsin.................................................. 31
Figure 2-5 Reduced 4-20% gradient SDS-PAGE of the trypsin sample used in
MALDI-TOF mass spectrometry................................................................... 31
Figure 2-6 MALDI-TOF mass spectrum of the rTxln-1-trypsin complex. .............. 32
Figure 2-7 The elution profile of the rTxln-1-trypsin complex by Superdex 200 size
exclusion chromatography. ............................................................................ 33
Figure 2-8 Non reduced 15% SDS-PAGE of fractions collected from Superdex 200
column. .......................................................................................................... 34
Figure 2-9 Calibration graph of the Superdex 200 column. ..................................... 34
Figure 2-10 MALDI-TOF mass spectrum of the rTxln-1-trypsin complex. ............ 35
Figure 2-11 The elution profile of the rTxln-1-trypsin complex by Superdex 75 size
exclusion chromatography. ............................................................................ 36
Figure 2-12 Calibration graph of the Superdex 75 column. ..................................... 37
Figure 2-13 Analysis of microplasminogen expression ........................................... 39
Figure 2-14 Reduced 12% SDS-PAGE of the purification of inclusion bodies of
microplasminogen.......................................................................................... 40
xviii
Figure 2-15 Elution profile of refolded microplasminogen from Sephacryl 300
chromatography. .............................................................................................42
Figure 2-16 Non reduced 15% SDS-PAGE of the activation of plasminogen with
urokinase.........................................................................................................43
Figure 2-17 Non reduced 15% SDS-PAGE of the rTxln-1–microplasmin complex.44
Figure 2-18 Sequence of ACII-4 as determined by ms/ms or tryptic digestion alone.
........................................................................................................................45
Figure 3-1 Crystals of free rTxln-1. ..........................................................................52
Figure 3-2 Diffraction pattern for rTxln-1.................................................................55
Figure 3-3 Crystals of the rTxln-1-trypsin complex..................................................57
Figure 3-4 Diffraction pattern for rTxln-1-trypsin complex. ....................................58
Figure 3-5 Diffraction pattern for rTxln-1-microplasmin complex...........................61
Figure 3-6 An ACII-4 crystal cluster grown from Hampton crystal screen I condition
17 ....................................................................................................................62
Figure 3-7 Diffraction pattern for ACII-4. ................................................................63
Figure 4-1 The crystal packing of rTxln-1. ...............................................................72
Figure 4-2 Stereoview of the 2Fo-Fc electron density map contoured at 1ı for
residues 16-20 and residue 40 of molecule A of rTxln-1. ..............................73
Figure 4-3 B-values (Å2) for rTxln-1 molecules A, B and C. Residues 14, 38, 39 and
42 are glycine and therefore have no side-chain B-values. ............................75
Figure 4-4 Ramachandran plot of the crystal structure of free rTxln-1.....................76
Figure 4-5 Wiring diagram of the secondary structure of rTxln-1. ...........................77
Figure 4-6 Stereo view of the overall fold of molecule A of rTxln-1. ......................78
Figure 4-7 Connolly surface with electrostatic surface potentials overlaid for
molecule A of rTxln-1. ...................................................................................78
Figure 4-8 Stereo view of superimposition of the three free rTxln-1 molecules within
the asymmetric unit. .......................................................................................80
Figure 4-9 Visualization of the main-chain B-values for the three rTxln-1 molecules.
........................................................................................................................81
Figure 4-10 Stereoview of interactions stabilizing the conformation of the canonical
loop in molecule C of rTxln-1. .......................................................................81
Figure 4-11 Superimposition of the three free rTxln-1 molecules. ...........................83
Figure 4-12 Two views, rotated by 90°, of the Connolly surface with electrostatic
potentials overlaid for molecule A of rTxln-1................................................85
xix
Figure 4-13 Three conserved buried water molecules.............................................. 86
Figure 4-14 Stereo diagram of the hydrogen bond formed between an internal water
molecule and Thr13O, Cys16N and Cys40O in molecule A of rTxln-1. ...... 87
Figure 4-15 Crystal contacts for molecule A, B and C of rTxln-1. .......................... 89
Figure 4-16 Stereoview of the packing of the three rTxln-1 molecules in the
asymmetric unit.............................................................................................. 89
Figure 4-17 Interactions between molecule A and C in the free rTxln-1 structure. . 91
Figure 4-18 Visualization of the main-chain B-values for the three molecules of
rTxln-1 in the asymmetric unit. ..................................................................... 92
Figure 4-19 Stereoview of the canonical loop in molecule C located between two A
molecules. ...................................................................................................... 94
Figure 4-20 Expanded view of the crystal packing of the free rTxln-1 molecules. . 95
Figure 4-21 Stereoview of the superimposition of the three rTxln-1 molecules and
aprotinin. ........................................................................................................ 98
Figure 4-22 Stereoview of the region between residues 40-45 (rTxln-1 numbering)
after superimposition of molecule A of rTxln-1 and aprotinin...................... 98
Figure 4-23 The Connolly surface and electrostatic potentials for molecule A of
rTxln-1 and aprotinin. .................................................................................. 100
Figure 4-24 Internal water molecules in rTxln-1 and aprotinin.............................. 101
Figure 4-25 Amino acid sequence alignment of Txln-1, aprotinin and two aprotinin
mutants (8PTI and 1LD6). The cysteine residues are highlighted in orange
and the mutations in aprotinin in yellow. .................................................... 102
Figure 4-26 Stereo view of the position of the side-chain of Tyr37 in molecule A of
rTxln-1 and Tyr35 in aprotinin. ................................................................... 104
Figure 4-27 Structural comparison of rTxln-1 and two aprotinin mutants.............. 105
Figure 4-28 Sequence alignment of rTxln-1 and the proteins mentioned in Table 4-7.
..................................................................................................................... 107
Figure 4-29 Structural comparison of rTxln-1 and four other proteins with the
aprotinin-like fold. ....................................................................................... 109
Figure 4-30 Location of six conserved residues. .................................................... 111
Figure 4-31 Superimposition of rTxln-1 and dendrotoxin K.................................. 112
Figure 4-32 Replacement of one internal water molecule, (in aprotinin), by an
asparagine side-chain in rTxln-1 and dendrotoxin K................................... 112
xx
Figure 4-33 Amino acid sequence alignment of the six textilinin molecules; Txln-1
to 6. ...............................................................................................................114
Figure 5-1 The crystal packing of the rTxln-1-trypsin complex. ............................120
Figure 5-2 B-values (Å2) for rTxln-1 in the complex. Residues 14, 38, 39 and 42 are
glycine and therefore have no side-chain B-values. .....................................122
Figure 5-3 B-values (Å2) for trypsin in the complex. Glycine residues have no side-
chain B-value................................................................................................123
Figure 5-4 Visualization of the B-values for the rTxln-1-trypsin complex.............124
Figure 5-5 Ramachandran plot of the rTxln-1-trypsin complex..............................125
Figure 5-6 Stereodiagram of the overall fold of the rTxln-1-trypsin complex........126
Figure 5-7 Interactions between rTxln-1 and trypsin. .............................................127
Figure 5-8 Stereo view of rTxln-1 bound in the active site of trypsin. ...................129
Figure 5-9 Stereo view of the 2Fo-Fc electron density map contoured at 1ı for the
rTxln-1-trypsin complex...............................................................................130
Figure 5-10 The interface between rTxln-1 and trypsin..........................................130
Figure 5-11 Crystal contacts between a symmetry related rTxln-1 molecule and
trypsin. ..........................................................................................................132
Figure 5-12 Two of the largest interfaces in the crystal packing of rTxln-1-trypsin
complex. .......................................................................................................132
Figure 5-13 Stereo view of the superposition of free rTxln-1 and trypsin bound
rTxln-1. .........................................................................................................134
Figure 5-14 Stereo view of the canonical loop region of free and trypsin bound
rTxln-1. .........................................................................................................135
Figure 5-15 B-values (Å2) for rTxln-1 bound to trypsin and the three free rTxln-1
molecules. .....................................................................................................136
Figure 5-16 Visualization of the B-values for rTxln-1 bound to trypsin.................137
Figure 5-17 Superposition of rTxln-1 and aprotinin bound to trypsin. ...................138
Figure 5-18 Superimposition of trypsin in the rTxln-1-trypsin complex and the
aprotinin-trypsin complex (2PTC). ..............................................................139
Figure 5-19 Residues P3-P4' in rTxln-1 and aprotinin............................................140
Figure 5-20 The P1'-P4' residues in rTxln-1 and aprotinin. ....................................141
Figure 5-21 The P4-P1 residues in rTxln-1 and aprotinin.......................................142
Figure 5-22 rTxln-1 and aprotinin bound to trypsin................................................143
Figure 5-23 Variation in the location of the secondary loop...................................144
xxi
Figure 6-1 The crystal packing of the rTxln-1-microplasmin complex.................. 149
Figure 6-2 Visualization of the main-chain B-values in the rTxln-1-microplasmin.
..................................................................................................................... 152
Figure 6-3 B-values (Å2) for molecule A (blue) and B (pink) of rTxln-1 in complex
with microplasmin. ...................................................................................... 153
Figure 6-4 B-values (Å2) for molecule A (blue) and B (pink) of microplasmin mol A
and B from respective complexes. ............................................................... 153
Figure 6-5 Ramachandran plot of the rTxln-1-microplasmin complex. ................. 155
Figure 6-6 Stereodiagram of the overall fold of complex A of rTxln-1-microplasmin.
..................................................................................................................... 156
Figure 6-7 Comparison of the binding modes of the two molecules of rTxln1 in the
asymmetric unit of the rTxln-1-microplasmin complex. ............................. 157
Figure 6-8 Interactions between the canonical loop and secondary loop of rTxln-1
and the active site of microplasmin. ............................................................ 158
Figure 6-9 Stereo view of the catalytic triad of microplasmin and interface residues
of rTxln-1 in complex A. ............................................................................. 161
Figure 6-10 Stereo view of the interaction between His603 and Glu606 of
microplasmin in complex A......................................................................... 163
Figure 6-11 The interface between rTxln-1 and microplasmin in complex A. ...... 164
Figure 6-12 Stereo view of the superimposition between complex A and B. ........ 166
Figure 6-13 Comparison of the binding modes of the two molecules of rTxln1 in the
asymmetric unit of the rTxln-1-microplasmin complex. ............................. 166
Figure 6-14 Crystal contacts for complex A and B of rTxln-1-microlplasmin ....... 168
Figure 6-15 Crystal contacts between rTxln-1 in complex A and surrounding
molecules. .................................................................................................... 169
Figure 6-16 Crystal contacts between rTxln-1 in complex B and surrounding
molecules ..................................................................................................... 169
Figure 6-17 Crystal contact between Arg19 of rTxln-1 and Asp28 of rTxln-1 from
complex B. ................................................................................................... 170
Figure 6-18 Crystal contacts between Glu41 and Arg644...................................... 171
Figure 6-19 Largest crystal contact between two rTxln-1 molecules..................... 172
Figure 6-20 Difference in crystal contacts between rTxln-1 from complex A and B
..................................................................................................................... 173
xxii
Figure 6-21 Difference in crystal contacts between rTxln-1 from complex A and B
......................................................................................................................174
Figure 6-22 Superposition of microplasmin and microplasminogen. .....................176
Figure 6-23 Formation of the oxyanion hole in microplasmin................................177
Figure 6-24 Formation of the specificity entrance of microplasmin. ......................178
Figure 6-25 Complex of staphylokinase-microplasmin and rTxln-1-microplasmin.
......................................................................................................................179
Figure 6-26 Complex of streptokinase-microplasmin and rTxln-1-microplasmin..180
Figure 6-27 Stereo view of the different positions of the side-chain of the catalytic
histidine. .......................................................................................................181
Figure 6-28 Stereo view of a water molecule in the position of catalytically
functional His603. ........................................................................................182
Figure 6-29 Stereo view of catalytic histidine forming an ionic bond with Glu606.
......................................................................................................................182
Figure 6-30 Stereo view of different positions of Asp646. .....................................183
Figure 6-31 Stereo view of a water molecule in the position of the catalytically
functional Asp646. .......................................................................................183
Figure 6-32 Stereo view of inhibitor in the active site of microplasmin.................184
Figure 6-33 Stereo view of interaction between Glu606 and bound molecule. ......184
Figure 6-34 Superimposition of all rTxln-1 structures............................................186
Figure 6-35 Visualization of the B-values in rTxln-1. ............................................187
Figure 6-36 B-values (Å2) for all rTxln-1 structures...............................................187
Figure 6-37 Amino acid sequence alignment of microplasmin and trypsin............189
Figure 6-38 Superposition of microplasmin and trypsin. ........................................189
Figure 6-39 Differences between microplasmin and trypsin...................................190
Figure 6-40 Interface between rTxln-1 and microplasmin or trypsin. ....................191
Figure 6-41 Interface between rTxln-1 and microplasmin or trypsin. ....................191
Figure 6-42 The docking angles between the bound rTxln-1 molecules when
superimposing trypsin onto microplasmin. ..................................................192
Figure 6-43 The difference in position of the secondary loop of rTxln-1 when
superimposing trypsin onto microplasmin. ..................................................193
Figure 6-44 The positions of the catalytic triads and rTxln-1 when microplasmin and
trypsin are superimposed. .............................................................................193
xxiii
Figure 6-45 Comparison of bovine trypsin and Asn102 Rattus norvegicus trypsin
mutant. ......................................................................................................... 195
Figure 6-46 Comparison of bovine trypsin and porcine pancreatic elastase. ......... 196
Figure 6-47 Stereo view of the environment around the catalytic histidine. .......... 196
Figure 6-48 The location of aprotinin when superposing the trypsin molecule from
the aprotinin-trypsin complex onto microplasmin....................................... 197
Figure 6-49 Two rTxln-1 molecules and one microplasmin molecule.................... 198
Figure 6-50 Residues in interface between complex A and symmetry related rTxln-
1. .................................................................................................................. 199
Figure 6-51 Residues in interface between complex B and symmetry related rTxln-1.
..................................................................................................................... 199
Figure 6-52 Possible dimer binding to microplasmin............................................. 200
Figure 7-1 Cumulative distribution of H. ............................................................... 206
Figure 7-2 The two ACII-4 molecules in the asymmetric unit............................... 209
Figure 7-3 Visualization of the B-values for the two molecules of ACII-4 in the
asymmetric unit............................................................................................ 211
Figure 7-4 B-values (Å2) for molecule A and B of ACII-4. ................................... 212
Figure 7-5 Ramachandran plot of the crystal structure of ACII-4.......................... 213
Figure 7-6 Wiring diagram of the secondary structure of ACII-4.......................... 215
Figure 7-7 Stereo view of the overall fold of molecule A of ACII-4 represented as a
cartoon drawing. .......................................................................................... 215
Figure 7-8 Superposition of the two ACII-4 molecules. ........................................ 216
Figure 7-9 Stereo view of the seven ligands that coordinate to the Ca2+ ion form a
distorted pentagonal bipyramid. .................................................................. 217
Figure 7-10 Stereo view of the two disulfide bonds securing the correct relative
orientation of the Ca2+ binding loop. ........................................................... 217
Figure 7-11 The calcium ion bound to the Ca2+ loop. ............................................ 218
Figure 7-12 The Ca2+ binding loop......................................................................... 219
Figure 7-13 The Ca2+ binding loop in ACII-4. ....................................................... 219
Figure 7-14 Ca2+ ions bound to PLA2..................................................................... 220
Figure 7-15 PLA2 with Lys49................................................................................ 220
Figure 7-16 The polyethylene glycol molecules in ACII-4. ................................... 221
Figure 7-17 The hydrophobic channel leads into the active site in ACII-4............ 222
Figure 7-18 Hydrophobic entrance to the active site of ACII-4. ............................ 222
xxiv
Figure 7-19 The 2Fo-Fc electron density map contoured at 1ı for His48, Asp49 and
Asp92, two water molecules, one polyethylene glycol molecule and one Ca2+
ion for ACII-4...............................................................................................223
Figure 7-20 The polyethylene glycol molecules and the catalytic diad. .................223
Figure 7-21 The catalytic diad and the catalytic water molecule. ...........................224
Figure 7-22 Stereo view of the two tyrosine residues stabilizing Asp92. ...............224
Figure 7-23 Comparison of active sites of ACII-4 and PLA2 from porcine pancrease.
......................................................................................................................225
Figure 7-24 Comparison of active sites of ACII-4 and PLA2 from Common Indian
krait venom. ..................................................................................................226
Figure 7-25 Comparison of bound molecules in the active site. .............................227
Figure 7-26 Comparison of the active site entrance. ...............................................228
Figure 7-27 The amino acid sequence of ACII-4 ....................................................228
Figure 7-28 Interfacial binding surface. ..................................................................229
Figure 7-29 Sequence alignment of PLA2 to show the elapid loop. .......................230
Figure 7-30 Comparison of group IA and group II PLA2. ......................................230
Figure 7-31 Sequence alignment of PLA2 proteins homologous to ACII-4. ..........231
Figure 7-32 Comparison of the structures of ACII-4 and the six top hits from a
BLAST search. .............................................................................................232
Figure 7-33 Differences between ACII-4 and notexin. ............................................234
Figure 7-34 Differences between ACII-4 and notexin. ...........................................235
Figure 7-35 Structural differences between ACII-4 and the BLAST top hits
belonging to group IA. .................................................................................235
Figure 7-36 The elapid loop in PLA2 belonging to group IA and the pancreatic loop
in PLA2 belonging to group IB.....................................................................236
Figure 7-37 Structural differences between ACII-4 and the BLAST top hits
belonging to PLA2s from group II................................................................237
Figure 7-38 Contacts between the surrounding atoms and molecule A of ACII-4. 238
Figure 7-39 The amino acid sequence of ACII-4. ...................................................238
Figure 7-40 Region 61-64 and Trp31 of ACII-4 participating in a hydrophobic
interface. .......................................................................................................239
Figure 7-41 Crystal contacts for ACII-4. ................................................................240
Figure 7-42 Crystal contacts for ACII-4. ................................................................240
Figure 7-43 Crystal contacts for ACII-4. ................................................................241
xxv
Figure 7-44 Crystal contacts for ACII-4................................................................. 241
Figure 7-45 Four views of molecule A of ACII-4. ................................................. 242
Figure 7-46 Four views of molecule B of ACII-4. ................................................. 242
Figure 7-47 AB dimer formation. ........................................................................... 243
Figure 7-48 AB' dimer formation. .......................................................................... 243
Figure 7-49 Interactions in the AB interface .......................................................... 244
Figure 7-50 Stereo view of the interactions in the AB interface. ........................... 245
Figure 7-51 Stereo view of the interactions in the AB' interface. .......................... 245
Figure 7-52 Superposing the PLA2 from Common Indian krait (1TC8) onto each
monomer of the two ACII-4 dimer formations shows the fitting of the fatty
acid............................................................................................................... 246
Figure 7-53 Superposing the PLA2 from Russell’s viper (1JQ9) onto each monomer
of the two ACII-4 dimer formations shows the fitting of the protein inhibitor.
..................................................................................................................... 246
Figure 7-54 Sequence alignment of PLA2 with anticoagulant activity. ................. 248
Figure 7-55 Comparison of residues with possible anticoagulant effect................ 251
Figure 7-56 Sequence alignment of PLA2 with anticoagulant activity. ................. 252
Figure 7-57 Comparison of residues with possible anticoagulant effect................ 254
Figure 7-58 Sequence alignment of PLA2s with anticoagulant activity. ................ 255
Figure 7-59 Comparison of the electrostatic surface potentials. ............................ 256
Figure 8-1 Two orthogonal views of the surface of the putative ACII-4 dimer. .... 259
Figure C- 1 Phase diagram for protein solubility. .................................................. 267
Figure C- 2 Protein crystallization vessels. ............................................................ 268
xxvi
List of Tables
Table 1-1 Existing crystal structures of plasminogen/plasmin structural domains. ..12
Table 1-2 Kinetic constants for the inhibition of plasmin by ....................................17
Table 3-1 Experimental conditions that led to the successful crystallization of rTxln-
1. .....................................................................................................................53
Table 3-2 Crystal parameters and data collection statistics for free rTxln-1.............56
Table 3-3 Experimental conditions that led to the successful crystallization of the
rTxln-1-trypsin complex.................................................................................57
Table 3-4 Crystal parameters and data collection statistics for the rTxln-1-trypsin
complex. .........................................................................................................59
Table 3-5 Experimental conditions that led to the successful crystallization of the
rTxln-1-microplasmin complex......................................................................60
Table 3-6 Crystal parameters and data collection statistics for the microplasmin-
rTxln-1 complex. ............................................................................................61
Table 3-7 Crystal parameters and data collection statistics for ACII-4. ...................64
Table 4-1 Molecular replacement solution: orientation of a single molecule ...........71
Table 4-2 Molecular replacement solution: orientations of two molecules ..............71
Table 4-3 Molecular replacement solution: orientations of three molecules ............71
Table 4-4 Refinement statistics for rTxln-1 ..............................................................74
Table 4-5 Mean B-values (Å2) for the three rTxln-1 molecules in the asymmetric
unit ..................................................................................................................75
Table 4-6 Ramachandran plot statistics for the three free rTxln-1 molecules...........76
Table 4-7 Hits from BLAST search versus the PDB ..............................................106
Table 5-1 Refinement statistics for the rTxln-1-trypsin complex ...........................121
Table 5-2 Mean B-values (Å2) for the rTxln-1-trypsin complex.............................122
Table 5-3 Ramachandran plot statistics for the rTxln-1-trypsin complex...............124
Table 6-1 Refinement statistics of the rTxln-1-microplasmin complexes ..............150
Table 6-2 Mean B-values (Å2) for the rTxln-1-microplasmin complexes in the
asymmetric unit ............................................................................................152
Table 6-3 Ramachandran plot statistics for the two rTxln-1-microplasmin complexes
......................................................................................................................154
Table 6-4 Table of rmsd values between the rTxln-1 structures, CĮ (all atoms) ....185
xxvii
Table 7-1 PDB entries with the best E-values ........................................................ 208
Table 7-2 Prepared search models with scores....................................................... 208
Table 7-3 Refinement statistics of ACII-4 crystal structure ................................... 210
Table 7-4 Mean B-values (Å2) for the two ACII-4 molecules. .............................. 211
Table 7-5 Ramachandran plot statistics for the two ACII-4 molecules.................. 212
Table 7-6 Hits from BLAST search versus the PDB.............................................. 231
Table A- 1 Family Elapidae.................................................................................... 263

1Chapter 1
Introduction
1.1 Background
The research described in this thesis covers the determination of the three-
dimensional structures by X-ray crystallography of two proteins isolated from
Australian snake venoms; textilinin-1 (Txln-1), a plasmin inhibitor from the venom
of the Australian Common Brown snake Pseudonaja textilis, and ACII-4, an
anticoagulant phoshpolipase A2 from the venom of the Australian King Brown
snake, Pseudechis australis. The structure of recombinant Txln-1 (rTxln-1) was
determined as the free molecule and in complex with trypsin and microplasmin. The
structure of ACII-4 was determined as the free molecule. No crystal structures of any
Australian snake venom component have been reported to date thus this study opens
the way to rational structural investigations of the pharmacological effects of these
molecules.
This chapter includes considerations of Australian snake venom components, blood
coagulation and fibrinolysis pathways, especially the role and structures of plasmin.
It incorporates a review of serine proteases and their mechanism of action and
inhibition by canonical serine protease inhibitors from the Kunitz/BPTI family. A
discussion on the mechanism of phospholipase A2 molecules is presented.
1.2 Australian snake venoms and their components
There are seven families of Australian snakes: file snakes, pythons, colubrids,
elapids, sea snakes, sea kraits and blind snakes (Tu, 1977; C.-Y. Lee, 1979; Tu,
1991; Swan, 1998). Members of three of these families, elapids (Elapidae), sea
snakes (Hydrophiidae) and sea kraits (Laticaudidae) are considered venomous. A
total of 81 out of the 143 species of snakes in Australia belong to the elapid family,
with another 99 elapid species existing worldwide (Swan, 1998).
Australian elapid snakes are amongst the most venomous in the world (Broad et al.,
1979; Sutherland and Tibballs, 2001). Much of their toxicity arises from the presence
of powerful prothrombin-activating proteins, and potent pre- and post-synaptic
2neurotoxins. Other components present in Australian snake venoms include
phospholipase A2 (PLA2) proteins, serine proteinase inhibitors, L-amino acid oxidase
and natriuretic peptides (Fry, 2005; St Pierre et al., 2005). Several of these are
pharmacologically important and known to affect the mammalian blood hemostatic
mechanism via coagulant, anticoagulant, and fibrinolytic actions. A unique feature of
the procoagulant properties of venoms from Australian elapid snakes is that they are
limited to prothrombin activation and contain no thrombin-like enzymes. These
prothrombin activators contain a component that is structurally and functionally
similar to that of mammalian coagulation factor Xa (Chester and Crawford, 1982).
The prothrombin activators can produce disseminated intravascular coagulation
(DIC) on envenomation of a human or prey species. The activated prothrombin is
converted to thrombin, and thrombin in turn converts fibrinogen to fibrin initiating
widespread clot formation. Extensive activation of thrombin can lead to depletion of
fibrinogen, (defibrinogenation) with the net effect of blood loss (Fry, 1999; Kini et
al., 2001; Sutherland and Tibballs, 2001).
The Australian Common Brown snake, Pseudonaja textilis, is native to Australia and
is found primarily in the eastern parts of the mainland. Its lethality is caused by both
neurotoxic and procoagulant compounds. The main component in its venom that
causes the rapid coagulation of blood is a potent prothrombin activator complex
named pseutarin C (Masci et al., 1988; Rao and Kini, 2002). This protein is a
complex of two main components and constitutes about 30% of the total venom
protein. One of the components is a large multisubunit non-enzymatic protein similar
to factor V found in mammalian blood (Rao et al., 2003), and the other is a factor
Xa-like enzyme that cleaves prothrombin to form thrombin (Masci et al., 1988).
Txln-1 which is a Kunitz-type serine protease inhibitor with a high specificity for
plasmin (Willmott et al., 1995) represents approximately 2% of the total venom
protein, and was isolated by Dr Paul Masci (Masci, 2000).
Phospholipases are found within most snake venoms regardless of genera and display
homologous primary sequences to their mammalian counterparts which are involved
in inflammatory responses, cancer metastasis, cell growth and signaling cascades. In
contrast to mammalian enzymes, phospholipases from venom may be highly toxic to
other animals, having a plethora of physiological effects. The neurotoxic, haemotoxic
3and myotoxic effects of Australian elapid envenomations are often the result of the
activity of a number of phospholipases within the venom. This variation in activity,
even within multiple isoforms from one snake, is observed despite the high degree of
conservation in their primary sequence, and in some cases appears to be independent
of the phospholipase catalytic activity of the protein (Fry, 1999). ACII-4 is a
phospholipase isolated from the Australian King Brown snake, Pseudechis australis,
and has shown to exhibit a strong anticoagulant activity but low phospholipase
activity (Masci, 2000) .
1.3 Blood clotting
Cross-linked fibrin clots are formed by a complex enzymatic cascade, in which the
activated form of one protein catalyzes the activation of the next. Blood coagulation
can be activated both by the “extrinsic” pathway and the “intrinsic” pathway. As
shown in Figure 1-1, both extrinsic and intrinsic pathways lead to the formation of
factor Xa. Factor Va form a complex with factor Xa (the prothrombinase complex)
which cleaves prothrombin to produce thrombin. Thrombin is the enzyme that
converts soluble fibrinogen to insoluble fibrin clots which are subsequently
covalently crosslinked by the action of factor XIIIa. Blood coagulation is vital for the
containment of bodily fluids. Equally important is the reversal of this process,
fibrinolysis, which must take place after tissue healing. The processes of coagulation
and fibrinolysis are tightly controlled, to achieve haemostasis (Biggs and Rizza,
1984; Furie and Furie, 1992).
Of major importance in fibrinolysis is plasminogen. Plasminogen, a normal
component of blood plasma, is deposited on the fibrin strands within a blood clot.
The activators of this protein diffuse into the clot and release plasmin, a serine
protease. Plasmin then breaks down the fibrin meshwork, and as a result the clot
dissolves (Rang et al., 1999; Castellino, 2004).
There is a fine balance between hemorrhage and thrombosis, and the clotting process
must be precisely regulated to not produce unrestrained excess of active enzymes
that can cause these pathological conditions. Inhibitors of the enzymes in the blood
coagulation cascade control hemorrhage and the termination of clotting.
4Figure 1-1 Blood coagulation and fibrinolysis pathways.
The suffix “a” denotes an active factor.
1.4 Serine proteases
Serine proteases are proteases with an active site serine residue and a catalytic
mechanism that includes an acyl-enzyme intermediate (Blow et al., 1969; Robertus
et al., 1972; Warshel et al., 1989; Liao and Remington, 1990). Serine proteases have
evolved to function in many biological processes. These processes in mammals
include fertilization, several pathways of differentiation and development, digestion
of protein, blood clotting, fibrinolysis and the complement system in humoral
immunity. Their activities are related to many diseases including emphysema,
asthma, arthritis, skin disorders and cancerous tumor growth (Unkeless et al., 1973;
Morioka et al., 1987; He et al., 1989).
fibrinogen
fibrin
degradation
product
Instrinsic pathway
of activation
Many stepsMany steps
plasminogen
Factor X Factor Xa
prothrombin thrombin
plasmin
fibrin
The prothrombin activation complex, involves the
formation of a complex between factor Xa, factor
Va, and prothrombin, in the presence of negatively
charged phospholipids and Ca2+.
Extrinsic pathway
of activation
5Serine proteases are often synthesized as somewhat larger inactive precursors known
as zymogens. Trypsin is a serine protease found in animals as a digestive enzyme
secreted by the exocrine pancreas into the small intestine (Kühne, 1876; Northrop
and Kunitz, 1931; Neurath and Zwilling, 1986). The pH optimum for activity is
approximately 8. Bovine trypsin is a 223 amino acid residue long protein.
Trypsinogen is the inactive precursor of trypsin which is activated by hydrolysis of a
hexapeptide at the N-terminus by specific cleavage between lysine 15 and isoleucine
16 (chymotrypsinogen numbering)(Maroux et al., 1971). This activation results in a
conformational change and formation of the oxyanion hole and specificity pocket
which are both important for catalytic activity (Kossiakoff et al., 1977; Marquart et
al., 1983; Halfon et al., 2004).
The serine proteases exhibit different substrate specificities, which are related to
amino acid substitutions in the various enzyme subsites interacting with substrate
residues. The nomenclature to describe the interaction of a substrate with a protease
considers the amino acid residues of the polypeptide substrate, P, binding to enzyme
subsites, S, of the active site. The amino acid residues on the N-terminal side of the
scissile bond are numbered P3, P2, P1 and those residues on the C-terminal side are
numbered P1', P2', P3' (Figure 1-2). The P1 and P1' residues are those residues
located either side of the scissile bond (Schechter and Berger, 1967). Substrate
specificity is critically dependent on the shape and size of the S1 site (Schechter and
Berger, 1967; Perona and Craik, 1995; Perona and Craik, 1997).
6Figure 1-2 Nomenclature for the description of protease subsites.
P3, P2, P1 are N-terminal amino acid residues of the scissile bond in the protein substrate or
inhibitor. P3', P2', P1' are C-terminal amino acid residues of the scissile bond in the protein
substrate or inhibitor. S3, S2, S1 are N-terminal subsite on the protease. S3', S2', S1' are
C-terminal subsites on the protease.
For serine proteases a common structural theme has evolved independently on
several separate occasions (Robertus et al., 1972; Liao and Remington, 1990; Ollis et
al., 1992). Three residues, one serine, one histidine and one aspartate, form the
“catalytic triad” are required to carry out catalysis. The side-chain of the aspartic
acid, with a pKa of ~4, is deprotonated and negatively charged. In general the
imidiazole ring of histidine has a pKa of ~6 and is not a strong base. The hydroxyl
group of the side-chain of the serine normally has a pKa of ~13 and is protonated. A
basic mechanistic scheme for the catalysis reaction has generally been agreed upon
(Blow et al., 1969; Warshel et al., 1989). Initially a non-covalent Michaelis complex
is formed when the serine protease recognizes an appropriate proteolytic cleavage
site in a substrate. The imidazole ring deprotonates the hydroxyl group of the serine
side-chain. The negatively charged side-chain of the aspartic acid stabilizes the
positively charged histidine side-chain or accepts a proton from the imidazolium ion
(Warshel et al., 1989). The deprotonated serine is a strong nucleophile and attacks
the carbonyl carbon on the P1 residue forcing the carbonyl oxygen to accept an
electron. Consequently the hybridization state of the carbonyl carbon changes from
sp2 to sp3 resulting in the formation of a tetrahedral intermediate. The carbonyl
oxygen can accommodate the electron pair of the carbon-oxygen double bond since
the carbonyl oxygen of the scissile peptide moves deeper into the active site to
occupy a previously unoccupied enzyme subsite with stabilizing interactions,
The subsite of the specificity
pocket of trypsin and plasmin.
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7designated the oxyanion hole (Robertus et al., 1972). Thus, formation of the high
energy tetrahedral intermediate is achieved not only because of the covalent bond
formed between the serine side-chain oxygen in the catalytic triad and the carbonyl
carbon in the substrate, but also because of the substrate destabilization by the
oxyanion hole (Stryer, 1996; Voet et al., 1998). During the second covalent stage or
deacylation, the acyl-enzyme intermediate is hydrolyzed by a water molecule to
release the peptide and to restore the hydroxyl of serine in the enzyme (Barrett et al.,
1998). The general mechanism of catalysis is given in Figure 1-3.
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Figure 1-3 The catalytic mechanism of the serine proteases.
The first stage in the basic mechanism of serine proteases is an acylation reaction;
(a) Michaelis complex, (b) tetrahedral intermediate and (c) acyl-enzyme intermediate.
The second stage is a deacylation reaction; (d) Water attacks the acyl-enzyme intermediate,
(e) tetrahedral intermediate and (f) the restoration of the catalytic triad and the departure of
the second product
91.5 Mechanism of inhibition of serine proteases
Three classes of protein serine protease inhibitors have evolved: canonical, non-
canonical and serpin inhibitors (Krowarsch et al., 2003). A canonical inhibitor
mimics the substrate but no product formation is observed during reaction time
(Bode and Huber, 1992). Most serine protease inhibitors are canonical inhibitors
acting on their protease by what is known as the standard mechanism (M. J.
Laskowski and Kato, 1980). All standard mechanism inhibitors have an exposed
substrate-like canonical inhibitory loop region with a single reactive site peptide
bond (M. J. Laskowski and Qasim, 2000). The inhibitory loops in the different
canonical inhibitors possess a common main-chain conformation, though, besides
this loop, each family of canonical inhibitors has its own overall three-dimensional
structure (Bode and Huber, 1992). There are at least 18 non-homologous families of
canonical inhibitors (Bode and Huber, 1991; M. J. Laskowski and Qasim, 2000;
Ibrahim and Pattabhi, 2004). For example the inhibitor, aprotinin (bovine pancreatic
trypsin inhibitor, BPTI), belongs to the Kunitz/BPTI family. Aprotinin has a
structure complementary to the active site of trypsin. The fit is tight with a strong
interaction and a long half-life for the complex (months). The Kunitz/BPTI family of
serine protease inhibitors including Txln-1 is expected to act on their proteases by the
standard mechanism. The carbonyl carbon of the scissile peptide bond in a canonical
inhibitor is distorted about half way towards the tetrahedral intermediate (Read and
James, 1986). The carbonyl carbon is much further away from the side-chain oxygen
of the catalytic serine residue of the enzyme than a covalent single carbon-oxygen
bond, but is shorter than a van der Waals contact. Contributing to the partial
tetrahedral distortion is the attraction between the carbonyl oxygen of the inhibitor
and the oxyanion hole of the enzyme. The carbonyl carbon in a substrate is fully
configured as a tetrahedral intermediate and positioned for a nucleophilic attack by
the side-chain oxygen of the catalytic serine residue, but in the stable inhibitor-
enzyme complex the attack has not yet taken place (M. J. Laskowski and Kato,
1980).
1.6 The properies of plasmin and its role in blood clotting
Blood clots are formed by a series of zymogen activations. Several of the activated
enzymes in the blood coagulation cascade are serine proteases, e.g. activated factor
X, thrombin and plasmin. Fibrinolysis is initiated to balance the overall blood
10
clotting system, when the coagulation cascade is activated. Plasmin, the enzyme
central to fibrinolysis, breaks down the fibrin clot formed by the coagulation cascade
of enzymes.
Figure 1-4 Enzymes and pathways involved in fibrinolysis
Plasminogen is synthesized in the liver, secreted into the plasma and bonds to fibrin
strands within a blood clot. The activators of this enzyme diffuse into the clot and
cleave plasminogen to release plasmin. Plasmin breaks down the fibrin meshwork,
and as a result the clot dissolves (Rang et al., 1999; Castellino, 2004). Plasmin is also
involved in a number of processes unrelated to clot lysis, such as the inflammatory
response, cell recruitment, and extracellular matrix remodeling (Unkeless et al.,
1973; Mullins and Rohrlich, 1983; He et al., 1989).
Plasminogen is a single-chain protein of 791 amino acids. It contains seven structural
domains: one N-terminal growth factor like domain, five homologous kringle
domains of approximately 80 residues each, and a C-terminal serine protease
catalytic domain (542-791) (Figure 1-5). Its catalytic domain is referred to as
microplasminogen when inactive and microplasmin once activated.
Tissue plasminogen activator (tPA)
Urinary plasminogen activator (uPA), also called urokinase
Fibrin
PlasminPlasminogen
Plasminogen activator
Fibrin degradation products
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Figure 1-5 Domain structure of plasminogen.
It consists of one N-terminal domain (N), five kringle domains (K1-K5) and a catalytic
serine protease domain.
Plasminogen activation by tissue plasminogen activator (tPA) on fibrin and by urine
plasminogen activator (uPA) on cell surfaces are the major mechanisms of defense
against thrombosis in human. Both of these proteins are serine proteases that cleave
the Arg561 - Val562 peptide bond in plasminogen to generate plasmin.
Two plasminogen activators have been isolated from bacteria, staphylokinase
produced by Staphylococci, and streptokinase from hemolytic strains of Streptococci.
These plasminogen activators are not enzymes themselves but instead are cofactors,
form 1:1 complexes with either plasminogen or plasmin and acquire the ability to
activate plasminogen. Staphylokinase (SAK) is the smallest known single domain
plasminogen activator, consisting of 136 residues with a single domain folded into a
compact and flattened structure. Streptokinase (STK) is a 414 residue protein with
the structure made up of three domains.
No crystal structure of the entire plasminogen or plasmin molecule has been
reported. However the structures of a number of the domains and complexes have
been determined. These include kringle domains 1, 2, 4, 5, microplasminogen by
itself, microplasminogen in complex with the Į domain of staphylokinase,
microplasmin in complex with staphylokinase and microplasmin in complex with
streptokinase (Table 1-1).
K2 K3 K4 K5N- Catalytic domain
1 791
Microplasminogen/microplasmin
K1
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Table 1-1 Existing crystal structures of plasminogen/plasmin structural domains.
Existing crystal structures of domains of plasminogen or plasmin
Kringle 1(Wu et al., 1994; Mathews et al., 1996)
Kringle 2 (Marti et al., 1999) (NMR)
Kringle 4 (Mulichak et al., 1991; Stec et al., 1997)
Kringle 5 (Chang et al., 1998)
Human microplasminogen (X. Wang et al., 2000)
Human microplasminogen in complex with the Į domain of staphylokinase
(Wakeham et al., 2002)
Human microplasmin in complex with staphylokinase (Parry et al., 1998)
Human microplasmin in complex with streptokinases (X. Wang et al., 1998)
Kringles are sequences of about 80 amino acids arranged in a triple-loop tertiary
structure rigidly stabilized by three disulfide bridges. Kringles domains 1 and 4 of
plasminogen contain a lysine binding site that mediates plasminogen binding to
lysine residues of fibrin and cell membrane proteins. On binding to fibrin and cells,
conversion of plasminogen to plasmin is facilitated. Thus, the kringle domains have
an important role in regulation of this system and considered to play a factor in e.g.
extracellular matrix degradation (Carmeliet and Collen, 1998), stimulate the release
of inflammatory mediators (Syrovets et al., 2001) and cell migration (Tarui et al.,
2002).
The crystal structure of microplasmin shows the conformational change of the
catalytic domain upon activation (X. Wang et al., 1998; X. Wang et al., 2000). This
takes place when the proteolytic target bond Arg561 – Val562 is cleaved. Two
polypeptide chains, one 229 amino acids and one 20 amino acids in length,
connected by two disulfide bonds are produced as the result of cleavage. After
cleavage the released Val562 moves about 12 Å inwards the enzyme. Structural
rearrangements take place to form the functional specificity pocket and oxyanion
hole (Castellino, 2004).
Microplasmin has a similar overall structure to bovine trypsin with an amino acid
sequence alignment of these two proteins showing 39% identity (Figure 1-6). Like
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trypsin, plasmin cleaves peptide bonds directly after arginine or lysine side-chains.
The overall structure of the catalytic domain of serine proteases consists of two six
stranded ȕ-barrels with the active site in a cleft between the barrels (Voet et al.,
1998).
Human microplasmin: AAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRTRFGMHFCG
||| | |||| | ||||
Bovine trypsin: IVGGYTCGANTVPYQVSLNS--GYHFCG
GTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPT------RKDIALLK
| || || |||| | | || | | | | | || | |
GSLINSQWVVSAAHCYK-----SGIQVRLGEDNINVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIK
LSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQ--GTFGAGLLKEAQLPVIENKVCNRYEFLN
| | | | || | | | ||| | || || | |
LKSAASLNSRVASISLPTSCASAG--TQCLISGWGNTKSSGTSYPDVLKCLKAPILSDSSCK--SAYP
GRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIE
| | ||| | || |||||||||| || | ||| ||| ||| |||||| | | ||
GQITSNMFCAGYLEGGKDSCQGDSGGPVVCSGK----LQGIVSWGSGCAQKNKPGVYTKVCNYVSWIK
GVMRNN
|
QTIASN
Figure 1-6 Human microplasmin aligned with bovine trypsin.
The catalytic triad of His57, Asp102, and Ser195 in bovine trypsin and the catalytic triad of
His603, Asp646 and Ser741 in microplasmin are shadowed. These two proteins show 39%
sequence identity.
1.7 Aprotinin in therapeutic use to regulate blood loss
Aprotinin (trademark name Trasylol) belongs to the Kunitz/BPTI family and is a
serine protease inhibitor which is used as a therapeutic agent to prevent blood loss
and reduce the need for blood transfusion in patients undergoing surgical operations
to replace a section of coronary artery (Filippovich et al., 2002). Using blood from
another donor involves risks with incompatibility and transfusion of transmitted
infections. Aprotinin is a broad-spectrum serine protease inhibitor, and when in use
in humans inhibits plasma kallikrein, an enzyme involved in inflammation and blood
coagulation, and then inhibits plasmin with tight binding kinetics. There is a risk of
hypersensitivity resulting in severe allergic reaction and a drop in blood pressure and
breathing difficulties in patients who are exposed to aprotinin. Vein-graft occlusion
associated with myocardial infarction and thrombosis can also occur following the
use of this inhibitor (Engles, 2005; Sodha et al., 2006).
An alternative kinetically distinct inhibitor of plasmin is rTxln-1 isolated from the
venom of the Australian Common Brown snake, Pseudonaja textilis. This molecule
14
could potentially have fewer side effects than aprotinin since it is a more specific
inhibitor and binds to plasmin with reversible binding kinetics. This inhibitor is being
studied as a potential anti bleeding agent in the Venomics research group at the
University of Queensland.
1.8 The properties of textilinin-1
Txln-1 is a 59 amino acid protein isolated from the venom of the Australian
Common Brown snake, Pseudonaja textilis. This inhibitor has 45% amino acid
identity with aprotinin. The six cysteine residues in Txln-1 and aprotinin can be
aligned (Figure 1-7).
Figure 1-7 Txln-1 aligned with aprotinin.
The cysteine residues are shadowed.
Txln-1 has been extensively studied due to its anti-fibrinolytic properties, which
were discovered when applied in a mouse tail vein bleeding model experiment
(Filippovich et al., 2002). With this in mind Txln-1 was cloned and the recombinant
protein was produced. The structure of recombinant Txln-1 (rTxln-1) was pursued to
determine its binding mode and its structural features that lead to its specificity.
When comparing rTxln-1 and aprotinin, differences exist in their amino acid
composition, overall charge, binding specificity, rate of inhibition, and reversibility
of inhibition. The number of amino acids only differs by one residue with rTxln-1
having two extra amino acids at the amino terminus, but one fewer at the carboxy-
terminus. rTxln-1 is an acidic molecule with a pI of 4.4 (Filippovich et al., 2002)
while aprotinin is basic with a pI of 8.9 (Gebhard et al., 1986). The reason for this
difference is that there are eleven negatively charged and seven positively charged
amino acids in rTxln-1 while in aprotinin there are only four negatively charged and
ten positively charged amino acids. Only four of the charged amino acids are in
identical positions in the two inhibitors. There are six changes from a charged amino
acid in rTxln-1 to one that is hydrophobic in aprotinin, while two other changes are
from charged to polar side-chains. Moreover three polar and three hydrophobic
amino acids in rTxln-1 are changed to six charged amino acids in aprotinin. In two
Txln-1: KDRPDFCELPADTGPCRVRFPSFYYNPDEKKCLEFIYGGCEGNANNFITKEECESTCAA 59
||||| | |||| | || | | |||| ||| | | ||
Aprotinin: RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA 58
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cases there is a complete change of charge between the proteins. The lysine residue
in aprotinin that binds to the S1 pocket in trypsin is aligned with an arginine in
rTxln-1.
A total of six textilinin (Txln-1 to Txln-6) sequences (i.e. cDNAs with close
sequence homology to textilinin-1) have been identified by cloning from venom
gland cDNA (Filippovich et al., 2002). All have a highly conserved propeptide,
serine/lysine propeptide cleavage site and can also be aligned to match up with the
characteristic six cysteine residues found in Kunitz/BPTI-type serine protease
inhibitors (Figure 1-8). The propeptide sequence is hydrophobic, which suggests that
it facilitates secretion of the protein prior to cleavage. Conservation of a serine lysine
sequence at the cleavage site suggested that all six peptides are processed by the
same protease, releasing the twenty-four amino acid propeptide.
All six mature textilinin peptides are 59 amino acids in length (Masci et al., 2000)
have moderately conserved sequences throughout their mature peptide regions. Their
sequence identities range from 67 to 93%, with the identity between Txln-1 and
Txln-2 being the highest. Txln-2 was found in Pseudonaja textilis venom by
monitoring plasmin inhibitory activity but the other textilinins were not found by this
test (Filippovich et al., 2002). Hence, they were either not present (or present only in
minute amounts) or have different inhibitory specificity to Txln-1 and Txln-2.
Figure 1-8 Sequences of Txln-1 to 6.
The 24 amino acid pro-peptide, the 59 amino acid mature peptide, the cysteine residues and
the conserved regions are shadowed. The expected disulfide bond connectivities in Txln-1
are also shown. The sequence identities between Txln-1 and 2, 3, 4, 5 and 6 (aligned with
BLAST (blastp) and ClustalW) are 93%, 67%, 71%, 67% and 71%, respectively.
The greatest variation across the six sequences is observed in the segment between
amino acids 17 and 21, the region principally responsible for making direct contacts
Txln-1 MSSGGLLLLLGLLTLWEVLTPVSSKDRPDFCELPADTGPCRVRFPSFYYNPDEKKCLEFIYGGCEGNANNFITKEECESTCAA
Txln-2 MSSGGLLLLLGLLTLWEVLTPVSSKDRPELCELPPDTGPCRVRFPSFYYNPDEQKCLEFIYGGCEGNANNFITKEECESTCAA
Txln-3 MSSGGLLLLLGLLTLWEVLTPVSSKDRPNFCKLPAETGRCNAKIPRFYYNPRQHQCIEFLYGGCGGNANNFKTIKECESTCAA
Txln-4 MSSGGLLLLLGLLTLWEVLTPVSSKDHPKFCELPADTGSCKGNVPRFYYNADHHQCLKFIYGGCGGNANNFKTIEECKSTCAA
Txln-5 MSSGGLLLLLGLLTLWEVLTPVSSKDRPKFCELLPDTGSCEDFTGAFHYSTRDRECIEFIYGGCGGNANNFITKEECESTCAA
Txln-6 MSSGGLLLLLGLLTLWEVLTPVSSKDRPKFCELPADIGPCDDFTGAFHYSPREHECIEFIYGGCKGNANNFNTQEECESTCAA
Pro-peptide
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to serine proteases (by comparison with aprotinin). An arginine residue in position 17
(the residue that binds in the S1 pocket in serine proteases) is common to Txln-1 and
Txln-2, while the other four textilinins have an asparagine, lysine, glutamate or
aspartate in this position.
1.8.1 Textilinin-1's mechanism of inhibition
Txln-1 was isolated from the Australian King Brown snake because of its known
plasmin inhibitory properties (Willmott et al., 1995; Filippovich et al., 2002). In an
earlier study, aprotinin was shown to inhibit plasmin with a slow-onset inhibition
consistent with the two-stage reversible mechanism described as (Morrison and
Walsh, 1988);
(1.1)
where enzyme E and inhibitor I form complex EI with a rate constant k1. The
complex EI can go in two different directions. It can dissociate to E and I with a rate
constant k -1, or it can proceed to form the product EI* with a rate constant k2. EI*
may dissolve with the rate constant k-2.
Between aprotinin and plasmin, formation of the initial complex EI is fast, with a
relatively loose binding, compared to the slow transition from EI to the very stable
complex EI* (Willmott et al., 1995; Filippovich et al., 2002; Flight et al., 2005;
Flight et al., 2007). Recent kinetic studies in our laboratory have shown that rTxln-1
inhibition of plasmin also follows the slow tight binding mechanism of equation 1
and reduces blood loss when injected intravenously in an animal model (mouse tail vein
excision) (Masci et al., 2000; Flight et al., 2007). Indeed aprotinin is greater than 15
times more efficient than rTxln-1 in inhibiting plasmin, and has a broader specificity
compared to rTxln-1 (Table 1-2) (Masci et al., 2000; Filippovich et al., 2002; Flight
et al., 2005; Flight et al., 2007). The rate of recovery of plasmin is 18 times faster
with rTxln-1 then aprotinin (Flight et al., 2007). Weaker binding of plasmin by
rTxln-1 could result in greater clinical efficacy through a reduction in the incidence
of vein-graft occlusion and thrombosis compared to aprotinin when used in vascular
surgery (Masci et al., 2000).
E + I E I*E I
k1
k-1 k-2
k2
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Table 1-2 Kinetic constants for the inhibition of plasmin by
aprotinin and rTxln-1.
Aprotinin rTxln-1
Ki nmol/L 9 ± 3 14 ± 3
Ki* nmol/L 0.032 ± 0.006 0.49 ± 0.02
k2/Ki s-1 M-1 2.3 ± 0.18 ·106 1.47 ± 0.10 ·106
k2 1/s 0.021 ± 0.004 0.020 ± 0.006
k-2 1/s 4.80 ± 0.54 ·10-5 8.50 ± 0.11 ·10-4
t½ (on) Sec 35 33
t½ (off) Min 240 14
In Table 1-2, Ki is the dissociation constant for the initial loose complex EI, and Ki*
is the dissociation constant for the final tight complex EI*. The k2 and k-2 are the rate
constants as defined by Equation 1.1. The half-life; t½ (on) is the half-life for inhibition
and t½ (off) is the half-life for recovery after removal of inhibitor calculated as
-ln(1/2)/k-2.
The k-2 constant for rTxln-1 is 18 times larger than the k-2 for aprotinin, and reflects
that the EI* complex of aprotinin and plasmin holds tighter together than the same
complex of rTxln-1 and plasmin, and that rTxln-1 has a much higher release. The
forward reactions are the same in rTxln-1 and aprotinin. The similarities in the
forward reactions are reflected in similar k2/Ki constant.
1.9 Phospholipases
PLA2s are widely distributed in nature and can be found both extracellularly and
intracellularly. The presence of PLA2s in pancreatic juices and in cobra venom was
discovered around the beginning of the twentieth century and the roles of these
secreted PLA2s in digestion and envenomation were investigated extensively (Bókay,
1877; Kyes, 1903; Ogawa, 1936). Evidence began to appear in the last twenty years
that PLA2s are present in most types of cells and that they are involved in many
different cellular functions including lipid metabolism and membrane homeostasis
(Dennis, 2000).
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Generally two different PLA2 molecules have evolved: low molecular weight
extracellular PLA2s (13–16 kDa) and high molecular weight cytosolic PLA2s (>40
kDa) (Dennis, 1994; Mounier et al., 2001; Kini, 2006). Division of PLA2s into
several sub-classes has been suggested based on criteria that include phospholipase
activity, Ca2+ dependence and structural features. These structural features comprise
for example the number of disulfide bonds and loop extensions (Dennis, 1994, 1997,
2000). The extracellular PLA2s occur abundantly in mammalian pancreatic juice and
in the venoms of snakes and insects (Roberts, 1996).
In humans, PLA2s are important in systems such as signal transduction and
eicosanoid production. Through these systems, the actions of PLA2s affect a wide
range of human physiological functions and diseases including asthma and allergy,
the initiation and maintenance of parturition, blood clotting, atherosclerosis, sepsis,
asthma, inflammatory bowel disease, arthritis and other inflammatory diseases
(Dennis, 2000; Mounier et al., 2000). It is mainly the human cytosolic PLA2s, which
are often membrane associated, that are involved in platelet aggregation and
generation of inflammatory mediators (Dennis, 1994; Nalefski et al., 1994; Perisic et
al., 1998).
PLA2s hydrolyse the sn-2 ester bond of phospholipids and release lysophospholipids
and fatty acids (van Deenen and de Haas, 1964) (Figure 1-9).
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Figure 1-9 Phospholipid hydrolysis by phospholipase A2.
R1 and R2 represent fatty acyl moieties. X represent polar head groups.
It has been established in bovine pancreatic PLA2s (Dijkstra et al., 1981a; Yu et al.,
1993; Arni and Ward, 1996; Steiner et al., 2001) and porcine pancreatic PLA2s
(Dijkstra et al., 1983; van den Bergh et al., 1989; Finzel et al., 1991) that calcium is
an essential cofactor for catalytic active PLA2. The Ca2+ ion is bound to a region
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called the Ca2+ binding loop. The catalytic mechanism of PLA2s has been well
characterized (Fohlman et al., 1979; Dijkstra et al., 1981a; Keith et al., 1981; Brunie
et al., 1985; Scott et al., 1990; White et al., 1990; Janssen et al., 1999). The
mechanism behind the phospholipase activity is similar to the mechanism of the
serine protease catalytic triad but instead of a catalytically active serine residue,
PLA2 has a water molecule acting as a nucleophile and a “catalytic diad” composed
of a histidine which accepts/donates a proton and an asparate which stabilizes the
charge developed on the imidazolium ion (Volwerk et al., 1974; Kumar et al., 1994).
The carboxylate group of the aspartate is stabilized by two tyrosine residues phenolic
hydroxyls (Scott et al., 1990). A PLA2 substrate binds in a hydrophobic channel
where the active site is situated. The Ca2+ ion is the counterpart of the oxyanion hole
in serine proteases aiding in the catalysis and also stabilizing the negative charge that
arises during the tetrahedral formation at a stage in the process of the catalytic
reaction (Figure 1-10) (Verheij et al., 1980b; Thunnissen et al., 1990b; Li and Tsai,
1993; Kumar et al., 1994; Berg et al., 2001).
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Figure 1-10 The catalytic mechanism of PLA2
(a) The “catalytic diad” and a water molecule acting as a nucleophile activates a second
water molecule to attack the scissile carbonyl carbon. (b) The Ca2+ stabilizes the tetrahedral
intermediate. (c) The tetrahedral intermediate decomposes to yield the products.
The PLA2s from venom possess, in addition to their phospholytic activity, a wide
variety of pharmacological activities such as (presynaptic and/or postsynaptic)
neurotoxicity, myotoxicity, initiation and/or inhibition of platelet aggregation,
haemolytic, anticoagulant, convulsant, hypotensive, cardiotoxic and oedema-
inducing effects (Kini and Evans, 1989; Arni and Ward, 1996). An individual PLA2
can exhibit one or more of these effects.
21
1.10 The properties of ACII-4
There is a high abundance of phospholipases in the venom of Australian elapids.
These molecules have a large number of actions apart from the enzymatic cleavage
of phospholipids. Two examples of actions are binding to molecules essential to the
coagulation process, thereby acting as anticoagulants (Fry, 1999), or acting as a
neurotoxin by binding to the extracellular face of calcium channels (Brown et al.,
1987).
Three phospholipases from the Australian King Brown snake, Pseudechis australis,
have been isolated by our group. They are speculated to be the same molecules as the
previously isolated PA11, PA3 and PA15 (Takasaki et al., 1989; Takasaki et al.,
1990b). From a sequence alignment of PA11, PA3 and PA15 and other
phospholipases it is not clear what region corresponds to the specific activity. One of
these molecules is called ACII-4, which is confirmed to correspond to PA11, and has
a strong anticoagulant activity and low phospholipase activity. The other two
molecules exhibit different activities, one has very strong phospholipase activity and
the second has strong haemolytic activity.
PA11 NLIQFGNMIQCANKGSRPSLDYADYGCYCGWGGSGTPVDELDRCCQVHDNCYEQAGKKGCFPKLTLYSWKC
PA3 NLIQFGNMIQCANKGSRPTRHYMDYGCYCGWGGSGTPVDELDRCCKVHDDCYGEAEKKGCYPKLTLYSWDC
PA15 NILQFRKMIQCANKGSRAAWHYLDYGCYCGPGGRGTPVDELDRCCKIHDDCYIEAGKDGCYPKLTWYSWQC
TGNVPTCNSKPGCKSFVCACDAAAAKCFAKAPYKKENYNIDTKKRCK
TGNVPICSPKAECKDFVCACDAEAAKCFAKATYNDANWNIDTKTRCK
TGDAPTCNPKSKCKDFVCACDAAAAKCFAKAAYNKANWNIDTKTRCK
Figure 1-11 Sequence alignment of PA11, PA3 and PA15.
The conserved regions are shadowed.
1.11 Aim and synopsis of this thesis
Txln-1 and ACII-4 have been selected from purified Australian snake venom
components to be structurally characterized using X-ray crystallography. The Txln-1
molecule was chosen because of its potential as an alternative to aprotinin when used
in humans to reduce blood loss during heart surgery. Txln-1 has already been
extensively characterized kinetically and is available as a recombinant protein in
large quantities for crystallization. The aim was to solve the structure of rTxln-1 as
the free molecule and also bound to the active site of both human plasmin and
trypsin. ACII-4 was chosen because of its anticoagulant properties and elucidating its
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structure was part of a larger project focused on clarifing the mechanism by which
the PLA2 exerts its potent anticoagulant effect. The aim was to solve the structure of
ACII-4 as the free molecule.
The structures of rTxln-1 can be compared directly with that of the crystal structures
of aprotinin as the free molecule and aprotinin in complex with trypsin. It is of
interest to map the changes in structure that occur to rTxln-1 upon forming
complexes with trypsin and microplasmin, and also to observe the stereochemistry of
the catalytic triad when rTxln-1 is docked to the active site.
The functions of staphylokinase and strepotokinase have already been investigated
by X-ray crystallography and their structures in complex with microplasmin solved.
These structures will be compared with microplasmin in complex with rTxln-1.
Detailed three dimensional pictures of the interactions made between rTxln-1 and the
active site of plasmin can make it possible to determine what the key interactions
between rTxln-1 and plasmin are that make it such a tight inhibitor. It can suggest
modifications to the structure of the rTxln-1 that might lead to the discovery of a
better or altered inhibitor which could have enhanced therapeutic value.
The specific aims are to give a structure based explaination of the mechanism of
inhibition, inhibitory efficiency and specificity of rTxln-1. From these studies it will
be possible to perform correlations between structure and inhibition mechanism. One
goal was to explain why rTxln-1 binds reversibly to plasmin and has a higher off rate
compared to aprotinin. From the complexes it would also be of significance to draw
conclusions about inhibition of plasmin since no structure with a Kunitz/BPTI-type
inhibitior in complex with plasmin exists.
Analysis of the structure of ACII-4 will allow us to determine the molecular basis for
the high anticoagulant activity and low phospholipase activity. The interest in this
study lies in the high sequence similarity of this molecule with the two other similar
molecules isolated from Pseudechis australis, yet all three have different biological
activities.
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Chapter 2
Preparation of Proteins for Crystallization
2.1 Introduction
One of the initial aims of the project was to determine the crystal structure of free
recombinant textilinin-1 (rTxln-1). Its study was of particular interest because of its
potential as a therapeutic agent to prevent blood loss in the case of patients
undergoing major surgery. The most likely target for its activity is to inhibit plasmin
(Filippovich et al., 2002). After six months working on the project a gene construct
of human microplasmin (the catalytic domain of plasmin) became available allowing
me the prospect of determining the structure of rTxln-1 in complex with this
fragment of the enzyme. For comparative studies and to understand the reasons for
the specificity of binding, the structure determination of a complex between trypsin
and rTxln-1 was also an aim for the project.
As a part of the overall effort of the Venomics group to discover and characterize
proteins from Australian snake venoms a phospholipase A2 referred to as ACII-4
with potent anticoagulant activity was isolated and purified from the venom of the
Australian King Brown snake, Pseudechis australis. Determination of the three-
dimensional structure of this molecule and comparison with the structure of other
phospholipase A2s which possess different activities should begin to explain the
reasons for the potent anticoagulant activity.
To determine the crystal structure of a protein requires that the protein of interest is
purified to high degree, usually greater than 95%, that at least one but generally tens
of milligrams be available and that the concentration of the protein to be in the range
of 1- 40 mg/mL. This chapter describes the experiments that were required to obtain
the proteins in the amounts and purity necessary to be able to undertake the X-ray
crystallographic studies.
One of the most significant advances in accelerating the rate of structure
determination by X-ray crystallography has been the revolution in molecular biology
and the development of recombinant protein technologies. To produce sufficient
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quantities of textilinin-1, recombinant protein was required. This protein was
supplied by BresaGen (Section 2.3). Since the complete plasmin molecule consists of
a number of domains that are connected by flexible linkers, recombinant
technologies were necessary to produce a form of plasmin that was amenable to
structural investigation. Cloning made it possible to produce a smaller form of
plasmin, referred to as microplasmin, which contains only the serine protease domain
(X. Wang et al., 1998). One of the challenges was to purify, solubilize, fold and
activate the recombinant human microplasmin in sufficient quantities for
crystallization experiments.
One of the difficulties with the preparartion of the microplasmin is that it is
expressed as inclusion bodies. As a result, the protein must be completely unfolded
and then refolded again. The question arises as to whether or not the protein has
folded into the correct three-dimensional structure. There are several methods
including dynamic light scattering (DLS) and circular dichroism (CD) to test that the
protein is correctly folded. However, neither of these is as predictive as measuring
the enzymatic activity of the sample using spectrophotometric assays. Enzymatic
activity assays were used to test that the complexes were formed and that the
enzymes were completely inhibited.
As mentioned earlier, the purity of the protein is critical to the outcome of the
crystallization experiment. Impurities can prevent crystals from forming, disturb the
formation of a lattice, or produce crystal defects that lead to a reduction in diffraction
quality. To monitor the purity of the samples SDS-PAGE, analytical
ultracentrifugation, and MALDI-TOF mass spectrometry experiments were carried
out.
2.2 Materials and methods
Preparation of rTxln-1, rTxln-1-trypsin complex, rTxln-1-microplasmin complex and
ACII-4 are described in the next four sections. rTxln-1 was produced by BresaGen
Ltd, Adelaide, South Australia. Bovine trypsin was purchased from Sigma-Aldrich,
and the plasmid containing human microplasmin was kindly donated by Professor
Chai Zhang, Oklahoma Medical Research Foundation, USA (Loy et al., 2001).
ACII-4 was supplied as native protein by Dr Paul Masci. Chemicals for SDS-PAGE
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were purchased from Bio-Rad. Prepacked Superdex 75 and HiLoad Superdex 200
(Prep Grade) columns were purchased from Amersham Biosciences. The Sephacryl
300 for gel filtration and CNBr-Sepharose were purchased from GE Healthcare.
Chromogenic substrate benzoyl-l-arginyl p-nitroanilide (BApNA) was purchased
from Sigma-Aldrich, and S-2251 was purchased from Chromogenix. All chemicals
used were of analytical grade.
2.3 Cloning, expression and purification of recombinant
textilinin-1
The cloning, expression and purification of rTxln-1 (NCBI accession number
AAK95519) was carried out by Dr Stan Bastiras (BresaGen Ltd, Adelaide, South
Australia). The cloned construct, abbreviated to “TVWT”consisted of a proprietary
N-terminal expression-enhancer sequence (TV), an internal tryptophan residue (W)
and the 59-amino-acid mature Txln-1 sequence (T). The protein was expressed as
inclusion bodies in Escherichia coli MM294 cells. The inclusion bodies were
dissolved at pH 11.7 and at a concentration of 2 mg/mL. Refolding of the fusion
protein was initiated by lowering the pH to 9.5 with 1 M HCl. The progression of
refolding was assessed by RP-HPLC. After 2 h, cleavage of the TVW moiety was
initiated by the addition of N-chlorosuccinimide (Lischwe and Sung, 1977). The
released rTxln-1 was purified by a combination of phenyl-Sepharose high
performance hydrophobic interaction chromatography and Q-Sepharose high
performance anion-exchange chromatography (Amersham Biosciences). The purified
rTxln-1 containing fractions from the Q-Sepharose high performance column were
pooled and applied onto a Sephadex G25M column equilibrated with 25 mM Tris–
HCl pH 7.8. The rTxln-1 was stored at 4oC in 25 mM Tris–HCl pH 7.8, 50 mg/mL
mannitol and 0.01% Tween-20.
Dr Simone Flight titrated a trypsin solution with p-nitrophenyl p-guanidinobenzoate
(Chase and Shaw, 1967) in the presence and absence of a sub-equimolar amount of
rTxln-1, which gave an estimate of the molar concentration of rTxln-1. This was in
excellent agreement with the molar concentration calculated from the UV spectrum
using a Hitachi U-2800 UV recording spectrophotometer (Hitachi). An İ280 = 4560
M-1 cm-1 was estimated by the method of Gill and von Hippel (Gill and von Hippel,
1989).
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2.4 Preparation of free recombinant textilinin-1 for
crystallization experiments
2.4.1 Concentration and SDS-PAGE of rTxln-1
Free rTxln-1 was supplied in a formulation buffer given above. I buffer exchanged
the protein into 25 mM Tris–HCl pH 7.8 at 4oC prior to crystallization. Samples were
concentrated up to 40 mg/mL using an Amicon stirred cell (Millipore) with a 1000
Da molecular weight cut-off membrane (Millipore). The concentration was
determined from the absorbance maximum at 280 nm. Its purity and molecular
weight was assessed by 4-20% SDS-PAGE by the method of Laemmli (Laemmli,
1970). Protein samples were mixed with loading buffer consisting of a final
concentration of 50 mM Tris-HCl pH 6.8, 0.05% (w/v) bromophenol blue, 10% (v/v)
glycerol, 2% (w/v) SDS (Sigma-Aldrich). Some samples were prepared under
reducing conditions in the presence of 100 mM ȕ-mercaptoethanol. All samples were
boiled for five minutes before gel loading. The samples were electrophoresed
through the stacking gel and separating gel at 80 V and 200 V, respectively, in a
Mini-Protean II vertical slab electrophoresis system. Gels were stained overnight in
0.1% (w/v) Coomassie Brilliant Blue R-250, 40% (v/v) methanol, 10% (v/v) acetic
acid and destained until clear in 40% (v/v) methanol 10% (v/v) acetic acid (Sigma-
Aldrich). The SDS-PAGE showed one band equivalent to approximately the same
molecular weight, as aprotinin (Figure 2-1).
Figure 2-1 Non-reduced 4-20% gradient SDS-PAGE of
purified rTxln-1.
The gel was stained with Coomassie Brilliant Blue R-
250. Lane 1 Protein standards from (Bio-Rad).
Lanes 2-4 were rTxln-1 at increasing concentrations.
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2.4.2 Mass spectral analysis of rTxln-1
Purified rTxln-1 was analysed using a VOYAGER-DE STR MALDI TOF mass
spectrometer (Applied Biosystems, Voyager Instrument Control Panel v 5.10)
operating in linear positive mode with an accelerating voltage of 25 kV, grid votage
93% and delay time of 1100 nsec, with the help of Chris Wood at the University of
Queensland. The machine was externally calibrated with bovine insulin (5734 Da),
thioredoxin (11674 Da), and E. coli myoglobin (16952 Da) (Sigma-Aldrich). rTxln-1
in 25 mM Tris–HCl pH 7.8 was mixed 1:1 with matrix. The matrix was 10 mg/mL
3,5-dimethoxy-4-hydroxycinnamic acid, which had been dissolved in 50% (v/v)
acetonitrile and 0.1% (v/v) trifluoroacetic acid (Sigma-Aldrich) in water. The
purpose of the matrix material was to absorb energy from the laser light preventing
the molecules from decomposition and to isolate the molecules from one another.
The low pH ensured that the molecules were positively charged (Hillenkamp et al.,
1991; Bahr et al., 1992; Lewis et al., 2000). The sample was mixed with the matrix
solution and allowed to air dry before being subjected to ionization and analysis by
the time-of-flight analyzer. A major peak was detected at 6690 Da (Figure 2-2),
which is within an accepted tolerance of 5 Da of the molecular weight of rTxln-1
determined by BresaGen Ltd and within 4 Da of the theoretical molecular weight of
the amino acid sequence (Mw = 6686 Da). Smaller fragments of 5054 Da, 6031 Da,
and 6493 Da were visible which could have been produced by the break down of
rTxln-1 when subjected to the ionization laser source. Another species was observed
at 13385 Da suggesting that rTxln-1 can also dimerize. This dimer must have strong
enough interactions to be sustained in the ionization laser source.
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Figure 2-2 MALDI-TOF mass spectrum of rTxln-1.
Sample buffer: 25 mM Tris–HCl pH 7.8; matrix: 10 mg/mL 3,5-dimethoxy-4-
hydroxycinnamic acid in 50% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid in water.
The major peak is at 6690 Da which is within 5 Da of the expected molecular mass for
rTxln-1. The smaller peaks are likely fragmentation products of rTxln-1 produced by the
ionization laser source. A peak at 13385 Da suggests the presence of a rTxln-1 dimer.
2.4.2.1 Analytical ultracentrifugation of rTxln-1
The degree of self association of rTxln-1 in 25 mM Tris–HCl pH 7.8 was assessed by
analytical ultracentrifugation. Sedimentation equilibrium experiments were carried
out to determine the molecular weight of rTxln-1 using a Beckman XL-I analytical
ultracentrifuge (Beckman Coulter). 200 µL of 81 µM or 0.54 mg/mL rTxln-1 in 25
mM Tris–HCl pH 7.8 was loaded into one of the cell chambers and as a reference
200 µL of 25 mM Tris–HCl pH 7.8 was loaded into the second cell chamber. The
cells were placed in an An-60 Ti rotor with absorption optics at 280 nm. The sample
was run at 33000 rpm at 20oC for sixteen hours. The experiments provided data to
plot ln Absorbance versus the square of the radial distance. The linear relationship
(Figure 2-3) indicates a normal behavior for a globular protein.
The molecular weight of the sample can be calculated using the equation
Mw = [2RT/ Ȧ2(1-vƍȡ)] Ȝ
where Mw is the molecular weight, R is the gas constant, T is the absolute
temperature, Ȧ is the angular velocity, vƍ the partial specific volume of the sample, ȡ
the buffer density and Ȝ is the determined slope (Tinoco et al., 1995; Hensley, 1996).
The partial specific volume was determined to be 0.71 mL/g, and the buffer density
1.02 g/mL. Using Ȧ2 = 11.9422 x 106 (33000 rpm), T = 293 K, Ȝ = 4862 cm-2 and
(1-vƍȡ) = 0.2764, a molecular weight of 7181 ± 500 Da was obtained (see Appendix
B for theory behind the equation used). Sedfit analysis (Schuck, 1998) gave a
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numerical value of the radius parameters of r0 = 1.27 nm (vertical radius), and rh =
1.51 nm (horizontal radius), and a molecular weight of 7200 ± 500 Da.
Figure 2-3 Sedimentation equilibrium experiments of rTxln-1 performed in the analytical
ultracentrifuge.
Sample buffer: 25 mM Tris–HCl pH 7.8. Data points are plotted as the ln absorbance as a
function of square radial distance. The data are consistent with a straight line indicating a
globular protein with a molecular weight in accordance with that of a monomer of rTxln-1.
2.5 Preparation of the recombinant textilinin-1-trypsin
complex for crystallization experiments
2.5.1 Mass spectrometry analysis, SDS-PAGE and activity assay
of bovine trypsin
Bovine trypsin (Product No. T1426, Sigma-Aldrich,) was purchased as a salt-free
lyophilized powder. The molecular weight specified by Sigma was 23.8 kDa. The
MALDI-TOF spectrum of the sample dissolved in water showed one large peak at
23324 Da and several lower molecular weight species. The major peak corresponds
to residues 16 to 245 of trypsin (according to chymotrypsin numbering), which gives
an expected molecular mass of 23293 Da (Figure 2-4). The MALDI ionisation
method results predominantly in the generation of singly charged molecules,
although instead of the sample being ionised by the addition of a proton H+, it can be
accompanied by salt adducts e.g. Na+ giving rise to a value that is 23 Da greater than
the expected molecular mass (Hillenkamp et al., 1991; Bahr et al., 1992). If there are
trace amounts of sodium ions present this could explain the slightly higher than
expected mass value. The lower molecular weight species can appear due to autolysis
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or fragmentation by the ionization laser source. The commercial sample of trypsin
(ȕ-trypsin) is produced when a N-terminal hexapeptide of trypsinogen is cleaved at
the Lys6 – Ile7 peptide bond, and other species may also form as a result of further
proteolysis of the intact chain. An SDS-PAGE showed one strong band
corresponding to intact trypsin between the 31 and 21.5 kDa, and several weaker
bands at about 20, 14, 10 and 7 kDa, which could be matched with peaks in the mass
spectrum (Figure 2-5). A cleavage in trypsin between Lys131 – Ser132 produces an
active two-chain form referred to as Į-trypsin, forming one 13.1 kDa and one 10.2
kDa polypeptide chain. A third, three-chain active form of trypsin has an additional
peptide bond cleaved between Lys176 and Asp177, forming three polypeptides of
13.2 kDa, 4.7 kDa, and 5.5 kDa molecular mass. These fragments bind substrate
poorly compared to ȕ-trypsin. Another two-chain form exists which has a cleaved
peptide bond between Arg105 and Val106 giving two species with molecular mass
of 10.6 kDa and 12.7 kDa. It is therefore understandable that these polypeptides are
represented as peaks in the mass spectrum. One of the lower molecular weight
species appears to be a doubly charged positive ion of trypsin 23324/2 = 11662 Da
(~11647 Da).
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Figure 2-4 MALDI-TOF mass spectrum of trypsin.
Trypsin dissolved in water; matrix: 10 mg/mL 3,5-dimethoxy-4-hydroxycinnamic acid in
50% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid in water.
The major peak at 23323.75 Da corresponds to an enzymatically cleaved fragment of trypsin.
A doubly charged positive ion with the same molecular weight, 23324/2 = 11662 Da
(~11647 Da) is also observed. Other smaller trypsin fragments are present due to autolysis or
fragmentation products formed by the ionization laser source.
Figure 2-5 Reduced 4-20% gradient SDS-PAGE of the trypsin
sample used in MALDI-TOF mass spectrometry.
The gel was stained with Coomassie Brilliant Blue R-250. Lane 1
Protein Standards (Bio-Rad), and Lane 2 trypsin dissolved in
water. The most intense band corresponds to activated trypsin
with a molecular weight of 23.3 kDa. The other bands represent
autolysis products.
The tryspin activity was assessed by using the chromogenic substrate benzoyl-l-
arginyl p-nitroanilide (BApNA) as a substrate. Four replicates were performed with a
reaction mixture consisting of 620 µL of 0.2 M Tris-HCl pH 7.6, 0.03 M CaCl2, 330
µL 1.84 mM BApNA, and 50 µL of 28 µM trypsin solution. Data were obtained by
monitoring realease of p-nitroaniline at 410 nm at 25oC for six minutes. Under these
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conditions, the rate of reaction was linear when plotted against time. The specific
activity of trypsin was calculated to be 0.108 µmol mg-1 min-1.
2.5.2 Mass spectrometry analysis of the rTxln-1-trypsin complex
To form the rTxln-1–trypsin complex the lyophilized trypsin was dissolved in a
solution containing concentrated rTxln-1 in 25 mM Tris–HCl pH 7.8, in the molar
ratio 1:1.1. This mixture was analyzed by MALDI-TOF mass spectrometry. Peaks at
6698 and 23312 Da, corresponding to rTxln-1 and trypsin were visible (Figure 2-6).
One peak at 17897 Da, which was also one of the smaller peaks visible in the mass
spectrum of trypsin alone, may be a product from autolysis or degradation by the
ionization laser source. Several peaks corresponding to low molecular masses may
be degradation of rTxln-1 by the ionization laser source or autolysis products of
trypsin.
Figure 2-6 MALDI-TOF mass spectrum of the rTxln-1-trypsin complex.
Sample buffer: 25 mM Tris–HCl pH 7.8; 10 mg/mL matrix: 3,5-dimethoxy-4-
hydroxycinnamic acid in 50% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid in water.
Peaks in agreement with the molecular mass of rTxln-1 and bovine trypsin, are clearly
visible. An autolysis product of trypsin is observed at 17899 Da.
2.5.3 Purification by gel filtration
Both Superdex 200 and 75 were tested as media for purification of the complex. Both
were successful as fractions could be pooled containing the complex after analysis by
SDS-PAGE.
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2.5.4 Superdex 200 column
A HiLoad Superdex 200 column (Prep Grade), 2.6 x 60.0 cm was equilibrated with
25 mM Tris–HCl pH 7.4 and 50 mM NaCl (Ajax Chemicals), and calibrated with
standard proteins of known molecular weight (Figure 2-9). Fractions were monitored
by absorbance at 280 nm. The rTxln-1-trypsin sample was spun at 3000 rpm using a
Beckman model TJ-6 centrifuge for five minutes at 25oC prior to being loaded onto
the column and eluted at a flow rate of 2 mL/min with the same solution that was
used to equilibrate the column (Figure 2-7). A 15% SDS-PAGE under non-reducing
conditions showed a smear of weaker bands between the 31 and 21 kDa (Figure 2-8).
Fractions that contained both trypsin and rTxln-1, lane 6-9 (Figure 2-8) were pooled.
Figure 2-7 The elution profile of the rTxln-1-trypsin complex by Superdex 200 size
exclusion chromatography.
The major peak appears to be the complex, with tail consisting of autolysis fragments and
free rTxln-1.
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Figure 2-8 Non reduced 15% SDS-PAGE of fractions collected from Superdex 200 column.
The gel was stained with Coomassie Brilliant Blue R-250. Lane 1 Protein Standard (Bio-
Rad), Lane 2 fraction D7 collected from 222-224 mL, Lane 3 fraction D5 collected from
226-228 mL, Lane 4 fraction D3 from 230-232 mL, Lane 5 fraction D2 collected from 232-
234 mL, Lane 6 fraction E1 collected from 236-238 mL, Lane 7 fraction E3 collected from
240-242 mL, Lane 8 fraction E5 collected from 244-246 mL, Lane 9 fraction E7 collected
from 250-252 mL, and Lane 10 fraction E8 collected from 252-254 mL. The strong band
between 31 and 21 kDa is trypsin and the weaker band at 6.5 kDa is rTxln-1.
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Figure 2-9 Calibration graph of the Superdex 200 column.
Both the complex and the free trypsin would be expected to elute at around 236-240 mLs of
column volume. With a molecular mass of 6.7 kDa free rTxln-1 would be expected to elute
at 290 mL.
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2.5.5 Mass spectral analysis of Superdex 200 fractions
The pooled sample was analyzed by MALDI-TOF mass spectrometry. The peaks at
6700 Da and 23346 Da correspond to rTxln-1 and bovine trypsin (Figure 2-10).
Peaks at 13395 Da, 30046 Da and 36768 Da correspond to a rTxln-1 dimer, the
rTxln-1-trypsin complex and a complex of two rTxln-1 molecules and one trypsin
molecule, respectively. A peak at 4797 Da could correspond to the polypeptide
consisting of residues 18-59 of rTxln-1.
Figure 2-10 MALDI-TOF mass spectrum of the rTxln-1-trypsin complex.
Sample buffer: 25 mM Tris–HCl pH 7.8; matrix: 10 mg/mL 3,5-dimethoxy-4-
hydroxycinnamic acid in 50% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid in water.
Peaks with molecular masses corresponding to free rTxln-1 and trypsin, a dimer of rTxln-1,
the complex, and trypsin complexed with two rTxln-1 molecules were all observed.
2.5.6 Activity assay of the rTxln-1-trypsin complex
Enzymatic activity of the rTxln-1-trypsin complex was measured using BApNA as
the substrate. From two assays, one of trypsin alone and the second with the
complex, it was possible to calculate the percentage of inhibition (A0 – Ai) / A0
where A0 is the absorbance per minute of the uninhibited reaction, and Ai is the
absorbance per minute of the inhibited reaction. The sample showed 93% and 95%
inhibition before and after, respectively, purification by Superdex 200
chromatography. This batch of material was then subjected to crystallization trials
(Chapter 3).
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2.5.7 Superdex 75 column
A second batch of the rTxln-1-trypsin complex was purified by FPLC on a Superdex
75 column, 1 x 30 cm. The column was equilibrated with 25 mM Tris–HCl pH 7.4
and 50 mM NaCl, and calibrated with standard proteins of known molecular weight
(Figure 2-12). Samples were eluted at a flow rate of 0.8 mL/min with the same buffer
that was used to equilibrate the column. The fractions were monitored by absorbance
at 280 nm. Aprotinin, rTxln-1 and trypsin where profiled by loading them onto the
same column. Surprisingly, rTxln-1 eluted at 13.20 mL, which corresponds to a
molecular weight of 27.5 kDa or four rTxln-1 molecules (Figure 2-12). Trypsin
eluted as expected at 13.56 mL corresponding to a molecular weight of 23.3 kDa.
The complex of rTxln-1-trypsin eluted at 11.52 mL. The fractions were pooled and a
non reduced 12% SDS-PAGE showed one strong band near 31 kDa and one band
above the 6.5 kDa marker in the ladder, corresponding to trypsin and rTxln-1
respectively. The samples showed 97% inhibition both before and after purification.
This batch of material was subjected to crystallization trials but no crystals were
obtained (Chapter 3).
Figure 2-11 The elution profile of the rTxln-1-trypsin complex by Superdex 75 size
exclusion chromatography.
Sample buffer: 25 mM Tris-HCl pH 7.8. One peak eluted at 11.5 mL followed by a tail of
smaller polypeptides.
37
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1 2 3 4 5 6
log(Mw)
P
ar
tit
io
n
co
ef
fic
ie
nt
K a
v
Adenosine
Vitamin B12
Ribonuclease
Ovalbumin
Bovine serum albumin
Aprotinin
Trypsin
rTxln-1
rTxln-1 trypsin
Figure 2-12 Calibration graph of the Superdex 75 column.
Aprotinin and trypsin elute at 16.54 mL and 13.56 mL, respectively. rTxln-1 and rTxln-1-
trypsin elute at 13.20 mL and 11.46 mL.
2.5.8 Concentration of rTxln-1-trypsin complex
Sodium chloride was removed by buffer exchange and the complex concentrated to
10 mg/mL using an Amicon stirred cell with a 1000 Da molecular weight cut-off
membrane. The protein concentration was determined by measuring the A280 value
using an İ280 = 40480 M-1 cm-1 for the complex (Gill and von Hippel, 1989).
2.5.9 Additional samples of rTxln-1-tryspin for crystallization
Three batches were made for crystallization trials by directly dissolving lyophilized
trypsin into a solution containing concentrated rTxln-1 in 25 mM Tris–HCl pH 7.8,
at a molar ratio of 1:1.1. All batches were >95% inhibited as tested by the activity
assay.
2.6 Cloning, expression and purification of human
microplasminogen
2.6.1 Extraction of plasmid
A plasmid containing the gene for human microplasminogen (residues 542-791) was
a gift from Professor Chai Zhang, Oklahoma Medical Research Foundation, USA.
The plasmid was a construct of a pET-11a vector (Novagen), carrying a N-terminal
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T7 epitope tag. The plasmid (~1.8 µg DNA), stored on blotting paper was dissolved
in 10 µL of Milli-Q water for two minutes, and spun at 3000 rpm in an Eppendorf
Centrifuge 5415 D (Eppendorf) at 25oC for 1 min. An A260/A280 of 1.7 signified that
the aqueous sample was relatively free of protein contamination. The A260 value
equated to a concentration of 138 ng/µL.
2.6.2 Expression and isolation of human microplasminogen
Recombinant microplasminogen was expressed in E. coli BL21(DE3) cells. The
DNA was transformed into BL21(DE3) competent cells (Invitrogen) by
electroporation 150 ng of the plasmid per 50 µL cells. The cells were grown at 37oC
and 220 rpm on a Bioline 4000 Serie shaking incubator for 1 hr in 1 mL of Luria
Bertani broth (LB) [10 g tryptone, 5 g yeast, 10 g NaCl dissolved in a total of 1 L
water]. Agar plates containing ampicillin were streaked with aliquots of 40 µL of the
cells and incubated at 37oC overnight. A single colony was picked and grown
overnight in 5 mL of LB broth containing 100 µg/mL ampicillin for immediate use.
Microplasminogen expression was confirmed by conducting a small scale
expression, 12% SDS-PAGE under reducing conditions (Figure 2-13), and Western
blot analysis with a monoclonal anti-T7 tag antibody (Novagen) (Figure 2-13).
Western blot analysis (Sambrook et al., 1989) was carried out by transfer of the
proteins from SDS-PAGE to a nitrocellulose membrane at 100 V for one hour at 4oC.
The transfer buffer consisted of 100 mM Tris-HCl, 40 mM glycine, 0.036% SDS,
and 20% methanol. The membrane was blocked against non-specific interactions by
immersion in 5% skim milk in phosphate buffered saline (PBS) containing 0.05%
Tween 20 (Merck). Milk protein attached to the membrane where the target protein
was not attached. The membrane was incubated overnight with a monoclonal anti-T7
antibody. After washing in PBS and 0.05% Tween 20, the membrane was probed
with a secondary antibody conjugated to horseradish peroxidase (Chemicon) and
incubated for one hour. After washing the membrane in PBS and 0.05% Tween 20,
the membrane was developed using enhanced chemiluminescence reagent (Western
Lightning) and visualized with a Fujilmager 3000 chemiluminescence detector. The
theoretical molecular weight of microplasminogen with the T7•tag is 28371 Da. The
major band on SDS-PAGE and Western blot was observed in this region.
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(a) (b)
Figure 2-13 Analysis of microplasminogen expression
(a) Reduced 12% SDS-PAGE stained with Coomassie Brilliant Blue R-250. (b) Western blot
with a monoclonal anti-T7 antibody. Lane 1 uninduced over-expression of
microplasminogen. Lane 2 induced over-expression of microplasminogen. Lane 3 Prestained
Protein Ladder (Fermentas). Microplasminogen appears as a strong band at about 28 kDa.
Some expression of the gene was also present in the uninduced sample.
Once it was confirmed that microplasmin had been transformed into the BL21 cells,
a large scale expression was carried out. Two batches (3L and 5L of media) of
microplaminogen were produced by the following procedure. Overnight cultures
were grown at 37oC and 225 rpm, in LB media containing 100 µg/mL ampicillin. 45
mL of these cultures were added to 1 L of LB media. When the optical density (OD)
at 600 nm had reached 0.6, the cells were induced to start transcription of the fusion
construct by adding 0.5 mM isopropyl ȕ-D-thiogalactopyranoside (IPTG, Sigma-
Aldrich). The cells were incubated for three hours at 37oC, 225 rpm after which the
cells were pelleted at 6,600 rpm for 5 min at 4oC. Each pellet from 1 L of cell culture
was resuspended in 50 mL of 50 mM Tris-HCl pH 8.0, 100 mM NaCl, and 250 µL of
one complete protease inhibitor tablet (Roche) dissolved in 1.5 mL Milli-Q water.
The cells were lysed by adding 2.5 mg/mL lysozyme per 50 mL resuspended pellet
solution and placed on ice for 30 min. 1.25 mL of 20% Triton X-100 (BDH
Chemicals) was added per 50 mL lysate before freezing the solution at -20oC for
overnight storage. The frozen solutions were thawed in 200 units of DNase (Roche)
per 1 L lysate, 2 mM MgCl2 and 2 mM MgSO4 (Sigma-Aldrich) and stirred at 4oC
for one hour. The high level of expression of human microplasminogen resulted in
the formation of inclusion bodies. The inclusion bodies were spun at 11,500 rpm for
15 min at 4oC using a Beckman J2-M1 centrifuge and washed twice with 0.5%
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Triton X-100, twice with 0.1% Triton X-100 made up in Tris-HCl buffer pH 8.0, and
once with buffer alone to remove soluble hydrophobic proteins and membranes. The
inclusion bodies were then dissolved in 100 mM Tris-HCl buffer pH 8.0 containing 2
mM EDTA, 8 M urea, 1 mM glycine, and 10 mM ȕ-mercaptoethanol (“solubilization
buffer”), and spun in 5 mL centrifuge tubes at 22,000 rpm for 30 min at 4oC using a
Beckman L8-70 Ultracentrifuge and a SW55Ti rotor. This was to remove any
unsolubilized protein. Samples taken after each step were analysed by reduced 12%
SDS-PAGE (Figure 2-14).
Figure 2-14 Reduced 12% SDS-PAGE of the purification of inclusion bodies of
microplasminogen.
The gel was stained with Coomassie Brilliant Blue R-250. Lane 1 Supernatant. Lanes 2-6
wash with decreasing amount of Triton X-100. Lane 7 solubilized inclusion bodies. Lane 8
Protein Marker, Broad Range (BioLabs).
The A280 of the solution was adjusted to 5.0 with the addition of solubilization buffer.
The microplasminogen was refolded by slow titration with 2 L of 20 mM Tris-HCl
buffer containing 2 mM EDTA, 4% glycerol, 0.3 M urea and 0.1 mM ȕ-
mercaptoethanol, for every 3 L of starting LB. The final pH was adjusted to 8.0 with
HCl and then stirred at 4oC for 72 h. The solution was then spun at 8,000 rpm for 20
min at 4oC, and filtered (0.45 µm) before being concentrated using an Ultrasette
tangential flow device (Pall Life Sciences) with a 10 kDa cut off membrane. The
filter was prewashed with 0.1 M NaOH before being equilibrated with the refolding
buffer. The refolded and concentrated protein (2.7 mg/mL) was spun at 3000 rpm at
25oC for five minutes to remove insoluble material from the solution.
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To monitor expression and refolding, samples were taken from uninduced, induced,
supernatant, washes, solubilized, refolded and concentrated batches. Activity assays
were carried out by adding tissue plasminogen activator (tPA) (Actylase, Genentech)
in a 1:10 (human microplasmin:tPA) molar ratio and incubating the mixture for sixty
minutes at 37oC, allowing the microplasminogen to be converted microplasmin. For
the activity assay, the chromogenic substrate H-D-valyl-L-leucyl-L-lysyl-p-
nitroaniline (S-2251; 3mM) was added in a 1:1000 (human microplasmin:
chromogenic substrate) molar ratio in the reaction buffer consisting of 0.05 M Tris-
HCl pH 7.4. The release of p-nitroaniline was detected by measuring the increase of
absorbance at 405 nm at 25oC. The plot of absorbance against time was linear for six
minutes. The specific activity of microplasmin from the refolded and concentrated
solution was 0.135 µmol mg-1 min-1.
2.6.3 Gel filtration of refolded human microplasminogen
The concentrated solution of microplasminogen was loaded onto a Sephacryl 300,
2.5 x 95.0 cm, size exclusion column. The column was equilibrated with 20 mM
HEPES (AppliChem) pH 7.0, 0.4 M urea, and 0.01% azide (Sigma-Aldrich). 10 mL
fractions were collected at a flow rate of 50 mL/h. The protein was eluted with the
same solution and the fractions were monitored by absorbance at 280 nm. Several
peaks eluted from the Sephacryl 300 column (Figure 2-15). Each fraction was tested
for plasmin (like) activity using tPA to convert microplasminogen to microplasmin.
The first peak had low activity and was therefore assumed to contain high molecular
weight aggregates. The third peak had the highest plasmin activity and eluted at a
time that would correspond to individual monomers of microplasmin. Fractions from
this peak were pooled and used for the preparation of the rTxln-1-microplasmin
complex.
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Figure 2-15 Elution profile of refolded microplasminogen from Sephacryl 300
chromatography.
Peaks (1) and (2) were assumed to be aggregates of microplasminogen. Peak (3) contained
monomeric microplasminogen with high activity. Peak (4) is a species derived from
microplasminogen but with lower molecular mass.
2.6.4 Preparation of rTxln-1-microplasmin complex
Active human microplasmin is susceptible to self-digestion, therefore it was
necessary to prevent degradation upon activation by forming the rTxln-1 inhibited
enzyme complex as quickly as possible. In the large scale production of
microplasmin, the microplasminogen was prepared for activation by adding 25%
glycerol as well as the inhibitor to prevent microplasmin autoproteolysis. Urokinase-
type plasminogen activator (Mitsubishi Pharma Corporation) bound to sepharose was
used to convert microplasminogen to active microplasmin; a small scale test was first
carried out and the protein solutions loaded onto 15% SDS-PAGE (Figure 2-16) to
determine efficiency.
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Figure 2-16 Non reduced 15% SDS-PAGE of the activation
of plasminogen with urokinase.
The gel was stained with Coomassie Brilliant Blue R-250 to
visualize the protein bands. Lane 1 Sample from a pilot run
without using beads, the major band at 52 kDa is urokinase,
the bands at 25 kDa and 3 kDa are the two microplasmin
chains, Lane 2 microplasminogen, and Lane 3 Precision Plus
Protein Standards (Bio-Rad).
After successful activation of microplasminogen in the small scale test, the
urokinase-type plasminogen activator was covalently coupled to CNBr-activated
Sepharose 4B beads for larger scale production of the complex and easy separation
of the urokinase-type plasminogen activator. The amount of 1 g of freeze-dried
CNBr-activated Sepharose 4B beads was swollen for 15 min in 1 mM HCl and
washed on a sintered glass filter with the same solution using a total of 200 mL 1
mM HCl. 0.5 mL of 1000 U/mL urokinase-type plasminogen activator concentrated
to 2.7 mg/mL (as determined by the BCA assay) was pipetted into 9.5 mL of 0.1 M
NaHCO3 (Sigma-Aldrich) pH 8.3 and 0.5 M NaCl. This solution was then mixed
with the swollen beads and centrifuged at 3000 rpm for 15 min. The supernant was
then decanted. 10 mL of blocking agent consisting of 0.2 M glycine pH 8.0 was
mixed for four hours with the gel to block the remaining active groups, and then
centrifuged at 3000 rpm for 15 min and the supernantant decanted off. The gel was
next washed with 50 mM Tris-HCl pH 7.4 and again centrifuged at the same speed
for 10 min.
The microplasminogen was preincubated in 25% glycerol and a five-fold molar
excess of rTxln-1. 20 mL of this solution was then mixed with the activated beads on
a rotating wheel overnight. The mixture was centrifuged at 3000 rpm at 4oC for 15
min to separate the beads with bound immobilized urokinase-type plasminogen
activator from the rTxln-1-microplasmin complex. The supernatant containing the
complex was shown to be >99% pure on both reduced and non reduced 15% SDS-
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PAGE. It was then concentrated using an Amicon Ultra centrifugal filter device with
a 10 kDa molecular weight cut-off membrane. rTxln-1 was added to the solution
during and after concentration to ensure that microplasmin was inhibited.
Two batches of rTxln-1-microplasmin complex were produced, one of 500 µL
concentrated to 3 mg/mL and a second of 500 µL concentrated to 6 mg/mL. The
concentration of the complex was determined by measuring absorbance at 280 nm
using an İ280 of 45460 M-1cm-1 for the complex. The purity was analyzed by 15%
SDS-PAGE (Figure 2-17), and the inhibition of microplasmin were assayed with S-
2251 by monitoring realease of p-nitroaniline at 405 nm at 25oC.
Figure 2-17 Non reduced 15% SDS-PAGE of the
rTxln-1–microplasmin complex.
The gel was stained with Coomassie Brilliant Blue
R-250. Lane 1 Microplasminogen. Lane 2 rTxln-1.
Lane 3 the microplasmin rTxln-1 complex. Lane 4
Precision Plus Protein Standards (Bio-Rad).
2.7 Purification and characterization of native ACII-4
The purification and characterization of native ACII-4 from Australian King Brown,
Pseudechis australis, snake was carried out by Dr Paul P. Masci in three successive
chromatography steps. Pseudechis australis venom (1 g) (Venom supplies) was
loaded onto a heparin-Sepharose 6B column, 5.0 x 25.0 cm, equilibrated with 0.1 M
ammonium acetate pH 6.5 at 4oC. The anticoagulant activity bound to the column
and a peak identified as ACII was eluted by a salt gradient (0.0 – 0.5 M NaCl). The
ACII peak was loaded onto a CM-Sepharose CL-6B column, 5.0 cm x 10.0 cm,
equilibrated with 0.05 M ammonium acetate pH 6.5. Four peaks were eluted with an
increasing concentration again by a salt gradient (0.0 – 0.5 M NaCl). A peak
identified as ACII-4 (peak 4) which possessed potent anticoagulant activity was then
loaded onto a Sephacryl 100 column, 2.5 cm x 95.0 cm, equilibrated with 0.05 M
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amomonium acetate pH 6.4. The elution profile showed a single peak of
anticoagulant and phospholipase A2 activity. Phospholipase activity was measured
by adding ACII-4 to egg yolk substrate suspension (Fohlmann et al., 1977) except
that Triton X-100 was used instead of sodium deoxycholate (Tan and Tan, 1988).
The anticoagulant activity was established by measurement of prothrombin time
(Ware and Seegers, 1949) using a Hyland-Clotek machine, magnetic steel ball and
light time monitoring system at 37oC, both with and without added heparin. Heparin
enhanced the anticoagulant activity. The prothrombin time clotting assay measures
the time taken for a clot formation via the extrinsic pathway. The anticoagulant
activity of ACII-4 citrated plasma increased with increased Ca2+ concentration. The
addition of platelinſ (as a source of phospholipids) to the prothrombin clotting assay
diminished under reducing and non-reducing conditions the anticoagulant effect but
did not completely overcome it. SDS-PAGE with and without ȕ-mercaptoethanol
established molecular weights of 14 kDa and 28 kDa suggesting that ACII-4 is a
dimer. Electrospray mass spectrometry (ESI, Applied Biosystem) showed a peak at
13 kDa in agreement with a monomer but no sign of the dimer was observed (Masci,
2000).
Subsequently, Miss Hayley Snelling prepared another batch of ACII-4 following the
procedure of Dr Paul Masci. This batch was used both for sequence determination by
tandem mass spectrometry (ms/ms) of polypeptide fragments of ACII-4 from trypsin
digestion carried out by Dr Geoff Birrell, and crystallization experiments. The
analysis confirmed 72% of the amino acids as corresponding to the NCBI deposited
PA11 sequence (NCBI assession number P04056) (Figure 2-18).
Figure 2-18 Sequence of ACII-4 as determined by ms/ms or tryptic digestion alone.
Data underlined in red corresponds to ms/ms data. Data underlined in blue is tryptic
fragment of corresponding mass but with no sequence (ms/ms) data. (Picture generated by
Dr Geoff Birrell)
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2.8 Preparation of ACII-4 for crystallization experiments
2.8.1 Concentration of ACII-4
Pure ACII-4 from the venom of the Australian King Brown, Pseudechis australis,
snake was supplied by Miss Hayley Snelling at a concentration of ~0.8 mg/mL in
0.05 M ammonium acetate pH 6.5. The protein was concentrated to 2 mg/mL using
an Amicon stirred cell (Millipore) with a 1000 Mw cut off membrane (Millipore
Corporation, PLAC). This value was determined by UV spectroscopy using an A280
value of 21180 M-1 cm-1 (Gill and von Hippel, 1989).
2.9 Discussion
rTxln-1 is extremely stable, pure (> 95%), and soluble in 25 mM Tris–HCl pH 7.8,
up to 40 mg/mL, making it ideal for crystallization experiments. Complexes with
trypsin or microplasmin were confirmed to have been formed by SDS-PAGE and
measurement of activity. The complexes were highly pure, stable and soluble, and
therefore ideal candidates for structural investigations by X-ray crystallography.
However, it was of concern that the lyophilized trypsin showed some evidence of
previous formed degradation products on SDS-PAGE, possible due to the
lyophilization process or autolysis.
An interesting observation was that under the conditions of sedimentation analysis
rTxln-1 existed as a monomeric species, but under the conditions of mass
spectrometry, a significant amount of a dimeric species was present. rTxln-1 is a very
acidic molecule with a pI of 4.4, and mixed with matrix, which is acidic, makes it
energetically favorable to form a dimer as seen in the mass spectrum, or a reaction is
taking place in the ionization source. The self association into a dimer may therefore
be driven by an increasing negative charge in the surrounding solvent.
The faster than expected elution of rTxln-1 on the Superdex 75 column could be
caused by the formation of intermolecular disulfide bonds between rTxln-1
molecules with a change in weight and a change in the shape to a more elongated
protein that would elute faster than a small spherical shaped protein. It may have also
been caused by a possible tetramer formation of the rTxln-1 dimer observed in the
mass spectrum. The faster elution of the rTxln-1-trypsin complex could be caused by
a change of shape since a trypsin molecule has the dimension of roughly 30 x 45 x 35
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Å and rTxln-1 which is presumable comparable to aprotinin in structure with the
dimesion of roughly 35 x 20 x 15 Å together would create a heavier molecule than
trypsin alone and with a more elongated “mushroom” shape.
Further experimental analysis regarding the oligomeric state of rTxln-1 and the
association of rTxln-1 with trypsin could have been undertaken by dynamic light
scattering (DLS), electrospray ionization mass spectrometry (ESI), and nuclear
magnetic resonance (NMR) but given the high purity of samples it was decided to
proceed with crystallization trials.
ACII-4 was >95% pure as determined by SDS-PAGE and after concentration to 2
mg/mL was ready for crystallization experiments. Previous studies on ACII-4
showed that its anticoagulant and phospholipase activites were Ca2+ dependent, but
that the individual activities were not dependent on each other (Masci, 2000). The
observation suggests that the different activities are located in separate regions of the
molecule. The earlier studies also stated that the ACII-4 molecule was possibly a
dimer. Anticoagulant phospholipase A2 molecules have been reported to show a
correlation between stronger anticoagulation potency with higher-order oligomeric
forms and increasing positively charged surface (Lok et al., 2005). The self
association of ACII-4 into a dimer may also be an important factor for anticoagulant
activity of ACII-4.
2.10 Summary
The rTxln-1, its complexes with bovine trypsin and human microplasmin, and the
phospholipase A2 (ACII-4) were prepared for crystallization experiments. All
proteins were acquired as pure proteins, in high concentrations, and in large
quantities. The human microplasmin was produced as a recombinant protein. This
procedure included over-expression, purificaction, solubilization, and folding of the
stable zymogen precursor protein (microplasminogen) from E. coli inclusion bodies,
followed by post-refolding purification before activation with urokinase plasminogen
activator to the less stable but active protease. This was carried out prior to the
formation of a pure rTxln-1-microplasmin complex.
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Chapter 3
Crystallization of proteins
3.1 Introduction
The previous chapter described the processes involved in obtaining the proteins
required for this study. Txln-1 and plasmin were obtained using recombinant
technology, while the phospholipase was obtained from the native snake venom and
trypsin was supplied commercially. All of the proteins were extensively analysed to
ensure they were of high purity and maximal activity. Under those conditions the
best prospects for successful crystallization and structure determination are achieved.
This chapter describes growing the high-quality crystals necessary to allow data
collection from the X-ray diffraction experiment. To date, no prescriptive and
completely general method has been developed that will automatically lead to the
successful crystallization of a protein. To find the successful crystallization
conditions requires a trial and error approach where combinations of buffers, salts,
pH values, precipitating agents, temperatures and additives are all tried to initiate and
propagate crystal growth.
The first crystal structure of a protein was determined by John Kendrew and his
colleagues (Kendrew et al., 1958). This structure determination took around twenty-
five years to complete. Since that time there have been major advances in techniques
aimed at improving the prospects of obtaining highly diffracting protein crystals.
Perhaps the most important amongst these have been the molecular biology
revolution which has lead to the successful crystallization of many proteins that are
naturally produced only in minute quantities. The introduction of affinity tags at
either the amino or carboxy termini of the polypeptide has greatly enhanced our
ability to purify such proteins. Nowadays, companies such as Hampton and Emerald
supply crystallization kits based on the sparse screening matrices that were initially
developed by Jancarik and Kim in the early 1990s (Jancarik and Kim, 1991). In
previous eras researchers were required to make up their own buffers and
precipitating agents in ways that were often not highly reproducible. The purity and
sources of such reagents often lead to variability in the success rate of the
crystallization experiment. Advances in recording instrumentation of the diffraction
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data such as the use of synchrotron radiation and the use of imaging plate devices
and charge coupled detectors have meant that crystals of a greatly reduced size can
produce interpretable three dimensional structures. Today, crystals less than 0.05 mm
in all three dimensions can be used in structure determination studies.
Crystallization experiments start with a protein solution which can be concentrated
anywhere in the range from 1 mg/mL to as high as 200 mg/mL. This solution is then
combined and incubated with other solutions that can promote crystal growth of the
protein of interest. Traditionally the size of the solution for crystal formation is in the
range of 1 to 10 µL, but robotic pipetting devices now allow drop sizes as low as tens
of nanolitres. As described previously, there are many factors that can lead to the
successful crystallization of a protein. These include the pH of the solution the
protein concentration and whether or not ligands, substrates, inhibitors, cofactors,
metal ions or other additives are required. The choice of temperature is also another
major factor in the success of the crystallization experiment. At low temperatures
proteins are less susceptible to proteolytic cleavage but at high temperatures the
protein may be more soluble.
Once a drop containing the protein has been made it must be kept in an environment
such that the water can evaporate, concentrating the protein until it reaches a
supersaturated state. If the conditions are appropriate, crystal nucleation may then
take place. In some instances crystals may begin to appear within hours while others
can take several months or years to appear.
The most common method for obtaining protein crystals is by supersaturation using
the hanging drop vapor diffusion technique. In this technique the protein is
suspended on a coverslip above a well solution that contains an appropriate
crystallization solution. The hanging drop method was the approach I used for most
of my crystallization experiments.
For producing the first crystals of a newly purified protein the sparse matrix
screening method has been most widely adopted (Bergfors, 1999). The commercial
screening kits from Hampton and Sigma were used to obtain the initial crystals for
all of the proteins that I studied. Once initial crystals were obtained I set up focused
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grid screens to begin to optimize the growth conditions. The concentration of protein,
precipitant agent, buffer, pH, temperature or the incorporation of additives were all
tried as variables.
Data collection can be undertaken at room temperature with the crystal mounted in a
capillary. Alternatively, data can be collected at 100 K with the crystal mounted in a
nylon loop. At room temperature most protein crystals are highly susceptible to
damage through the production of free radicals upon exposure to X-rays. At
temperatures around 100 K the formation of free radicals is greatly reduced thus
minimizing the effects of radiation. To achieve maximum resolution for data
collection at 100 K it is necessary to find suitable conditions whereby a crystal can
be cryocooled and yet still maintain its integrity. It is also highly desirable that the
cryocooling solution freezes as a vitreous glass so as to prevent the formation of ice
crystals which would interfere with the X-ray diffraction image of the protein.
For more detailed description of the methods involved in protein crystallization and
X-ray data collection the reader is referred to Appendix C.
3.2 Methods and Materials
All chemicals used for crystallization were of analytical grade. The crystallization
plates, coverslips and individual reagents were purchased from Hampton Research.
Hampton Crystal Screens 1 and 2, and Sigma Crystallization Cryo Kit were used for
all of the proteins, except for ACII-4 where only the Hampton Screens were used.
Generally, each drop consisted of 1 µl of well solution and 1 µl of protein solution,
and the wells were filled with 200 µl crystallization solution, using VDX48 plates
from Hampton Research. X-rays were produced by a Rigaku FR-E Super Bright
generator operating at 45 kV and 45 mA, and the X-rays focused with confocal X-ray
optics Osmic mirrors. Images were recorded on a Rigaku R-Axis IV++ image plate
detector.
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3.3 Crystallization experiments with free recombinant
textilinin-1
Most of the screens for the crystallization trials were set up using the vapor diffusion
hanging drop technique. VDX48 trays from Hampton Research were used for most
of the experiments. Some sitting drops utilizing the 96 well Intelli-Plate from
Hampton Research were also set up. All of the experiments were undertaken at 17oC.
Successful crystallization conditions are shown in Table 3-1. Initial attempts to
crystallize free rTxln-1 at a concentration of 5 mg/mL were unsuccessful, with
virtually all of the experiments yielding clear solutions after several weeks of
incubation. Subsequent trials, increasing the protein concentration to 15 mg/mL were
also disappointing, with no crystals obtained after three months, and most (> 95%)
drops clear of precipitation. To further encourage supersaturation of the protein 200
mM NaCl was added to the well solutions but again this did not yield any crystals.
A survey of the literature showed that adding phenol to the crystallization media was
effective in promoting the crystallization of Į-dendrotoxin, (Skarzynski, 1992),
which is a Kunitz-type molecule isolated from the Green mamba, Dendroaspis
angusticeps, venom. Phenol was therefore added to both the drops and the wells such
that the final concentration was 100 and 200 mM respectively. Phase separation was
observed and ascribed to the presence of phenol. This phenomenon was believed to
be the reason for a localized concentration of the protein thereby leading to
supersaturation and crystallization of the sample. Precipitation was also observe and
recognized as the characteristic of phenol as a denaturing agent forcing the protein
concentration closer to supersaturation in some of the conditions. With this approach,
crystals began to appear in some of the drops. At about the same, crystals also begun
to appear in some of the initial experiments that were set up (in the absence of either
sodium chloride or phenol). These crystals took around six months to appear. These
initial crystals were tested for diffraction on the beam either by mounting them in
capillaries at room temperature or in nylon loops for irradiation at 100 K. However,
none of these crystals produced strong diffraction to enable high resolution data to be
obtained. All of the crystals mounted at room temperature were not stable enough to
collect any significant diffraction data while the crystals in the nylon loop did show
diffraction to ~5 Å.
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In attempts to further optimize the crystallization conditions (Table 3-1) hanging
drop experiments were set up with rTxln-1 concentrated to 15 mg/mL, using
Hampton Crystal Screen I and II and the Sigma CryoKit screen but 10% (v/v) 1,4-
butanediol was added to all drops. The theory behind the use of 1,4-butanediol is
that it can interpose itself between two protein molecules and mediate as a
crosslinker by forming electrostatic interactions and hydrogen bonds with its two
hydroxyl groups to neighboring protein molecules. Thereby the protein molecules
come closer to one another, stabilizing the crystal and promoting growth. In a
separate experiment, the concentration of rTxln-1 was increased to 40 mg/mL and
Hampton Crystal Screen I and II and the Sigma CryoKit were all surveyed. No
additives (i.e. sodium chloride, phenol or 1,4-butanediol) were included in these
screens. Both strategies grew large single crystals which produced X-rays that
diffracted to at least 2 Å resolution. The rate of crystallization also improved from
months to weeks.
Figure 3-1 Crystals of free rTxln-1.
These grow from condition (a) HCSI-9 with addition of 200 mM phenol to the drop and 200
mM NaCl to the well solution (size 0.25 x 0.5 x 0.5 mm) (b) HCSI-39 with addition to the
drop and 200 mM NaCl to the well solution (size 0.15 x 0.05 x 0.05 mm) and (c) HCSII-14
with the addition of 10% (v/v) butanediol to the drop (size 0.6 x 0.07 x 0.07 mm).
cb
a
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Table 3-1 Experimental conditions that led to the successful crystallization of rTxln-1.
Legend HD = hanging drop; SD = sitting drop; SCK = Sigma cryo kit; HCSI = Hampton
crystal screen 1; HCSII = Hampton crystal screen II; ND = not determined
[Protein]
(mg/mL)
Screen
solution
Buffer, salt,
ppt agent
Comments Resolution
15 SCK-13 0.1 M Tris-HCl
pH 8.5
0.2 M Na-citrate
30% (v/v) PEG 400
200 mM phenol
HD. 200 mM NaCl
added to the well.
Crystals grew after three
weeks.
2.9 Å.
15 SCK-13 0.1 M Tris-HCl
pH 8.5
0.2 M Na-citrate
30% (v/v) PEG 400
HD. Crystals grew after
six months
ND, did not
collect a data
set.
15 HCSI-9 0.1 M tri-sodium citrate
dihydrate pH 5.6
0.2 M ammonium acetate
30% (w/v) PEG 4000
200 mM phenol
SD. 200 mM NaCl in
the well solution.
Crystals grew within a
month.
~5 Å.
See
Figure 3-1(a).
15 HCSI -9 0.1 M tri-sodium citrate
dihydrate pH 5.6
0.2 M ammonium
acetate
30% (w/v) PEG 4000
HD. Crystals grew after
six months.
ND, did not
collect a data
set.
15 HCSI-39 0.1 M HEPES Na pH 7.5
2% (v/v) PEG 400
2.0 M ammonium sulfate
200 mM phenol
SD. 200 mM NaCl
added to well.
Crystals grew within a
month.
~5 Å.
See
Figure 3-1(b).
15 HCSI-39 0.1 M HEPES Na pH 7.5
2% (v/v) PEG 400
2.0 M ammonium sulfate
SD. Crystals grew
within six months.
1.63 Å.
15 HCSII-13 0.1 M sodium acetate
trihydrate pH 4.6
0.2 M ammonium sulfate
30% (w/v) PEG
monomethyl ether 2000
200 mM phenol
SD 200 mM NaCl
added to the well.
Crystals grew within a
month.
~5 Å.
15 HCSII-13 0.1 M sodium acetate
trihydrate pH 4.6
0.2 M ammonium sulfate
30% (w/v) PEG
monomethyl ether 2000
HD. Crystals grew after
six months.
ND, did not
collect a data
set.
15 HCSII-14 0.1 M tri-sodium citrate
dihydrate pH 5.6
0.2 M potassium sodium
tartrate tetrahydrate
2.0 M ammonium sulfate
HD. Crystals grew after
four months.
Dissolved in
cryoloop
15 HCSII-14 0.1 M tri-sodium citrate
dihydrate pH 5.6
0.2 M potassium sodium
tartrate tetrahydrate
2.0 M ammonium
sulfate
10% (v/v) 1,4 -
butanediol
HD. Crystals grew
within a month.
ND, did not
collect a data
set. See
Figure 3-1(c).
15 HCSII-32 0.1 M HEPES Na pH 7.5
0.1 sodium chloride
1.6 ammonium sulfate
HD. Crystals grew after
four months.
2.7 Å.
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3.3.1 Cryoprotection of free rTxln-1 crystals
Crystals grown from Hampton Crystal Screen II condition 14 were soaked in
cryoprotectant made up of 70% (v/v) well solution, and 30% (v/v) glycerol, but
dissolved when mounted in nylon loops. Four conditions that produced free rTxln-1
crystals contained sufficient PEG 400, PEG 4000 or PEG monomethyl ether 2000 to
act as cryoprotectant. Therefore these crystals were directly transferred from the drop
inside a cryoloop to the cryostream. However, the best diffraction data were obtained
from a crystal that was from a drop that was incubated for six months in Hampton
Crystal Screen I condition 39. The results of the data processing for this crystal are
described in the next section. One condition, Hampton Crystal Screen II condition
14, grew crystals that produce good diffraction without the need to add
cryoprotectant.
3.3.2 Data collection and processing of free rTxln-1 crystals
X-ray data were collected using the oscillation method. All of the images had an
oscillation width of 0.5° and an exposure time of 240 s (Figure 3-2). The crystal to
detector distance was 100 mm. Data were integrated, scaled and merged with
HKL2000 (Otwinowski and Minor, 1997). The data collection statistics are presented
in Table 3-2.
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Figure 3-2 Diffraction pattern for rTxln-1.
A 0.5° oscillation image of a cryocooled crystal of rTxln-1. Diffraction data were observed
to 1.63 Å. The zoomed square is centered on the 1.76 Å resolution ring.
3.3.3 Space group determination of free rTxln-1 crystals
Crystals of free rTxln-1 belong to the space-group I422 with unit cell parameters of
a = b = 99.9 Å, c = 77.5 Å, D = E = J = 90o. The number of protein molecules per
asymmetric unit can be estimated according to the Matthews coefficient, VM
(Matthews, 1968) and the solvent content. If two molecules of rTxln-1 are present in
the asymmetric unit, the solvent content is calculated to be 65%, with a
corresponding VM = 3.5 Å3 Da-1. If three rTxln-1 molecules are present in the
asymmetric unit solvent content is 49% and VM = 2.42 Å3 Da-1. These values are
within the normally expected range for both solvent content and Matthews
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coefficient, thus based on this argument alone it is impossible to unambiguously
assign two or three molecules of rTxln-1 to the asymmetric unit.
Table 3-2 Crystal parameters and data collection statistics for free rTxln-1
Protein rTxln-1
Crystal Parameters:
Unit cell lengths (Å) a = b = 99.92 c = 77.71
Unit cell angles (o) Į = 90.0 ȕ = 90.0 Ȗ = 90.0
Unit cell volume (Å3) 775,841
Space group I422
Crystal dimensions (mm) 0.5 x 0.05 x 0.05
Mosaicity (o) 0.572
Diffraction Data:
Wavelength (Å) 1.54178
Temperature (K) 100
Resolution range (Å) 50.00 – 1.63
No of observations 224,218
No of unique reflections 24,804
Data completeness (%) 99.6 (98.8)
Rmerge 0.075 (0.360)
<I /ı(I)> 16.9 (7.2)
Values in brackets refer to the highest resolution shell (1.69 – 1.63 Å).
Rmerge = hkl i |Ii - <I>| / hkli | Ii | where Ii is the intensity of the ith measurement
of reflection hkl and <I> is the average value over multiple measurements. <I/ı(I)>
is the intensity to noise ratio, where I is intensity and ı(I) is the standard deviation of
the measurements.
3.4 Crystallization experiments with recombinant
textilinin-1-trypsin
Crystallization trials on the rTxln-1-trypsin complex were carried out at 4oC or 17oC
in VDX48 trays by the hanging drop method using a protein concentration of 10
mg/mL. Successful crystallization conditions are shown in Table 3-3. The first
crystals that were obtained grew from Hampton Crystal Screen I condition 38 as
small thin rods attached to precipitate. Subsequent crystals grew in condition
Hampton Crystal Screen I condition 39 as bundles of rods or needles, also with a rod
like morphology, from a clear solution. A grid screen (Bergfors, 1999) was carried
out for Hampton Crystal Screen I condition 27 but failed to produce better crystals.
Temperature was an important factor for Hampton Crystal Screen I condition 38.
Changing from 17oC to 4oC resulted in obtaining larger crystals and improved
resolution of data.
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Table 3-3 Experimental conditions that led to the successful crystallization of the
rTxln-1-trypsin complex.
HCSI = Hampton crystal screen 1
Screen
solution
Buffer, salt,
ppt agent
Comments Resolution
HCSI- 38 0.1 M HEPES-Na
pH 7.5
1.4 M tri-sodium
citrate dehydrate
Crystal formed
on the side of
precipitation at
17oC,
Crystals grew in
clusters as
needles 4oC.
See
Figure 3-3 (a).
Crystals grown at 17oC
Diffracted to 2.5 Å
Crystals grown at 4oC
diffracted to 1.63 Å.
HCSI- 27 0.1 M HEPES-Na
pH 7.5
0.2 M tri-sodium
citrate dihydrate
20% (v/v) iso-
propanol
Grown at 17oC.
Crystals grew in
clusters as
needles. See
Figure 3-3 (b)
Diffracted to 2.0 Å.
HCSI-39 0.1 M HEPES-Na
pH 7.5
2% (v/v) PEG 400
2.0 M ammonium
sulfate
Grown at 17oC.
Crystals grew in
clusters as rods.
See
Figure 3-3(c)
Diffracted to 2.3 Å.
Figure 3-3 Crystals of the rTxln-1-trypsin complex.
These grew from condition (a) HCSI-38 (size 0.4 x 0.04 x 0.04 mm), (b) HCSI-27 (size 0.2 x
0.02 x 0.02 mm) and (c) HCSI-39 (size 0.3 x 0.03 x 0.03 mm).
3.4.1 Cryoprotection of the rTxln-1-trypsin crystals
All crystals of the trypsin-rTxln-1 complex were transferred from their growth drop
to a new drop containing 70% (v/v) well solution and 30% (v/v) glycerol. The
crystals were then soaked for 5 min in this solution before being transferred to the
cryostream.
b ca
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3.4.2 Data collection for the best rTxln-1-trypsin crystals
For data collection, oscillation images of 0.5o with exposure times of 360 seconds
were obtained. A representative image of the data is shown in Figure 3-4. The crystal
to detector distance was 100 mm for all the images allowing a complete data set to a
1.63 Å resolution to be measured. All of the data were processed with the program
HKL2000 (Otwinowski and Minor, 1997). The data collection statistics are presented
in Table 3-4.
Figure 3-4 Diffraction pattern for rTxln-1-trypsin complex.
A 0.5° oscillation image of a cryocooled crystal of the rTxln-1-trypsin complex. Diffraction
data were observed to 1.63 Å.
3.4.3 Space group determination of the rTxln-1-trypsin complex
crystals
All of the crystals examined belonged to space group P3121, and had similar unit-cell
parameters, a = b = 79.8 Å, c = 107.4 Å, Į = ȕ = 90o, Ȗ = 120o. Based on solvent
content and Matthews coefficient arguments it is most likely that there is one
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complex in the asymmetric unit. For one complex, the solvent content would be 59%
and VM = 3.0 Å3 Da-1.
Table 3-4 Crystal parameters and data collection statistics for the rTxln-1-trypsin complex.
Protein rTxln-1–trypsin complex
Crystal Parameters:
Unit cell lengths (Å) a = 79.84 b = 79.84 c = 107.39
Unit cell angles (o) Į = 90.0 ȕ = 90.0 Ȗ = 120.0
Unit cell volume (Å3) 592,841
Space group P3121
Crystal dimensions (mm) 0.4 x 0.04 x 0.04
Mosaicity (o) 0.432
Diffraction Data:
Wavelength (Å) 1.54
Temperature (K) 100
Resolution range (Å) 50.00 – 1.63
No of observations 192,531
No of unique reflections 49,994
Data completeness (%) 97.1 (90.7)
Rmerge 0.055 (0.494)
<I /ı(I)> 22.2 (11.47)
Values in brackets refer to the highest resolution shell (1.69 – 1.63 Å).
Rmerge = hkl i |Ii - <I>| / hkli | Ii | where Ii is the intensity of the ith measurement
of reflection hkl and <I> is the average value over multiple measurements.
<I /ı(I)> is the intensity to noise ratio, where I is intensity and ı(I) is the standard
deviation of the measurement deviations.
3.5 Crystallization experiments for the recombinant
textilinin-1- microplasmin complex
Two batches of purified complex were produced for crystallization trials, one at 3
mg/mL, the other at 6 mg/mL. Crystallization trials were set up using the hanging
drop technique employing VDX48 trays from Hampton, at 17oC. For a summary of
the successful crystallization conditions see Table 3-5. Initial crystals grew from the
3 mg/mL protein batch and had a feather like morphology. A grid screen was carried
out around this condition, but without any success. However this exhausted all of the
material for further crystallization trials. For the next batch of experiments the
complex was concentrated to 6 mg/mL and another round of crystallizaton screening
trials was attempted. New crystals were obtained that had the same shape, but were
larger, easier to handle and diffracted to higher resolution. From one of these crystals
a data set to 2.8 Å resolution was obtained. It was not necessary to soak the crystals
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in cryosolution since they already had enough PEG 8000 or glycerol to act as
cryoprotectant.
Table 3-5 Experimental conditions that led to the successful crystallization of the
rTxln-1-microplasmin complex.
SCK = Sigma cryo kit; HCSI = Hampton crystal screen 1
[Protein]
(mg/mL)
Screen
solution
Buffer, salt, ppt
agent
Resolution
3 mg/mL HCSI - 28 0.1 M sodium
cacodylate pH 6.5
0.2 M sodium
actetate trihydrate
30% (w/v) PEG
8000
X-ray data
measured to 3 Å,
but crystal twinned
6 mg/mL SCK- 31 0.17 M ammonium
sulfate
25.5% (v/v) PEG
4000 15% (v/v)
glycerol
2.8 Å data were
collected
3.5.1 Data collection and processing of the rTxln-1-
microplasmin crystals
For data collection, oscillation images of 0.5o with exposure times of 180 seconds
were obtained (Figure 3-5). The crystal to detector distance was 150 mm. The data
set to 2.8 Å resolution was integrated, scaled and merged with the program
CrystalClear 1.3.6 (Pflugrath, 1999). The data collection statistics are presented in
Table 3-6. The complex crystallized in the space group P21 with unit cell parameters
a = 81.9 Å, b = 48.0 Å, c = 82.6 Å, Į = 90o, ȕ = 102.1o, Ȗ = 90o. Based on the
assumption of two molecules per asymmetric unit, the solvent content and Matthews
number were 48% and VM = 2.35 Å3 Da-1 respectively.
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Figure 3-5 Diffraction pattern for rTxln-1-microplasmin complex.
A 0.5° oscillation image of a cryocooled crystal of the rTxln-1-microplasmin complex.
Diffraction data were measured to 2.8 Å.
Table 3-6 Crystal parameters and data collection statistics for the microplasmin-rTxln-1
complex.
Protein Human microplasmin-rTxln-1 complex
Crystal Parameters:
Unit cell lengths (Å) a = 81.40 b = 48.52 c = 82.63
Unit cell angles (o) Į = 90.0 ȕ = 102.1 Ȗ = 90.0
Unit cell volume (Å3) 319,115
Space group P21
Crystal dimensions (mm) 0.4 x 0.02 x 0.01
Mosaicity (o) 0.754
Diffraction Data:
Wavelength (Å) 1.541
Temperature (K) 100
Resolution range (Å) 41.60 – 2.78
No of observations 53,569
No of unique reflections 15,858
Data completeness (%) 99.8 (99.3)
Rmerge 0.117 (0.284)
<I /ı(I)> 7.9 (3.6)
Values in brackets refer to highest resolution shell (2.90 – 2.80 Å).
Rmerge = hkl i |Ii - <I>| / hkli | Ii | where Ii is the intensity of the ith measurement
of reflection hkl and <I> is the average value over multiple measurements.<I /ı(I)>
is the intensity to noise ratio, where I is intensity and ı(I) is the standard deviation of
the measurement deviations.
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3.6 Crystallization experiments with ACII-4
Crystallization trials were carried out by vapor diffusion using hanging drops in
VDX48 trays from Hampton incubated at 17oC with a protein concentration of 2
mg/mL. ACII-4 crystals had a trigonal morphology. The best crystallization
condition was Hampton Crystal Screen I condition 17 which consisted of 0.2 M
lithium sulfate monohydrate 0.1 M Tris-HCl pH 8.5 and 30% (w/v) PEG 4000. The
crystals grew as clusters which could be separated from each other by applying
pressure with a needle. The 30% (w/v) PEG 4000 in the crystallization buffer was
sufficient to act as a cryoprotectant.
Figure 3-6 An ACII-4 crystal cluster grown from Hampton
crystal screen I condition 17
The largest crystal is 0.2 x 0.05 x 0.05 mm.
3.6.1 Data collection of ACII-4 crystals
For data collection, oscillation images were 0.5o with exposure times of 180 s (Figure
3-7). The crystal to detector distance was 90 mm. Data was collected to 1.56 Å
resolution and was integrated, scaled and merged with the program HKL2000
(Otwinowski and Minor, 1997). The data collection statistics are presented in Table
3-7. The data successfully processed in the space group P31 with unit cell parameters
of a = b = 82.38 Å, c = 28.90 Å, Į = 90°, ȕ = 90°, Ȗ = 120°. Based on the assumption
of two molecules per asymmetric unit, the solvent content of the crystals was
calculated to be 43%, with a corresponding Matthews coefficient of VM = 2.17 Å3
Da-1 (Matthews, 1968).
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Figure 3-7 Diffraction pattern for ACII-4.
A 0.5° oscillation image of a cryocooled crystal of ACII-4. Diffraction data were observed to
1.56 Å.
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Table 3-7 Crystal parameters and data collection statistics for ACII-4.
Protein ACII-4
Crystal Parameters:
Unit cell lengths (Å) a = 82.38 b = 82.38 c = 28.90
Unit cell angles (o) Į = 90.0 ȕ = 90.0 Ȗ = 120.0
Unit cell volume (Å3) 169,847
Space group P31
Crystal dimensions (mm) 0.2 x 0.05 x 0.05
Mosaicity (o) 0.347
No of molecules in asymmetric unit 2
Diffraction Data:
Wavelength (Å) 1.54178
Temperature (K) 100
Resolution range (Å) 50.00 – 1.56
No of observations 101,238
No of unique reflections 31,296
Data completeness (%) 96.2 (88.9)
Rmerge 0.043 (0.183)
<I /ı(I)> 23.4 (8.4)
Values in brackets refer to the highest resolution shell (1.62 – 1.56 Å).
Rmerge = hkl i |Ii - <I>| / hkli | Ii | where Ii is the intensity of the ith measurement
of reflection hkl and <I> is the average value over multiple measurements.<I /ı(I)>
is the intensity to noise ratio, where I is intensity and ı(I) is the standard deviation of
the measurement deviations.
3.7 Discussion
Diffraction quality crystals were obtained for rTxln-1, its complexes with bovine
trypsin and human microplasmin, and for ACII-4. The most challenging crystals to
obtain were those of free rTxln-1. Determination of appropriate conditions for
crystallization of free rTxln-1 free structure was first pursued by using a low protein
concentration (i.e. ~5 mg/mL) and no additives. With an increase of protein
concentration to ~15 mg/mL small, delicate crystals that showed weak or low
resolution data could be obtained. Once the protein concentration was raised to 40
mg/mL or upon the addition of organic solvents phenol and 1,4 butanediol high
quality crystals of free rTxln-1 could be obtained. The addition of phenol to the
crystallization trials of free rTxln-1 was employed because it had been shown
previously to aid in the crystallization of another small multiply disulfide bonded
venom peptide, Į-dendrotoxin (Skarzynski, 1992; Chayen, 1998). Phenol was also
previously successful as an additive for crystallization of both porcine and human
insulin (Ciszak et al., 1995; Whittingham et al., 1995). The phase separation upon
addition of phenol caused the protein to concentrate leading to supersaturation and
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subsequently result in crystal growth. Phenol also acts as a denaturating agent forcing
the protein concentration closer to supersaturation in some of the conditions, leading
to precipitation of the protein. Crystal growth from this precipitation also occurred. It
is hypothesized that 1,4–butandiol may help create and stabilize protein crystals by
interposing themselves between proteins and form intermolecular crosslinks through
non-covalent bonds between 1,4-butanediol two hydroxyl groups and two proteins.
These crossbridges may involve both electrostatic interactions and hydrogen bonding
arrangements (McPherson, 1999; McPherson and Cudney, 2006). The pH of the
condition that grew crystals of free rTxln-1 ranged from 5.6 to 8.5. All of the crystals
that were X-rayed had the same space group and unit cell parameters suggesting that
all contained the interlocking of the individual molecules in a specific organization
which is highly favored across a range of pH values and ionic strengths.
The best crystals obtained for the rTxln-1-trypsin were obtained at 4 °C, this is not
surprising given the protease is likely to be subjected to more degradation at higher
temperatures. It was somewhat alarming to find that the trypsin purchased from
Sigma contained a significant amount of degraded enzyme, but for the most part
these impurities did not impede the crystallization process. Perhaps, if these
impurites could have been removed then better quality crystals could have been
obtained.
The preparation of the rTxln-1-microplasmin complex was technically challenging in
that enzyme had to be activated by urokinase plasminogen activator but at the same
time be inhibited by rTxln-1 so as to prevent autolysis. Fortunately, crystals of the
complex appeared within a few days of setting up the crystallization experiments and
these crystals were able to diffract sufficiently to obtain a 2.8 Å resolution data set.
The crystallization of ACII-4 did not pose any major technical difficulties. Purified
native protein at concentration of 2 mg/mL and the use of Hampton Crystal Screen
were the only requirements to produce high quality crystals of this venom
component.
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3.8 Summary
Free rTxln-1, and its complexes with bovine trypsin and human microplasmin, as
well as the phospholipase, ACII-4 were all crystallized. A range of different
techniques were used to promote crystallization including the hanging drop and
sitting drop methods. Screening of suitable crystallization conditions was by the
incomplete factorial approach. Once a suitable concentration of protein was found,
conditions leading to crystal growth could be obtained using the commercial kits. In
some instances optimization of the conditions resulted in improved X-ray data.
Sometimes a major bottleneck in the structure determination of the proteins by X-ray
crystallography is to find a suitable cryoprotection protocol. There were some initial
difficulties in finding such a protocol for the free rTxln-1 crystals but once larger
crystals were obtained there was no significant problem. Crystals of the rTxln-1-
trypsin complex could easily be transferred to cryosolution before being flash cooled,
while the rTxln-1-microplasmin complex and the phospholipase grew in condition
with enough cryoprotectant. Complete data sets were collected to 1.63 Å, 1.63 Å, 2.8
Å, and 1.56 Å resolution for the rTxln-1, rTxln-1-trypsin complex, rTxln-1-
microplasmin complex, and ACII-4 respectively.
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Chapter 4
Crystal structure of free recombinant textilinin-1
4.1 Introduction
rTxln-1 is a trypsin and plasmin inhibitor, consisting of a single polypeptide chain of
59 amino acid residues with a molecular weight of 6.8 kDa. The amino acid
sequence of rTxln-1 suggests it has an aprotinin-like fold. A search for similar
sequences to rTxln-1 in the Protein Data Bank using the ‘Basic Local Alignment
Search Tool’ (BLAST) (Schäffer et al., 2001) shows the highest identity, 57%, with
a chymotrypsin inhibitor from the Banded krait (Bungarus fasciatus) and 45%
sequence identity to aprotinin. Six cysteine residues forming three disulfide bonds
are in conserved locations in these molecules. Their shape is of an elongated
ellipsoid and contains two antiparallel ȕ-strands with connecting loops and two
helices (one N-terminal and one C-terminal).
The aprotinin-like fold is found to exist as an independent, single domain, e.g.
aprotinin. There are also proteins that consist of multiple aprotinin-like domains. For
example bikuninin found in human blood serum and urine (Y. Xu et al., 1998) and
ornithodorin isolated from the blood sucking soft tick Ornithodoros moubata (van de
Locht et al., 1996) contain two such domains, while the tissue factor pathway
inhibitor contains three such domains (Burgering et al., 1997; Mine et al., 2002).
Aprotinin-like domains are also found within larger structures where they are
covalently linked to another protein e.g. human type VII and Type VI (D 3 chain)
collagens, which contain an aprotinin-like inhibitor domain at their C-termini
(Zweckstetter et al., 1996; Krowarsch et al., 2003). The ȕ1-bungarotoxin from Indian
Common krait, Bungarus caeruleus (Sharma et al., 1999) and ȕ2-bungarotoxin from
Taiwanese Banded krait, Bungarus multicinctus (Kwong et al., 1995) consist of an
aprotinin-like domain linked by a disulfide bond to a phospholipase A2 domain.
Many proteins with an aprotinin-like fold are serine proteinase inhibitors. Their
protruding protease inhibitory loop is referred to as the canonical loop and is
associated with a canonical substrate-like inhibition. The canonical loop features a
residue which projects into the specificity pocket of serine proteases. This residue is
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a crucial determinant of the specificity for different serine proteases. Many important
physiological and pathological processes are under the control of serine proteinases
such as blood coagulation, fibrinolysis, the kinin-kallikrein system, the complement
system, and fertilization. Their regulation by protease inhibitors could lead to the
establishment of new methods to treat diseases associated with these processes (Daci
et al., 1999; Busuttil et al., 2004; Chun et al., 2004).
Snake venoms are a rich source of molecules that have an aprotinin-like fold (M. J.
Laskowski and Kato, 1980). For example, Į-dendrotoxin (Skarzynski, 1992) and
calcicludine (Gilquin et al., 1999) from green mamba, Dendroaspis angusticeps,
dendrotoxin I (Lancelin et al., 1994) and dendrotoxin K (Berndt et al., 1993) from
Black mamba, Dendroaspis polylepis polylepis, ȕ1-bungarotoxin and ȕ2-
bungarotoxin. Many of these molecules act as protease inhibitors but also exhibit
targeting capabilities seemingly unrelated to this function (Dufton, 1985; Pritchard
and Dufton, 1999). For example, dendrotoxin K is a K+ channel blocker (Smith et al.,
1997) and calcicludine is a Ca2+ channel blocker (Schweitz et al., 1994).
Six textilinin molecules have been identified from the Australian Common Brown
snake, Pseudonaja textilis. All have a similar size and the six cysteine residues are in
conserved locations (Figure 1-8). Thus all are predicted to have an aprotinin-like
fold. However, based on their sequence differences particularly in the canonical loop
they are likely to have different functionalities and specificities. Thus there appears
to be broad potential for these molecules as drug candidates for a range of
pathological processes.
rTxln-1 and aprotinin are both trypsin and plasmin inhibitors but they have very
different sequences in their canonical loops. In rTxln-1, the sequence in the canonical
loop is Pro-Cys-Arg-Val-Arg-Phe, while in aprotinin it is Pro-Cys-Lys-Ala-Ile.
Furthermore, their overall sequences differ to such an extent that their pI values are
4.4 and 8.9 for rTxln-1 and aprotinin, respectively (Masci et al., 2000). Therefore, it
can be expected that the exposed surface of these two molecules and hence their
activities are very different even though their overall folds are conserved.
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This chapter describes the steps used to solve the structure the rTxln-1, and compares
the structure of this molecule with aprotinin and other aprotinin-like molecules.
Finally, I speculate about the structure and functions of the other five textilinins from
the Australian Common Brown snake, Pseudonaja textilis.
4.2 Introduction to solving the phase problem of the
rTxln-1 crystal
Chapter 3 described the experimental procedures and step required to produce X-ray
quality crystals of rTxln-1. That chapter then went onto describe the preliminary X-
ray analysis of the crystal and the results of the complete data collection. A data set
to 1.63 Å resolution was obtained and the crystals belonged to the space group I422.
The electron density is the Fourier transform of the structure factors, which contain
both the amplitudes and the phase angles of the diffracted rays (for a mathematical
description see Appendix D). To determine the electron density it is necessary to
measure the intensity of the reflections, which are proportional to the square of the
amplitude of the structure factors. However, the phase angle for each diffracted ray
can not be measured directly. The lack of phase information is commonly called the
“phase problem”. Different methods have been developed to solve the phase
problem, including multiple isomorphous replacement (MIR), multiple anomalous
scattering or multiple anomalous dispersion (MAD), and molecular replacement
(MR). The processed data in Chapter 3 was used in molecular replacement to find the
phases so that complete structure factors could be obtained.
Molecular replacement is a method which relies on the existence of a previously
solved protein structure homologous to the unknown structure from which the
diffraction data is derived. The crystal structure of the rTxln-1-trypsin complex
(Chapter 5) was solved prior to the structure of the free rTxln-1, therefore this
molecule could be used as the probe molecule in MR studies. The MR method
encompasses calculations to determine the orientation and position of the molecule in
the unit cell. In general, these calculations are carried out in two steps consisting of
one rotational search and one translational search. If successful, a preliminary model
will be obtained by correctly orienting and positioning the homologous structure.
This solution can then be further optimized by rigid body refinement. Finally, the
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model goes through cycles of refinement and model building to reduce bias
introduced by the starting model.
In obtaining a solution to the phase problem two factors can be critical; the search
model should not deviate significantly from the unknown structure, and the dataset
needs to be highly complete to at least ~3 Å resolution. For a detailed description of
the methods see Appendix D and E.
4.3 Phase determination of free rTxln-1
Several attempts were made to determine the structure of free rTxln-1 using the
molecular replacement program EPMR (Kissinger et al., 1999) (see Appendix E.3).
The intensities measured were converted to structure factors using TRUNCATE
(French and Wilson, 1978). CAD (CCP4, 1994) sorted the data and put it into the
correct asymmetric unit and MTZ2VARIOUS (Dodson, 1992) produced a file for
EPMR and for refinement calculations. The initial studies were based on the
hypothesis that there were two molecules of rTxln-1 in the asymmetric unit. These
results gave a plausible packing arrangement, but the refinement stalled with an Rfree
value of 0.48. Since this result appeared to not be correct the program Phaser
(McCoy et al., 2005) (see Appendix E.4 for Phaser and maximum-likelihood
method) within CCP4 (CCP4, 1994) was next tried for molecular replacement
studies. In Phaser, data between 22.41 Å and 2.5 Å resolution was used for all
calculations and the search model was the rTxnl-1 that was determined when bound
to trypsin (Chapter 5).
In keeping with the EPMR studies, a search for two molecules of rTxln-1 in the
asymmetric unit was attempted but subsequently a search for three molecules in the
asymmetric unit was also undertaken. For selection of solutions Phaser uses the Z-
score and the Log-Likelihood Gain (LLG) score. The Z-score is the number of
standard deviations above the mean value of the maximum-likelihood function. After
a fast translation function, this should generally be > 5 as an indication that the fitting
of a molecule is correct. The LLG score is the difference between the log-likelihood
score of a molecular replacement trial and the log-likelihood calculations for a
Wilson distribution, and it indicates how much better the data can be predicted from
the model than with a random distribution of the same atoms (Storoni et al., 2004).
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The search for three molecules in the asymmetric unit gave four peaks in the fast
rotation function with values greater than 75% of the top peak. The top solution
showed an LLG score of 22 and a Z-score of 5. All four peaks were passed to the fast
translation function and the top solution had an LLG score of 114 and a Z-score of
14. The crystal packing was checked and no clashes were observed. This solution
was then refined with Phaser which improved the LLG to 131 (Table 4-1).
Table 4-1 Molecular replacement solution: orientation of a single molecule
Euler angles (o) Fractional coordinates LLG
54.9 83.4 154.3 0.767 -0.464 -0.058 131
In the next stage, the first molecule was fixed, and a search was conducted to find the
second molecule. Three peaks were obtained in the fast rotation function. The top
solution had a LLG score of 152 and a Z-score of 5. These three peaks were then
passed to the fast translation function with the top solution showing an LLG score of
338 and a Z-score of 19. The packing of this solution showed no clashes and
refinement improved the LLG to 390 (Table 4-2).
Table 4-2 Molecular replacement solution: orientations of two molecules
Euler angles (o) Fractional coordinates LLG
34.9 96.8 333.7 -0.464 0.768 0.051 390
350.0 115.6 241.7 -0.427 0.546 -0.400
The fast rotation function was run again to search for a third molecule. Four peaks
were found. The top solution showed a LLG score of 411 and a Z-score of 6. These
four peaks were passed to the fast translation function with the top solution showed
an increased LLG score of 764 and a Z- score of 23, with no clashes in the packing.
The final refinement of this solution gave a LLG of 1311 (Table 4-3).
Table 4-3 Molecular replacement solution: orientations of three molecules
Euler angles (o) Fractional coordinates LLG
34.4 97.0 333.3 -0.460 0.770 0.047 1311
277.1 151.1 165.1 -0.795 0.560 -0.399
9.2 64.1 62.8 -0.429 0.446 0.397
Examination of the crystal packing indicated reasonable contacts between the three
molecules and no overlap of symmetry related molecules (Figure 4-1).
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Figure 4-1 The
crystal packing of
rTxln-1.
The three rTxln-1
molecules in the
asymmetric unit are
colored green, blue
and purple. The unit
cell is shown in black
with the a and b axis
marked in red.
4.4 Initial model building of the rTxln-1 crystal structure
The results from Phaser were used in the software suite ARP/wARP (Morris et al.,
2003) (see Appendix E.5) to build the initial model of rTxln-1. This set of programs
fit the sequence of rTxln-1 into the electron density. For selection of solutions the
value of the connectivity index should increase if the tracing is successful. The
connectivity index indicates the progress of the number of consecutive residues in
the sequence traced in the electron density. A value below 0.6 is considered not very
promising, a value around 0.8 indicates good progress, while a value above 0.95
indicates an essentially complete tracing. Fragments of five residues or shorter are
converted back to free atoms. The sequence coverage is reported which is defined as
the ratio between the number of docked residues and the total number of traced
residues. A value higher than 0.8 is judged as being good sequence coverage. The
first building cycle showed 159 residues in five chains, with the longest chain
comprising 54 residues, and a connectivity index of 0.94. After the last building
cycle 169 residues in three chains were obtained. These had a connectivity index of
0.94 and a sequence coverage of 99%.
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4.5 Refinement of model of free rTxln-1
The model determined by ARP/wARP was refined with REFMAC5 (Murshudov et
al., 1997) (see Appendix E.7) by maximum likelihood. Restrained refinement was
undertaken with no prior phase information. Data used in refinement ranged from
22.41–1.63 Å, with 5.1% of reflections used for the Rfree test set (1259 reflections).
All atoms were refined with individual isotropic B-factors. Arp_water (Lamzin and
Wilson, 1993) was used to place the water molecules. Model building between the
cycles of refinement was undertaken with the program Coot (Emsley and Cowtan,
2004) (see Appendix E.6).
4.6 Refinement statistics and quality of free rTxln-1
structure
There are three rTxln-1 molecules in the asymmetric unit. The electron density map
is, in general, well defined and the majority of the amino acid residues could be fitted
into the electron density (Figure 4-2). In the final model, residues 1–58 for molecule
A, residues 2–59 for molecule B, and residues 1–58 for molecule C, one sulfate ion,
two PEG molecules, and 240 water molecules could be fitted. The final Rfactor and
Rfree are 0.191 and 0.218, respectively. A difference between the two values of only
0.027 is an indication that the model has not been over refined. The final model has
excellent geometry with an rmsd from ideal bond lengths of 0.01 Å, and an rmsd
from ideal bond angles of 1.24o (Table 4-4).
Figure 4-2 Stereoview of the 2Fo-Fc electron density map contoured at 1ı for residues 16-
20 and residue 40 of molecule A of rTxln-1.
The electron density map is displayed as a light grey mesh. Carbon, nitrogen and oxygen are
colored green, blue and red respectively.
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Table 4-4 Refinement statistics for rTxln-1
Non-hydrogen atoms
Molecule A 462
Molecule B 457
Molecule C 462
Total number of protein atoms 1381
Solvent (H2O) 240
Solvent (SO4) 5
Solvent (PEG) 12
Resolution (Å) 22.41 – 1.63
Rfactor 0.191
Rfree 0.218
rmsd from ideal geometry
Bond lengths (Å) 0.010
Bond angles (o) 1.24
Rfactor = ||Fobs| – |Fcalc||/|Fobs|, 5.1% of the data were excluded from the refinement
to calculate Rfree.
Thermal parameters (B-values) reflect to a first approximation positional variation of
atoms over time. The B-value is a consequence of the dynamic disorder in the crystal
caused by the temperature-dependent vibration of the atoms in the structure. High
B-values can also serve as markers for problem areas in models undergoing
crystallographic refinement. A high B-value indicates that the atom moves
extensively, which gives low registration of the intensity and weak electron density,
resulting in difficulties to build the model. This can lead to an incorrect structure
description in these areas. The highest values are often found in flexible surface
loops and flexible N- and C-termini. In this structure, the average B-values for all
main-chain atoms are 17.10 Å2, 17.72 Å2 and 16.21 Å2 for molecules A, B, and C,
respectively, while for side-chain atoms these values are 20.00 Å2, 20.52 Å2 and
18.87 Å2 (Table 4-5). An analysis of the B-values as a function of position in the
polypeptide of the three rTxln-1 molecules is shown in Figure 4-3. It shows that the
N- and C- terminal tails of molecule A and B have the largest B-values. The next
highest B-values observed are for residues 27-29 in all the three molecules. These
residues form a solvent exposed loop. No obviously aberrant B-values were observed
for the three rTxln-1 molecules.
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Table 4-5 Mean B-values (Å2) for the three rTxln-1 molecules in the asymmetric unit
Molecule A
Main-chain 17.1
Side-chain 20.0
all atoms (462 atoms)
Molecule B
main-chain
side-chain
all atoms (457 atoms)
Molecule C
main-chain
side-chain
all atoms (462 atoms)
H2O (240 atoms)
SO4 (5 atoms)
PEG chain G (6 atoms)
PEG chain H (6 atoms)
Total
main-chain
side-chain and waters
all atoms (1638 atoms)
18.5
17.7
20.5
19.1
16.2
18.9
17.5
30.6
26.0
43.4
33.8
17.0
22.8
20.4
Figure 4-3 B-values (Å2) for rTxln-1 molecules A, B and C. Residues 14, 38, 39 and 42 are
glycine and therefore have no side-chain B-values.
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A Ramachandran plot informs as to which regions of the polypeptide adopt
secondary structure and illustrates the various regions of dihedral space (phi and psi
backbone angles) that are the most energetically favored (Ramachandran and
Sassiekharan, 1968; R. A. Laskowski et al., 1993). It can therefore detect unusual
backbone conformations in the protein. The Ramachandran plot of the free rTxln-1
crystal structure showed 89.4% of residues in most favored regions, 8.5% of residues
in additionally allowed regions, and 2.1% of residues in generously allowed regions (
Table 4-6). There are no residues in disallowed regions. The amino acid side-chains
that have additionally allowed backbone dihedral angles are Arg17 in molecules A
and B, Arg19 in molecule C, Asn43 in molecule A and C, and Glu41, Asn45 and
Asn46 in all three molecules (Figure 4-4). The consistent occurrence of Glu41,
Asn45 and Asn46 adopting high energy dihedral angles in all three of the molecules
indicate that these conformations are nonetheless favorable for the structures and do
not occur as the result of crystal packing.
Table 4-6 Ramachandran plot statistics for the three free rTxln-1 molecules
Residues (%)
Most favored regions 89.4
Additionally allowed regions 8.5
Generously allowed regions 2.1
Disallowed regions 0.0
Figure 4-4 Ramachandran
plot of the crystal structure of
free rTxln-1.
A (Į-helix), B (ȕ-sheet) and L
(left handed Į-helix) are the
most favored regions. a, b and
c are additionally allowed
regions, and ~a, ~b, ~l, ~p
are generously allowed
regions. Glycine residues are
identified as triangles.
Residues 17, 18, 19, 41, 43,
45 and 46 of rTxln-1 are
labeled. Amino acids with
high backbone energy
conformations are Arg17 in
molecules A and B, Val18 in
molecule B, Arg19 in
molecule C, Asn43 in
molecule A and C, and
Glu41, Asn45 and Asn46 in
molecules A, B and C.
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4.7 Crystal structure of free rTxln-1
The three rTxln-1 molecules in the asymmetric unit all have a shape of an ellipsoid
and measure 35 Å x 17 Å x 15 Å. Their accessible surface areas are 4041 Å2, 4047
Å2 and 3926 Å2 for molecules A, B and C, respectively, as calculated by CCP4
AREAIMOL (B. Lee and Richards, 1971). All three rTxln-1 molecules consist of;
one 310-helix (Asp5-Glu8) near the N-terminus, one Į-helix (Lys50-Cys57) near the
C-terminus, and two ȕ-strands (Phe20-Asn26) and (Lys30-Tyr37) linked by a short
loop (residues Pro27-Glu29). The ȕ-strands form an antiparallel ȕ-sheet, which is
twisted through 180o, and together with the loop that connects the ȕ-strands form a
ȕ-hairpin motif in the central part of the protein. Three disulfide bonds stabilize the
overall structure, Cys7-Cys57, Cys16-Cys40 and Cys32-Cys53. Cys7-Cys57 joins
the N- and C-termini and Cys16-Cys40 links the canonical loop (Pro15-Phe20) with
the secondary binding loop (Ile36-Glu41) (see Chapter 5). Cys32-Cys53 stabilizes
the structure by connecting the second ȕ-strand with the C-terminal Į-helix. The
wiring diagram of the secondary structure is shown in Figure 4-5, and the
stereodiagram of the overall fold is shown in Figure 4-6. The overall surface is
mainly negatively charged except for the canonical loop region which contains
Arg17-Val18-Arg19. The side-chains of Arg17 and Arg19 point out from the
molecule giving the canonical loop a positively charged surface with a high degree of
flexibility due to the length of these side-chains. The side-chain of Val18 points in
the opposite direction to the side-chains of Arg17 and Arg19 (Figure 4-7).
Figure 4-5 Wiring diagram of the secondary structure of rTxln-1.
H1 = N-terminal 310-helix, H2 = C-terminal Į-helix, A = ȕ-strands that form the antiparallel
ȕ-sheet, yellow circles = cysteine residues forming disulfide bridges (orange solid line
defines the connection), ȕ = ȕ-turn, Ȗ = Ȗ-turn and = ȕ-hairpin. The three ȕ-turns
are formed by Asn26-Glu29, Pro27-Lys30 and Asn43-Asn46. The Ȗ-turn is formed by
Ala44-Asn46. The ȕ-hairpin is formed by Phe20-Asn26. Picture generated by PDBsum (R.
A. Laskowski et al., 2005).
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Figure 4-6 Stereo view of the overall fold of molecule A of rTxln-1.
Helices are colored red, ȕ-strands are colored yellow, the loops are colored green and the
disulfide bonds are shown as orange sticks. The same numbering is applied as for the wiring
diagram (Figure 4-5).
Figure 4-7 Connolly surface with electrostatic surface
potentials overlaid for molecule A of rTxln-1.
Regions of positive potential are colored blue, negative
potential are colored red and neutral regions are white.
The side-chains of Arg17 and Arg19 irradiate out from
the core structure making the top portion of the molecule
positively charged. The side-chain of Val18 points away
from the positively charged surface and finds stabilizing
hydrophobic contacts with the side-chain of Phe20.
Least-squares fitting of topologically equivalent CĮ atoms (and all atoms including
side-chains) of residues 2-58 in rTxln-1 using the program Superpose (E. Krissinel
and Henrick, 2004), gave an rmsd of 0.81 Å (1.63 Å), 0.88 Å (2.15 Å) and 1.21 Å
(2.34 Å), for molecule A and B, A and C and B and C, respectively. On visual
inspection of the superposition, the majority of the polypeptide backbone overlays
well except for the canonical loop region and the N- and C-termini (Figure 4-8). Both
termini of molecule B differ from the position of the termini of molecules A and C.
The N- and C-termini of rTxln-1 are regions with fewer internal contacts and
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consequently less restrictions in their conformations, which is reflected in their high
B-values.
The canonical loop region adopts a different conformation in molecule C compared
to molecules A and B. This difference is highlighted by the rmsd values after least-
squares fitting of Pro15-Phe20, which are 0.50 Å (1.88 Å), 1.69 Å (4.73 Å) and 1.43
Å (4.93 Å) for A and B, A and C, and B and C, respectively. The largest separation
after superimposition is between Val18CĮ in molecule A and the equivalent atom in
molecule C (Figure 4-8). This distance is 5.8 Å. The change is due to rotations in the
backbone dihedral angles around Arg17 and Arg19. The overall result is that the side
chain of Val18 is flipped through ~180° in molecule C relative to its position in the
A or B molecules. The (ĭ, Ȍ) angles of Arg17 have changed from (-126.4o, 33.1o) in
molecule A or (-125.9o, 36.4o) in molecule B to (-54.2o, 133.9o) in molecule C.
Arg17 in molecule C has a slightly more favorable dihedral angle conformation
compared to Arg17 in molecule A and B (Figure 4-4). Thus Arg17 changes from a
ȕ-sheet conformation in molecule A and B to an Į-helical region in molecule C. The
(ĭ, Ȍ) angles of Arg19 have changed from (-83.1o, 102.9o) in molecule A or
(-133.6o, 110.9o) in molecule B to (-140.9o, -18.0o) in molecule C (Figure 4-4). Thus
Arg19 changes from Į-helical in molecule A and B to ȕ-sheet in molecule C.
Therefore, the three backbone conformations all appear to be energetically favored
but may ultimately be influenced by neighboring contacts within the protein or the
crystal.
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Figure 4-8 Stereo view of superimposition of the three free rTxln-1 molecules within the
asymmetric unit.
Molecule A is green, molecule B is blue and molecule C is purple. Disulfide bonds are
shown as orange sticks. The canonical loop of molecule C has a different conformation
compared to molecule A and B. The distance between Val18CĮ of molecule A and C is
highlighted by a black line and is in Å units. In general, the main chains of all thee copies of
rTxln-1 overlay well and the chirality of the three disulfide bonds is the same in all three
molecules.
A B-value analysis reveals that the canonical loop (Pro15-Phe20) and secondary loop
of all three molecules (Ile36-Glu41) have relatively low overall B-factors for the
main-chain atoms. The canonical loop in molecule C is firmly held in place, with
about equally rigidity as molecule B and more rigidly than molecule A (Figure 4-3;
Figure 4-9). The interactions that stabilize molecule C are; van der Waals contacts
between the side-chain of Val18 and Thr13, and Ile36, and the backbone nitrogen of
Arg19 hydrogen bonds to the carbonyl oxygen of Tyr37 (3.05 Å). The Ȥ1 angle of
Thr13 is rotated ~180o in molecule C compared to molecule A and B. Instead of
Thr13OȖ1 forming a hydrogen bond with Ile36O as in molecule A and B, in molecule
C it forms a hydrogen bond with Gly14O (3.07 Å). Thr13 is locked in position in all
three structures as reflected by it having the smallest overall B-values of any residue
(Figure 4-3). There is one water molecule stabilizing the location of the canonical
loop in molecule C. One of the Arg19NȘ atoms in molecule C forms a hydrogen
bond to this water molecule (2.98 Å), which in turn form hydrogen bonds to Arg17O
(2.85 Å) and Gly38O (2.81 Å) in molecule C (Figure 4-10).
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Figure 4-9 Visualization of the main-chain B-values for the three rTxln-1 molecules.
High B-values are in yellow, thick tubes. Lower B-values are in blue, thin tubes.
Figure 4-10 Stereoview of interactions stabilizing the conformation of the canonical loop in
molecule C of rTxln-1.
Carbon is purple, nitrogen dark blue and oxygen red. The water molecule is displayed as a
red sphere. Distances are shown as dashed lines with their lengths in Å units.
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Most globular proteins contain a core of hydrophobic residues that are inaccessible to
solvent in the folded state. In rTxln-1, several residues with aromatic side-chains are
partially buried in the structure. Tyr25 is the most buried with a solvent accessible
area of only 3.6 Å2 (M. E. Chen et al., 2007). Phe47, Phe35, Tyr37, Phe23 and Tyr24
are all partially buried with solvent accessible surface areas of 10.2 Å2, 20.7 Å2, 35.3
Å2, 36.7 Å2 and 41.9 Å2, respectively. However, Phe6 and Phe20, have solvent
accessible surface areas of 66.2 Å2 and 105.5 Å2, respectively. Likewise the
hydrophobic amino acids Leu9, Ala11, Val18, Leu33, Ile36, Ala44, Ile48, Ala58 and
Ala59 are all on the surface of rTxln-1. Thus >1/5 of all the surface amino acids are
hydrophobic. In comparison, the structure of aprotinin is much less hydrophobic with
Leu33 a glutamine, Ala44 an arginine and Ile48 a lysine in aprotinin.
Some of the core residues in rTxln-1 appear to have a stabilizing effect on the
structures of the canonical and secondary loops. Phe35 and Tyr37 are located in the
centre of the rTxln-1 structure with some of the atoms in the side-chain within
hydrophobic contact. Tyr37, in turn, stabilizes the side-chain of the Phe20 residue
(~4.50 Å) which is in contact with Val18 in molecule A and B (3.48 Å and 3.79 Å,
respectively) and stabilizes the conformation of the canonical loop in molecule A and
B. Moreover, the aromatic side-chain of Tyr37 fits under the backbone of the
secondary loop and the hydroxyl group of Tyr37 forms a hydrogen bond with
Glu41O (2.70 Å, 2.66 Å and 2.62 Å in molecule A, B and C, respectively),
contributing to the position of the secondary loop in all three structures.
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Figure 4-11 Superimposition of the three free rTxln-1 molecules.
Carbon atoms from molecule A are green, molecule B are blue and molecule C are pink. The
side-chains are displayed as sticks. Oxygen atoms are red and nitrogen atoms are blue.
Disulfide bridges are displayed as yellow sticks.
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There are three disulfide bonds that stabilize rTxln-1; Cys16-Cys40, Cys7-Cys57,
and Cys32-Cys53. The structure of a disulfide bond can be described by its F3
dihedral angle between the Cȕ í SȖ í SȖ' í Cȕ' atoms. A right-handed disulfide bond
has a F3=95.0±10.3o and a left-handed disulfide bond has a F3=-86.4±8.5o. The three
disulfide bonds in rTxln-1 molecules A, B and C overlay perfectly (Figure 4-8).
Cys7-Cys57 (Ȥ3=-82.3o) and Cys32-Cys53 (Ȥ3=-85.8o) are left-handed, while Cys16-
Cys40 is right-handed (Ȥ3=95.5o) (average F3 for molecule A, B and C). Cys16 (from
the canonical loop) and Cys40 form a solvent exposed disulfide bond and its location
suggests that this bond can play a role in serine protease inhibition. The N-terminal
310-helix is linked to the first residue of the C-terminal Į-helix by the Cys7-Cys57
disulfide bond. In the N-terminal 310-helix the side-chain of Phe6 is on the surface of
the molecule but fits in a hydrophobic pocket made up by residues Pro4, Ala44,
Phe47, and the Cys7-Cys57 disulfide bond, while the charged side-chains of the 310-
helix, residues Asp5 and Glu8, are facing the solvent. The disulfide bond between
Cys32 and Cys53 attaches the C-terminal Į-helix to the second ȕ-strand. This Į-helix
has a highly charged surface with all the side chains of Lys50, Glu51, Glu52, Glu54,
Ser55 and Thr56 facing the solvent. The aromatic rings of Phe23, Tyr25 and Phe47
are partly nestled against this Į-helix and packed against the ȕ-sheet structure.
Glycine is often present in proteins because of its unique flexibility and proline
because it can place a "kink" in polypeptide chains (Kuntz, 1972; Branden and
Tooze, 1991). rTxln-1 contains four glycine residues (14, 38, 39 and 42). All are
found in loop regions, close to the canonical loop and secondary loop or part of the
secondary loop. The five proline residues (4, 10, 15, 21 and 27) produce significant
bends in the structure, especially Pro15 which starts the canonical loop and Pro21
which directly proceeds the canonical loop. The ȕ-hairpin loop in rTxln-1 consists of
three residues Pro27, Asp28 and Glu29. The kink introduced by Pro27 in rTxln-1
makes the loop form a negatively charged protrusion on the surface due to the
presence of Asp28 and Glu29 (Figure 4-12).
85
Figure 4-12 Two views, rotated by 90°, of the Connolly surface with electrostatic potentials
overlaid for molecule A of rTxln-1.
Regions of positive potential are colored blue, negative potential are colored red and neutral
regions are white. The ȕ-hairpin loop Pro27-Asp28-Glu29 protrudes from the surface and the
side-chains of Asp28 and Glu29 extend out to the solvent. This region forms a negatively
charged protrusion on the surface.
The region of polypeptide chain from Cys16 to Thr49 which crosses the ȕ-sheet is
stabilized by the hydrogen bond formed between the amide nitrogen atom of Phe47
and the carbonyl oxygen atoms of Phe23 in the ȕ-sheet. Further hydrogen bonds
stabilizing this part of the structure are formed between the side-chain Oį1 and Nį2
atoms of Asn45, and the backbone oxygen of Leu9, and amide nitrogen and oxygen
atoms of Tyr25 (Figure 4-11).
In general, polar residues in the core are energetically unfavorable except when they
are able to form intra-molecular hydrogen bonds. Four polar residues are buried to a
different extent in the structure of rTxln-1, these are; Ser22, Asn43, Asn45 and
Asn46. Stabilizing hydrogen bonds are formed between the side-chain hydroxyl
group of Ser22 and the backbone carbonyl oxygens of Phe20 and Pro21. The side-
chain Nį2 atom of Asn43 forms stabilizing hydrogen bonds with the backbone
carbonyl oxygen of Pro10, and its Oį1 atom form hydrogen bonds with the backbone
nitrogen atom of Asn45 and one internal water molecule. The backbone dihedral
angles of Asn45 and Asn46 in all three structures are in the additionally allowed
region of the Ramachandran plot, however, their low B-values confirm that they
have in rigid conformations (Figure 4-3; Figure 4-4). The side-chain of Asn45 is
completely buried and its side-chain Nį2 atom forms hydrogen bonds with the
backbone carbonyl oxygens of Leu9 and Tyr25. The side-chain of Asn46 is not
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hydrogen bonded to any protein atoms, its closest potential hydrogen bond partners
are Ser22OȖ and Tyr37OH which are situated ~4 Å away. However, the side-chain
Nį2 atom does form a hydrogen bond with a buried water molecule.
There are three conserved water molecules buried in the core of all three rTxln-1
molecules. These molecules have B-values between 10.8 Å2 and 13.7 Å2,
significantly lower than those water molecules found on the surface of rTxln-1 where
the average B-value is 30.6 Å2, and lower than the average B-value for protein atoms
(18.4 Å2). Two water molecules are centrally located in the structure of rTxln-1 and
are hydrogen bonded to each other. One is hydrogen bonded to Asp12N, Asn45O
and the side-chain Asn43Oį1, while the other is hydrogen bonded to Asp12O,
Asn43N, Asn43O and Asn46Nį2. The third of the water molecules forms hydrogen
bonds to Cys16N, Thr13O and Cys40O (Figure 4-14). This water molecule therefore
plays a critical role in stabilizing and orienting the canonical and secondary loop
regions.
Figure 4-13 Three conserved buried water molecules.
Superimposition of molecule A (green), B (blue) and C (purple) of rTxln-1 and the three
conserved and buried water molecules.
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(a)
(b)
Figure 4-14 Stereo diagram of the hydrogen bond formed between an internal water
molecule and Thr13O, Cys16N and Cys40O in molecule A of rTxln-1.
Carbons are shown as green sticks, nitrogen in dark blue, oxygen in red and the disulfide
bridge in orange. The water molecule is displayed as a red sphere. (a) The 2Fo-Fc electron
density is displayed as light grey mesh and contoured at 1ı. (b) Hydrogen bonds are marked
with dashed black lines and their lengths are in Å units.
4.8 Crystal contacts
The protein backbone conformation as well as the side-chain conformations are
influenced by the surrounding environment, and the densely packed environment of
proteins in crystal structures can be dissimilar to their environment in the native state
(Janin and Rodier, 1995; Carugo and Argos, 1997). Packing contacts in protein
crystals can be artifacts due to the way the crystals grow and can be considered
nonspecific protein-protein interactions referred to as “crystal contacts”. Regions of a
protein in crystal contact are more rigid and have lower B factors than these atoms
exposed to solvent (Kossiakoff et al., 1992; Jacobson et al., 2002). These contacts
make use of the same forces that govern specific recognition in protein-protein
complexes and oligomeric proteins. Thus, crystal contacts provide examples of
nonspecific protein-protein interactions which can be compared to interactions that
are biologically relevant. All possible crystal contacts from surrounding molecules in
the rTxln-1 crystal were investigated to see if the important features of rTxln-1 were
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affected by these artificial contacts and to find out if there existed an oligomeric
formation.
Analysis of the crystal packing reveals that there are crystal contacts between all
three rTxln-1 molecules in the asymmetric unit and that these three molecules also
have crystal contacts with symmetry related molecules. Molecule C has the most
number of surrounding atoms within a distance of 5 Å (Figure 4-15). These adjacent
atoms are distributed over the canonical and secondary loops, the N- and C-terminal
helices, the ȕ-hairpin and the grove on the opposite side of the ȕ-hairpin of molecule
C. Molecule A and B have about the same number of surrounding atoms within a
distance of 5 Å (Figure 4-15). These are distributed at about the same place as in
molecule C. However, the side-chains of Arg17 and Arg19 in molecule B are
surrounded with more atoms from adjacent molecules and more rigid than equivalent
side-chains in molecule A. This is reflected in the B-values of the side-chains in the
canonical and secondary loops. The side-chains of Arg17 and Arg19 are highly
mobile in molecule A (30.9 Å2 and 24.6 Å2, respectively) but are relatively stable in
molecule B (19.1 Å2 and 18.6 Å2) and C (20.2 Å2 and 19.4 Å2) (Figure 4-3).
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Figure 4-15 Crystal contacts for molecule A, B and C of rTxln-1.
The Connolly surface of molecule A is green, molecule B is blue and molecule C is purple.
Atoms within 5 Å are shown as stick models. Carbon atoms from molecule A are green,
from molecule B are blue and from molecule C are purple. Carbons atoms from PEG
molecules are yellow or salmon. Sulfur atoms from sulfate ions are yellow. Nitrogen is blue
and oxygen is red.
In the crystal, molecules A and C face one another with their ȕ-sheets forming the
interface, while molecule B is located with its canonical loop region and secondary
loop region nearest to molecule A and the amino and carboxy terminal regions
nearest to molecule C. Molecules A and C are related by a pseudo-2-fold rotation
(Figure 4-16).
Figure 4-16 Stereoview of the packing of the three rTxln-1 molecules in the asymmetric
unit.
Molecule A is colored green, molecule B is colored blue and molecule C is colored purple.
The ȕ-sheets and molecules A and C face each other.
Mass spectrometric analysis of the free rTxln-1 indicated that a portion of these
molecules form dimers in solution (see Chapter 2). Apart from NMR spectroscopy,
there is no other method to visualize how this dimer might look in solution.
However, calculations that determine the amount of surface area that is buried upon
interaction between two neighboring molecules in a crystal can sometimes be a good
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indication as to whether or not such an interaction might also be important in
solution. In comparing the surface areas buried, molecules A and C have the largest
buried surface of 1286 Å2 while for molecules A and B this value is 499 Å2 and for
molecules B and C it is only 397 Å2 (AREAIMOL (B. Lee and Richards, 1971)).
Thus the most likely mimic for the dimer in solution is the A and C pairing.
Closer analysis of the interactions between molecules A and C shows that this
pairing is stabilized by six inter-molecular hydrogen bonds involving (Thr13, Arg17,
Tyr24, Glu29 and Ile36 from molecule A and Thr13, Glu41, Tyr24, Lys31 and Ala11
from molecule C). Thr13N(A) forms a hydrogen bond with Thr13OȖ(C) (2.94 Å)
and Thr13OȖ(A) forms a hydrogen bond with Thr13N(C) (2.85 Å). The canonical
and secondary loops are also involved in monomer interactions; Arg17 Nİ(A) forms
an ionic bond with the carboxylate group of Glu41(C) (2.86 Å). Ile36N(A) and
Ala11O(C) form a hydrogen bond (2.82 Å). A further ionic bond is observed
between Glu29Oİ1(A) and Lys31Nȗ (2.91 Å). Three water molecules bridge
between residues in molecule A and C in the interface. Ala11O(A) forms a hydrogen
bond to a water molecule (2.68 Å), which in turn forms a hydrogen bond to
Ile36N(C) (2.98 Å) and Ile36O(C) (2.80 Å). Glu34N(A) form a hydrogen bond to the
second water molecule (2.97 Å), which hydrogen bonds to Asp28Oį2(C) (2.80 Å).
Tyr24OH(A) hydrogen bonds to the third water molecule (2.74 Å), which bonds to
Glu34O(C) (2.89 Å) and Asn26Nį2(C) (2.97 Å). This overall interaction has
stabilized the ȕ-hairpin loop in molecule A and C. This is reflected in the higher B-
values for this region in molecule B, as compared to both molecule A and C (Figure
4-3; Figure 4-16). Thus, not only is there a very large contact surface, there are
fourteen hydrogen bonds that add to the stabilization of this pairing. It is therefore
highly conceivable that this arrangement of molecules is the dimer that is observed in
the mass spectrometer.
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(a)
(b)
Figure 4-17 Interactions between molecule A and C in the free rTxln-1 structure.
Molecule A is green and molecule C is purple. Residues making contact are shown as sticks
and labeled. Red is oxygen and blue is nitrogen. Water molecules are red spheres. The two
molecules form a contact surface of 1286 Å2 which is stabilized by six inter-molecular
hydrogen bonds and three bridging water molecules. Hydrogen bonds are black dashed lines.
(a) Distances are in Å units. (b) Stereo view of the interactions.
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Figure 4-18 Visualization
of the main-chain B-values
for the three molecules of
rTxln-1 in the asymmetric
unit.
The colouring and thickness
of the tubing are indications
of the relative motion. High
B-values are in yellow, thick
tubes. Lower B-values are in
blue, thin tubes.
The AB interface is mostly stabilized by ionic interactions between Arg17 and Arg19
from molecule A and Glu41 from molecule B. Hydrophobic interactions are also
observed between Phe20 in A and the Cys16-Cys40 disulfide bridge in molecule B.
This disulfide bridge in molecule B, together with the same disulfide bridge in
molecule C from another asymmetric unit form a hydrophobic crevice which the
side-chain of Phe20 from A fits into. The BC interface is formed by hydrogen bonds
between Asp2 and Asp5 in B and Lys1 and Asp5 in molecule C. No water molecules
are visible in any of the small interfaces that include molecule B.
There are also stabilizing interactions that hold adjoining asymmetric units together.
The largest contact surface is between molecule A and molecule C from another
asymmetric unit related by the symmetry operation (y, 1-x, z). Here the buried
surface area is 844 Å2. The next largest inter asymmetric unit buried surface is 703
Å2 which is between molecule B and the same C molecule.
The canonical loop in molecule C is situated between two neighboring A molecules
where it is stabilized by inter-molecular bonds. One A molecule (A1) is from the
same asymmetric unit as molecule C, the other (A2) is from an adjacent asymmetric
unit related by (1-y, x, z). The side-chain of Val18(C) points toward a neutral surface
on one side of molecule A1, while the side-chains of Arg17(C) and Arg19(C) face
the opposite direction and point towards a negatively charged groove on molecule
A2.
93
Hydrogen bonds between the canonical loop of molecule C and molecule A2 are
observed between the following, Arg17N of molecule C and Gly39O of molecule A2
(2.81 Å), Arg17NȘ1 atom of molecule C and Glu41O of molecule A2 (2.90 Å) and
Arg17NȘ2 and Ans43O of molecule A1 (2.99 Å), Arg19NȘ1 atom of molecule C and
Asn46Oį1 of molecule A2 (2.79 Å), Arg19NȘ1 of molecule C and a water molecule
(2.86 Å), which also forms a hydrogen bond to Ser22OȖ (2.87 Å) of molecule A2.
There are two water molecules forming bridges between the canonical loop in the
molecule C and the two A molecules. Val18N of molecule C form a hydrogen bond
with a water molecule (2.94 Å), which in turn forms a hydrogen bond to Asp12Oį2
(2.79 Å) of the molecule A1. This water molecule forms a hydrogen bond with a
negatively charged sulphate ion (2.64 Å), which is located ~5 Å from the positively
charged guanidino group of Arg17 in molecule C.
There is extra electron density which makes it possible to model an alternate
conformation of the guanidino group of Arg17 in molecule C where its Nİ atom and
one of its Nȗ atoms make two hydrogen bonds to the sulphate ion (2.95 Å and 2.97
Å, respectively). There is one PEG molecule located in the space created by
molecules A1-C-A2. It is situated ~4 Å from the Cys16-Cys40 disulfide bridge in the
molecule C and molecule A1.
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(b)
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Figure 4-19 Stereoview of the canonical loop in molecule C located between two A
molecules.
Arg17, Val18 and Arg19 of molecule C have purple carbon atoms. Molecule A within the
same asymmetric unit is green. The adjoining molecule A is blue. For all structures, oxygen
is red and nitrogen is blue. Cys16-Cys40 disulfide bond is shown in orange in all three
molecules. A sulfate ion and PEG molecule are represented as balls and sticks. (a) Hydrogen
bonds are drawn with black dashed lines and their lengths in Å units. (b) Stereo view of the
location of the canonical loop in molecule C relative to neighboring A molecules. (c) The
2Fo-Fc electron density contoured at 1ı is displayed as light grey mesh.
95
A more extensive view of the molecular packing within the crystal shows that an
alternating pattern of A and C molecules occurs such that a circle of eight molecules
is apparent. The buried surfaces between A and C alternate between 1286 Å2 and 844
Å2. Four B molecules are attached to the AC pair to form a dodecamer of rTxln-1
molecules. However, the buried surface areas for the AB interface and BC interface
are only 499 Å2 and 397 Å2, respectively. Four sulphate ions and eight PEG
molecules are located in the circle, but these are on opposite faces. This situation is
somewhat analogous to what is observed in the crystal packing of aprotinin, where
two rings of five molecules are formed and five sulphate ions are situated in between
the two pentamers to make a decamer (Hamiaux et al., 2000).
(a) (b) (c)
Figure 4-20 Expanded view of the crystal packing of the free rTxln-1 molecules.
A molecules are colored green, B molecules are colored blue and C molecules are colored
purple. (a) Four A and four C molecules form a tight circle with four sulphate ions located
internally, the associated B molecule packing is also shown. (b) Eight PEG molecules are
also located internally but on the opposite face. (c) Sixteen PEG molecules located between
two dodecamers of rTxln-1.
Solution studies of aprotinin showed that decamer formation is not simply a crystal
packing artifact, and that aprotinin becomes a mixture of two particles, a monomer
and decamer, in acidic or neutral pH, high salt concentration, high protein
concentration, and the fraction of decamers increased with increasing salt
concentration (Hamiaux et al., 2000). Three types of buried surface area are observed
in the aprotinin decamer. One aprotinin molecule has two buried surfaces of 650 Å2
with its two neighbors within a pentamer involving four to six hydrogen bonds. Two
other buried surfaces with subunits belonging to the facing pentamer; one surface of
750 Å2 that was mainly hydrophobic (only two hydrogen bonds) and a more
extensive surface of 1200 Å2, with at least eleven hydrogen bonds (Hamiaux et al.,
2000).
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Possible interpretations of the crystal packing analysis;
x Molecule A and B have fewer crystal contacts than molecule C, but any of
these conformations could plausibly exist in solution (Section 4.10, Figure
4-29).
x The AC dimer pair could be the species observed in the mass spectrometer.
x The view of the expanded crystal packing is analogous to what occurs in
aprotinin and suggests dodecamers of rTxln-1 could occur.
4.9 Comparison between textilinin-1 and aprotinin
To compare the structures of rTxln-1 and aprotinin (PDB entry 1BPI), least-squares
fitting and visual analysis were undertaken. Least-square fitting of topologically
equivalent CĮ atoms of aprotinin and residues 3-58 of molecules A, B and C of free
rTxln-1, resulted in rmsd values of 0.91 Å, 1.10 Å, and 0.95 Å, respectively. Thus,
the overall folds of rTxln-1 and aprotinin are very similar. On visual inspection, the
polypeptide chains overlay well and the chirality of the dihedral angles around the
sulfur-sulfur disulfide bonds are conserved. Least-squares fitting of main-chain
atoms in the canonical loop region (residues 15-20 rTxln-1 numbering) of aprotinin
and rTxln-1 resulted in rmsd values of 0.60 Å, 0.42 Å and 1.31 Å for molecules A, B
and C, respectively. Thus, residues 15-20 in molecule A and B of rTxln-1 have a
typical canonical loop structure, where as this loop in molecule C is substantially
different. The largest difference is in the location of the CĮ atoms of Val18 in
molecule C of rTxln-1 and Ala16 in aprotinin. These two atoms are 4.31 Å apart
after superimposition. This change is due to rotations in the backbone dihedral angles
around Arg17 and Arg19 in molecule C of rTxln-1. The side-chain of Thr11 in
aprotinin has the same conformation as molecule A and B in rTxln-1, while it has
rotated ~180o in molecule C of rTxln-1. This is to accommodate the side-chain of
Val18 in molecule C (Section 4.7).
Another region where the three dimensional structure of the two proteins deviate
significantly is between residues 40 and 45 (rTxln-1 numbering), with the maximal
difference at Gly42 in Txln-1 (Ala40 in aprotinin) where the positions of the CĮ
atoms of Gly42 of rTxln-1 in molecule A and Ala40 of aprotinin deviate by 3.60 Å.
For Glu41 of rTxln-1 (Arg39 of aprotinin), the dihedral angle ĭ stays the same,
however, Ȍ changes by ~180o. Average values for Glu41 in molecule A, B and C are
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ĭ=57.2 and Ȍ=-137.6o, compared to ĭ=58.4o and Ȍ=43.8o in Arg39 of aprotinin.
These angles correspond to a generously allowed region in the Ramachandran plot
for Glu41 of rTxln-1 and a most favored region for Arg39 in aprotinin. In rTxln-1
Glu41O forms a hydrogen bond with the side-chain hydroxyl of Tyr37 (2.70 Å, 2.66
Å and 2.62 Å in molecule A, B and C, respectively). The side-chain of Tyr37 in
rTxln-1 is located in the centre of the structure and its role is likely to be of major
importance in stabilizing the core of the structure. However, Arg39O and Tyr35OH
in aprotinin do not form such a hydrogen bond. Thus the higher energy dihedral
angle observed for Glu41 in rTxln-1 is offset by the formation of a hydrogen bond to
Tyr37. The following residue in the sequence is Gly42 in rTxln-1 and Ala40 in
aprotinin. In the rTxln-1 structure, the ĭ, Ȍ dihedral angles for Gly42 in molecule A,
B and C are (77.1°, -152.3°), (69.1°, -149.1°) and (86.9°, -148.7°), respectively. This
is a generously allowed region in the Ramachandran plot that can be occupied by a
glycine residue, however, it is a high energy area for all of the other amino acid
residues including alanine and therefore not in a conformational space that could
easily be explored by aprotinin. The ĭ, Ȍ dihedral angles for Ala40 in aprotinin are -
53.9° and 146.9°, values that are in the ȕ-sheet region.
In rTxln-1 the side-chain of Asn43Oį1 forms a hydrogen bond with an internal water
molecule (section 4.7), while the side-chain of Lys41 in aprotinin extends out into
the solvent. Thus the side-chain of Asn43 plays a role in stabilization of the rTxln-1
fold, whereas the Lys41 in aprotinin appears to have no such function. One
underlying reason for the difference in structure in this region is the nearby presence
of Tyr10 in aprotinin (Asp12 in rTxln). In aprotinin the side-chain of this residue is
situated on the surface making van der Waals contacts with both the side-chain and
backbone of Arg39 and side-chain of Lys41. Asp12 in rTxln-1 has its side-chain
extending out into the solvent. If the Arg39O in aprotinin was flipped and in the
same position as Glu41O appears in rTxln-1 and Ala40 in aprotinin is in the same
position as Gly42 in rTxln-1, the tyrosine side-chain would make unfavourable
contacts (< 1 Å) with both backbone atoms and the side chain of Ala40. Therefore,
these changes in sequence between rTxln-1 and aprotinin gain both a formation of a
hydrogen bond between Glu41O and Tyr37OH in rTxln-1 and rigidify the structure
by forming hydrogen bonds to the side-chain of Asn43 in rTxln-1.
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Figure 4-21 Stereoview of the superimposition of the three rTxln-1 molecules and
aprotinin.
Molecule A of the rTxln-1 is colored green, molecule B is colored blue, molecule C is
colored purple and aprotinin (1BPI) is colored yellow. Disulfide bonds are shown as orange
sticks. The largest deviations in structure are in the canonical loop of molecule C of rTxln-1
and in the region between residues 40-45 (rTxln-1 numbering). Distances represented by
dashed lines are in Å.
Figure 4-22 Stereoview of the region between residues 40-45 (rTxln-1 numbering) after
superimposition of molecule A of rTxln-1 and aprotinin.
rTxln-1 is colored green and aprotinin (1BPI) is colored yellow. Distances are marked as
black dashed lines and are in Å units.
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The sequence identity between rTxln-1 and aprotinin is 47 % with the major
differences ascribed to residues that appear on the surfaces of the two proteins. To
analyze these differences Connolly surfaces with electrostatic surface potentials
mapped were constructed. While the overall surfaces vary in electrostatic potential,
with a dominating negative potential on the surface of the rTxln-1 molecule and
positive potential on aprotinin, the surfaces of the canonical loop in both molecules
are similar. In rTxln-1 the helices and the ȕ-hairpin loop have a negatively charged
surface, while in aprotinin this helix is less negatively charged. The ȕ-hairpin loop in
aprotinin has a neutral surface but with one positively charged region where the side-
chain of Lys26 points out to the solvent.
An interesting observation with the aprotinin structures is that there are four highly
conserved water molecules buried in the core of the structure (Figure 4-24)
(Deisenhofer and Steigemann, 1975). Three of these water molecules in aprotinin are
also found in the same location in rTxln-1. The fourth water molecule has been
replaced by the side-chain of Asn43 in rTxln-1. The equivalent residue is Lys41 in
aprotinin where its side-chain extends in solvent (Figure 4-22).
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Figure 4-23 The Connolly surface and electrostatic potentials for molecule A of rTxln-1
and aprotinin.
Regions of positive potential are colored blue, negative potential are colored red and neutral
regions are white. Two views (rotated by 180°) of each molecule are shown. The major part
of the canonical loop has a positively charged surface in both rTxln-1 and aprotinin (1BPI).
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(a) (b)
(c)
Figure 4-24 Internal water molecules in rTxln-1 and aprotinin.
Molecule A of rTxln-1 is colored green and aprotinin (1BPI) is colored blue. Disulfide bonds
are displayed as orange sticks. Water molecules are displayed as spheres. (a) There are three
internal water molecules in rTxln-1, displayed as red spheres. (b) There are four internal
water molecules in aprotinin, displayed as red spheres. (c) Stereo view of rTxln-1 and
aprotinin superimposed.
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Several aprotinin structures were analyzed in order to get an overview of the
polypeptide structure. In particular, I was interested to see if the canonical loop
structure observed in molecule C of rTxln-1 is also found in any other aprotinin
structures. Superimposition of 41 structures of aprotinin (free aprotinin, aprotinin in
complexes, and mutants of aprotinin) (1AAL, 1G6X, 1QLQ, 1NAG, 1TPA, 2PTC,
2TGP, 2TPI, 3TPI, 4TPI, 1CBW, 1MTN, 1BTH, 2KAI, 1CO7, 3TGI, 3TGJ, 1D0D,
1FAK, 1K6U, 7PTI, 2HEX, 1BHC, 1B0C, 1BPI, 1BZ5, 4PTI, 5PTI, 6PTI, 7PTI,
8PTI, 9PTI, 1PIT (NMR), 1LD5 (NMR), 1LD6 (NMR), 1JV8 (NMR), 1JV9 (NMR),
1BTI , 1FAN, 1BPT and 1BRB) showed that only two of these exhibited major
differences in their structure. These were a crystal structure of a Tyr35Gly mutant
(8PTI) (Housset et al., 1991), and the NMR structure of an aprotinin mutant with
residues Thr11, Pro13, Arg17, Ile18, Ile19, Val34, Gly37, Arg39 substituted by
alanine, Lys15 was mutated to arginine and Met52 was mutated to leucine (1LD6)
(Cierpicki and Otlewski, 2002). These alterations, except for the Met52Leu mutation,
are mutations of residues influencing the canonical loop and the secondary loop
(Figure 4-25). While none of these structures showed a loop with an identical
conformation as to that observed in molecule C of rTxln-1, the two 8PTI and 1LD6
showed equally large structural variation as observed in molecule C of rTxln-1.
Figure 4-25 Amino acid sequence alignment of Txln-1, aprotinin and two aprotinin mutants
(8PTI and 1LD6). The cysteine residues are highlighted in orange and the mutations in
aprotinin in yellow.
In both rTxln-1 and aprotinin, the side-chain of Tyr37 in rTxln-1 and the
topologically equivalent Tyr35 in aprotinin is situated in the centre of the structures,
with the hydroxyl group positioned inside a semi circle lined by the backbone atoms
of the residues Gly39-Gly42 (rTxln-1 numbering) (Figure 4-26). The B-values of
Tyr37 main-chain and side-chain of molecule A, B and C of rTxln-1 and are among
the lowest for all the protein atoms (11.0 Å2 and 12.4 Å2 for molecule A, 12.4 Å2 and
12.3 Å2 for molecule B, and 12.3 Å2 and 11.9 Å2 for molecule C, average B value for
1 5 10 15 20 25 30 35 40 45 50 55 59
| | | | | | | | | | | | |
Txln-1 KDRPDFCELPADTGPCRVRFPSFYYNPDEKKCLEFIYGGCEGNANNFITKEECESTCAA
Aprotinin RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
8PTI RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVGGGCRAKRNNFKSAEDCMRTCGGA
1LD6 RPDFCLEPPYAGACRAAAARYFYNAKAGLCQTFAYGACAAKRNNFKSAEDCLRTCGGA
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protein atoms is 18.37 Å2), which confirm a stable position. In the Tyr35Gly
aprotinin mutant, rearrangements of the canonical loop and secondary loop region
have occurred, especially the secondary loop. This change in conformation was
reported (Housset et al., 1991) to be one of the largest alterations in aprotinin arising
from a single amino acid substitution. The secondary loop has collapsed and the
backbone has moved 3.54 Å relative to aprotinin (PDB entry 1BPI), measured at the
backbone nitrogen atom of residue Arg39 (aprotinin numbering, which corresponds
to Glu41 in rTxln-1). Therefore, this indicates that Tyr37 of rTxln-1 has a central
role in the structure of rTxln-1. Since the secondary loop and the canonical loop are
linked by a disulfide bond (Cys14-Cys38 in aprotinin), the movement of the
secondary loop also moved the disulfide bond and the canonical loop (Figure 4-27).
The side-chains of the canonical loop were still pointing towards the solvent, and the
aprotinin Thr35Gly mutant was reported to still be an inhibitor of trypsin (Housset et
al., 1991). This furthermore suggests that rTxln-1 with the canonical loop in the
conformation found in molecule C could still be a weak inhibitor, since the side-
chains in the canonical loop are exposed and can still interact with trypsin or
potentially other serine protease inhibitors.
The aprotinin mutant with eight alanine substitutions and Lys15Arg and Met52Leu
mutations showed a 8.2 Å shift of the Tyr35 position relative to aprotinin (PDB entry
1BPI) measured between CĮ atoms of Tyr35 (aprotinin numbering). The Tyr35 side
chain has rotated out towards the solvent, and the secondary loop is on the opposite
side of the canonical loop when compared to aprotinin (Figure 4-27). It was
suggested that the loss of hydrophobic interactions between the aromatic side chain
of Tyr35 and the side chains of Ile18, Ile19 and Val34, which had been mutated to
alanine residues in this protein, were a probable reason for the alteration in the
structure (Cierpicki and Otlewski, 2002). These three hydrophobic amino acids
superimpose with three hydrophobic residues of rTxln-1 (Phe20, Pro21, and Ile36)
and the side-chains of Phe20 and Tyr37 are close enough to have a stabilizing
hydrophobic effect on each other (~4.5 Å). Both aprotinin mutants lost the
interaction between the side chains of Tyr35 and Asn44 (aprotinin numbering)
(Housset et al., 1991; Cierpicki and Otlewski, 2002). Asn44 in aprotinin is located at
the same position as Asn46 in rTxln-1 and suggests that also Asn46 has a stabilizing
effect on Tyr37 in rTxln-1. Although the canonical loop in the multiply mutated
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aprotinin is less structured than aprotinin, and mainly consisting of alanine residues
Ala11-Gly12-Ala13-Cys14-Arg15-Ala16-Ala17-Ala18-Ala19, the side chain of
Arg15 is exposed to solvent and the cysteine bridge still located on the same side of
the first loop as aprotinin. The mutant was reported to have inhibitory activity against
trypsin and chymotrypsin, suggesting that the canonical conformation of the binding
loop can be regained to enable interactions with these enzymes (Cierpicki and
Otlewski, 2002). This again suggests that rTxln-1 with the canonical loop in the
conformation found in molecule C can still interact with serine proteases.
Figure 4-26 Stereo view of the position of the side-chain of Tyr37 in molecule A of rTxln-1
and Tyr35 in aprotinin.
rTxln-1 is colored green and aprotinin (1BPI) is colored blue. The tyrosine side-chains are
shown as sticks and labeled accordingly. Disulfide bonds are shown as orange sticks. The
tyrosine side-chain is partially buried in the core of the protein.
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(a) (b)
Figure 4-27 Structural comparison of rTxln-1
and two aprotinin mutants.
Molecule A, B and C in rTxln-1 are green.
Disulfide bonds are shown as orange sticks.
(a) Superposition of molecule A, B and C of
rTxln-1 and aprotinin mutant 8PTI (pink). The
secondary loop has collapsed. The movement of
the Cys14-Cys38 disulfide bridge in aprotinin
has also moved the canonical loop. (b)
Superposition of molecule A, B and C of rTxln-1
and 10 NMR models of aprotinin mutant 1LD6
(yellow). The secondary loop is on the opposite
side of the canonical loop compared to rTxln-1.
(c) Superposition of molecule A of rTxln-1, 8PTI
(yellow) and model 1 of 1ld6 (purple).
(c)
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4.10 Comparison between textilinin-1 and proteins with
highest amino acid sequence identity
A search for proteins with similar fold and sequence to rTxln-1 in the PDB was
performed using the program BLAST (Schäffer et al., 2001). This was done to
identify homologs, compare their structures to rTxln-1 and analyze if rTxln-1 could
have other biological functions unrelated to serine protease inhibition. Several
molecules with aprotinin-like fold isolated from snake venoms are Ca2+ channel
blockers e.g calcicludine or K+ channel blockers e.g -dendrotoxin, dendrotoxin K
and dendrotoxin I. rTxln-1 is the first crystal structure determined from a molecule
isolated from an Australian snake and justifies such a comparison even though its
trypsin and plasmin inhibition already is well established. The BLAST search
resulted in the top four hits listed in Table 4-7.
Table 4-7 Hits from BLAST search versus the PDB
PDB entry Score
(bits)
Amino acid
sequence
identity (%)
Name
1JC6 65.5 34/59=57 NMR structure of Banded krait,
(Bungarus fasciatus), fraction IX, a
chymotrypsin inhibitor
1ZR0 58.2 27/56=48 Crystal structure of Kunitz domain 1
of tissue factor pathway inhibitor-2
1DTK 58.2 29/52=55 NMR structure of dendrotoxin K
from Black mamba (Dendroaspis
polylepis polylepis)
1LD5 56.6 28/57=49 NMR structure of aprotinin mutant
Lys15Arg, Ala16Val and Met52Leu
The four proteins in Table 4-7 have different targets. The protease inhibitor from
Banded krait was reported to inhibit chymotrypsin and not trypsin (C. Chen et al.,
2001a). Kunitz domain I of tissue factor pathway inhibitor-2 inhibits trypsin, plasmin
and factor VIIa/tissue factor (Schmidt et al., 2005). Dendrotoxin K blocks K+
channels but has negligible trypsin and chymotrypsin inhibitor activities (Dufton,
1985; Berndt et al., 1993; Smith et al., 1997). Dendrotoxin K has positively charged
residues in the N-terminus and the ȕ-hairpin loop. It is believed these could interact
with K+ channels (Smith et al., 1997).
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The three disulfide bonds in rTxln-1 (Cys7-Cys57, Cys16-Cys40 and Cys32-Cys53)
are conserved in all four proteins (Figure 4-28). Superimposition of the structures of
these proteins shows that the disulfide bonds overlay well (Figure 4-29). The largest
difference between the backbone conformation between rTxln-1 and these four
proteins is seen between rTxln-1 and the inhibitor from Banded krait. The major
difference between the backbone conformation of rTxln-1 and the inhibitor from
Banded krait is from residue Glu8 to Phe20 (rTxln-1 numbering) (Figure 4-29 (a)).
There are only four residues that are conserved (Leu8, Thr13, Gly14 and Cys16,
rTxln-1 numbering) in this region which is a contributing factor to the difference.
The structures of rTxln-1 and the Kunitz domain 1 of tissue factor pathway inhibitor-
2 do not show significant differences in the backbone conformation, except when
compared to the canonical loop in molecule C in rTxln-1 (as discussed in the
subsections 4.7 and 4.8) (Figure 4-29 (b)). This protein is the only one in Table 4-7
that has a glutamate at position 41 (rTxln-1 numbering) and the sequence from Tyr37
to Phe47 (rTxln-1 numbering) is completely conserved suggesting its importance for
plasmin binding and selectivity. A major difference between the backbone structure
between rTxln-1 and dendrotoxin K is in the region which forms the ȕ-hairpin loop
(Figure 4-29 (c)). The change from Pro27 in rTxln-1 to Trp25 in dendrotoxin K
contributes to the different directions of the backbone of the ȕ-hairpin loop. The loop
residue Asp28 in rTxln-1 is Lys26 in dendrotoxin K and Glu29 in rTxln-1 is Ala27 in
dendrotoxin K. These differences result in this loop being negatively charged in
rTxln-1 and neutral to positively charged in dendrotoxin K. The Trp25 and Lys26 in
dendrotoxin K have been reported to be responsible for recognition of K+ channels
(F. C. Wang et al., 1999). Thus it is unlikely that rTxln-1 could have a similar
function.
Figure 4-28 Sequence alignment of rTxln-1 and the proteins mentioned in Table 4-7.
1 5 10 15 20 25 30 35 40 45 50 55 59
| | | | | | | | | | | | |
Txln-1 KDRPDFCELPADTGPCRVRFPSFYYNPDEKKCLEFIYGGCEGNANNFITKEECESTCAA
1JC6 KNRPTFCNLLPETGRCNALIPAFYYNSHLHKCQKFNYGGCGGNANNFKTIDECQRTCAA
1ZR0 PTGNNAEICLLPLDYGPCRALLLRYYYDRYTQSCRQFLYGGCEGNANNFYTWEACDDACWRIE
1DTK AAKYCKLPLRIGPCKRKIPSFYYKWKAKQCLPFDYSGCGGNANRFKTIEECRRTCVG
1LD5 RPDFCLEPPYTGPCRVRIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCLRTCGGA
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The backbone of the canonical loop region of the Kunitz domain 1 of tissue factor
pathway inhibitor-2 and dendrotoxin K (Berndt et al., 1993) have a similar
conformation to molecule A and B of rTxln-1 (Figure 4-29). The backbone of the
canonical loop region in the NMR structure of inhibitor from Banded krait (C. Chen
et al., 2001a) varies in position with two NMR models having similar structures as in
molecule A and B of rTxln-1, and eight NMR models having similar structures to
molecule C of rTxln-1 (Figure 4-29). In the inhibitor from Banded krait, Asn17 is
flipped through ~180° in a similar way as occurs when molecule A and B of rtxln-1
are compared to molecule C.
The BLAST hit number five, the Lys15Arg, Ala16Val and Met52Leu triple aprotinin
mutant has a reduced association constant with trypsin, chymotrypsin and plasmin
compared to wild type aprotinin. The Ala16Val substitution was reported to
destabilize the canonical loop conformation in the triple aprotinin mutant. However,
a glycine, alanine, serine, leucine, arginine or tryptophan residue at this position did
not destabilization the canonical loop conformation (Grzesiak et al., 2000; Cierpicki
and Otlewski, 2002). This indicates that the valine at this position may be unique in
contributing to the different conformations of the canonical loop in molecules A, B
and C.
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(a) (b)
(c) (d)
Figure 4-29 Structural comparison of rTxln-1 and four other proteins with the aprotinin-like
fold.
Molecule A, B and C of rTxln-1 are colored green. Disulfide bonds are shown as orange
sticks. (a) rTxln-1 and ten NMR models of inhibitor from Banded krait (1JC6) (yellow)
superimposed. (b) rTxln-1 and two crystal structures of Kunitz domain 1 of tissue factor
pathway inhibitor-2 (1RZ0) (blue) superimposed. (c) rTxln-1 and twenty NMR models of
dendrotoxin K (1DTK) (pink) superimposed. (d) rTxln-1 and ten NMR models of the triple
mutant of aprotinin (1LD5) (purple) are superimposed. Structural differences are discussed
in the text.
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Apart from the cysteine residues there are six other conserved residues in the five
proteins (Table 4-7; Figure 4-28). These are Gly14, Tyr25, Phe35, Tyr37, Gly39,
Asn45 and Phe47 (rTxln-1 numbering) (Figure 4-30). All these residues overlay well
upon superimposition of the structures. The side-chain of Ans45 bridges between the
N-terminal 310-helix and the second ȕ-strand, which suggests that its conservation is
important for stabilization. The conservation of Gly14 and Gly39 indicate that these
residues are important in orienting the canonical and secondary loops. The Phe35 and
Tyr37 play important roles in stabilizing the hydrophobic core of the fold. The
general roles of the other conserved amino acids may be more obscure.
It is also evident that all the aromatic residues in rTxln-1 (Phe6, Phe23, Tyr24,
Tyr25, Phe35, Tyr37 and Phe47), except Phe20, correspond to residues with
aromatic side-chains in the other three proteins. The conservation of the residues
with aromatic side-chains again signifies their importance in stabilization of the
hydrophobic core. Phe20 in rTxln-1 corresponds to a leucine residue in the Kunitz
domain 1 of tissue factor pathway inhibitor-2 and an isoleucine residue in the
inhibitor from Banded krait and dendrotoxin K. Leucine and isoleucine are aliphatic
therefore suggesting that a hydrophobic side-chain is needed in this position.
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Figure 4-30 Location of six conserved residues.
Superposition of rTxln-1 molecule A (green), inhibitor from Banded krait (1JC6)
(yellow), Kunitz domain 1 of tissue factor pathway inhibitor-2 (1ZR0) (blue),
dedrotoxin K (1DTK) (pink) and aprotinin triple mutant (1LD5) (purple). The
conserved residues Gly14, Tyr25, Phe35, Tyr37, Gly39, Asn45 and Phe47 are
labeled and their side-chains are shown as sticks. Disulfide bonds are orange sticks.
Aprotinin has four buried waters, with three of these also conserved in rTxln-1. In
both rTxln-1 and dendrotoxin K, one internal water molecule is replaced by the side-
chain atoms of Asn43 (rTxln-1 numbering). The water molecule, located between the
canonical loop and the secondary loop in rTxln-1 and aprotinin, is replaced by the
hydroxyl group of the side-chain of Ser36 (Gly38 in rTxln-1 and Gly36 in aprotinin)
in dendrotoxin K (Berndt et al., 1993). This indicates that it is important to maintain
a hydrogen bond between the secondary and canonical loops in this region. The
replacement of a serine for a glycine and water molecule could subtly alter the
structural relationships between canonical and secondary loops and therefore may be
important for inhibitor interactions, specificity and selectivity.
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Figure 4-31 Superimposition of rTxln-1
and dendrotoxin K.
Molecule A of rTxln-1 is colored green and
dendrotoxin K is yellow. Waters are shown
as spheres. One internal water molecule in
rTxln-1 is replaced by a serine side-chain in
dendrotoxin K. Molecule A of rTxln-1 is
green. Dendrotoxin K is yellow and its
Ser36 side-chain is displayed as a yellow
stick with an oxygen colored red. Internal
water molecules are represented as green
spheres.
(a) (b)
Figure 4-32 Replacement of one internal water molecule, (in aprotinin), by an asparagine
side-chain in rTxln-1 and dendrotoxin K.
Waters are shown as spheres. rTxln-1 is green, aprotinin blue and dendrotoxin K yellow.
(a) Overall view. (b) Zoomed in on the asparagine residues.
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4.11 Comparison between the six amino acid sequences of
textilinin-1 to 6
The sequences of five other textilinin molecules have been determined (Filippovich
et al., 2002). They all possess the six conserved cysteine residues, which form three
disulfide bridges in rTxln-1, and the six conserved residues that make up the
aromatic hydrophobic core (Phe23, Tyr24 (His in Txln-5 and -6), Tyr25, Phe35,
Tyr37 and Phe47) in rTxln-1. Thus it is likely these molecules have an aprotinin like
fold. Interestingly, the residues Tyr37-Gly38-Gly39 in the secondary loop are also
absolutely conserved.
One region where rTxln-1 and aprotinin differ in backbone structure is between
Gly42 and Asn46. In all of the textilinin sequences this region is also conserved. One
reason for the difference in the structure is that the side-chain of Tyr10 in aprotinin
makes van der Waals contacts with both the side-chain and backbone of Arg39 and
side-chain of Lys41, while the corresponding side-chain Asp12 in rTxln-1 extends
out into the solvent. In the sequences of Txln-1, -2, -4, -5 and -6, position 12 is an
asparagine while in Txln-3 it is a glutamate. The conservation of residues 42-46 and
an asparagine or a glutamate at position 12 suggests that the other five textilinin
molecules will adopt a similar structure to rTxln-1 in this region. Gly42 in rTxln-1
gives the polypeptide chain of rTxln-1 flexibility to form a stabilizing hydrogen bond
to the hydroxyl group of Tyr37, Asn43 replaces one of the four internal water
molecules typically observed in aprotinin, Asn45 bridges the N-terminal 310-helix
(residue 9) with the ȕ-hairpin and Asn46 is likely to contribute with stability of the
hydroxyl group of Tyr37. The conservation of these residues indicates that they have
a similar role in all texilinin molecules.
The greatest variation of residue type occurs in the canonical loop region and the
ȕ-hairpin loop region. Arg17 in the canonical loop of rTxln-1 is a determinant for its
plasmin inhibition activity. Txln-1 and 2 have an arginine residue and Txln-4 has a
lysine residue at position 17, followed by a small amino acid (valine residue in
textilinin-1 and 2, and a glycine residue in textilinin-4). This suggests that Txln-4 has
a specificity for serine proteases that binds residues with a positively charged side-
chain in their specificity pocket similar to trypsin and plasmin. Residues 12-18 of
Txln-3 align with identical residues in the canonical loop of the inhibitor from
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Banded krait, which has been reported to bind to chymotrypsin with the side-chain of
Asn17 protruding into the specificity pocket (C. Chen et al., 2001a). This indicates
Txln-3 may be a chymotrypsin inhibitor even though chymotrypsin typically binds a
hydrophobic side-chain in its specificity pocket. Both Txln-5 and -6 have a residue
with a negatively charged side-chain in the P1 position (Glu17 in Txln-5 and Asp17
in Txln-6) followed by the sequence Asp18-Phe19-Thr20-Gly20-Ala21. This
indicates that these inhibitors may have similar targets to each other but have
different specificities when compared to Txln-1.
Phe20 in rTxln-1 is isoleucine in Txln-3, valine in Txln-4 and threonine in Txln-5
and Txln-6. Phe20 in rTxln-1 is at the extremity of the canonical and may only play a
minor role in binding to proteases. The large variation in sequence suggests it is a
residue responsible for fine tuning the selectivity and specificity of these inhibitors.
The sequence in the ȕ-hairpin loop in the rTxln-1 (27-29) all the six Txln molecules
varies considerably. Position 27 is generally occupied by a small hydrophobic
residue, typically proline for Txln-1, -2, -3 and 6. The amino acid at position 28 is
always charged, with three Txln molecules having aspartate and three having
arginine. Position 29 tends to be negatively charged with three Txln molecules
having a glutamate and one aspartate. In contrast aprotinin has the sequence Ala25-
Lys26-Ala27 for the ȕ-hairpin loop.
Figure 4-33 Amino acid sequence alignment of the six textilinin molecules; Txln-1 to 6.
24 amino acid pro-peptide and 59 amino acid mature peptide, the cysteine residues and
conserved regions are shadowed and the disulfide bonds in Txln-1 are shown. Canonical,
secondary and ȕ-hairpin loops are marked with orange bars.
Txln-1 MSSGGLLLLLGLLTLWEVLTPVSSKDRPDFCELPADTGPCRVRFPSFYYNPDEKKCLEFIYGGCEGNANNFITKEECESTCAA
Txln-2 MSSGGLLLLLGLLTLWEVLTPVSSKDRPELCELPPDTGPCRVRFPSFYYNPDEQKCLEFIYGGCEGNANNFITKEECESTCAA
Txln-3 MSSGGLLLLLGLLTLWEVLTPVSSKDRPNFCKLPAETGRCNAKIPRFYYNPRQHQCIEFLYGGCGGNANNFKTIKECESTCAA
Txln-4 MSSGGLLLLLGLLTLWEVLTPVSSKDHPKFCELPADTGSCKGNVPRFYYNADHHQCLKFIYGGCGGNANNFKTIEECKSTCAA
Txln-5 MSSGGLLLLLGLLTLWEVLTPVSSKDRPKFCELLPDTGSCEDFTGAFHYSTRDRECIEFIYGGCGGNANNFITKEECESTCAA
Txln-6 MSSGGLLLLLGLLTLWEVLTPVSSKDRPKFCELPADIGPCDDFTGAFHYSPREHECIEFIYGGCKGNANNFNTQEECESTCAA
| | | | | | | | | | | | |
1 5 10 15 20 25 30 35 40 45 50 55 59
Pro-peptide
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4.12 Summary
The structure of rTxln-1 has been determined by molecular replacement to a
resolution of 1.63 Å. Unusually, three molecules of rTxln-1 are observed in the
asymmetric unit of the crystals. All of these molecules have an aprotinin-like fold
stabilized by three disulfide bonds and three internal water molecules. For two of the
rTxln-1 molecules, the canonical loop adopts a classical shape, extending out into the
solvent. However, for the third molecule this loop is inverted, with the side-chain of
Val18 forming non-covalent interactions with Thr13 and Ile36. While it is a rare
observation that this loop can become inverted, it is not without precedence, as a
similar structure has been observed in the NMR models of the inhibitor from Banded
krait (C. Chen et al., 2001a). In addition, an Ala16Val mutant of aprotinin was also
shown to have a destabilized canonical loop (Grzesiak et al., 2000; Cierpicki and
Otlewski, 2002). If the canonical loop is more flexible in rTxln-1 compared to
aprotinin, this could begin to explain the faster off-rate this molecule has for plasmin
than what does aprotinin (Chapters 1 and 6).
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Chapter 5
Crystal structure of the rTxln-1-trypsin complex
5.1 Introduction
rTxln-1 is a nanomolar inhibitor of both human plasmin (Ki=14±3 nM and
Ki*=0.49±0.02 nM) and bovine trypsin (Ki*=0.76±0.2 nM) (Flight et al.,
unpublished). Kinetic analysis revealed a competitive, reversible mechanism for the
binding of rTxln-1 to trypsin, prior to inhibitor modification. Previously, a slow
inactivation of rTxln-1 was observed, presumably due to enzymatic cleavage
(Willmott et al., 1995). Regulation of serine proteases by inhibition has evolved to
include three types of natural inhibitors that have been categorized based on their
mode of binding to their target serine protease. These inhibitors are canonical, non-
canonical and serpin inhibitors (Krowarsch et al., 2003). The canonical inhibitors
have an exposed loop, which interacts in a substrate-like manner with their target
enzyme (Bode and Huber, 1992; Krowarsch et al., 2003). Aprotinin is a canonical
inhibitor of serine proteases and rTxln-1 is predicted to be a canonical inhibitor of
trypsin and plasmin. Both molecules have the same fold and disulfide bond
connectivities (Chapter 4). However, aprotinin is greater than 1.3 x 104 times more
efficient than rTxln-1 in inhibiting trypsin and 15 times more efficient in the
inhibition of plasmin (Flight et al., unpublished). The canonical loop of aprotinin fits
with precise structural complementary to the active site of trypsin (pdb file 2PTC
(Marquart et al., 1983)). The fit is tight with strong interactions and a life time, of the
order of several months. Based on these data it is suggested that rTxln-1 binds in a
similar but not identical fashion to trypsin as aprotinin. Some preliminary
mutagenesis studies were carried out to identify the binding residues of rTxln-1
(Filippovich et al., 2002). This work showed that plasmin inhibition was completely
lost with the Arg17Ala mutation suggesting that the side-chain of this residue binds
in the specificity pocket of plasmin or trypsin, and is a major contributor to the
affinity of rTxln-1 towards these proteases (Filippovich et al., 2002).
rTxln-1 and aprotinin only share 45% sequence identity, suggesting that there should
be differences in the mode of binding of these inhibitors. The slow inactivation of
rTxln-1 is an observation in common with the serpin inhibitors, but is in direct
contrast to most other serine proteases inhibitors, which remain active after being
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cleaved by their target enzyme (M. J. Laskowski and Kato, 1980; M. J. Laskowski
and Qasim, 2000).
Trypsin has a strong preference for cleaving protein substrates after the positively
charged residues arginine or lysine (Craik et al., 1985). The important catalytic triad
consists of an aspartate, histidine and serine. In trypsin, Ser195 (chymotrypsin
numbering system which is used throughout this chapter) acts as a nucleophile in the
hydrolysis, His57 is believed to act as a general base and Asp102 stabilizes the
positive charge developed during the catalytic reaction (Warshel et al., 1989; Perona
and Craik, 1995). A high-affinity calcium binding site is also a structural feature of
trypsin (Bode and Schwager, 1975).
A nomenclature to describe the interaction of a substrate with a protease applies
numbers to the amino acid residues of the polypeptide substrate on the N-terminal
side of the scissile bond as P3, P2, P1, and those residues on the C-terminal side as
P1', P2', P3' (Schechter and Berger, 1967). The subsites on the protease that
accommodate the substrate residues are numbered S3, S2, S1, S1', S2', S3'
accordingly. In trypsin, the substrate specificity is primarily determined by the
negatively charged Asp189 side-chain, which lies at the bottom of the S1 specificity
pocket and interacts with the positively charged side-chain of the P1 residue of the
substrate (Graf et al., 1987). In the interaction between a canonical inhibitor and
protease, the side-chain of the P1 residue of the canonical loop is inserted into the S1
specificity pocket and the carbonyl oxygen of the P1 residue extends towards the
oxyanion hole formed by the main chain amides of Gly193 and Ser195 (Ruehlmann
et al., 1973; M. J. Laskowski and Kato, 1980; Bode and Huber, 1992). Another
highly conserved feature of canonical inhibitor-serine protease complexes is a short
antiparallel ȕ-sheet interaction that occurs between the P1-P3 residues of the
canonical inhibitor and the three residues on the surface of the protease (214-216)
(Ruehlmann et al., 1973; Otlewski et al., 2005).
Trypsin is produced in the pancreas as the inactive precursor, trypsinogen. It moves
to the small intestine where it becomes activated and degrades other proteins.
Pancreatitis is inflammation of the pancreas. When the pancreas becomes inflamed,
digestive enzymes attack the tissue that produces them. One is trypsin, which causes
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tissue damage and bleeding, and can cause the pancreatic blood cells and blood
vessels to swell. Pancreatitis most often begins at an acute stage and may become
chronic. One risk group is patients who undergo endoscopic procedures (mainly
endoscopic retrograde cholangiopancreatography), while other contributing factors
include alcohol or gallstones. Hereditary and/or sporadic pancreatitis may be due to
enhanced trypsinogen autoactivation and/or reduce trypsin autolysis (J.-M. Chen et
al., 2001b) (Whitcomb et al., 1996). Trials using aprotinin to therapeutically treat
pancreatitis have had mixed success. One study using a high dose of aprotinin
reduced mortality (Trapnell et al., 1974), however, subsequent studies did not
confirm this result (MRC, 1977; Imrie et al., 1978; MRC, 1980). Knowledge of the
crystal structure of the rTxln-1-trypsin complex will help to further establish the
structural features necessary for the development of trypsin specific inhibitors that
could be developed to treat diseases such as pancreatitis.
A crystal structure of the rTxln-1-trypsin complex allows the determination of the
binding mode of rTxln-1 to bovine trypsin and helps to understand the specificity and
potency of binding. It also permits comparison with the structure of free rTxln-1 to
determine the structural changes upon binding and comparison with aprotinin
binding to trypsin. This chapter describes the procedures to determine the structure of
the rTxln-1-trypsin complex and then goes on to analyse this structure by comparison
with the structures described above.
5.2 Phase determination, model building and refinement
of rTxln-1-trypsin
The program EPMR (Kissinger et al., 1999) which carries out a six-dimensional
search for molecular replacement solutions by randomly changing the three
positional coordinates and the three rotational parameters and then applying an
evolutionary search algorithm was chosen to solve the phase problem. The search
model for the study was bovine trypsin with pdb code 3PTN.
The calculation of correlation coefficient for the molecular replacement is based on
structure factors. Therefore, the intensities measured (Chapter 3) were converted to
structure factors using TRUNCATE (French and Wilson, 1978). This data was then
sorted and put into the correct asymmetric unit using CAD (CCP4, 1994).
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MTZ2VARIOUS (Dodson, 1992) converted the file to import into EPMR and CNS
(Brünger et al., 1998). Based on solvent content arguments it appeared most likely
that there was only one complex in per asymmetric unit. Therefore, the search model
was a single molecule of trypsin. The space group for the crystal was assumed to be
P3121 (Chapter 3) with all the data between 15–4 Å resolution used in these
calculations. The evolutionary search procedure was set to run ten times unless the
correlation coefficient value for any solution was greater than 0.30. In that case the
program would terminate early. Each evolutionary search was carried out over 50
generations using a population size of 300. The correlation coefficient between Fo
and Fc was used to evaluate the fitness of the solutions. In this search, the program
stopped after the seventh run by finding a solution with a correlation coefficient of
0.60 and a crystallographic Rfactor of 0.40.
5.3 Refinement of the rTxln-1-trypsin complex crystal
structure
The electron density was visualized in the graphics program O (Jones and
Kjeldgaard, 1998) and revealed the presence of a rTxln-1 molecule bound in the
active site of the trypsin molecule. The rTxln-1 was then docked into the vacant
electron density. Examination of the packing within the unit cell indicated reasonable
contacts between the complexes and no overlap of symmetry related molecules
(Figure 5-1). The structure factors used for refinement in CNS were divided into two
sets, with 90% of the data used for refinement (Rfactor) and 10% used for cross-
validation (Rfree). To encourage adjustment of the model to the data, the two
molecules in the asymmetric unit were initially treated as two single rigid bodies.
Next, simulated annealing was carried out, using the data from 50.0-2.5 Å resolution.
This reduced the Rfactor to 0.32 and Rfree to 0.35. Several cycles of model building and
simulated annealing were then performed and water molecules were added reducing
the Rfactor to 0.23.
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Figure 5-1 The crystal packing of the rTxln-1-trypsin complex.
rTxln-1 is yellow and trypsin is purple. The unit cell is shown in green with the a and c axes
marked in red.
This crystal structure was used as the starting point for further refinement when a
second data set, collected to 1.63 Å was obtained. This refinement was carried out in
REFMAC5 (Murshudov et al., 1997), with modeling using Coot (Emsley and
Cowtan, 2004). Data used in the refinement ranged from 37.42–1.64 Å, with 5% of
reflections used for the Rfree test set (2413 reflections). All atoms were refined with
individual isotropic B-factors. Arp_water (Lamzin and Wilson, 1993) was used to
place all of the water molecules and a Ca2+ ion.
5.4 Refinement statistics and quality of rTxln-1-trypsin
complex crystal structure
The final model includes residues 3-58 of rTxln-1 and residues 16-245 of bovine
trypsin. The electron density map is, in general, well defined for both the rTxln-1
molecule and trypsin molecule and an unambiguous trace of the backbone atoms
could be made. One Ca2+ ion with 60% occupancy and 279 water molecules were
also fitted to the electron density. The final Rfactor and Rfree were 0.21 and 0.24,
respectively. The difference of only 3% suggests that the model was not overrefined
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or biased. The overall geometry of the model is excellent with an rmsd from ideal
bond lengths of 0.019 Å and an rmsd from ideal bond angles of 1.67o (Table 5-1).
Table 5-1 Refinement statistics for the rTxln-1-trypsin complex
Non-hydrogen atoms
rTxln-1 445
Trypsin 1629
Total number of protein atoms 2074
Solvent (H2O)
Ca2+
279
1
Resolution (Å) 37.42 – 1.64
Rfactor 0.2127
Rfree 0.2455
rmsd from ideal geometry
Bond lengths (Å) 0.019
Bond angles (o) 1.67
Rfactor = ||Fobs| – |Fcalc||/|Fobs|, 5% of the data were excluded
from the refinement were used to calculate Rfree.
The average B-value for the main-chain (side-chains) atoms is 29.8 Å2 (33.7 Å2) for
rTxln-1 and 22.4 Å2 (24.4 Å2) for trypsin (Table 5-2). Thus, rTxln-1 is on average
marginally more mobile than trypsin. Residues 26–31 and the N-terminal and C-
terminal residues in the rTxln-1 and the C-terminal residues and the solvent exposed
loop consisting of residue 125-155 in trypsin have the highest B-values (Figure 5-2;
Figure 5-3; Figure 5-4). The rigid positions of Pro15, Cys16 and Arg17 in the
canonical loop are demonstrated by a local minimum B-value for both backbone and
side-chain atoms (Figure 5-2). In trypsin, B-values for residues in the catalytic triad
His57, Asp102 and Ser195 are lower than the average B-values for the other atoms in
trypsin (Figure 5-3). This B-value analysis which shows gradual changes in values
throughout the polypeptide chains supports that the structure has been correctly
refined. Moreover, high B-values are generally associated with mobile loop regions,
N- and C-termini or exposed side-chains while low B-values correspond to the core
amino acids residues.
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Table 5-2 Mean B-values (Å2) for the rTxln-1-trypsin complex
rTxln-1
main-chain
side-chain
all atoms (445 atoms)
Trypsin
main-chain
side-chain
all atoms (1629 atoms)
H2O (279 atoms)
Ca2+ (1 atom)
Total
29.8
33.7
31.7
22.4
24.4
23.2
35.1
23.0
main-chains 23.8
side-chains and waters 28.5
all atoms (2354 atoms) 26.2
Mean B-values were calculated using the CCP4 program
BAVERAGE (CCP4, 1994)
Figure 5-2 B-values (Å2) for rTxln-1 in the complex. Residues 14, 38, 39 and 42 are glycine
and therefore have no side-chain B-values.
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Figure 5-3 B-values (Å2) for trypsin in the complex. Glycine residues have no side-chain
B-value.
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Figure 5-4 Visualization of the B-values for the rTxln-1-trypsin complex.
High main-chain high B-values are represented by red, thick tubes. Low B-values are
represented by blue, thin tubes. Side-chains are shown as sticks and are color coded.
The Ramachandran plot shows 87.6% of residues in the most favored regions, 12.0%
of residues in additionally allowed regions, and 0.4% in generously allowed regions
(Table 5-3). There are no residues in disallowed regions. The only residues of
rTxln-1 outside the most favored regions in the plot are Glu41, Asn43, Asn45 and
Asn46. These residues are in additionally allowed regions except Glu41 which is in a
generously allowed region, as previously identified in free rTxln-1 (Chapter 4).
Arg17, Val18 and Arg19 which are part of the canonical loop all have favorable
dihedral angles. There are no trypsin residues in disallowed regions. His57 and
Ser195 of the catalytic triad have backbone dihedral angles in the most favored
regions, while Asp102 is in a generously allowed region (Figure 5-5).
Table 5-3 Ramachandran plot statistics for the rTxln-1-trypsin complex
Residues (%)
Most favored regions 87.6
Additionally allowed regions 12.0
Generously allowed regions 0.4
Disallowed regions 0.0
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Figure 5-5 Ramachandran plot of the rTxln-1-trypsin complex.
A (Į-helix), B (ȕ-sheet) and L (left handed Į-helix) are the most favoured regions. a, b and c
are additionally allowed regions, and ~a, ~b, ~l, ~p are generously allowed regions. Glycine
residues are identified as triangles. Residues of rTxln-1 are denoted by an I after their residue
number. Arg17I, Val18I, Arg19I, Glu41I, Asn43I, Asn45I and Asn46I of rTxln-1 and the
catalytic triad His57, Asp102 and Ser195 of trypsin are marked with white circles. This plot
was generated by Procheck (R. A. Laskowski et al., 1993).
5.5 Crystal structure of the rTxln-1-trypsin complex
The rTxln-1-trypsin complex measures 56 Å in length, with the trypsin and rTxln-1
having dimensions of 32 x 45 x 36 Å and 35 x 17 x 15 Å, respectively. The complex
has the shape of a mushroom, with trypsin acting as the head and rTxln-1 as the
stalk. The trypsin model consists of one 223 amino acid polypeptide chain that
comprises two open-ended ȕ-barrels, one in the N-terminal domain with 7 strands,
and one in the C-terminal domain with 6 strands (Figure 5-6). The active site is made
up of loop regions from each domain and is situated in a crevice between the two
domains, with the catalytic residues His57, Asp102, and Ser195 bridging the two
barrels. The calcium binding loop consists of residues Glu70-Glu80 which connects
two antiparallel ȕ-strands. This ion is bound by six ligands, Glu70Oİ1, Asn72O,
Val75O, Glu80İ2 and two water molecules positioned at the edges of an almost
regular octahedron. Trypsin and the rTxln-1 have the same secondary structures as
observed in their free structures.
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Figure 5-6 Stereodiagram of the overall fold of the rTxln-1-trypsin complex.
The rTxln-1 is colored yellow (ȕ-strands), red (Į-helices) and green (loops). Trypsin is
colored purple (ȕ-strands), blue (Į-helices), pink (loops) and green (Ca2+ as a sphere). Shown
is how rTxln-1 docks into the crevice created by the two ȕ-barrels in trypsin.
5.6 The interface between rTxln-1 and trypsin
The total buried surface area in the complex is 1354 Å2, 588 Å2 from rTxln-1 and
768 Å2 from trypsin (CCP4 AREAIMOL, (B. Lee and Richards, 1971)). Only a
minor portion of both molecules are in contact in the complex with 8 residues out of
59 of the inhibitor, and 15 residues out of 225 of trypsin forming interactions.
However, the fit is highly complementary and the interface is tightly packed due to a
complex network of hydrogen bonds, an ionic bond, hydrophobic interactions and
numerous van der Waals contacts. The majority of interactions are between residues
15-19 (P3-P2') and trypsin (Figure 5-7). This region binds in a canonical-like manner
to trypsin (Bode and Huber, 1992). Residues 36-40 (secondary binding loop) also
form interactions with trypsin.
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Figure 5-7 Interactions between rTxln-1 and trypsin.
Distances between atoms are marked with dashed lines and are in Å units. rTxln-1 residues
are labeled in red and are identified by an I. Trypsin residues are labeled in blue. An ionic
bond is formed between Arg17(I) and Asp189 which is at the bottom of the specificity
pocket of trypsin. Ser195 of trypsin makes a closer than van der Waals interaction (2.68 Å)
with the carbonyl carbon of Arg17(I). (Figure generated using ChemSketch (ACD/Labs,
2003).
One common structural feature in canonical inhibitor serine protease complexes is an
antiparallel ȕ-sheet interaction formed between the P1-P3 residues, Pro15-Cys16-
Arg17 in rTxln-1, and three residues in trypsin (Gly216-Trp215-Ser214). In this
complex a hydrogen bond between Pro15O(I) and Gly216O of trypsin (3.01 Å) is
observed but Arg17N(I) and Ser214O are just outside hydrogen bonding distance
(3.31 Å). A kink in the rTxln-1 polypeptide at Pro15(I) puts its amide nitrogen 4.48
Å from Gly216O of trypsin. However, Cys16O(I) and the side-chain nitrogen of
Gln192 do form a hydrogen bond (2.90 Å). Pro15(I) is further stabilized by
hydrophobic contacts to Trp215 (Figure 5-7).
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The S1 specificity pocket in trypsin is lined by backbone atoms from residues
190-195, 214-220 and 226-227, the disulfide bridge Cys191-Cys220, and the side-
chains of Tyr228 and Ser190. Asp189 is situated at the bottom of this pocket. The P1
residue of rTxln-1, Arg17(I) protrudes into this pocket with the guanidine group
forming an ionic bond with the carboxylate of Asp189 (2.67 Å and 2.87 Å) and a
hydrogen bonds to Ser190O (3.15 Å) and Ser190OȖ (2.91 Å). While Arg17NȘ2(I)
hydrogen bonds to Gly219O (2.85 Å). There are two buried water molecules present
in the pocket. One bridges between Arg17NȘ1(I) (3.23 Å) and Val227O (3.04 Å).
The other water molecule bridges between Arg17Nİ(I) (2.86 Å), Gly216O (2.87 Å)
and Gln192Nİ2 (2.91 Å). The carbonyl oxygen of Arg17(I) extends towards the
oxyanion hole formed by the backbone atoms of Gly193N (2.75 Å) and Ser195N
(2.85 Å) (Figure 5-7).
The S1' subsite in trypsin is lined by the side-chains of Phe41, and His57, and the
Cys42-Cys58 bridge. The side-chain of the P1' residue, Val18(I), points inside this
pocket and is stabilized by hydrophobic interactions with the side-chains of these
residues. The S2' subsite is a half open channel bordered by the side-chains of Tyr39
and Tyr151. The side-chain of the P2' residue, Arg19(I), fills this site but is also
exposed to solvent and forms a hydrogen bond to a water molecule (2.80 Å) which
bridges to His40O (3.06 Å) of trypsin. Arg19N(I) also forms a hydrogen bond to
Phe41O (3.16 Å) (Figure 5-7).
The disulfide bond between Cys16(I) and Cys40(I) connects the canonical loop to
the secondary loop. It interacts with the surface of trypsin by forming a hydrophobic
contact with side-chain of Leu99 (~ 3.7 Å). Both the Gly38(I)CĮ and the side-chain
of Ile36(I) are in hydrophobic contact with the side-chain of Gln192 (3.8 Å and 3.4
Å, respectively) (Figure 5-7).
The reaction carried out by trypsin is to cleave the P1-P1' bond. It is believed that
initially, Ser195 transfers a proton from its side chain hydroxyl group to the
imidazole ring of His57 in trypsin. This activates the hydroxyl oxygen of Ser195 to
attack the carbonyl carbon atom of the susceptible peptide bond in the substrate,
leading to the formation of a covalent bond between the carbonyl carbon atom in the
substrate and Ser195OȖ (Barrett et al., 1998; Radisky et al., 2006). In the rTxln-1-
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trypsin complex Ser195OȖ is 2.68 Å away from the P1 carbonyl carbon atom. This
distance is therefore shorter than a van der Waals bond (>3.4-4 Å), but longer than a
covalent bond (~1.43 Å). The bond angle between Ser195Cȕ-Ser195OȖ-Arg17C is
103.3o. This angle is close to that for a sp3 bent hybridization configuration of an
oxygen atom in a water molecule (the H-O-H angle in water is 105o). His57Nİ2 in
trypsin is 2.62 Å away from Ser195OȖ, which is the shortest distance to any of its
surrounding neighbors, with a bond angle of 97.4o for His57Cİ1-His57Nİ2-
Ser195OȖ. The His57Nİ2 is therefore ideally placed to deprotonate Ser 195OȖ
activating the oxygen for nucleophilic attack on the carbonyl carbon of the P1
residue. However, the normal proteolytic reaction is arrested somewhere along the
reaction coordinate between the Michaelis complex and the tetrahedral intermediate
(Figure 5-8).
Figure 5-8 Stereo view of rTxln-1 bound in the active site of trypsin.
Residues Arg17 and Val18 of rTxln-1 are yellow, the catalytic triad of trypsin (His57,
Asp102 and Ser195) is purple. Oxygen and nitrogen atoms are red and blue respectively. The
hydrogen atom (grey) of Ser 195OȖ has been modeled into the active site to show it bonding
to His57Nİ2. Distances are in Å units.
The electron density around the scissile peptide bond is well defined. It is clear that
in the crystal structure no tetrahedral intermediate formation has taken place, and that
the P1-P1' bond is still intact. The shape of the electron density suggests that there is
some distortion towards the tetrahedral intermediate. Unfortunately, it is not possible
to determine the extent of movement towards the intermediate in detail at a
resolution of 1.64 Å (Figure 5-9).
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Figure 5-9 Stereo view of the 2Fo-Fc electron density map contoured at 1ı for the rTxln-1-
trypsin complex.
The electron density is displayed as light grey mesh. Carbon atoms of rTxln-1 and trypsin
are colored yellow and purple, respectively.
Figure 5-10 The interface between rTxln-1 and trypsin.
Pro15(I)-Arg19(I) and Cys40(I) of rTxln-1 are shown as yellow sticks and covered with a
transparent Connolly surface. Carbon atoms are yellow, nitrogen blue, oxygen red. The
disulfide bridge is orange. rTxln-1 is covered with a transparent Connolly surface. The
Connolly surface of trypsin is shown with the electrostatic surface mapped. Residues of
rTxln-1 are in black labels and residues of trypsin are in white labels or grey. The side-chain
of Arg17(I) reaches into the specificity pocket, and its carbonyl oxygen is positioned in the
oxyanion hole. Arg19(I) in rTxln-1 is between the side-chains of Tyr39 and Tyr151 of
trypsin.
5.7 Crystal contacts
Mass spectrometry (Chapter 2) indicated that not only a 1:1 complex of trypsin and
rTxln-1 could form upon incubation (MW = 30 kDa) but also a species of 37 kDa was
present, suggesting that one molecule of trypsin could combine with two molecules
of rTxln-1. An analysis of the crystal packing contacts could reveal how the ternary
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complex could form. Therefore, all possible crystal contacts were investigated to see
if two rTxln-1 molecules docked to trypsin and if the important features of rTxln-1 or
trypsin were affected by these contacts.
Analysis of the crystal packing revealed that rTxln-1 and trypsin are forming crystal
contacts. In forming the complex, one rTxln-1 molecule binds in the active site of
trypsin but a second rTxln-1 molecule within the crystal is observed to bind tightly to
trypsin with a buried surface area of 852 Å2 (Figure 5-11(a)). Contact is through
interactions between the Į-helix of rTxln-1 and the C-terminal Į-helix of trypsin. In
particular the side-chains of Ile48(I) and Thr49(I) are shielded from the solvent by
Cys128 and Cys232 of trypsin. A hydrogen bond is formed between one side-chain
oxygen atom of Glu51(I) and the side-chain atom Asn233Nį2 of trypsin (3.11 Å).
This oxygen atom also forms a hydrogen bond to a water molecule (2.62 Å), which
bridges to Ser178O (2.61 Å) and Lys230Nȗ (2.76 Å) of trypsin, and to another water
molecule (2.39 Å) bridging to Asn233Oį1 (2.76 Å) of trypsin. The second side-chain
oxygen atom of Glu51(I) forms a hydrogen bond to Ser178OȖ (2.74 Å). The side-
chain of Glu52(I) locks neatly into the C-terminal Į-helix of trypsin, with its side-
chain interacting with the backbone nitrogen atoms of Val235, Ser236 and Trp237
and with three water molecules (Figure 5-11(b)). This is the only surface where a
second molecule of rTxln-1 interacts with trypsin and is therefore the only candidate
representative to show how a second molecule of rTxln-1 could bind to trypsin based
on crystal packing.
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(a) (b)
Figure 5-11 Crystal contacts between a symmetry related rTxln-1 molecule and trypsin.
rTxln-1 is yellow and trypsin is purple. (a) The buried surface area between the C-terminal
Į-helix of rTxln-1 and the C-terminal Į-helix of trypsin is 852 Å2. (b) Residues and waters
that form interactions at the interface. Side-chains are represented as sticks with carbon in
yellow for rTxln-1 and purple for trypsin, nitrogen atoms are in blue and oxygen atoms are in
red. Water molecules are shown as red spheres.
Figure 5-12 Two of the largest interfaces in the crystal packing of rTxln-1-trypsin complex.
The rTxln-1 is yellow and trypsin purple. Two large contact areas one 842 Å2 and the other
787 Å2 are formed between trypsin molecules.
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Two large buried surface areas are formed between the central trypsin molecule and
two neighboring trypsin molecules at 842 Å2 and 787 Å2 (Figure 5-12). Neither of
these contacts is in the active site or affects the conformation of the canonical loop or
the secondary loop of rTxln-1. Thus none of the crystal contacts appears to influence
how rTxln-1 inhibits trypsin in this structure.
5.8 Comparison between rTxln-1 in the trypsin complex
and free rTxln-1
To study whether the interaction between rTxln-1 and trypsin induces
conformational changes, the structures of the free and complexed rTxln-1 to trypsin
are compared. The B-value graphs for all atoms can also be compared as a measure
of differences in conformational dynamics between the rTxln-1 structures.
Visual analysis of a superposition of rTxln-1 bound to trypsin and molecule A, B and
C of free rTxln-1, reveals that the overall main-chain overlays well, the disulfide
bonds all have the same chirality and the location of three internal water molecules is
completely conserved (Figure 5-13). Least-square fitting of CĮ atoms (and all atoms
including side-chains) for residues 3-58 of rTxln-1 bound to trypsin compared to
molecules A, B and C of free rTxln-1, resulted in rmsd values of 0.64 Å (1.96 Å),
0.41 Å (1.72 Å), and 0.88 Å (2.63 Å), respectively. The difference in the canonical
loop structure explains the high rmsd when molecule C of rTxln-1 is compared with
trypsin bound rTxln-1. The rmsds between residues in the canonical loop (residues
15-20), comparing trypsin bound rTxln-1 with molecule A, B and C of free rTxln-1
are 0.49 Å (2.71 Å), 0.24 Å (2.39 Å), and 1.46 Å (5.43 Å), respectively, showing that
molecule B and to lesser extent molecule A in the free rTxln-1 structure mimic the
structure when bound to trypsin. Comparing only trypsin bound rTxln-1 to molecule
A and B of free rTxln-1, the dihedral angles for Arg17, Val18 and Arg19 are ĭ=-
108.3o and Ȍ=32.6o, ĭ=-73.24o and Ȍ=159.4o and ĭ=-103.8o and Ȍ=110.4o,
respectively, in trypsin bound rTxln-1, ĭ=-126.35o and Ȍ=33.1o, ĭ=-96.0o and
Ȍ=101.6o and ĭ=-83.1o and Ȍ=102.9o, respectively, in molecule A of free rTxln-1,
and ĭ=-125.9o and Ȍ=36.4o, ĭ=-110.5o and Ȍ=176.7o and ĭ=-103.8o and Ȍ=110.4o,
respectively, in molecule B of free rTxln-1. Thus, the dihedral angles for Arg17,
Val18 and Arg19 vary less between trypsin bound rTxln-1 and molecule B of free
rTxln-1 (the total variation is 113.0o) than trypsin bound rTxln-1 and molecule A of
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free rTxln-1 (the total variation is 127.1o). Thus overall there is only a small
difference between the structure of the backbone of the canonical loop when bound
to trypsin and in molecule A and B of free rTxln-1. However, most of the side-chains
in trypsin bound rTxln-1 and molecule A and B of free rTxln-1 have different
dihedral angles. The side-chain of Arg17 has to rotate its dihedral angle Ȥ4 120o in
molecule A of free rTxln-1 and its dihedral angle Ȥ3 120o in molecule B of free
rTxln-1 to obtain the elongated conformation observed in the trypsin bound rTxln-1.
The side-chain of Val18 in molecule A of free rTxln-1 has the same Ȥ1 as observed in
the rTxln-1-trypsin complex, but in molecule B of free rTxln-1 this value differ by
100o. The dihedral angles Ȥ1, Ȥ3 and Ȥ4 of Arg19 in molecule A of free rTxln-1 have
to rotate by 210o, 70o and 160o, while the dihedral angles Ȥ3 and Ȥ4 of Arg19 in
molecule B of free rTxln-1 have to rotate by 160o and 180o to have a similar
conformation as Arg19 in trypsin bound rTxln-1 (Figure 5-14). Thus, the side-chains
of Arg17 and Arg19 in molecule A and B of free rTxln-1 and the side-chain of Val18
in molecule B of free rTxln-1 have to adjust their dihedral angles to dock into
trypsin.
Figure 5-13 Stereo view of the superposition of free rTxln-1 and trypsin bound rTxln-1.
Trypsin bound rTxln-1 is yellow, molecule A of free rTxln-1 is green, molecule B of free
rTxln-1 is blue and molecule C of free rTxln-1 is purple. Disulfide bonds are displayed as
orange sticks. The canonical loop of trypsin bound rTxln-1 has a similar conformation as
molecule A and B of free rTxln-1 but is different compared to molecule C of free rTxln-1.
The distance between Val18CĮ of trypsin bound rTxln-1 and free rTxln-1 molecule C is
shown as a dashed black line and is in Å units.
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Figure 5-14 Stereo view of the canonical loop region of free and trypsin bound rTxln-1.
Bound rTxln-1 (pink), free rTxln-1 molecule A (green), molecule B (blue) and molecule C
(purple). Disulfide bonds are displayed as orange sticks. Side-chains of Arg17-Val18-Arg19
are displayed as sticks. The canonical loop in rTxln-1 bound to trypsin and molecule A and
B of free rTxln-1 overlay well.
B-values reflect to a first approximation positional variation of atoms over time and
are therefore provide insight into the dynamics of the protein (Ringe and Petsko,
1986; Parthasarathy and Murthy, 2000). However, B-values are also influenced by
crystal order, diffraction resolution, atom occupancy and restraints used for the
refinement. The crystal morphology and size varied between the crystals of rTxln-1-
trypsin and free rTxln-1, and most likely the overall order. It is evident from Figure
5-15 that the overall patterns of the main-chains and side-chains B-values are similar
for the structures of trypsin bound rTxln-1 and free structures. However, the main-
chain B-values for trypsin bound rTxln-1 are systematically larger than those for the
free rTxln-1 structures. The overall patterns of the side-chain B-values are similar.
The most striking change upon forming the compex is the reduction in B-factor value
of the side-chain of Arg17. The main-chain B-values for residues 18-22 are in a more
obvious peak in the graph in the rTxln-1-trypsin complex compared to the
corresponding graph for molecule B and C of the free structure, and is a dip in the
free structure of molecule A, which is a bit surprising as this indicates that this part
of the canonical loop has not found a stabilizing position upon forming the complex
with trypsin (Figure 5-15; Figure 5-16). The side-chain of Glu52 is in a dip which is
due to the crystal contacts described in Section 5.7 (Figure 5-15).
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Figure 5-15 B-values (Å2) for rTxln-1 bound to trypsin and the three free rTxln-1
molecules.
The orange blocks highlight the canonical loop and secondary loop region. Residues 14, 38,
39 and 42 are glycine and therefore have no side-chain B-values.
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(a) (b)
Figure 5-16 Visualization of the B-values for rTxln-1 bound to trypsin.
The main-chain of the rTxln-1 molecule is displayed with high B-values in red, thick tubes,
low B-values in blue, thin tubes and side-chains as sticks. The Connolly surface of the
trypsin molecule is colored grey. (a) rTxln-1 docked to trypsin. (b) Zoom in of the active site
of trypsin. The side-chain of Arg17 is locked into the specificity pocket of trypsin. Arg19 fits
loosely in the active site.
5.9 Comparison of the rTxln-1 trypsin complexes with an
aprotinin trypsin complex
To analyze differences in binding modes between rTxln-1 and aprotinin with trypsin
(pdb file 2PTC determined to 1.90 Å resolution (Marquart et al., 1983)), the
structures of the complexes are compared.
Visual analysis of a superposition of rTxln-1 bound to trypsin and aprotinin bound to
aprotinin bound to trypsin, shows that the main-chain atoms overlay well and the
disulfide bonds have the same chirality. Least-squares fitting of topologically
equivalent CĮ atoms between rTxln-1 and aprotinin bound to (residues 3-59 in rTxln-
1 and 1-57 in aprotinin) gives an rmsd of 0.83 Å. The canonical and secondary loops
do not deviate significantly in their backbone structures. However, a large difference
between the two structures is in the region between residues 40-45 (rTxln-1
numbering). This variation is discussed in Chapter 4, since it is also present when the
free molecules are compared (Figure 5-17).
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Figure 5-17 Superposition of rTxln-1 and aprotinin bound to trypsin.
rTxln-1 and aprotinin bound to trypsin (2PTC) are colored yellow and green respectively.
Disulfide bonds are shown as orange sticks. The distance between Gly42 of rTxln-1 and
Ala40 (red) aprotinin is 3.07 Å.
On visual inspection of a superposition of the trypsin molecules, the main-and side-
chain atoms overlay well, with the residues of the catalytic triad perfectly
superposed. The least-squares fitting of topologically equivalent CĮ (and all atoms
including side-chains) of the two trypsin molecules gave an rmsd of 0.53 Å (0.64 Å)
(residues 16-245). Interestingly, however, the superposition shows that the rTxln-1
and aprotinin have different docking angles in their complexes with trypsin. The
difference is ~24.5o (Figure 5-18). In this alignment (trypsin alone), the only region
where the rTxln-1 and aprotinin structures overlay is the canonical loop.
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Figure 5-18 Superimposition of trypsin in the rTxln-1-trypsin complex and the aprotinin-
trypsin complex (2PTC).
rTxln-1 is colored yellow, aprotinin green and trypsin purple. Only the trypsin molecule
from the rTxln-1-trypsin complex is shown, the trypsin molecule from aprotinin complex
was omitted for clarity. rTxln-1 deviates 24.5o from the binding direction of aprotinin to
trypsin.
Least-squares fit of the main-chain atom of the P3-P3' residues of rTxln-1 and
aprotinin gives an rmsd of 0.44 Å, which verifies that the backbone conformation of
this region is conserved in the two proteins. The main-chain atoms of the P3-P1
residues, overlay best with an rmsd of 0.17 Å while the P1'-P3' residues overlay with
an rmsd of 0.36 Å. This implies that the P3-P1 region of the canonical loop is bound
in a more consistent manner to trypsin than the P1'-P3' (Figure 5-19). This is mainly
due to the short antiparallel ȕ-sheet formed between residues 214-217 of trypsin and
the P3-P1 residues of rTxln-1 or aprotinin and the conserved location of the
specificity pocket and the oxyanion hole in trypsin.
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Figure 5-19 Residues P3-P4' in rTxln-1 and aprotinin.
Superimposition of the trypsin in the rTxln-1-trypsin complex and in the aprotinin-trypsin
complex (2PTC). rTxln-1 is colored yellow, aprotinin green. Oxygen is red, nitrogen blue
and sulfur is orange. The Connolly surface of the trypsin molecule from the rTxln-1-trypsin
complex is transparent and shown in purple. (a) Residues P3-P4' are shown as sticks. The
disulfide bridge linking the canonical and secondary loops is shown as stick. Residues in
rTxln-1 are labeled in yellow and residues in aprotinin are labeled in white and black. (b)
Stereo view.
The differences in sequence of the canonical loop are Arg17 in rTxln-1 vs Lys15 in
aprotinin, Val18 in rTxln-1 vs Ala16 in aprotinin and Phe20 in rTxln-1 vs Ile18 in
aprotinin. The two Arg17NȘ atoms in rTxln-1 form an ionic bond with the
carboxylate of Asp189, while Lys15 in aprotinin only uses the 15Nȗ atom to form an
ionic bond. However, the side-chain of Lys15 in aprotinin does not form a hydrogen
bond to Gly219O in trypsin or a water bridge such as the one between Arg17Nİ in
rTxln-1 and Gly216O and Gln192Nİ2. For Arg17 in rTxln-1 ĭ= -108.3o and
Ȍ=32.6o, compared with Lys15 in aprotinin where ĭ=-116.9o and Ȍ=39.1o. The next
residue, Val18 in rTxln-1 is more bulky than Ala16 in aprotinin. For Val18 in rTxln-
1 ĭ=-73.2o and Ȍ=159.4o compared with Ala16 in aprotinin where ĭ=-87.5o and
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Ȍ=164.2o. Thus, the dihedral angles (ĭ and Ȍ) for the P1 and P1' residues are similar
in rTxln-1 and aprotinin.
The dihedral angles for Arg19 in rTxln-1 and Arg17 in aprotinin are ĭ=-103.8o and
Ȍ=110.4o, and ĭ=-112.4o and Ȍ=79.3o, respectively. Thus ĭ varies by 8.6o and Ȍ by
31o. Therefore, the canonical loop structure in the two proteins starts to deviate here
on the C-terminal side of the scissile bond. For Phe20 in rTxln-1 its dihedral angles
are ĭ=-122.6o and Ȍ=101.3o compared to Ile18 in aprotinin where ĭ=-105.5o and
Ȍ=121.7o. Thus for this residue, both dihedral angles vary by ~20o. Pro21 in rTxln-1
has ĭ=-149.0o and Ȍ=128.0o. Compared to ĭ=-89.5o and Ȍ=122.4o for Ile19 in
aprotinin. Thus the ĭ angle varies by 59.5 o. This difference can be described to
conformational restriction on main-chain due to the presence of proline in rTxln-1
(Figure 5-19; Figure 5-20).
(a)
(b)
Figure 5-20 The P1'-P4' residues in rTxln-1 and aprotinin.
The Connolly surface of the trypsin molecule from the rTxln-1-trypsin complex is shown in
purple. Residues in rTxln-1 are shown as stick with carbon atoms in yellow. Residues in
aprotinin (2PTC) are shown as sticks with carbon atoms in green. Oxygen is red and nitrogen
blue. (a) Stereo view. (b) Residues in rTxln-1 are labeled in yellow. Residues in aprotinin are
labeled in white and black. The dihedral angles vary ~20o between Phe20 of rTxln-1 and
Ile18 of aprotinin. The following residue in the sequence of rTxln-1 is Pro21, while it is
Ile19 in aprotinin.
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On the N-terminal side of the scissile bond all residues of rTxln-1 and aprotinin, have
similar dihedral angles (Figure 5-17; Figure 5-19; Figure 5-21). For Cys16 in rTxln-1
and Cys14 in aprotinin the dihedral angles are ĭ=-70.5o and Ȍ=155.5o, and ĭ=-65.7o
and Ȍ=149.8o, respectively. For Pro15 in rTxln-1 and Pro13 in aprotinin the dihedral
angles are ĭ=-83.9o and Ȍ=-27.4o and ĭ=-77.5o and Ȍ=-29.4o. However, the
position of the Gly14CĮ in rTxln-1 and Gly12CĮ in aprotinin differs with 0.96 Å
(Figure 5-21).
(a)
(b)
Figure 5-21 The P4-P1 residues in rTxln-1 and aprotinin.
The Connolly surface of the trypsin molecule from the rTxln-1-trypsin complex is shown in
purple. Residues in rTxln-1 are shown as stick with carbon atoms in yellow. Residues in
aprotinin (2PTC) are shown as sticks with carbon atoms in green. Oxygen is red, nitrogen is
blue and sulfur is orange. (a) Stereo view. (b) Residues in rTxln-1 are labeled in yellow.
Residues in aprotinin are labeled in white. The distance between Gly14CĮ in rTxln-1 and
Gly12CĮ in aprotinin is 0.96 Å.
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In comparing the docking of aprotinin and rTxln-1 to trypsin all of the side-chains of
Val18, Phe20 and Pro21 in rTxln-1 would come too close to the surface of trypsin if
it was in the same orientation as aprotinin. The side-chain of Val18 in rTxln-1 would
be 2.18 Å from the catalytic His57 and 2.61 Å from Ser195, while the side-chain of
Phe20 would be 2.42 Å from His57O and Pro21 would be only 1.04 Å from
Tyr39OȘ of trypsin. Therefore, rTxln-1 can not dock to the active site of trypsin in
the same way as aprotinin. It can be seen in Figure 5-22 that the hydrophobic
residues Val18 and Phe20 on the surface and Phe35 and Tyr37 which are buried in
rTxln-1 move in unison with the residues of the inhibitor while the P3-P1' residues in
the canonical loop remain fixed.
Figure 5-22 rTxln-1 and aprotinin
bound to trypsin.
rTxln-1 is colored yellow, aprotinin
(2PTC) green. The Connolly surface
of the trypsin molecule from the
rTxln-1-trypsin complex is shown in
purple. Residues in rTxln-1 are
labeled in yellow and residues in
aprotinin are labeled in white. The
side-chains of Val18, Phe20, Tyr37
and Phe35 in rTxln-1, and Ala16,
Ile18, Tyr35 and Phe33 in aprotinin
are shown as sticks. Oxygen is red.
The secondary loop of rTxln-1 and aprotinin are 2.07 Å apart as measured by the
distance between rTxln-1’s Gly39CĮ and the aprotinin’s Gly37CĮ (Figure 5-23). The
major difference in sequences in this loop is a change from Glu41 in rTxln-1 to
Arg39 in aprotinin. While the glutamate residue can form water bridges to trypsin,
the difference in loop position allows the arginine residue of aprotinin to form a
direct hydrogen bond with the carbonyl oxygen atom of trypsin’s Asn97 from
trypsin.
The different location of the second loop reflects upon the size of the area of rTxln-1
and aprotinin which contacts trypsin. The buried surface area of aprotinin in contact
with trypsin is 658 Å2 while for rTxn-1 this value is 588 Å2.
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In comparing the binding of rTxln-1 and aprotinin to trypsin the interaction between
the P3-P1' residues and the enzyme is highly conserved. This is in spite of the change
from lysine to arginine at the P1 position. The major difference in binding occurs at
the P1'-P3', where there are substantial changes in sequence Ala16-Arg17-Ile18 in
aprotinin vs Val18-Arg19-Phe20 in rTxln-1. These changes to the sequence appear to
affect the way which the two molecules dock into the active site of trypsin. The Ki
value for aprotinin is 1.3 x 104 times tighter than for rTxln-1. An obvious difference
is the change from arginine to lysine at the P1 site which could contribute
significantly to the difference in binding. It is also observed that the buried surface
area of rTxln-1 is 77 Å2 less, suggests that this molecule would have a reduced
affinity as compared to aprotinin.
Figure 5-23 Variation in the location of the secondary loop.
Superimposition of the trypsin structure in the rTxln-1-trypsin complex and in the aprotinin-
trypsin complex (2PTC). rTxln-1 is colored yellow, aprotinin green and trypsin purple. The
Connolly surface of the trypsin molecule from the rTxln-1-trypsin complex is shown in
purple. Residues of rTxln-1 are labeled in yellow and residues of aprotinin are labeled in
green. Distance is a dashed black line and are in Å units. Glu41 in rTxln-1 and Arg39 in
aprotinin are shown as sticks with nitrogen atoms in blue and oxygen atoms given in red.
Disulfide bonds are orange. The canonical loops overlay well, while the shorter loop in
rTxln-1 has moved as compared to aprotinin. Glu41 of rTxln-1 can make water mediated
contact to trypsin and Arg39 of aprotinin makes direct contact with trypsin.
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5.10 Summary
The structure of the rTxln-1-trypsin complex has been determined by molecular
replacement to a resolution of 1.64 Å. rTxln-1 docks to trypsin through a canonical
loop and a secondary loop in a similar mode to that which occurs when aprotinin
binds to trypsin. The side-chain of Arg17 protrudes into the specificity pocket of
trypsin forming an ionic bond with Asp 189. The distance between the carbonyl
carbon of Arg17 and the catalytic Ser195OȖ of trypsin is sub van der Waals. At this
resolution, it is not possible to tell if the carbonyl carbon of Arg17 is pyramidally
distorted. However, it is clear that the complex is arrested somewhere along the
reaction coordinate between the Michaelis complex and the formation of the
tetrahedral intermediate. The secondary loop of aprotinin docks closer to the surface
of trypsin than rTxln-1. This is reflected in the greater surface area of aprotinin that
is in contact with trypsin than rTxln-1. If rTxln-1 would dock as aprotinin to trypsin,
the side-chains of Val18, Phe20 and Pro21 would clash with the surface of trypsin.
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Chapter 6
Crystal structure of the rTxln-1 recombinant human
microplasmin complex
The primary function of plasmin is to remove intravascularly formed thrombin by the
degradation of fibrin. rTxln-1 is a serine protease inhibitor that works as an anti-
fibrinolytic agent by blocking the activity of plasmin and/or other proteases involved
in fibrinolysis. rTxln-1 has been shown to inhibit plasmin with a Ki of 14 nM, Table
1-2 in Chapter 1 (Filippovich et al., 2002; Flight et al., 2007). It is therefore highly
likely that the physiological target for rTxln-1 is plasmin.
In surgery, the plasmin inhibitor aprotinin is administered to control excessive
bleeding. It has previously been shown that rTxln-1 is a less potent and more rapidly
reversible inhibitor of plasmin in comparison to aprotinin and therefore less likely to
cause the adverse risk of thrombosis (Masci et al., 2000; Filippovich et al., 2002).
Plasmin is centrally involved in a number of physiological processes other than
heamostasis. The phenotype of homozygous plasminogen-deficient mice shows not
only serious thrombosis (Bugge et al., 1995; Ploplis et al., 1995), but also impaired
wound healing (Romer et al., 1996) and reduced fertility (Ploplis et al., 1995). It is
believed that plasmin functions either directly or indirectly in processes such as
macrophage invasion in inflammation, breaking of the follicular wall for ovulation
(Reich et al., 1985), angiogenesis (Gross et al., 1983) and keratinocyte accumulation
after wound healing (Morioka et al., 1987). Plasmin can also degrade extracellular
matrix molecules such as fibronectin, laminin, thrombospondin and type IV collagen.
(Edmonds-Alt et al., 1980; Ott et al., 1982; Coligan and Slayter, 1984), activates
metalloproteinases (Stricklin et al., 1977; He et al., 1989; Shah, 1997) and
collagenase (Gross et al., 1983), protolyses mediators of the complement system
(Pillemer et al., 1953; Ratnoff and Naff, 1967), modify coagulation factors (Omar
and Mannj, 1987) and activate growth factors (Sato and Rifkin, 1989; Khalil et al.,
1996).
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The crystal structures of microplasmin in complex with staphylokinase (Parry et al.,
1998) or with streptokinase (X. Wang et al., 1998) have helped to understand why
plasmin is such a diverse molecule. For example, the purpose (Parry et al., 1998) of
the Į domain of streptokinase (X. Wang et al., 1998; Loy et al., 2001; Wakeham et
al., 2002) is to create a new subsite for improved substrate presentation in plasmin.
The suggested function of the Ȗ domain of streptokinase (X. Wang et al., 1998) or
the N-terminal flexible peptide of streptokinase (Terzyan et al., 2004) is to induce
conformational changes in microplasminogen for microplasmin activation.
Knowledge of the crystal structure of the rTxln-1-microplasmin complex will help to
establish the structural features necessary for the development of a plasmin selective
inhibitor. It is suggested that rTxln-1 binds in a similar fashion to microplasmin as it
is bound to trypsin but there will be differences since the substrate binding sites for
plasmin and trypsin are different. Mutagenesis studies have been carried out to
identify the binding residues of rTxln-1 (Filippovich et al., 2002). Plasmin inhibition
was completely lost with the Arg17Ala mutation. This further suggested that side-
chain of Arg17 binds in the specificity pocket of plasmin (Filippovich et al., 2002).
An analysis of a crystal structure of the rTxln-1-microplasmin complex allows the
determination of the contacts between rTxln-1 and microplasmin. Comparison with a
structure of the free rTxln-1 (Chapter 4) will show whether the structure of rTlxn-1 is
altered upon binding. rTxln-1 is speculated to induce a non-reactive conformation of
the active site residues of microplasmin not seen in the other structures of
micoplasminogen/microplasmin. Knowledge of the rTxln-1 inhibited microplasmin
structure is useful to compare with structures of both microplasminogen (Peisach et
al., 1999; Terzyan et al., 2004), staphylokinase and streptokinase inhibited
microplasmin. As a result, a selective plasmin inhibitor might be able to control
inflammation, cancer metastasis and angiogenesis (Ossowski and Reich, 1983;
Ossowski, 1992; Chapman, 1997).
This chapter describes the procedures used to solve the structure of the rTxln-1-
microplasmin complex, a description of the structure and comparison of this
structure with free rTxln-1, rTxln-1-trypsin complex, microplasmin-staphylokinase,
microplasmin-streptokinase and microplasminogen structures.
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The identity of the amino acids in the peptide substrate is as described in Chapter 5.
6.1 Phase determination of rTxln-1-microplasmin
complex
The molecular replacement program EPMR (Kissinger et al., 1999) was used to
solve the phase problem. The coordinates of microplasmin from the complex with
streptokinase (pdb file 1BML) were used as a search model. Based on solvent
content and Matthews coefficient arguments (Chapter 3) it was anticipated that there
are two complexes per asymmetric unit.
The calculation of correlation coefficient is based on structure factor values.
Therefore TRUNCATE converted the intensities to structure factors (French and
Wilson, 1978), CAD sorted the data and put it into the correct asymmetric unit for
CCP4 (CCP4, 1994) and MTZ2VARIOUS (Dodson, 1992) produced a reflection file
for CNS (Brünger et al., 1998).
A search for the location of the two complexes in space group P21 using EPMR was
performed with data in the resolution range 15-4 Å. The evolutionary search
procedure was run ten times and carried out over 50 generations using a population
size of 300. In the search for a single molecule of plasmin a correlation coefficient of
0.24 and a crystallographic Rfactor of 0.56 were first obtained. The contribution of this
first solution was added to the calculation to search for the second molecule. This
search was repeated twenty times, again using data from 15-4 Å. The highest
correlation coefficient was 0.46 and the lowest crystallographic Rfactor was 0.47.
6.2 Refinement of the rTxln-1-microplasmin crystal
structure
The two plasmin molecules were refined by simulated annealing in CNS and
subsequently using REFMAC5 in maximum likelihood mode. The structure factors
were divided into two sets, 90% of the data was used for refinement (Rfactor) and 10%
for cross-validation (Rfree). Simulated annealing reduced the Rfactor and Rfree to 0.33
and 0.41, respectively. The electron density was visualized in the graphics program
O (Jones and Kjeldgaard, 1998). Inspection of the initial electron density maps
revealed the presence of a rTxln-1 molecule bound in the active site of each
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microplasmin molecule. The coordinates of rTxln-1 were then manually docked into
the electron density. Examination of the packing within the unit cell indicated
reasonable contacts between the complexes and no overlap of symmetry related
molecules (Figure 6-1). Simulated annealing refinement of the two rTxln-1-
microplasmin complexes reduced the Rfactor to 0.29 and Rfree to 0.36.
Figure 6-1 The crystal
packing of the rTxln-1-
microplasmin complex.
Microplasmin is blue and
rTxln-1 is yellow. The unit
cell is overlayed.
Subsequent refinement was carried out in REFMAC5 (Murshudov et al., 1997) using
restrained refinement with no prior phase information and the weighting term
between X-ray and geometric residuals set to 0.01. Two different groups of non-
crystallographic symmetry (NCS) restraints were defined; group 1 consisted of
residues 4–56 of rTxln-1, and group 2 consisted of residues 550-559 and 562–785 of
human microplasmin. Tight non-crystallographic symmetry restraints were set for
main-chain atoms and medium restraints for side-chains atoms. Data used in this
refinement ranged from 40.03–2.77 Å, with 5% of reflections used for the Rfree test
set (800 reflections). All atoms were refined with individual isotropic B-factors. The
program Arp_water (Lamzin and Wilson, 1993) was used to place water molecules
and the last cycles of model building were carried out with Coot (Emsley and
Cowtan, 2004).
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6.3 Refinement statistics and quality of rTxln-1-
microplasmin crystal structure
The electron density map of the structure is, in general, well defined for both the
rTxln-1 molecules and microplasmin molecules. An unambiguous trace of the
backbone of the rTxln-1 and microplasmin molecules could be made. There are two
rTxln-1-microplasmin complexes in the asymmetric unit. The final model includes
residues 547-559 and 562-791 of human microplasmin and residues 3-58 of rTxln-1
in complex A and residues 545-559 and 562-791 of human microplasmin and
residues 3-59 of rTxln-1 in complex B. Due to insufficient electron density for the
side chains, the following residues were mutated to alanine in the final model; 552,
554, 557, 582, 583, 585 and 750 in human microplasmin, 3, 5, 8, 30 and 31 in rTxln-
1 in complex A, and 546, 554, 582, 583, 585, 615, 629 and 750 in human
microplasmin, and 3 and 31 in rTxln-1 in complex B. 43 water molecules and two
sulfate ions could also be fitted to the electron density. Refinement with NCS
restraints brought the Rfactor and Rfree down to 0.24 and 0.29, respectively. The
difference of only ~5% suggests that the model is not overrefined or biased. The
overall geometry of the model is excellent with an rmsd from ideal bond lengths of
0.006 Å and an rmsd from ideal bond angles of 0.98o (Table 6-1).
Table 6-1 Refinement statistics of the rTxln-1-microplasmin complexes
Non-hydrogen atoms
rTxln-1 complex A 423
Microplasmin complex A 1838
rTxln-1 complex B 445
Microplasmin complex B 1852
Total number of protein atoms 4558
Solvent (H2O) 43
Solvent (SO4) 10
Resolution (Å) 40.03 – 2.78
Rfactor 0.24
Rfree 0.29
rmsd from ideal geometry
Bond lengths (Å) 0.006
Bond angles (o) 0.976
Rfactor = ||Fobs| - |Fcalc||/|Fobs|, 5% of the data were excluded from the refinement
were used to calculate Rfree.
The refinement of the two rTxln-1-microplasmin structures with NCS gave similar
B-values for the two rTxln-1 molecules and for the two microplasmin molecules. B-
values are strongly correlated to completeness of data and/or restraints (Kleywegt,
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1996, 2001). Therefore, a direct comparison of temperature factors between NCS-
related molecules is not always possible, since the NCS-related molecules in the
crystal sometimes may have different average temperature factors. However, the
correlation coefficient of the temperature factors of the NCS-related CĮ atoms should
be high (Kleywegt, 1996).
The average B-value for main-chain (side-chain) atoms for rTxln-1 in complex A
and B are 22.9 Å2 (22.7 Å2) and 22.9 Å2 (23.2 Å2), respectively, and for
microplasmin in complex A and B are 19.6 Å2 (19.8 Å2) and 19.7 Å2 (19.7 Å2),
respectively (Figure 6-2). The same residues in the rTxln-1 structures described in
Chapter 4 and 5 for free rTxln-1 and rTxln-1 in complex with trypsin have higher B-
values than average in the rTxln-1 of complex A and B. These are the residues 26–31
and the N-terminal and C-terminal residues. In microplasmin, the short solvent
exposed chain as well as the N-terminus of molecule B and two solvent exposed
loops consisting of residues 583-627 and 625–628 have higher B-values than the rest
of the molecule (Figure 6-3; Figure 6-4; Figure 6-2). Overall, the rTxln-1 molecules
are marginally more mobile than the microplasmin. The lowest B-values for both
backbone and side-chain atoms in rTxln-1 in the complex with microplasmin are
residues 15-20 (Figure 6-3). This shows that Arg17 has both a stable main-chain and
side-chain which is clearly visible as a dip in the graph over the B-values for the
side-chains (Figure 6-3). Both the main-chain and side-chain B-values for the
catalytic triad His603, Asp646 and Ser741 of microplasmin are also low (Figure
6-4). No obvious aberrant B-values were noticed for the atoms in the three rTxln-1
molecules in the asymmetric unit. Therefore, this B-value analysis supports that the
structure is correct.
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Table 6-2 Mean B-values (Å2) for the rTxln-1-microplasmin complexes in the asymmetric
unit
rTxln-1 in complex A
main-chain
side-chain
all atoms (423 atoms)
Microplasmin in complex A
main-chain
side-chain
all atoms (1838 atoms)
rTxln-1 in complex B
main-chain
side-chain
all atoms (455 atoms)
Microplasmin in complex B
main-chain
side-chain
all atoms (1852 atoms)
H2O (43 atoms)
SO4 (10 atoms)
Total
main-chains
side-chains and waters
all atoms (4611 atoms)
22.9
22.7
22.8
19.6
19.8
19.7
22.9
23.2
23.0
19.7
19.7
19.7
7.0
30.4
20.3
20.2
20.2
Figure 6-2 Visualization of the main-chain B-values in the rTxln-1-microplasmin.
High B-values are represented by red thick tubes and lower B-values are represented by blue
thin tubes.
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Figure 6-3 B-values (Å2) for molecule A (blue) and B (pink) of rTxln-1 in complex with
microplasmin.
Residues 14, 38, 39 and 42 are glycine and therefore have no side-chain B-values.
Figure 6-4 B-values (Å2) for molecule A (blue) and B (pink) of microplasmin mol A and B
from respective complexes.
Glycine residues have no side chain B-value.
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The two complexes within an asymmetric unit refined using NCS would be expected
to have a similar set of backbone dihedral angles (Kleywegt, 1996). This, for
example is observed in Figure 6-5, which shows that Arg17 has similar backbone
dihedral angles in both molecules. The Ramachandran plot of the complex shows
83.2% of residues in most favored regions, 15.7% of residues in additionally allowed
regions, 0.6% in generously allowed regions, and 0.4% in disallowed regions (Table
6-3). Amino acid residues Glu41, Asn45 and Asn46 in rTxln-1 have unusual
backbone dihedral angles which are also observed in free rTxln-1 (Chapter 4) and
rTxln-1 in complex with trypsin (Chapter 5). Cys57 and Ala 58, in complex B have
backbone dihedral angles that are in additionally and generously allowed regions,
respectively. Arg17, Val18 and Arg19 in the canonical loop of rTxln-1 are located in
approximately the same position in the Ramachandran plot as in the rTxln-1-trypsin
complex. In the rTxln-1-microplasmin complex, Arg17 and Arg19 of rTxln-1 have
dihedral angles less commonly observed in proteins, while Val18 has dihedral angles
found in ȕ-sheet structures of proteins. One residue, Phe715 of microplasmin in
complex A and B, is found in a region classified as “generously allowed”, and one
N-terminal residue, Asp547 of microplasmin in complex B, is found in a region
classified as “disallowed”, in the Ramachandran plot, these residues do not form
interactions between rTxln-1 and microplasmin. The His603 and Ser741 of the
catalytic triad in microplasmin have backbone dihedral angles most favorable in
proteins, while Asp646 has dihedral angles less commonly observed in proteins,
similar is observed in the catalytic triad of trypsin in the rTxln-1-trypsin complex
(Figure 6-5).
Table 6-3 Ramachandran plot statistics for the two rTxln-1-microplasmin complexes
Residues in Ramachandran plot (%)
Most favored regions 83.2
Additionally allowed regions 15.7
Generously allowed regions 0.6
Disallowed regions 0.4
155
Figure 6-5 Ramachandran plot of the rTxln-1-microplasmin complex.
A (Į-helix), B (ȕ-sheet) and L (left handed Į-helix) are the most favoured regions. a, b and c
are additionally allowed regions, and ~a, ~b, ~l, ~p are generously allowed regions. Glycine
residues are identified as triangles. Residues Arg17, Val18, Arg19, Glu41, Asn45 and Asn46
of rTxln-1 in complex A and B, and Cys57 and Ala58 in complex B are marked with white
circles and discussed in the text. The catalytic triad His603, Asp646 and Ser741, and Phe715
of microplasmin in complex A and B, and Asp547 in complex B are marked with white
circles and discussed in the text. This plot was generated by Procheck (R. A. Laskowski et
al., 1993).
6.4 Crystal structure of the rTxln-1 microplasmin
complex
The rTxln-1-microplasmin complex measures 57 Å in length with the microplasmin
being 31 x 42 x 39 Å, and the rTxln-1 is 35 x 16 x 15 Å. The complex has a
mushroom shape similar to the rTxln-1-trypsin complex, with the microplasmin
acting as the head and the rTxln-1 acting as the stalk. The two microplasmin
structures in the asymmetric unit consist of two polypeptide chains of 13 and 230
residues (complex A), and 15 and 230 residues (complex B). The short and long
chains in each complex are linked by two disulfide bonds (Cys548-Cys666 and
Cys558-Cys566). The tertiary structure of microplasmin is similar to trypsin with
two open-ended ȕ-barrels, one in the N-terminal domain with 7 strands, and one in
the C-terminal domain with 6 strands (Figure 6-6). The active site is situated between
the two domains, with the CĮ atoms of the catalytic residues His603, Asp646, and
Ser741 located in the same positions in the structure as in trypsin. The secondary and
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tertiary structure of rTxln-1 bound to microplasmin is similar to that seen in free
rTxln-1 and rTxln-1 bound to trypsin.
Figure 6-6 Stereodiagram of the overall fold of complex A of rTxln-1-microplasmin.
The rTxln-1 is colored yellow (ȕ-strands), red (Į-helices) and green (loops). Microplasmin is
colored blue (ȕ-strands), purple (helices) and pink (loops). The image shows how rTxln-1
docks into the crevice created by the two ȕ-barrels in microplasmin.
After least-squares fitting of topologically equivalent CĮ (and all atoms including
side-chains) using CCP4 Superpose (E. Krissinel and Henrick, 2004), the two rTxln-
1 molecules have an rmsd of 0.21 Å (0.75 Å) for residues 3-58, while the rmsd of the
two microplasmin molecules is 0.09 Å (0.68 Å) for residues 545-559 and 562-791.
Therefore the polypeptide traces of the rTxln-1 and microplasmin structures are
essentially identical within experimental error. However, least-square fitting of the
two complexes as a whole shows an rmsd of 0.76 Å (1.01 Å), is significantly larger.
Inspection of the superposition shows that there is a difference in the relative docking
angle of 7.8o for the two rTxln-1 molecules (Figure 6-7). rTxln-1 interacts with
microplasmin through its canonical loop and secondary loop. The canonical loops of
the two rTxln-1 molecules superpose well, but there is a difference in the location of
the remainder of the structure (Figure 6-10). It can be speculated that the difference
in position between the two rTxln-1 molecules is due to crystal packing contacts.
However, the different docking angles could also give information about the flexible
nature of the interaction between rTxln-1 and microplasmin.
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Figure 6-7 Comparison of the binding
modes of the two molecules of rTxln1 in
the asymmetric unit of the rTxln-1-
microplasmin complex.
rTxln-1 from complex A is colored
yellow, rTxln-1 from complex B is
colored green. Microplasmin from
complex A is colored blue.
Microplasmin from complex B is not
shown. After superimposition of the
microplasmin molecules, rTxln-1
molecules deviate by 7.8o in their
docking.
6.5 The interface between rTxln-1 and microplasmin
The total buried surface area in complex A is 1383 Å2, 621 Å2 from rTxln-1 and 762
Å2 from microplasmin and in complex B 1384 Å2, 626 Å2 from rTxln-1 and 758 Å2
from microplasmin (CCP4 AREAIMOL, (B. Lee and Richards, 1971)). The fit
between rTxln-1 and microplasmin is highly complementary and tightly focused.
Only a small portion of both rTxln-1 and microplasmin are in contact in the complex,
with 9 out of 59 residues of rTxln-1 and 15 out of 249 residues of microplasmin
forming interactions. The contacts are characterized by a complex network of
hydrogen bonds, van der Waals contacts, hydrophobic interactions and ionic bonds.
rTxln-1 is docked into the active site of microplasmin through its canonical loop
(residues 15-20) and secondary binding loop (36-40). Residues 15-20 (P3-P3ƍ) are all
in direct contact with microplasmin and bind in a canonical-like manner to
microplasmin (Bode and Huber, 1992).
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Figure 6-8 Interactions between the canonical loop and secondary loop of rTxln-1 and the
active site of microplasmin.
Distances between atoms are marked with dotted lines and their lengths are in Å. Values for
complex A and B are given. rTxln-1 residues are labeled in red and identified by an I.
Microplasmin residues are labeled in blue. Residues 15-20 and 39-40 of rTxln-1 are in direct
contact with microplasmin through hydrogen bonds, hydrophobic interactions, van der
Waals interactions, cysteine-aromatic ring interaction and an ionic bond. There is a short
antiparallel ȕ-sheet formed between Pro15-Arg17 of rTxln-1 and Ser760-Gly762 of
microplasmin. An ionic bond is made between the guanidino group of Arg17 of rTxln-1 and
the carboxylate group of microplasmin’s Asp735 which is at the bottom of the specificity
pocket. Ser741 in microplasmin makes a closer than a van der Waals interaction (2.85 and
3.02 Å in complex A and B, respectively) with the carbonyl carbon of Arg17 in rTxln-1.
Figure generated using ChemSketch (ACD/Labs, 2003).
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A short antiparallel ȕ-sheet is formed between the S3-S1 residues (Gly762-Trp761-
Ser760) and Pro15-Cys16-Arg17, the P3-P1 residues of rTxln-1. In this complex two
hydrogen bonds are formed, one is between Pro15O(I) and Gly762N of
microplasmin (2.99 Å and 2.77 Å in complex A and B, respectively) and the other is
between Arg17N(I) and Ser760O of microplasmin (3.01 Å in both complexes).
Pro15(I) makes a kink which positions its amide nitrogen too far away from the
microplasmin surface to form any hydrogen bonds with microplasmin. Pro15(I) is
however stabilized by hydrophobic contacts to Trp761. Another stabilizing hydrogen
bond is between Cys16O(I) and the side-chain nitrogen of Gln738 (2.66 Å and 2.71
Å) (Figure 6-8).
The specificity pocket in microplasmin consists mainly of backbone atoms for
residues 760-765 and 736-741, the Cys735-Cys765 disulfide bridge, the side-chains
of Tyr774, Ser736 and Asp735 which is situated at the bottom of this pocket. The
side-chain of residue Arg17(I) is inserted into the specificity pocket (S1). An ionic
bond is formed between the guanidino group of Arg17(I) and the carboxylate of the
Asp735 (2.49 Å and 2.76 Å). Hydrogen bonds are also formed between Arg17NȘ(I)
and Gly764O (2.98 Å and 2.81 Å) and between the second Arg17NȘ(I) and Ser736O
(2.92 Å and 2.81 Å). In complex B Arg17NȘ1(I) forms a hydrogen bond with
Ser736OȖ (2.68 Å). The carbonyl oxygen atom of Arg17(I) is positioned in the
oxyanion hole of microplasmin, fixed via a bifurcated hydrogen bond to Gly739N
(2.83 Å and 2.61 Å) and Ser741N (2.85 Å and 3.02 Å) (Figure 6-8). There is a
continuous electron density between the Ser741OȖ and the carbonyl carbon Arg17(I).
A sub-van der Waals distance (3.00 Å and 2.88 Å) is observed, but due to the limited
resolution, the exact geometry around the carbonyl carbon atom cannot be fully
described (Figure 6-8).
The S1' subsite is partly open, delimited by the hydrophobic side-chain of Phe587
and the Cys588-Cys604 disulfide bridge. The side-chain of the P1' residue Val18(I)
has different conformations in the two complexes in the asymmetric unit (Figure 6-9;
Figure 6-11). This result shows that the S1' subsite in microplasmin cannot be
completely filled by a single valine side-chain. The S2' subsite is also partly open.
The side-chain of Arg19(I) binds in this subsite in an extended conformation
pointing towards solvent. The Arg19(I) side-chain is not firmly packed against any
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side-chains of microplasmin. However, this subsite has three backbone carbonyl
oxygens and the side-chains of both Glu623 and Glu686 point towards the guanidino
group of Arg19(I). These negatively charged or polarized groups are all within 5 Å
of this side-chain (Figure 6-11). The main-chain of Arg19(I) is stabilized by a
hydrogen bond between the amide nitrogen of Arg19(I) and Phe587O (2.84 Å and
3.07 Å). The S3' subsite consists only of the side-chain of Phe587 and the
hydrophobic part of the side-chain of Lys607 with the aromatic group of Phe20(I)
stacked in between (Figure 6-8). The side-chain of Phe20(I) also stabilizes the side-
chain of Val18(I) (Figure 6-11).
An unusual arrangement of the side-chains of the catalytic triad, Ser741-His603-
Asp646, is observed in the rTxln-1-microplasmin complex. The side-chain of the
catalytic His603 points out of the active site cleft, which creates a more open S1'
subsite compared to if the side-chain is in its normal position. This space is occupied
by a water molecule hydrogen bonded to Ser741OȖ and one of the side-chain Oį
atoms of Asp646 (2.94 Å and 2.47 Å in complex A, and 3.02 Å and 2.57 Å in
complex B). It is not possible to unambiguously assign the position of the Nį1 and
Nİ2 atom of the imidazolium ring of His603. However, there is a possible interaction
between the side-chain of His603 and the side-chain of Asp646, if the Nį1 atom is
oriented toward the carboxylate of Asp646 (3.36 Å and 3.06 Å in complex A, and
3.23 Å and 2.81 Å in complex B). In either conformation, the imidazolium ring of
His603 forms a stabilizing interaction with the Cys16(I)-Cys40(I) disulfide bridge. In
this orientation, the His603Nİ2 atom is within ~3.5 Å of a water molecule (Figure
6-9).
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(a)
(b)
Figure 6-9 Stereo view of the catalytic triad of microplasmin and interface residues of
rTxln-1 in complex A.
The canonical loop residues 16-19 and Cys40 of rTxln-1 as yellow sticks. The catalytic triad,
His603, Asp646 and Ser741 of microplasmin, is shown as blue sticks. Nitrogen atoms are in
dark blue, oxygen atoms in red and disulfide bridge in orange. The water molecules are
displayed as red spheres. (a) The 2Fo-Fc electron density is displayed as light grey mesh and
contoured at 1ı. (b) Both rotamers of Val18 are shown. Polar contacts are marked with
dotted black lines and their lengths in Å.
The secondary binding loop of rTxln-1 is stabilized by a hydrogen bond between
Gly39O(I) and the side-chain of Glu606 together with the earlier described cysteine-
aromatic ring interaction (Figure 6-8). In the Txln-1 structure, the ĳ,ȥ dihedral
angles for Gly39(I) are 122.73° and -22.57° in complex A and 123.27° and -20.97°
in complex B, which are generously allowed values for other amino acid residues
including alanine and therefore not in a conformational space that could easily be
explored by any residue other than glycine. One of the contacts with the shortest
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distance in the interface between rTxln-1 and microplasmin is between the
Gly39O(I) and the carboxylate of Glu606 (2.59 Å and 2.71 Å in complex A, and 2.69
Å and 3.00 Å in complex B) (Figure 6-8). Attempts to model the side-chain of
Glu606 in any other position resulted in a negative electron density indicating the
wrong location. Positive electron density only appeared at the position close to the
Gly39O(I). This suggests that the Glu606 carboxylate group is protonated, which is
unusual, since this side-chain is generally assumed to be deprotonated at a pH >3. A
water molecule not visible in the electron density or the imidazolium ring of His603
could be the proton donor. The catalytic Ser741OȖ or the water molecule situated
outside the active site cleft may have protonated His603 which was then transfered to
the carboxylate of Glu606. There is a hydrogen bond between the Glu606
carboxylate and the His603 imidazolium ring. If the His603 has the Nį1 atom closest
to the Glu606 carboxylate, the distance becomes shorter (2.90 Å and 4.23 Å) than if
the His603 imidazolium ring Nİ2 atom mediated the suggested ionic bond (3.85 Å
and 5.16 Å) (Figure 6-10). The distance between Gly39O(I) and His603Nİ2 is 4.81
Å in complex A, and 3.91 Å in complex B, alternatively, 4.13 Å in complex A, and
3.10 Å in complex B, if His603Nİ1 is placed closest to Gly39O(I). It can be
speculated that the Gly39O(I) is protonated instead of the side-chain of Glu606.
However, the pKa for protonation of carbonyl oxygen atoms is estimated to be ~0
(Eriksson et al., 1995; Shan and Herschlag, 1996) and it is therefore more likely that
the side-chain of Glu606 with a pKa of 4.07 (Dawson et al., 1986) is protonated.
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Figure 6-10 Stereo view of the interaction between His603 and Glu606 of microplasmin in
complex A.
The carbon atoms of the secondary loop of rTxln-1, consisting of residues 38, 39 and the
Cys16-Cys40 disulfide bridge are shown as yellow sticks. His603, Glu606 and Asp646 of
microplasmin are shown as blue sticks. Nitrogen atoms are in dark blue, oxygen atoms in red
and the disulfide bridge in orange. The water molecule is displayed as a red sphere. (a) The
2Fo-Fc electron density is contoured at 1ı and displayed as a light grey mesh. (b) & (c) show
the two different possible orientations of the imidazolium ring of His603 in microplasmin
and the different possible contacts marked with dotted black lines. All lengths are in Å.
164
Figure 6-11 The interface between rTxln-1 and microplasmin in complex A.
rTxln-1 residues are shown as sticks, carbon is yellow, nitrogen is blue, oxygen is red,
disulfide bridge is orange. A transparent Connolly surface is overlayed. The water molecule
that has replaced the side chain of the catalytic His603 in the active site of microplasmin is
represented as a green sphere. The Connolly surface of microplasmin is shown with the
electrostatic surface mapped. Residues of rTxln-1 and the water molecule are labeled in
black and residues of microplasmin are labeled in white except Gln738 which is labeled in
grey. The side chain of Arg17 of rTxln-1 protrudes into the specificity pocket and its
carbonyl oxygen atom is positioned in the oxyanion hole. Val18 of rTxln-1 is shown with its
two different rotamers from complex A and B. The hydrophobic side chain of Phe20 is
positioned inside the active site lined up against the side chain of Lys607 of microplasmin.
Arg19 reaches out towards solvent. The imidazolium ring of His603 in microplasmin is lined
up close to the Cys16-Cys40 bridge in rTxln-1. Gly39O in rTxln-1 makes a hydrogen bond
to Glu606 in microplasmin.
An explanation for the difference in location of the secondary loop of rTxln-1 in the
active site of microplasmin could be that complex A and complex B show two
different steps in the reaction between rTxln-1 and microplasmin. It could be that the
different steps are favoured as the result of differences in crystal packing. The larger
average B-values for the rTxln-1 molecules compared to the microplasmin molecules
support this idea. The side-chains of Asp646 and Ser741 in the catalytic triad overlay
almost identically. However, there is a difference in the positions of the side-chains
165
of the catalytic His603 (maximum 0.6 Å between Cİ1 atoms) and the side-chain of
Glu606 (maximum 1.4 Å between Oİ atoms) (Figure 6-12). A difference of ~1 Å is
observed in the location of the Gly39O(I) and the disulfide bridge Cys16(I)-Cys40(I)
in rTxln-1 in complex A and complex B (Figure 6-13). It is also obvious that the
rTxln-1s have different docking angles to microplasmin (Figure 6-7). Thus, the
secondary loop of rTxln-1 has different position in complex A and B of
microplasmin. However, it is not possible to deduce that the different positions of the
secondary loop are due to the different positions of the side-chains of His603 and
Glu606 as a step in the inhibition mechanism. Therefore, it is not clear if the
structures of the two rTxln-1-microplasmin complexes show two different steps in
the reaction between rTxln-1 and microplasmin.
Possible interpretations are;
x Two modes of binding exist which leads to the observation that there are two
molecules per asymmetric unit
x In one of the complexes, the secondary loop has not completely locked in to
its optional bending conformation
x The observations are solely due to crystal packing effects
(a)
(b)
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Figure 6-12 Stereo view of the superimposition between complex A and B.
The canonical and secondary loop of rTxln-1 from complex A and B colored yellow and
green, respectively. Stick representation of rTxln-1’s Cys16-Cys40 disulfide bond and
Gly39O. His603 and Glu606 of microplasmin colored light blue and magenta in complex A
and B, respectively. Nitrogen atoms are given in dark blue, oxygen atoms in red and
disulfide bridge in orange. (a) and (b) 2Fo-Fc electron density map contoured at 1ı for the
disulfide bond Cys16-Cys40 and Gly39 of rTxln-1 and His603 and Glu606 of microplasmin,
in complex A and B, respectively. (c) Superposition of rTxln-1 and residues His603 and
Glu606, from complex A and B. Displaying the differences in location.
Figure 6-13 Comparison of the binding modes of the two molecules of rTxln1 in the
asymmetric unit of the rTxln-1-microplasmin complex.
rTxln-1 from complex A is colored yellow, rTxln-1 from complex B is colored green. The
Connolly surface of microplasmin from complex A is colored blue. Microplasmin from
complex B is not shown. The canonical loop of rTxln-1 in complex A and B overlay well,
while the secondary loop has moved by up to 1.04 Å (measuring between Cys16CĮ in
molecule A and B of rTxln-1).
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6.6 Crystal contacts
The protein backbone conformation as well as the side-chain conformations are
influenced by the surrounding environment, and the dense packed environment of
proteins in crystal structures is dissimilar from the environment in the native state of
proteins (Janin and Rodier, 1995; Carugo and Argos, 1997). Packing contacts in
protein crystals are artifacts from the way the crystals grow and are considered
nonspecific protein-protein interactions called “crystal contacts”. Regions of a
protein in crystal contact are more rigid and the B factor of atoms having crystal
contacts is lower than solvent exposed atoms (Kossiakoff et al., 1992; Jacobson et
al., 2002). These contacts make use of the same forces that govern specific
recognition in protein-protein complexes and oligomeric proteins. Thus, crystal
contacts provide examples of nonspecific protein-protein interaction which can be
compared to biologically relevant ones. All possible crystal contacts from
surrounding molecules in the rTxln-1-microplasmin crystal were investigated to see
if the important features of rTxln-1 or microplasmin were affected by these artificial
contacts and to find out if there are other binding sites than the canonical and
secondary loop of rTxln-1 and the active site cleft of microplasmin.
Analysis of the crystal packing reveals that there are different crystal contacts for
rTxln-1-microplasmin complex A and rTxln-1-microplasmin complex B (Figure
6-14). The rTxln-1 molecules are held in the crystalline array both by crystal packing
contacts from symmetry related molecules and through their attachments to the
microplasmin molecules. Interfaces formed between the rTxln-1 molecules and
adjacent molecules are shown in Figure 6-15 and Figure 6-16.
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(a) (b)
Figure 6-14 Crystal contacts for complex A and B of rTxln-1-microlplasmin
Connolly surface of complex A (a) and B (b), rTxln-1 is yellow and microplasmin is blue.
Atom within 5 Å are shown as spheres. Symmetry related rTxln-1 atoms are green,
symmetry related microplasmin atoms are salmon. Yellow and blue spheres are atoms from
the complex within the same asymmetric unit.
There is a small buried surface area of 221 Å2 formed between the rTxln-1-
microplasmin complex B and the rTxln-1 molecule from complex A in the
asymmetric unit (Figure 6-15; Figure 6-16). In this interface is one crystal contact
that could be argued to affect the true native interface between rTxln-1 and
microplasmin. The side-chain of the P2' residue Arg19 of rTxln-1 from complex B,
which is situated in the partly open S2' subsite of microplasmin, does not point
towards the surface of microplasmin but extends out to make use of an ionic contact
with the side chain Asp28 of rTxln-1 from complex A (3.03 Å and 3.99 Å; Figure
6-17). The conformation and location of the side-chain of Arg19 of rTxln-1 is similar
in both complexes. Therefore, it appears that the interaction between rTxln-1 and
microplasmin is unaffected by crystal contacts.
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Figure 6-15 Crystal contacts between rTxln-1 in complex A and surrounding molecules.
Molecules making contacts with rTxln-1 in complex A are shown. rTxln-1 in complex A and
complex B are colored yellow. Microplasmin in complex A is colored blue. Symmetry
related rTxln-1 and microplasmin molecules are colored green and purple, respectively. The
interface area between rTxln-1 in complex A and surrounding molecules are marked.
(a) (b)
Figure 6-16 Crystal contacts between rTxln-1 in complex B and surrounding molecules
Molecules making contacts with rTxln-1 in complex B are shown. rTxln-1 in complex A and
B are colored yellow. Microplasmin in complex B is colored blue. Symmetry related rTxln-1
and microplasmin molecules are colored green and purple, respectively. (a) Molecules in
contact with rTxln-1 in complex B are shown. (b) Same molecules as (a) in a different
orientation. The interface surface areas are marked.
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(a) (b)
Figure 6-17 Crystal contact between Arg19 of rTxln-1 and Asp28 of rTxln-1 from
complex B.
rTxln-1 is yellow and microplasmin blue. Side-chains are represented as sticks, nitrogen
atoms are blue and oxygen atoms are red. (a) Crystal contact close to the interface of
complex B. (b) Crystal contact between the side-chain of Arg19 of rTxln-1 from complex B
and Asp28 of rTxln-1 from complex B.
The rTxln-1 molecules from complex A and complex B form buried surfaces with
different crystallographic symmetry related microplasmin molecules (258 Å2 and 431
Å2 in complex A and B, respectively) (Figure 6-15; Figure 6-16) which include a key
contact between Glu41 of rTxln-1 and Arg 644 (3.43 Å and 4.41 Å in complex A and
B, respectively; Figure 6-18). The side-chain of Glu41 of rTxln-1 does not make a
direct contact to microplasmin and therefore does not have a contribution to the
conformation of the canonical loop of rTxln-1 to microplasmin, thus the crystal
contact of Glu41 of rTxln-1 does not affect the structure of the canonical loop bound
to microplasmin.
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(a) (b)
(c) (d)
Figure 6-18 Crystal contacts between Glu41 and Arg644.
rTxln-1 is yellow and microplasmin blue. Side-chains are represented as sticks, nitrogen
atoms are blue and oxygen atoms are red. Crystal contacts between the side-chain of Glu41
of rTxln-1 and Arg644 of a symmetry related microplasmin (a) and (b) showing complex A,
(c) and (d) showing complex B.
The largest of the buried surface areas with crystal contacts is 684 Å2 (Figure 6-15;
Figure 6-16) and made between the C-terminal Į-helix of rTxln-1 from complex A
and B. Two negatively charged residues (Glu51 and Glu52) and two polar residues
(Thr56 and Ser55) form the interactions in the interface (Figure 6-19).
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(a)
(b)
Figure 6-19 Largest crystal contact between two rTxln-1 molecules.
rTxln-1 from complex A is yellow, rTxln-1 from complex B is green and microplasmin blue.
Side-chains are represented as sticks, nitrogen atoms are blue and oxygen atoms are red. (a)
The buried surface area between the C-terminal Į-helices of rTxln-1 from complex A and B
is 684 Å2. (b) Residues Glu51, Glu52, Ser55 and Thr56 form contacts in this interface.
If the different docking angles of rTxln-1 in the two complexes are not due to two
different steps in the reaction between rTxln-1 and microplasmin, then one
explanation might be that rTxln-1 and microplasmin have crystal contacts locking
their bodies relative each other in different positions in complex A and B. After
superposition of the microplasmin molecules, rTxln-1 from complex A clashes with
the crystal contacts if it was docked as rTxln-1 from complex B to microplasmin
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(Figure 6-20). However, rTxln-1 from complex B does not clash with any crystal
contacts if it was docked as rTxln-1 from complex A to microplasmin. The crystal
contacts around the Į-helix may keep rTxln-1 from complex B in its position (Figure
6-21). Therefore, the different crystal contacts in complex A and B may account for
the two observed docking angles of rTxln-1 to microplasmin.
(a) (b)
Figure 6-20 Difference in crystal contacts between rTxln-1 from complex A and B
Complex A, rTxln-1 is yellow and microplasmin is blue. Connolly surface of complex A is
transparent. rTxln-1 from complex B is magenta. Atoms within 5 Å are shown as spheres.
Green is symmetry related rTxln-1 atoms, salmon is symmetry related microplasmin atoms.
Yellow and blue spheres are atoms from the complex within the same asymmetric unit. (a)
Complex A. (b) rTxln-1 from complex A clash with atoms at distance  5 Å if it would be
docked as rTxln-1 from complex B.
174
(a) (b)
Figure 6-21 Difference in crystal contacts between rTxln-1 from complex A and B
Complex B, rTxln-1 is yellow and microplasmin is blue. Connolly surface of complex B is
transparent. rTxln-1 from complex A is magenta. Atoms within 5 Å are shown as spheres.
Green is symmetry related rTxln-1 atoms, salmon is symmetry related microplasmin atoms.
Yellow and blue spheres are atoms from the complex within the same asymmetric unit. (a)
Complex B. (b) rTxln-1 from complex B does not clash with atoms at distance  5 Å if it
would be docked as rTxln-1 from complex A.
6.7 Comparison between rTxln-1-microplasmin and
existing microplasminogen and microplasmin
structures
The structure of the entire plasminogen or plasmin molecule has not been determined
(Chapter 1). However, the structures of a number of the domains and complexes have
been determined separately. These are the structures of kringle 1 (Wu et al., 1994),
kringle 2 (Marti et al., 1999), kringle 4 (Stec et al., 1997) , kringle 5 (Chang et al.,
1998), microplasminogen with the nonessential mutations Met585Gln, Val673Met
and Met788Leu (pdb file 1QRZ) (Peisach et al., 1999), the inactive
microplasminogen Ser741Ala mutant (pdb file 1DDJ) (X. Wang et al., 2000), the
Lys698Met mutant (pdb file 1RJX) (Terzyan et al., 2004), the microplasminogen
Arg561Ala and Ser741Ala mutant in complex with deletion mutant of streptokinase
Į domain (pdb file 1L4D and 1L4Z) (Wakeham et al., 2002), two microplasmin
molecules in complex with staphylokinase (pdb file 1BUI) (Parry et al., 1998) and
microplasmin Ser741Ala mutant in complex with streptokinase (pdb file 1BML) (X.
Wang et al., 1998).
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Superposition of the microplasminogen and microplasmin structures illustrates large
regional differences, but overall small structural differences. Human plasminogen
has in its catalytic domain (microplasmin) a loop (558-566) where, upon activation
by the physiological activators tissue-type plasminogen activator and urokinase-type
plasminogen activator, a peptide bond located between Arg561 and Val562 which is
proteolytically cleaved resulting in conformational changes and formation of a
functional active site. Urokinase-type plasminogen activator bound to sepharose was
used to convert microplasminogen to active microplasmin. Due to the limited
resolution, residue 560-562 could not be modeled in either complex A or B.
However, the distance between Pro559CĮ and Val562CĮ is ~15 Å and there is no
extra density around Val562. Therefore, confirming that the peptide bond between
Arg561 and Val562 is cleaved. The cleavage produced two polypeptide chains, one
short at the N-terminus (13 and 15 residues in complex A and B, respectively) and
one longer (230 residues in both complexes), connected by two disulfide bonds
(Cys548-Cys666 and Cys558-Cys566). The Val562CĮ has moved, in the
microplasmin complex structures (rTxln-1-microplasmin, 1BUI and 1BML), an
average distance of ~12 Å, from a solvent exposed position in the structures of
microplasminogen (1DDJ, 1QRZ, 1L4D, 1L4Z and 1RJX) to a position in the core of
microplasmin. The microplasmin Į-amino group of Val562 forms an essential ionic
bond with the side-chains of Asp740 in microplasmin, 2.91 Å and 2.63 Å in the
rTxln-1-microplasmin complex A and B, respectively (Figure 6-22). The same ionic
bond formation is found in the complex between microplasmin and staphylokinase
and in the streptokinase-microplasmin complex.
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Figure 6-22 Superposition of microplasmin and microplasminogen.
Microplasmin from complex A of rTxln-1-microplasmin is blue and microplaminogen
(1QRZ) is brown. Val562 moves ~12 Å from a solvent exposed position in
microplasminogen to a position in the core of microplasmin.
The Gln738CĮ and Gly739CĮ atoms have moved ~6 Å in microplasmin (rTxln-1-
microplasmin, 1BUI and 1BML) compared to microplasminogen (1DDJ and 1QRZ).
This movement allowed the creation of the oxyanion hole. In the rTxln-1-
microplasmin structure Gly739N has moved 6.87 Å compared to the
microplasminogen structures (1DDJ and 1QRZ), and Gly739N and Ser741N make
hydrogen bonds to Arg17O in rTxln-1. The Gln738 side-chain of microplasmin is
directed away from the oxyanion hole in the rTxln-1-microplasmin structure, which
is also the case in the complex between microplasmin and staphylokinase. The
Gln738 side-chain of microplasmin in the streptokinase-microplasmin structure is
occupying about the same position as the Arg17O in rTxln-1 (Figure 6-23).
177
Figure 6-23 Formation of the oxyanion hole in microplasmin.
Microplasmin and rTxln-1 of complex A are in blue and yellow, respectively. Nitrogen
atoms are blue and oxygen atom is red. Microplasmin (1BML) is green. Microplasminogen
(1QRZ) is brown. Distances are in Å.
The loop region made up of residues 737-741 is disulfide linked by Cys737-Cys765
to the specificity (S1) entrance residues 760-765. The CĮ atoms of the Cys737-
Cys765 disulfide bridge have moved ~3 Å and ~5 Å, respectively, in the rTxln-1-
microplasmin structure compared to the microplasminogen structures (1DDJ and
1QRZ). This has also been observed in microplasmin complex structures (1BUI and
1BML). This movement expands the entrance size of the S1 specificity pocket
relative to microplasminogen. One of the most important structural changes is the
location of the side-chain of Trp761. In microplasminogen, the side-chain of Trp761
covers the S1 entrance preventing binding of the side-chain of a P1 residue (1DDJ
and 1QRZ). In the rTxln-1-microplasmin complex, the side-chain of Trp761 is folded
away form the entrance of the specificity pocket (Figure 6-24), as in the other
microplasmin complex structures (1BUI and 1BML). This allows the side-chain of
Arg17 in rTxln-1 to protrude into the specificity pocket. The Asp735CĮ of
microplasmin has moved an averaged distance of 7.5 Å, from its solvent exposed
position in microplasminogen (1DDJ and 1QRZ) to the bottom of the specificity
pocket of microplasmin in all the microplasmin complex structures (rTxln-1-
microplasmin, 1BUI and 1BML) and determines the specificity for a positively
charged P1 residue. The position of the residues 737-741, the disulfide bridge
Cys737-Cys765, and side-chain of Trp731 are the same in the microplasminogen
structures 1RJX, 1L4D and 1L4Z, but somewhat different to that in either the
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microplasminogen structures 1DDJ and 1QRZ and the microplasmin structures of the
rTxln-1-microplasmin complex, 1BUI and 1BML.
Figure 6-24 Formation of the specificity entrance of microplasmin.
Microplasmin of rTxln-1-microplasmin complex A is blue. Microplasminogen (1QRZ) is
brown. The side-chain of Trp761 is represented as a stick model. Nitrogen atoms are blue
and oxygen atoms are red. Disulfide bonds are orange.
Contrary to the physiological activators tPA and uPA that protelytically activate
plasminogen, the two plasminogen activators from bacteria, staphylokinase and
streptokinase, form tight-binding stoichiometric complex with human plasminogen
or plasmin. These complexes act as plasminogen activators, a property neither
plasminogen nor plasmin have by themselves. The structure of the microplasmin
complex with staphylokinase was reported to show that staphylokinase does not
affect the active-site geometry, but instead provide additional docking sites for
enhanced presentation of the Arg561-Val562 bond in other plasminogen molecules
(Parry et al., 1998). Superimposition of the microplasmin from the complex of rTxln-
1 and staphylokinase reveals that a molecule such as rTxln-1 can fit into the active
site cleft of microplasmin when staphylokinase has bound to microplasmin (Figure
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6-25). Therefore it may suggest that staphylokinase could contribute to an amplified
specificity for a number of molecules similar in size and shape to rTxln-1 and
possibly occlude larger ones by limiting the size of the active site cleft of
microplasmin.
(a) (b)
Figure 6-25 Complex of staphylokinase-microplasmin and rTxln-1-microplasmin.
(a) Structure of microplasmin and staphylokinase (1BUI), magenta and green, respectively.
(b) RTxln-1 fits into the active site of microplasmin when staphylokinase is docked to
microplasmin. Rtxln-1 and microplasmin complex A are blue and yellow, respectively.
Streptokinase consists of an Į, ȕ and Ȗ domain and is a much larger molecule then
staphylokinase. The N-terminal Į domain of streptokinase was suggested to provide
substrate recognition when bound to microplasmin (X. Wang et al., 1998).
Moreover, it was suggested that the C-terminal Ȗ domain of streptokinase induced an
active site formation in microplasminogen (X. Wang et al., 1998), but was later
proposed to be the function of the N-terminus of streptokinase (Terzyan et al., 2004).
It was suggested that binding of streptokinase to microplasminogen made it possible
to form a functional active site because of the formation of the essential ionic bond
with Asp740 of microplasminogen. In activation of microplasminogen by
streptokinase, this critical ionic bond was proposed to be formed between the Lys698
side-chain and Asp740 side-chain of microplasminogen (X. Wang et al., 1998), but it
was later suggested that the N-terminus of streptokinase assumes the role in critical
ionic bond formation with Asp740 of microplasminogen (Terzyan et al., 2004),
which induces a catalytic active site without cleaving the activation bond between
Arg561 and Val562 of microplasminogen. Superimposition of the microplasmin
from the complex of rTxln-1 and streptokinase shows that a molecule with the same
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size and shape as rTxln-1 could attach to the active site cleft of microplasmin when
staphylokinase has bound to microplasmin (Figure 6-26). The Į and ȕ domains of
streptokinase were closer to rTxln-1 and the active site of microplasmin, than the Ȗ
domain of streptokinase. By superimposing all the three structures of microplasmin
onto each other shows that the staphylokinase and the Į domain of streptokinase
overlay well. It may suggests that both the Į domain of streptokinase and
staphylokinase could increase specificity of molecules similar to rTxln-1, however,
the ȕ and Ȗ domains in streptokinase may even contribute to a more stringent
specificity for a range of molecules similar in size and shape to rTxln-1, than
staphylokinase, which consist of only one domain.
(a) (b)
Figure 6-26 Complex of streptokinase-microplasmin and rTxln-1-microplasmin.
(a) Structure of streptokinase-microplasmin (1BML), dark blue and green, respectively. (b)
rTxln-1 fits into the active site of microplasmin when streptokinase is bound to
microplasmin. Rtxln-1 and microplasmin from complex A are light blue and yellow,
respectively.
The backbone atoms of the catalytic triad, His603, Asp646 and Ser741, superposed
at about the same place in the microplasminogen and microplasmin structures,
however, the conformations of the side-chains varies. Overall, the Ȥ1 angle of the
Ser741 residues varies by 80o in the structures of microplasminogen and
microplasmin. The side-chain of His603 points out of the active site in the
microplasminogen structures in two directions that differ by ~70o (1QRZ, 1RJX,
three of four molecules in the asymmetric unit of the 1DDJ structure in one group
and 1LD4, 1L4Z, one of the 1DDJ molecules in the other group) (Figure 6-27).
However, the side-chain of His603 points into the formed active site in the structures
of microplasmin in complex with staphylokinase or streptokinase. In this position the
imidazolium ring of His603 can make interactions with Ser741 and Asp646 and
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hydrolyse substrates. The side-chain of the catalytic His603 in the rTxln-1-
microplasmin complex has an orientation not observed in the other microplasmin
structures. As mentioned earlier, the His603 side-chain of microplasmin from the
rTxln-1-microplasmin complex is replaced by a water molecule in the active site, so
it can not participate in a catalytic activity with Ser741 and Asp646, but has found
stabilizing bonds with the Cys16-Cys40 disulfide bridge of rTxln-1, the solvent and
possibly also an ionic bond with the side-chain of Glu606. The side-chain of His603,
in the microplasminogen structures 1DDJ and 1QRZ also has a water molecule in the
position of a catalytically functional His603 imidazolium ring of microplasmin, and
is oriented away from Asp646 while forming an ionic bond with the side-chain of
Glu606 (Peisach et al., 1999; X. Wang et al., 2000) (Figure 6-28; Figure 6-29). All
microplasminogen structures have the His603 side-chain and the Glu606 side-chain
facing each other at an ionic bond distance, except the 1L4D structure. Therefore, it
is possible to assume that the side-chain of His603 points out of the active site in
microplasminogen or when microplasmin is not active, and a water molecule can
form the necessary bonds in the active site, while the side-chain of His603 is forming
an ionic bond with the side-chain of Glu606.
Figure 6-27 Stereo view of the different positions of the side-chain of the catalytic histidine.
rTxln-1 and microplasmin from complex A are light blue and yellow, respectively. Side-
chains are represented as sticks. Nitrogen atoms are blue and oxygen atoms are red. The
side-chain of His603 of microplasmin structure 1BML is green, His603 of
microplasminogen structure 1L4Z is purple and His603 of microplasminogen structure 1DDJ
is pink.
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Figure 6-28 Stereo view of a water molecule in the position of catalytically functional
His603.
rTxln-1 and microplasmin from complex A are light blue and yellow, respectively. Side-
chains are represented as sticks. Nitrogen atoms are blue and oxygen atoms are red. The
side-chain of His603 of microplasminogen structure 1DDJ is pink. The water molecule
belonging to the rTxln-1-microplasmin structure is red and the water molecule belonging to
the microplasminogen structure 1DDJ is pink.
Figure 6-29 Stereo view of catalytic histidine forming an ionic bond with Glu606.
rTxln-1 and microplasmin from complex A are light blue and yellow, respectively. Side-
chains are represented as sticks. Nitrogen atoms are blue and oxygen atoms are red. His603
and Glu606 of microplasminogen structure 1L4Z are pink, and His603 and Glu606 of
microplasminogen structure 1DDJ are purple.
All of the Asp646 side-chains in the microplasminogen structures point out of the
active site, except one, the side-chain of Asp646 from one of four molecules in the
asymmetric unit of the 1DDJ structure which points inwards just as the side-chain of
Asp646 of microplasmin (Figure 6-30). Visual inspection shows that the
microplasminogen structures 1L4Z and 1QRZ have a water molecule in the position
of Asp646 in microplasmin (Figure 6-31). Therefore it is possible to assume that a
water molecule can replace the side-chain of Asp646 in a non-functional active site
of microplasminogen.
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Figure 6-30 Stereo view of different positions of Asp646.
rTxln-1 and microplasmin from complex A are light blue and yellow, respectively. Side-
chains are represented as sticks. Nitrogen atoms are blue and oxygen atoms are red. His603
and Asp646 of microplasminogen structure 1L4Z are purple, and His603 and Asp646 of
microplasminogen structure 1QRZ are brown.
Figure 6-31 Stereo view of a water molecule in the position of the catalytically functional
Asp646.
rTxln-1 and microplasmin from complex A are light blue and yellow, respectively. Side-
chains are represented as sticks. Nitrogen atoms are blue and oxygen atoms are red. His603
and Asp646 of microplasminogen structure 1L4Z are purple, and His603 and Asp646 of
microplasminogen structure 1QRZ are brown. The water molecule belonging to the
microplasminogen structure 1L4Z is purple and the water molecule belonging to the
microplasminogen structure 1QRZ is colored brown.
The complex of microplasmin with staphylokinase is a ternary complex where two
microplasmin molecules and one staphylokinase have combined. One microplasmin
has a covalent bound chloromethylketone inhibitor (deoxo-methylarginine) bound to
the catalytic His603 and Ser741 of microplasmin, and the inhibitor’s arginine side-
chain is projecting into the specificity pocket. Superimposing the microplasmin with
the chloromethylketon inhibitor onto the rTxln-1-microplasmin structure shows that
the inhibitors overlays well (Figure 6-32). The other microplasmin molecule in this
microplasmin-staphylokinase-microplasmin complex is docking in a substrate-like
manner onto the first microplasmin molecule. In this structure it is proposed that an
ionic bond between Lys556 of the microplasmin (that is substrate-like) and Glu606
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assists in proper substrate orientation (Figure 6-33). Therefore it is possible to
suggest that the side-chain of Glu606 of microplasmin has more than one function. It
stabilizes the His603 side-chain, as in the microplasminogen and rTxln-1-
microplasmin structures, and it binds to a molecule docked into the active site of
microplasmin, as in the rTxln-1-microplasmin complex and the microplasmin-
staphylokinase-microplasmin complex.
Figure 6-32 Stereo view of inhibitor in the active site of microplasmin.
rTxln-1 and microplasmin from complex A are light blue and yellow, respectively. Side-
chains are represented as sticks. Nitrogen atoms are blue and oxygen atoms are red.
Microplasmin structure 1BUI is green and the chloromethylketon inhibitor is purple.
Superimposing shows that the inhibitors overlay well.
Figure 6-33 Stereo view of interaction between Glu606 and bound molecule.
rTxln-1 and microplasmin from complex A are light blue and yellow, respectively. Side-
chains are represented as sticks. Nitrogen atoms are blue and oxygen atoms are red.
Microplasmin structure 1BUI is green and purple. Glu606 of microplasmin forms an
interaction with bound molecule.
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6.8 Comparison between rTxln-1 in the microplasmin
complex, in the trypsin complex and free rTxln-1
To study conformational differences between the rTxln-1 structures in the
microplasmin complex, trypsin complex and the free structure, least-squares fitting
and visual analyses of superposition were undertaken. The B-value patterns were
examined as a measure of differences in conformational dynamics between the
rTxln-1 structures.
Visual analysis of superposition of the structures shows that the overall main-chains
overlay well, except for the free structure of molecule C, and all the disulfide bonds
have the same chirality. Least-squares fitting of topologically equivalent CĮ (and all
atoms including side-chains) in residues 3-58 of all rTxln-1 structures resulted in
rmsd values given in Table 6-4. The largest rmsd values appear when comparing the
free rTxln-1 molecule C to all the other structures of rTxln-1. The high rmsd value is
explained by the large structural difference of the canonical loop of molecule C
(Figure 6-34).
Table 6-4 Table of rmsd values between the rTxln-1 structures, CĮ (all atoms)
rTxln-1
free
A
rTxln-1
free
B
rTxln-1
free
C
rTxln-1
trypsin
cplx
rTxln-1
µplm
cplx A
rTxln-1
µplm
cplx B
rTxln-1
free A
0
rTxln-1
free B
0.66
(1.19)
0
rTxln-1
free C
0.87
(1.66)
1.09
(1.76)
0
rTxln-1
trypsin cplx
0.64
(1.48)
0.41
(1.25)
0.88
(1.95)
0
rTxln-1
µplm
cplx A
0.43
(1.22)
0.43
(1.01)
0.87
(1.86)
0.40
(0.96)
0
rTxln-1
µplm
cplx B
0.54
(1.27)
0.41
(1.11)
0.93
(1.86)
0.38
(1.06)
0.21
(0.75)
0
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Figure 6-34 Superimposition of all rTxln-1 structures.
Microplasmin complexes are in yellow. rTxln-1 from the trypsin complex (pink) and all
three structures of free rTxln-1 (molecule A green, molecule B blue and molecule C purple).
Disulfide bonds are displayed as orange sticks. rTxln-1 from microplasmin-rTxln complex is
yellow, and from trypsin-rTxln complex is in pink. Free rTxln-1 molecules are green, blue
and purple. It is a 5.2 Å distance between Val16CĮ in rTxln-1 in the rTxln-1-microplasmin
complex and Val16CĮ in molecule C of free rTxln-1.
B-values reflect to a first approximation positional variation of atoms over time and
are therefore likely to provide insight into the dynamics of the protein (Ringe and
Petsko, 1986; Parthasarathy and Murthy, 2000). However, B-values are also
influenced by crystal order, diffraction resolution, atom occupancy and restrains used
for the refinement. The crystal morphology and size varied between the crystals of
the rTxln-1-microplasmin, rTxln-1-trypsin and free rTxln-1, as well as the overall
order, as reflected by the resolution limits of 2.8 Å, 1.63 Å and 1.63 Å, for each of
the crystals. Furthermore, because of the lower resolution of data the rTxln-1-
microplasmin complex was also refined with NCS restraints. However, as illustrated
by Figure 6-35, it can be seen that there is more motion in the same parts among the
rTxln-1 structures.
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Figure 6-35 Visualization of the B-values in rTxln-1.
The highest main-chain B-values are in red thick tubes and lowest main-chain B-values are
in blue thin tubes. Side-chains are shown as sticks and color coded according to B-values. (a)
The three free rTxln-1 molecules. (b) rTxln-1 bound to trypsin. (c) The two rTxln-1
molecules bound to microplasmin.
Figure 6-36 B-values (Å2) for all rTxln-1 structures.
Orange lines mark the canonical loop and the secondary loop of rTxln-1. Residues 14, 38, 39
and 42 are glycine and therefore have no side-chain B-values.
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The most striking change in the B-values profiles for rTxln-1 upon complexation
with microplasmin or trypsin is the reduction in B-factor for the side-chain of Arg17.
Thus, confirming the stabilization of this residue upon forming the complex with
serine protease. There is a notable difference in the B-values profile for rTxln-1 in
the complex with microplasmin or trypsin between residues 18-22. The results
suggest that the P' residues are bound more rigidly to the plasmin than to trypsin in
these complexes. Also, the main-chain B-values for residues 38-40 of the secondary
loop are in a dip in the rTxln-1-microplasmin complex and in a peak in the rTxln-1-
complex. Thus the bond between Gly39O of rTxln-1 and the side-chain of Glu606 of
microplasmin makes the secondary loop more stable in the rTxln-1-microplasmin
complex than in the rTxln-1-trypsin complex.
Analysis of the water structure in the rTxln-1-microplasmin complex showed that,
only one water molecule between the canonical and secondary loops is visible in
complex B. It is highly likely that if higher resolution data were available the water
molecules in the other highly conserved sites would also be visible.
6.9 Comparison between the rTxln-1-microplasmin
complex, the rTxln-1-trypsin complex and an
aprotinin-trypsin complex
Microplasmin has a similar overall structure as trypsin. However, the active site cleft
is more open in microplasmin than in trypsin. The differences are confined to
external loops at four places around the active site, one in the loop region between
residues 37-39 in trypsin where two residues are omitted in microplasmin, and the
second is due to the removal of six residues deleted in a loop region of microplasmin,
the so-called 94-shunt in microplasminogen (Parry et al., 1998), between residues
94-101 of trypsin, and a third where the residues 145-152 of trypsin have a different
conformation to that of microplasmin. The formation of the 94-shunt of
microplasmin may permit entry of larger molecules such as cross-linked fiber clots
(Peisach et al., 1999). Nevertheless, there is one region where microplasmin narrows
the active site cleft more than in trypsin, which is a loop region with five residues
insertion between residues 605-613 of microplasmin (Figure 6-37; Figure 6-38).
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Figure 6-37 Amino acid sequence alignment of microplasmin and trypsin.
Orange bars highlight places in the sequences which correspond to difference in external
loops close to the active site of microplasmin and trypsin. These loops are marked out in
Figure 6-38.
Figure 6-38 Superposition of microplasmin and trypsin.
The active site cleft is more open in microplasmin than in trypsin. Microplasmin is blue and
trypsin purple. Differences in external loop close to the active site are marked out.
The interfaces between rTxln-1 and microplasmin and rTxln-1 and trypsin cover
areas which are about the same in size, only 2% larger in the rTxln-1-microplasmin
complexes (1384 Å2 in the rTxln-1-microplasmin complexes and 1356 Å2 in the
rTxln-1-trypsin complex). Comparing the respective contact areas in the rTxln-1-
Microplasmin AAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRTRFGMHFCGG
Trypsin IVGGYTCGANTVPYQVSLNS-G-YHFCGG
TLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRK------KD
SLINSQWVVSAAHCY-K--S--GIQVRLGEDNINVVEGNEQFISASKSIVHPSYNSYNTLNND
IALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQTF—FGA-GLLKEAQLPVIEN
IMLIKLKSAASLNSRVASISLPTS-C-ASAGTQCLISGWGNTKSSGTSYPDVLKCLKAPILSD
KVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDAGGPLVCFEADKYILQGVTSWGLGCARPNK
SSCKS--AYPGQITSNMFCAGYLEGGKDSCQGDSGGPVVCSG----KLQGIVSWGSGCAQKNK
PGVYVRVSRFVTWIEGVMRNN
PGVYTKVCNYVSWIKQTIASN
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microplasmin complex (762:621 Å2 in complex A and 758:626 Å2 in complex B) and
rTxln-1-trypsin complex (768:588 Å2) reveals that more surface of rTxln-1 is
covered by microplasmin. This is mostly due to the five residues insertion between
residues 605-613 of microplasmin. The side-chain of His603 together with the side-
chains of Glu606 and Lys607 of microplasmin create a “wall” (Figure 6-39; Figure
6-40), which covers the canonical loop of rTxln-1 and makes contact with the
secondary loop of rTxln-1, in the rTxln-1-microplasmin complex. The contact areas
of microplasmin and trypsin are about the same. However, differences are that the
S1ƍ subsite is more open in microplasmin compared to the S1ƍ subsite in the rTxln-1-
trypsin complex, due to the side-chain of microplasmin’s His603 is pointing away
from the active site (Figure 6-41). Another noticeable difference is that there are
more contacts to the side-chain of Arg19 of rTxln-1 in the rTxln-1-trypsin complex.
Figure 6-39 Differences between
microplasmin and trypsin.
rTxln-1 and microplasmin from
complex A are light blue and yellow,
respectively. Trypsin is purple. Side-
chains are represented as sticks.
Nitrogen atoms are blue and oxygen
atoms are red. The side-chains of
Glu606 and Lys607 of microplasmin are
situated in a loop, which is not present
in trypsin.
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(a) (b)
Figure 6-40 Interface between rTxln-1 and microplasmin or trypsin.
The Connolly surface of microplasmin and trypsin is shown with the electrostatic surface
mapped. RTxln-1 is yellow sticks. Nitrogen atoms are blue and oxygen atoms are red.
Residues of rTxln-1 are labeled in white and residues of microplasmin and trypsin are
labeled in black. (a) The interface of the rTxln-1-microplasmin complex A. A “wall” is
formed by the side-chains of His603, Glu606 and Lys607 of microplasmin, which cover the
canonical loop of rTxln-1 and makes contacts to the secondary loop of rTxln-1. (b) The
interface of the rTxln-1-trypsin complex. The side-chain of Arg19 of rTxln-1 is fitted
inside a half open tunnel of trypsin.
(a) (b)
Figure 6-41 Interface between rTxln-1 and microplasmin or trypsin.
The Connolly surface of microplasmin and trypsin is shown with the electrostatic surface
mapped. RTxln-1 is yellow sticks. Nitrogen atoms are blue and oxygen atoms are red.
Residues of rTxln-1 are labeled in white and residues of microplasmin and trypsin are
labeled in black. (a) The interface of the rTxln-1-microplasmin complex A. The side-chain of
His603 is pointing out of the active site of microplasmin. The P1ƍ residue Val18 of rTxln-1
has different rotamers in the rTxln-1-microplasmin complex A and B. (b) The interface of
the rTxln-1-trypsin complex. The side-chain of His57 is positioned inside the active site.
This creates a more open S1ƍ subsite in microplasmin than trypsin.
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Visual analysis of the superposition of microplasmin from complex A and B and
trypsin reveals that the docking angles between all three rTxln-1 molecules vary
considerably. The largest angle is between the rTxln-1 bound to trypsin and rTxln-1
bound to microplasmin in complex B, 18.3o, while the angle is 11.4o between the
rTxln-1 bound to trypsin and rTxln-1 bound to microplasmin in complex A (Figure
6-42). The canonical loops overlays well, but the distances between the secondary
loops are 1.21 Å and 2.24 Å, measured between Cys40CĮ of rTxln-1 from the
trypsin complex to the microplasmin complex A and B, respectively (Figure 6-43).
Therefore, it is possible to speculate that the extra contact surface of rTxln-1 to the
“wall” of microplasmin has influenced the docking and created a change in docking
angle of 11.4o and 18.3o and a corresponding change in position of 1.21 Å and 2.24
Å of Cys40CĮ.
(a) (b)
Figure 6-42 The docking angles between the bound rTxln-1 molecules when superimposing
trypsin onto microplasmin.
rTxln-1 bound to microplasmin is yellow and purple bound to trypsin. Microplasmin is light
blue. (a) Docking angle between rTxln-1 from complex A and rTxln-1 from trypsin is 11.4o.
(b) Docking angle between rTxln-1 from complex B and rTxln-1 from trypsin is 18.3o.
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(a) (b)
Figure 6-43 The difference in position of the secondary loop of rTxln-1 when
superimposing trypsin onto microplasmin.
rTxln-1 bound to microplasmin is yellow and purple bound to trypsin. Cys16-Cys40
disulfide bond of rTxln-1 is orange. The Connolly surface of microplasmin is light blue. (a)
Distance between Cys40CĮ of rTxln-1 from complex A and rTxln-1 from trypsin is
1.21 Å. (b) Distance between Cys40CĮ of rTxln-1 from complex B and rTxln-1 from trypsin
is 2.24 Å.
The catalytic triads are located in the same spatial arrangement at the same positions
and align well in all complexes and the side-chain of rTxln-1 Arg17 is pointing into
the S1 specificity pocket in all complexes. However, the side-chain of the catalytic
His603 has rotated out of the active site in the microplasmin complex, while it is
positioned inside the active site in the trypsin complex (Figure 6-44). Therefore it
seems possible to speculate that the reaction between rTxln-1 and microplasmin and
rTxln-1 and trypsin are different.
Figure 6-44 The positions of the catalytic triads and rTxln-1 when microplasmin and
trypsin are superimposed.
The rTxln-1 molecules bound to microplasmin are yellow and rTxln-1 bound to trypsin is
purple. Microplasmin is blue. The catalytic triad of trypsin is green. Side-chains are
represented as sticks. Nitrogen atoms are blue and oxygen atoms are red. Residues are
labeled and labels are colored according to their residue color. The catalytic triads overlay
well when microplasmin and trypsin are superimposed. The rTxln-1 side-chain Arg17 point
in the same direction in the two structures.
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In most crystal structures of hydrolases, the side chain of the catalytic histidine
residue is rotated towards the catalytic active site, often with the His-Asp/Glu pair
hydrogen bonded (Jing et al., 1998). However, in some instances the side chain of
the histidine has rotated out of its normal location in the active site. Comparing two
structures of Rhodococcus sp. cocaine esterase, one with an inhibitor and the other
with a product bound in the active site, revealed that both the catalytic serine and
histidine side-chains had rotated ~45o away from their catalytically functional
positions when the product was bound (Larsen et al., 2001). In the structures of
Streptomyces griseus protease A the histidine was rotated by ~90o from a
catalytically functional position in a structure with a tetrapeptidealdehyde in the
active site but not with a tetrapeptide (Brayer et al., 1979; James et al., 1980). An
additional example of a mobile histidine side-chain was revealed when comparing
two structures of Torpedo californica acetylcholinesterase complexed with two
products consecutively formed after each other when reacting with an
organophosphorus inhibitor. The structures of Torpedo californica
acetylcholinesterase showed reversible movement of the histidine, where the
conformational changes involved forming a bond to two different glutamatic acid
residues (Millard et al., 1999). In the structure of tonin, the catalytic histidine is
positioned out of the active site and has a role as a ligand for a Zn ion (Fujinaga and
James, 1987). In structures of factor D (Narayana et al., 1994; Cole et al., 1997; Cole
et al., 1998; Jing et al., 1998), the catalytic hisitidine rotates 180o out of the active
site and into a stabilizing pocket, after an obstructing loop has moved. It can be
concluded that the different positions of the catalytic histidine side-chain are
dependent on the environments surrounding the histidine side-chain.
It is possible to theoretically model the microplasmin side-chain of His603 without
having it clashing with any other side-chains to a catalytic functional position inside
the active site, however, the short distance between His603Cį2 of microplasmin and
one of the Val18CȖ atoms of rTxln-1 (~1.8 Å) make it unfavorable (Figure 6-47).
Therefore, it can be speculated that the rTxln-1 side-chain of Val18 forces the side-
chain of His603 to rotate out.
In bovine trypsin the side-chain of His57 can be theoretically modeled out of the
active site, but not at the same location as the one in the rTxln-1-microplasmin
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complex because it come too close to the side-chains of Tyr94 and Leu99 of bovine
trypsin. The histidine has been seen to rotate ~90o away from the catalytically
functional position when the residue at the same location as Tyr94 in bovine trypsin
is phenylanaline in a Rattus norvegicus trypsin mutant (Sprang et al., 1987) (Figure
6-45) or tryptophan in porcine pancreatic elastase (Sawyer et al., 1978; Meyer et al.,
1985; Radhakrishnan et al., 1987; Meyer et al., 1988) (Figure 6-46). Modeling the
side-chain of His57 of bovine trypsin in the rTxln-1-trypsin complex in any other
position away from its catalytically functional position and without it clashing with
rTxln-1 reveals that there is no residue such as Glu606 of microplasmin at the same
position as in microplasmin to stabilized trypsin’s His47 side-chain (Figure 6-47).
Therefore, it may be less likely that the side-chain of His57 would rotate out of the
active site.
(a)
(b)
Figure 6-45 Comparison of bovine trypsin and Asn102 Rattus norvegicus trypsin mutant.
The Asn102 Rattus norvegicus trypsin mutant (1TRM) is yellow. His57, Phe94, Asn102 and
Ser195 in the Rattus norvegicus trypsin mutant are shown as sticks with carbon atoms
colored purple. Oxygen atoms are red and nitrogen blue. (a) His57 in the Rattus norvegicus
trypsin mutant is partitioned between to position related with ~90o. (b) Bovine trypsin from
the rTxln-1-trypsin complex is superimposed onto the Rattus norvegicus trypsin mutant.
His57, Tyr94, Asp102 and Ser195 in bovine trypsin from the rTxln-1-trypsin complex are
shown as sticks with carbon atoms colored cyan.
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(a)
(b)
Figure 6-46 Comparison of bovine trypsin and porcine pancreatic elastase.
Porcine pancreatic elastase is green (1JIM). (a) His57, Phe94, Asp102 and Ser195 in porcine
pancreatic elastase are shown as sticks. Carbon atoms are colored orange in elastase (3EST)
with the His57 in its normal position. Carbon atoms are colored salmon (1INC) and yellow
(1JIM) with the side-chain of His57 ~90o from its normal position. Oxygen atoms are red
and nitrogen blue. (b) Bovine trypsin from the rTxln-1-trypsin complex is superimposed onto
porcine pancreatic elastase. His57, Tyr94, Asp102 and Ser195 in bovine trypsin from the
rTxln-1-trypsin complex are shown as sticks with carbon atoms colored cyan.
Figure 6-47 Stereo view of the environment around the catalytic histidine.
rTxln-1 and microplasmin from complex A are yellow and light blue, respectively. Trypsin
is purple. Side-chains are represented as sticks. Nitrogen atoms are blue and oxygen atoms
are red. Residues are labeled and labels are colored according to their residue color. The
side-chain of microplasmin’s His603 would be very close to the side-chain of rTxln-1’s
Val18 if it is positioned at the location of the side-chain of trypsin’s His57. The side-chain of
trypsin’s His57 would be too close to the side-chains of trypsin’s Tyr94 and Leu99 if it is
positioned at the location of the side-chain of microplasmin’s His603.
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A structure of the aprotinin-microplasmin complex has not been determined to date.
However, by superimposing trypsin from the aprotinin-trypsin complex (pdb file
2PTC) onto microplasmin reveals that the secondary loop of aprotinin docks even
closer to the surface of microplasmin than the secondary loop of rTxln-1 (Figure
6-48). An additionally favorable contact can form between Lys46Nȗ of aprotinin and
Lys607N of microplasmin (2.73 Å). Furthermore, the side-chain of Arg20 of
aprotinin have to adjust not to clash with the side-chain of Lys607 of microplasmin,
having the potential to form a favorable “sandwiched” interactions among the side-
chains of Arg20 of aprotinin, Lys607 of microplasmin and Ile18 of aprotinin.
Another contribution to a possible closer contact of the secondary loop of aprotinin
to the surface of microplasmin is the residue Arg39 of aprotinin, which has a longer
side-chain than the corresponding side-chain of Glu41 of rTxln-1. This theoretical
approach may explain why aprotinin binds harder to microplasmin than rTxln-1 and
also why aprotinin is less reversible than rTxln-1. However, another important
difference between rTxln-1 and aprotinin is the change from a valine in rTxln-1 to
alanine in aprotinin at the P1' position. Alanine is smaller than valine and is likely to
not expel the His603 side-chain of microplasmin, which could greatly affect the off
rate.
(a) (b)
Figure 6-48 The location of aprotinin when superposing the trypsin molecule from the
aprotinin-trypsin complex onto microplasmin.
rTxln-1 from the microplasmin complex is yellow, rTxln-1 from the trypsin complex is
purple and aprotinin from a complex with trypsin is green. Microplasmin is light blue. (a)
Visualizing the different docking angles and aprotinin docks closer to the microplasmin
surface than rTxln-1. (b) The Connolly surface of microplasmin is light blue. Aprotinin is
approaching close to the surface of microplasmin, the canonical loops, secondary loops and
disulfide bridge overlay well.
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6.10 Discussion of rTxln-1 dimer
Mass spectrometry (Chapter 2) of both rTxln-1 alone and of the rTxln-1 trypsin
complex indicated that rTxln-1 might form a dimer. A possible dimer formation of
rTxln-1 was seen in the crystal packing (Chapter 4). Mass spectroscopy of the rTxln-
1-trypsin complex showed the presence of a species of 37 kDa, suggesting that one
molecule of trypsin could combine with two molecules of rTxln-1 (Chapter 2). The
structural proofs of two rTxln-1 molecules docking to microplasmin or trypsin within
this study are discussed briefly in the following.
In the crystal lattice of rTxln-1-microplasmin, two rTxln-1 molecules have an
interface of 342 Å2 between their C-terminal Į-helices. One of the rTxln-1 molecules
is docked to the active site of microplasmin and the other rTxln-1 molecule has also
an interface with the microplasmin molecule. This latter interface is 215 Å2 and 129
Å2, in complex A and B respectively (Figure 6-49). The interface of 342 Å2 between
the two rTxln-1 molecules are likely to be too small for a dimer formation, therefore,
this is not likely to occur (Figure 6-49; Figure 6-50; Figure 6-51).
(a) (b)
Figure 6-49 Two rTxln-1 molecules and one microplasmin molecule.
The rTxln-1-microplasmin complex is yellow and light blue. The symmetry related rTxln-1
is green. Interfaces are marked. (a) The rTxln-1-microplasmin complex A and symmetry
related rTxln-1, interfaces are 324 Å2 and 215 Å2. (b) The rTxln-1-microplasmin complex B
and symmetry related rTxln-1, interfaces are 324 Å2 and 129 Å2.
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Figure 6-50 Residues in
interface between complex
A and symmetry related
rTxln-1.
The rTxln-1 and
microplasmin from complex
A are yellow and light blue.
The symmetry related rTxln-
1 is green. Residues in the
interface are marked.
Figure 6-51 Residues in
interface between complex
B and symmetry related
rTxln-1.
The rTxln-1 and
microplasmin from
complex B are yellow and
light blue. The symmetry
related rTxln-1 is green.
Residues in the interface
are marked.
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Another possible dimer formation of rTxln-1 with an interface area of 643 Å2 was
mentioned in Chapter 4. Superposition of the structure of free rTxln-1 molecule A or
molecule C onto the rTxln-1 molecule in the trypsin complex and rTxln-1 in the
microplasmin complex A and B, reveals that this dimer formation of rTxln-1 may not
function as an efficient inhibitor of plasmin or trypsin because the canonical loop is
hindered to some extent to enter the active site, less so with microplasmin than with
trypsin (Figure 6-52). Therefore, this is not an ideal dimer formation of rTxln-1 as
efficient inhibitor of plasmin or trypsin.
(a) (b)
Figure 6-52 Possible dimer binding to microplasmin.
The rTxln-1 and microplasmin from complex B are yellow and light blue. The dimer
formation of free rTxln-1 molecule A and C is purple. (a) The rTxln-1-microplasmin
complex A. The free rTxln-1 molecule A is superposed onto rTxln-1 from complex A and
showing the position of the free rTxln-1 molecule C. (b) The rTxln-1-microplasmin
complex B. The free rTxln-1 molecule A is superposed onto rTxln-1 from complex B and
showing the position of the free rTxln-1 molecule C. The free rTxln-1 molecule C clashes
with microplasmin.
6.11 Summary
The structure of the rTxln-1-microplasmin complex has been determined by
molecular replacement to a resolution of 2.78 Å. rTxln-1 docks to microplasmin
through its canonical loop and secondary loops in a similar manner as it docks to
trypsin. A stable Michaelis complex is formed with a buried surface of 1384 Å2.
The Arg17 from rTxnl-1 protrudes into the specificity pocket of microplasmin
making an ionic bond with aspartate at the bottom of this pocket, while the distance
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between the carbonyl carbon of Arg17 and the catalytic Ser741OȖ in microplasmin
are within a sub van der Waals distance (2.94 Å). His603 in microplasmin adopts an
altered non-catalytically competent position such that its side-chain has swiveled
around its Ȥ1 bond and out of its classical catalytic triad location. To compensate, a
water molecule is observed bridging, the serine and aspartate side-chains. The reason
for this movement appears to be due to the close approach of Val18 in rTxln-1
forcing His603 to move. The side-chain orientation of His603 has not previously
been observed in other plasmin structures. In addition, the His603 side-chain is
situated close to the Cys16-Cys40 disulphide bridge in rTxln-1.
An interesting observation is that the two complexes in the asymmetric unit differ in
docking angles by, ~8° suggesting that there is flexibility at the interface. This is
either due to rTxln-1 not being completely locked into its optimal conformation in
one of the complexes or as a result of crystal packing effects. This variability may be
related to rTxln-1’s fast off rate for plasmin.
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Chapter 7
Crystal structure of native ACII-4 from Australian
King Brown snake (Pseudechis australis) venom
Snake venoms are a rich source of molecules that have a PLA2 fold. As well as their
phospholytic activities, the PLA2s from venom possess a wide variety of
pharmacological activities such as presynaptic and/or postsynaptic neurotoxicity,
myotoxicity, initiation and/or inhibition of platelet aggregation, haemolytic,
anticoagulant, convulsant, hypotensive, cardiotoxic and oedema-inducing effects
(Kini and Evans, 1989; Arni and Ward, 1996).
PLA2 isolated by our group from the Australian King Brown snake, ACII-4, has low
phospholipase activity and strong anticoagulant activity. It consists of a single
polypeptide chain of 118 amino acid residues and has a molecular weight of 14 kDa.
The phospholipase activity has been shown to be dependent on the presence of Ca2+
(Masci, 2000). However, the phospholipase and anticoagulant activity are not
dependent on each other and should therefore relate to different regions of the
molecule. ACII-4 has also been reported to have both presynaptic neurotoxic and
myotoxic activities on isolated nerve-muscle preparations (Rowan et al., 1989).
Nitrophenylsulfenylation of tryptophanyl residues at positions 31 and 69 in ACII-4
caused loss of all activities (Takasaki et al., 1990a). The region containing the
anticoagulant activity in PLA2s from the genus Naja (group I) was correlated to the
region around a trypsin residue which corresponds to Phe61 in ACII-4 (Kini and
Evans, 1987; Kini, 2006). It has been suggested that the ACII-4 molecule is
functional as a dimer (Masci, 2000). A search for similar sequences to ACII-4 in the
Protein Data Bank using the ‘Basic Local Alignment Search Tool’ (BLAST)
(Schäffer et al., 2001) shows the highest identity, 65%, with a presynaptic neurotoxic
PLA2, Notexin, from Mainland Tiger snake (Notechis scutatus scutatus). All fourteen
cysteine residues in these molecules are in conserved locations in these two proteins.
The overall architecture of molecules with a PLA2 fold consists in general of three
major and two minor Į-helices, and a double-stranded antiparallel ȕ-sheet (referred
to as the ȕ-wing), a Ca2+ binding loop and the presence of several disulfide bonds
(Arni and Ward, 1996). For PLA2 to be catalytically active a Ca2+ ion needs to be
203
bound to the Ca2+ binding loop (Dijkstra et al., 1983; Steiner et al., 2001). One of the
ligands coordinating the Ca2+ ion is generally an asparatate at position 41,
contributing its two side-chain oxygen atoms to the coordination.
Crystal structures have been solved of PLA2s from the venom of Chinese cobra, Naja
naja atra, Indian cobra, naja naja sagittifera (Jabeen et al., 2005), Guangxi cobra,
Naja naja kaouthia (Gua et al., 2002), Eastern Cottonmouth snake, Agkistrodon
piscivoris piscivorus, (Maraganore and Heinrickson, 1986; van den Bergh et al.,
1988, 1989), Bothrops pirajai (Rigden et al., 2003) and a pit viper Bothrops asper
(Arni et al., 1995). An individual PLA2 can exhibit one or more pharmacological
activities. For example, a PLA2 from Russell's viper, Vipera russelli russelli, has
anticoagulant properties while PLA2 from Australian Tiger snake, Notechis scutatus
scutatus, has presynaptic neurotoxic properties (Carredano et al., 1998), and the
PLA2 from King cobra, Ophiophagus hannah has cardiotoxic and myotoxic activity
(Zhang et al., 2002).
There are three phospholipases in the venoms of the Australian King Brown snake,
Pseudechis australis. These have been identified as PA11, PA3 and PA15 (Takasaki
et al., 1989; Takasaki et al., 1990b). ACII-4 corresponds to PA11. The other two
PLA2s exhibit different activities. One has very strong phospholipase activity and the
second has strong haemolytic activity. From a sequence alignment of PA11, PA3 and
PA15 and other phospholipases it is not clear what region corresponds to the specific
activity. However, structural analysis and comparison with other PLA2 sequences
and structures should help to better define the source of the individual activities,
thereby leading to novel lead drug candidates.
This chapter describes the steps used to solve the structure of the ACII-4, and
compares the structure of this molecule with other molecules with a PLA2 fold.
7.1 Introduction to hemihedral crystal twinning
During the growth of a crystal, an intergrowth of two crystals can sometimes occur in
a symmetrical configuration. This so called twinning can be classified as merohedral
or nonmerohedral (Friedel, 1928). Nonmerohedrally twinned crystals share only
some sets of the same crystal lattice points in three dimensions, while for
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merohedrally twinned crystals diffraction patterns overlay exactly. The most
common type of merohedral twinning is hemihedral twinning, where only two
different orientations of the different crystals are present (Parsons, 2003). Diffraction
patterns of hemihedrally twinned crystals look the same as diffraction patterns of
crystals without twinning. It is not possible to distinguish a diffraction pattern of a
hemihedrally twinned crystal from a crystal without twinning without further
analysis. In a diffraction pattern from a hemihedrally twinned crystal, each observed
diffraction intensity is a weighted sum of two twin-related reflections (Stanley, 1955,
1972; Dauter, 2003). The weights are determined by the fractional volume of each of
the two crystal orientations within the twinned crystal, represented by the “twinning
fraction” Į, corresponding to the fractional volume of the crystal that the smaller of
the two domains occupies. The observed intensity Iobs is equal to
Iobs(hkl) = (1-Į) I(hkl) + Į I(h'k'l') (7.1)
where (hkl) and (h'k'l') are twin-related Miller indices. The twinning fraction takes
values between 0.0 and 0.5. The specimen is untwinned if Į = 0. When Į is nonzero
but less than 0.5 it is referred to as “partial twinning” and the special case of Į = 0.5
as mimetic or “perfect twinning”. In the case of partial twinning, the structure can
still be solved by statistically estimating the twinning fraction followed by
detwinning the data and refining the structure against the detwinned dataset.
As outlined and described below, the diffraction pattern of the ACII-4 crystal was
produced from a hemihedrally twinned crystal. It was therefore possible to determine
the twinning fraction and to detwin the processed intensities. Assuming that the
ACII-4 molecule had a structure similar to other PLA2 structures molecular
replacement could be applied as the technique to solve the phase problem, since
several structures of PLA2s are deposited in the PDB.
7.2 Phase determination of free ACII-4
Extensive attempts at solving the phase problem were carried out. Initially, AMoRe
(Navaza, 1994) (see Appendix E.2), was used to perform fast rotation, translation
functions and rigid body refinements. Based on the analysis of the X-ray diffraction
pattern the space group P3121 was assigned to this crystal form. Solvent content
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arguments indicated that there is only one molecule in the asymmetric unit. The
rotation function was run searching for Patterson correlation within a sphere centered
on the origin. This allowed the Patterson correlation function to be expressed in
terms of spherical harmonics, and the calculation to exploit fast Fourier transform
techniques (see Appendix D and E for AMoRe and Patterson calculations).
Searching for one molecule and subsequently checking for two molecules in the
translation step was carried out by employing the Crowther and Blow translation
function. This function tests each orientation solution in turn and searches for the
best resultant translational. There was no improvement when searching for two
molecules. After carrying out rigid-body refinement, the solution with one molecule
gave a correlation coefficient of 0.49 and an Rfactor of 0.48. Refinement by utilizing
the CNS suite of programs (Brünger et al., 1998) and model building with the
Program O (Jones and Kjeldgaard, 1998) could not refine the structure to better than
an Rfactor of 0.38. The data was reprocessed in space group P31 and AMoRe was run
in space groups P31, P32 and P3, but no correct solution was found. The molecular
maximum-likelihood program Phaser (McCoy et al., 2005) (see Appendix E.4 for
Phaser and maximum-likelihood method), available through the CCP4 software
suite, was also tried to find the initial set of phases, using the same space groups. A
model was found in P31, but this would not refine any better than to an Rfactor of 0.38
using CNS. ARP/wARP (Morris et al., 2003) was used to auto build a completely
new model based on phases from the previous molecular-replacement solution.
However, only dummy atoms could be placed and a new model could not be built.
The conclusion was that the data had either been processed in the wrong space group
or the data was twinned.
The CCP4 program SFCHECK was used to test for merohedral twinning and to
detwin the data. SFCHECK first tested the reflection file which had been processed
in space group P31 for merohedral twinning. Initially the perfect twinning test was
performed. Each observed intensity is a sum of two true crystallographic intensities.
The crystallographic intensities obey ordinary Wilson statistics (Wilson, 1949), while
the sum of two such values does not. Expected properties of intensity distributions
for perfect hemihedral twinning have been given by (Stanley, 1972). For acentric
data the formulae for the perfect twinning test are
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<Iobs2>/<Iobs>2 = 2 for untwinned data (7.2a)
<Iobs2>/<Iobs>2 = 1.5 for perfectly twinned data (7.2b)
The calculation showed a value of 1.67 for the dataset collected from the ACII-4
crystal indicating that the crystal is neither untwinned nor perfectly twinned. Next a
partial twin test parameter H (Yeates, 1997) was computed for the pairs of acentric
reflections
H = | Iobs(h) – Iobs(hƍ)| / (Iobs(h) + Iobs(hƍ) (7.3)
where (h) and (hƍ) represent (hkl) and (hƍkƍlƍ), respectively. To calculate H requires
that the twin operator is already known. The twin operator is the symmetry operation
that relates the two orientations in the twinned crystal. SFCHECK tested all possible
twin operators and reported (-h-k,+k,-l) as the correct one. If Wilson statistics applies
to the two independent intensities it is possible to derive the expected distribution for
H as a function of Į (the twinning fraction). The expected cumulative distribution for
H, S(H), is linear in H for acentric reflections and given by
S(H) = H / (1 – Į ) (7.4)
The cumulative distribution of H for the observed intensity data was calculated in
Figure 7-1 and the plot indicates a twinning fraction of about 0.43.
Figure 7-1 Cumulative distribution of H.
Cumulative distribution of H as a function of H and twinning fraction Į.
207
The curves plotted with + are the linear curves based on Wilson statistics. The curve plotted
with o is based on the observed intensity data and indicating a twinning fraction Į § 0.43.
The partial twinning test was followed by calculating the twinning fraction Į
according to (Yeates, 1997)
Į = ½ - <H> (7.5)
which gave a twinning fraction Į = 0.438. This is in agreement with the graph
produced by SFCHECK.
The processed reflection file, from 26.79–1.56 Å, was detwinned by utilizing the
determined twinning fraction and the following equations
Iobs(h) = (1- Į) Io(h) + Į Io(hƍ) (7.6a)
Iobs(hƍ) = Į Io(h) + (1- Į) Io(hƍ) (7.6b)
thus
Io(h) = ((1- Į) Iobs(h) – Į Iobs(hƍ)) / (1-2Į) (7.7a)
Io(hƍ) = ((1- Į) Iobs(hƍ) – Į Iobs(h)) / (1-2Į) (7.7b)
where Iobs is the observed intensity, Io is the true, detwinned intensity, h and hƍ
denote twin-related indices. For perfect twinning, Į = 0.5, the Equations 7.6 and 7.7
give no solutions as the denominators are zero.
The resultant intensities were converted into a mtz file and used in MrBump that
directs CCP4 supported programs to automatically discover and prepare a search
model in addition to carrying out cycles of refinement (Keegan and Winn, 2007) (see
Appendix E.8). MrBump was given the amino acid sequence of the ACII-4 molecule,
and the detwinned experimental structure factors. The run was entered to search for
homologous structures, and created a set of suitable search models from the template
structures by using the default multiple sequence alignment program, Multiple
Alignment using Fast Fourier Transform (MAFFT) (Katoh et al., 2005), with the E-
value for the Fasta search set to 0.02. The sequence was compared to the sequences
in the SwissProt database using MAFFT to find similarities. The obtained data for
these sequences are reported as percent identical residues, Z-score and E-value. If
two proteins have over 45% identical residues in their optimal alignment, they
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probably have very similar structures and a similar function. The Z-score is a
measure of how a score compares to the mean and standard deviation of the
alignments of randomized sequences. If the alignment has a score S, the Z-score is
given by
Z-score = (S-mean)/standard deviation (7.9)
A Z-score of 0 means that the similarity is no better then the average of the random
permutations of the sequence and might have happened by chance. A higher Z-score
increases the probability that the observed alignment has not happened by chance. A
Z-score 5 is considered significant. The E-value of an alignment is the expected
number of sequences that give the same score or better. If the E-value 0.02 the
sequences are probably homologous (Lesk, 2002).
The Fasta search found several good alignments with the three best scores:
Table 7-1 PDB entries with the best E-values
PDB E-value
1AE7 5.3e-37
2NOT Mol A 3.2e-36
2NOT Mol B 3.2e-36
The models were prepared with Molrep (Vagin and Teplyakov, 1997) and Chainsaw
(Stein, 2006). Molrep contains a model preparation function which aligns the
template sequence with the target sequence and prunes the non-conserved side-
chains accordingly. Chainsaw removes un-aligned residues from the model and
prunes non-conserved residues back to the CȖ atom, which preserves more atoms
than a polyalanine model. After the models had been prepared with Molrep and
Chainsaw, the log file showed the three best scores as the following:
Table 7-2 Prepared search models with scores
Prepared search
models
Molrep Score Chainsaw Score
1AE7 0.346 0.66
2NOT Mol A 0.345 0.65
2NOT Mol B 0.353 0.65
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MrBump was set to use PHASER for the molecular replacement and thereafter 30
cycles of restrained refinements in REFMAC5 (Murshudov et al., 1997). The
prepared search model 1AE7 was used in PHASER. The log file of MrBump showed
two molecules in the asymmetric unit (Figure 7-2); the results of the final translation
function in PHASER had a Z-value of 18, and the refinement results from
REFMAC5 had an Rfactor of 0.38. Examination of the crystal packing indicated
reasonable contacts between the two molecules and no overlap of symmetry related
molecules (Figure 7-2).
Figure 7-2 The two ACII-4 molecules in the asymmetric unit.
The two ACII-4 molecules in the asymmetric unit are colored blue and purple. The
monoclinic unit cell is shown in purple with the a and b axis marked in black.
7.3 Refinement of model of PLA2 crystal structure
The model and map from REFMAC5 was visualized with Coot (Emsley and Cowtan,
2004). The side-chains that differed were mutated into the amino acid sequence of
ACII-4 and fitted into the electron density. The model was fitted into the 2Fo-Fc
map, using a sigma level of 1 for both the 2Fo-Fc and Fo-Fc maps. The model
building was refined with cycles of restrained refinement with REFMAC5 with no
prior phase information, and with the weighting term between X-ray and geometric
residuals set to 0.4. Data used in refinement ranged from 22.46-1.56Å, with 5%
reflections used for Rfree test set (1142 reflections). All atoms were refined with
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individual isotropic B-factors. The first rounds were cycled with the ARP_water
feature in REFMAC5 to analyze the solvent model.
7.4 Refinement statistics and quality of ACII-4 crystal
structure
There are two ACII-4 molecules in the asymmetric unit. The electron density map is,
in general, well defined and the majority of the amino acid residues for the two
ACII-4 molecules in the asymmetric unit could be fitted into the electron density.
The final model included residues 1–118 in both molecules A and B in the
asymmetric unit. 309 water molecules, two sulfate ions, four PEG molecules and two
Ca2+ ions could also be fitted into the electron density. It was not necessary to
truncate any of the side-chains to alanine. The final Rfactor and Rfree are 0.20 and 0.24,
respectively. A difference between the two values of only 0.04 is and indication that
the model has not been over refined. The final model has excellent geometry with an
rmsd from ideal bond lengths of 0.014 Å, and an rmsd from ideal bond angles of
1.60o (Table 7-3).
Table 7-3 Refinement statistics of ACII-4 crystal structure
Non-hydrogen atoms
Molecule A 899
Molecule B 899
Total number of protein atoms 1798
Solvent (H2O)
Solvent (Ca2+)
309
2
Solvent (SO4) 10
Solvent (PEG) 28
Resolution (Å) 22.46 – 1.56
Rfactor 0.20
Rfree 0.24
rmsd from ideal geometry
rmsd bond lengths (Å) 0.014
rmsd bond angles (o) 1.520
Rfactor = | |Fobs| - |Fcalc||/|Fobs|, 5% of the data were excluded from the refinement
were used to calculate Rfree.
The average B-values for all main-chain atoms are 13.1 Å2 and 14.0 Å2 for molecule
A and B, respectively, while for side-chains atoms these values are 14.7 Å2 and 15.9
Å2 (Table 7-4). This shows that the two molecules display a similar level of
structural order. An analysis of the B-values as a function of position in the
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polypeptide of the two ACII-4 molecules shows that there are four areas with higher
values than the average. They consist of residues 10–24 (part of solvent exposed
loop), 29–36 (part of Ca2+ binding loop), 70–84 (part of ȕ-wing), and the C-terminal
residues (Figure 7-4). Lys81 and Pro82 were the only two residues with weaker
electron density and difficult to model. These two residues are both situated in a
solvent exposed loop region and Lys81 has, except for the C-terminal Lys118, the
highest B-values in the structure.
Table 7-4 Mean B-values (Å2) for the two ACII-4 molecules.
Molecule A
main-chain
side-chain
all atoms (899 atoms)
Molecule B
main-chain
side-chain
all atoms (899 atoms)
H2O (309 atoms)
Ca2+ (2 atoms)
SO4 (10 atoms)
PEG (28 atoms)
Total
main-chains
side-chains and waters
all atoms (2147 atoms)
13.1
14.7
13.9
14.0
15.6
14.7
22.1
13.8
28.7
25.3
13.6
17.3
15.6
Figure 7-3 Visualization of the B-values for the two molecules of ACII-4 in the asymmetric
unit.
Main-chain high B-values are in yellow, thick tubes and lower B-values are in blue, thin
tubes. Side-chains are shown as sticks and color coded. Molecule A and B are labeled.
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Figure 7-4 B-values (Å2) for molecule A and B of ACII-4.
Glycine residues have no side-chain B-value.
The Ramachandran plot calculated over the two molecules showed 89.9% of residues
in most favored regions, 9.1% residues in additional allowed regions, and 1.0% in
generously allowed regions. There were no residues in disallowed regions (Table
7-5). The main-chains that have unusual dihedral angles are Lys81 and Pro82 (Figure
7-5). This was the only place in the structure where the electron density was weak.
The cyclic side-chain of proline residues limit the range of Phi angles to values of
around -60o, making it the most conformationally restricted residue.
Table 7-5 Ramachandran plot statistics for the two ACII-4 molecules
Residues (%)
Most favored regions 89.9
Additionally allowed regions 9.1
Generously allowed regions 1.0
Disallowed regions 0.0
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Figure 7-5 Ramachandran plot of the crystal structure of ACII-4.
A (Į-helix), B (ȕ-sheet) and L (left handed Į-helix) are the most favored regions. a, b and c
are additionally allowed regions, and ~a, ~b, ~l, ~p are generously allowed regions. Glycine
residues are identified as triangles. Amino acids with high backbone energy conformations
are Lys81 and Pro82 in both molecule A and B.
Pro82 is situated in a solvent exposed loop region and has created a bend in the loop.
The Cys78-Cys89 disulfide bond holds this loop close to the core of ACII-4. This has
set restrains on the side-chain of Lys81 which was modeled in a cis-conformation.
The side-chain of this residue is aligned with the core of the protein. A water
mediated bond is also formed between Lys81 and Lys85.
Lys81 is part of the tryptic fragment for which a mass has been determined (ms).
However, no ms/ms data have been obtained to unambiguously assign the sequence
(personal communication , Geoff Birrell). Otherwise, the undetermined regions in the
sequence (Gly59-Lys63, Pro82-Lys85, Cys98-Lys106 and Lys115-Lys118) have
well defined electron density except for small parts of the side-chains of Lys85,
Arg116 and Lys118 in molecule A and Lys118 in molecule B. The tryptic digest and
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mass spectrometry results together with the crystal structure confirm that ACII-4 is
the same molecule as the previously isolated PA11 (Takasaki et al., 1990b).
7.5 Crystal structure of free ACII-4
ACII-4 has an L shape with a height of a 34 Å (measured from residue Gly59CĮ to
Lys105CĮ) and a width of 40 Å (measured from Gly73CĮ to Lys114CĮ). The solvent
accessible surface of each ACII-4 is 6719 Å2 (average of the two molecules in the
asymmetric unit) AREAIMOL (B. Lee and Richards, 1971). Both ACII-4 molecules
consist of; three major Į-helices (residues 2-12, 40-57 and 83-101), one minor Į-
helix (113-116), two minor 310-helices (residues 19-22 and 106-108) and one double-
stranded antiparallel ȕ-sheet (residues 69-72 and 75-78). Seven disulfide bonds
stabilize the structure (Cys11-Cys71, Cys27-Cys117, Cys29-Cys45, Cys44-Cys98,
Cys51-Cys91, Cys60-Cys84 and Cys78-Cys89). Three disulfide bonds; Cys44-
Cys98, Cys51-Cys91 and Cys60-Cys84, rigidify the two core helices (40-57 and 83-
101). Cys78-Cys89 secure the ȕ-sheet, referred to as the ȕ-wing, to one of the core Į-
helices (83-101) and Cys11-Cys71 secure the ȕ-sheet to N-terminal Į-helix. Two
disulfide bridges (Cys 27-Cys117 and Cys29-Cys45) secure the correct relative
orientation of the Ca2+ binding loop (residues 28-32). The Ca2+ ion is bound by seven
ligands: the carbonyl oxygens of Tyr28O, Gly30O, Gly32O, the side-chain oxygens
of Asp49, and two water molecules. The geometry of the Ca2+ coordination is best
described as a distorted pentagonal bipyramid. The wiring diagram of the secondary
structure is shown in Figure 7-6, and the stereo-diagram of the overall fold is shown
in Figure 7-7.
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Figure 7-6 Wiring diagram of the secondary structure of ACII-4
H1 = N-terminal Į-helix, residues 2-12 H2= 310-helix, residues 19-22, H3= Į-helix 40-57,
residues, H4= Į-helix, residues 83-101, H5= 310-helix, residues 106-108, H6= C-terminal Į-
helix, residues 113-116, A = antiparallel ȕ-strands forming a ȕ-sheet, yellow circles =
cysteine residues forming disulfide bridges (orange solid line defines the connection), ȕ = ȕ-
turn, Ȗ = Ȗ-turn and = ȕ-hairpin. Picture generated by PDBsum (R. A. Laskowski
et al., 2005).
Figure 7-7 Stereo view of the overall fold of molecule A of ACII-4 represented as a cartoon
drawing.
The strands are colored yellow, helices red, loops green and the Ca2+ is illustrated as a blue
colored sphere.
Least-squares fitting of topologically equivalent CĮ atoms (and all atoms including
side-chains) of residues 1–118 in ACII-4 using the program Superpose (E. Krissinel
and Henrick, 2004), resulted in an rmsd of 0.41 Å (0.98 Å). All seven disulfide
bonds in both molecules have the same chirality (Figure 7-8). Five of the disulfide
bonds have left handed chirality Cys27-Cys117 (Ȥ3 -87.0º), Cys44-Cys98 (Ȥ3 -74.6º),
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Cys51-Cys91 (Ȥ3 -81.1º), Cys60-Cys84 (Ȥ3 -84.5º) and Cys78-Cys89 (Ȥ3 -97.5º) and
two disulfide bonds have right handed chirality Cys11-Cys71 (82.9º) and 29-45
(94.2º). A closer look at the superposition shows that the only region with different
conformations in the two molecules is the segment of residue Trp31-Ser43, which is
part of the Ca2+ loop. This difference is discussed in the next section.
Figure 7-8 Superposition of the two ACII-4 molecules.
Molecule A (blue) and B (green) have the same overall fold. All disulfide bonds (orange
sticks) have the same chirality. The two disulfide bridges that stabilize the ȕ-wing in ACII-4
are labeled.
The ȕ-wing in ACII-4 is built up by a ȕ-hairpin motif created by the two antiparallel
ȕ-strands, (residues 69-72 and 75-78), and a short loop (residues Gly73-Asn74) that
connects the ȕ-strands. This region is further stabilized by two disulfide bonds
(Cys11-Cys71 and Cys78-Cys89) connecting the ȕ-wing to the Į-helical core of the
molecule. The ȕ-wing extends away from the core of ACII-4, and the ‘wingtip’
(Thr72-Gly73-Asn74-Val75) is poorly anchored (Figure 7-8).
7.6 The calcium ion in the structure of ACII-4
The crystal structure of ACII-4 contains one calcium ion coordinated to seven
ligands. No Ca2+ ions were added during the purification of ACII-4 or in the
crystallization conditions. Thus the Ca2+ ion must have been present with the ACII-4
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and carried through from the venom. The Ca2+ ion has an average B-value of 13.8 Å2
which is similar to the average B-value of 15.6 Å2 for all atoms (Table 7-4),
indicating that the Ca2+ ion is firmly bound. This Ca2+ ion is bound to the protein by
the seven ligands consisting of the carbonyl oxygen atoms of Tyr28 (2.27 Å), Gly30
(2.36 Å), Gly32 (2.26 Å), the side-chain oxygens of Asp49 (2.58 Å and 2.62 Å) and
two water molecules (2.45 Å and 2.35 Å). Five of the seven Ca2+ ligands in ACII-4
lay in one plane (Gly30O, Gly32O, side-chain oxygens of Asp49 and one water
molecule), with Tyr28O below the plane and one water molecule above the plane.
The ligands form a distorted pentagonal bipyramid (Figure 7-9). Two disulphide
bridges (Cys 27-Cys117 and Cys29-Cys45) secure the correct relative orientation of
the Ca2+ binding loop (Figure 7-10).
Figure 7-9 Stereo view of the seven ligands that coordinate to the Ca2+ ion form a distorted
pentagonal bipyramid.
ACII-4 is colored green with the Ca2+ as a yellow sphere. Two water molecules are
represented as red spheres. The side-chain of Asp49 is shown as a stick model. The carbonyl
oxygen of Gly28, Gly30 and Gly32 are shown as stick models. Carbon atoms are colored
green and oxygen red.
Figure 7-10 Stereo view of the two disulfide bonds securing the correct relative orientation
of the Ca2+ binding loop.
Molecule A of ACII-4 is colored green. The Cys27-Cys117 and Cys29-Cys45 disulfide
bridges are shown as sticks. Sulfur atoms are orange.
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In bovine pancreatic PLA2 (Dijkstra et al., 1981b; Yu et al., 1993; Arni and Ward,
1996; Steiner et al., 2001) and porcine pancreatic PLA2 (Dijkstra et al., 1983; van
den Bergh et al., 1989; Finzel et al., 1991) a calcium ion is also an essential cofactor.
A superimposition is shown in Figure 7-11.
(a) (b)
Figure 7-11 The calcium ion bound to the Ca2+ loop.
(a) Superposition of a PLA2 from porcine pancrease (4P2P) (colored pink with Ca2+ as a
purple sphere) and a PLA2 from bovine pancrease (1BP2) (colored steel with Ca2+ ion as a
green sphere). (b) Superposition of a PLA2 from porcine pancrease (4P2P) and molecule A
of ACII-4 (colored green with Ca2+ as a yellow sphere).
Superimposition of ACII-4 with the PLA2s from bovine pancreas (Dijkstra et al.,
1981b) and Indian cobra, Naja naja sagittifera (Jabeen et al., 2005) showed that the
seven ligands and the Ca2+ ion were in nearly identical positions in all three PLA2s.
However, the Ca2+ binding loop has different conformations. A reason for this is that
the indole group of Trp31 in ACII-4 is lined against the surface of ACII-4. Similarly
the side-chain of the Leu31 in the bovine pancreatic PLA2 rotates towards the surface
of the molecule. However, the side-chain of Arg31 in the PLA2 from Indian cobra
does not interact with the surface of the molecule but instead is rotated out towards
the solvent (Figure 7-12). A PEG molecule packed close to the Trp31 side-chain
(~3.5 Å) in the ACII-4 structures is likely to influence the orientation of the indole
group.
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The Ca2+ binding loop has different conformations in the two ACII-4 molecules in
the asymmetric unit. The largest separation, 2.66 Å, is between Gly32CĮ in molecule
A and the equivalent atom in molecule B (Figure 7-13). The reason for the difference
in the conformation of the Ca2+ binding loop between the two ACII-4 molecules are
the three glycine residues (Gly30, Gly32 and Gly33) which contribute to a flexibility
of this loop yet still allow three main chain oxygen atoms (Tyr28O, Gly30O and
Gly32O) to participate in coordinating the calcium ion.
Figure 7-12 The Ca2+ binding loop.
The different position of the side-
chain of residue 31 in the Ca2+ binding
loop between ACII-4, PLA2 from
bovine pancrease and Indian cobra.
Molecule A (green) and molecule B
(blue) of ACII-4. PLA2 from bovine
pancreas (1BP2) is purple and PLA2
from Indian cobra is orange (1YXH).
The side-chains of residue 31 are
shown as sticks. Oxygen is red and
nitrogen blue.
Figure 7-13 The Ca2+ binding loop in
ACII-4.
The largest distance between the Ca2+
binding loop in molecule A (green)
and molecule B (blue) of ACII-4 is
2.66 Å (between Gly32CĮ A and
Gly32CĮ B).
Several crystal structures of PLA2s have been determined with Ca2+ ion bound.
These include PLA2s from Indian cobra, Naja naja naja, Chinese cobra, Naja naja
atra and Indian cobra, Naja naja sagittifera (Gua et al., 2002; Jabeen et al., 2005).
The sequence of the Ca2+ binding loop is the same in these four PLA2s. It has also
been shown that PLA2 from porcine pancreas can bind a second Ca2+ ion outside the
Ca2+ binding loop (Slotboom et al., 1978; Dijkstra et al., 1983; Finzel et al., 1991)
(Figure 7-14(a)). The crystal structure of a PLA2 from the snake venom of the
Chinese cobra, Naja naja atra, contains an additional Ca2+ with a functional role in
phospholipase activity (Scott et al., 1990; White et al., 1990) (Figure 7-14(b)). A
human nonpancreatic extracellular PLA2 also contains a second Ca2+ with a role in
the phospholipase activity (Scott et al., 1991) (Figure 7-14(c)).
220
Figure 7-14 Ca2+ ions bound to PLA2.
(a) PLA2 from porcine pancrease (4P2P) colored red with two Ca2+ ions as blue spheres. (b)
PLA2 from Chinese cobra (1POA) colored brown with two Ca2+ ions as light blue spheres.
(c) Human PLA2 (1POE) colored purple with two Ca2+ ions as green spheres.
However, a myotoxin protein from pit viper species Bothrops asper (Arni et al.,
1995) and a PLA2 from the Eastern Cottonmouth snake, Agkistrodon piscivoris
piscivorus, has a lysine residue at position 49 with the side-chain İ-amino group
filling the site normally occupied by the Ca2+ ion situated in the Ca2+ binding loop
(Holland et al., 1990). Non-catalytic PLA2-like proteins from snake venom are
characterized by the substitution of an aspartate at position 49 to a lysine (Figure
7-15).
Figure 7-15 PLA2 with Lys49.
The Ca2+ is replaced by the İ-amino group of the side-chain of Lys49. (a) Superposition of a
myotoxin protein from Pit viper (1CLP) (light blue) and a PLA2 from Eastern Cottonmouth
snake (1PPA) (light yellow). Lys49 is shown as a stick model. Nitrogen atoms are colored
blue. (b) Molecule A of ACII-4 is superimposed onto the myotoxin protein from Pit viper
(1CLP). ACII-4 is colored green with the Ca2+ ion as a yellow sphere and Asp49 as a stick
model. Nitrogen atoms are colored red.
(a) (b) (c)
(a) (b)
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7.7 Active site
Polar groups of either monomeric or micellar lipid substrates can easily diffuse into
the active site of PLA2s (Roberts, 1996). Two polyethylene glycol molecules were
found in molecule A and B of ACII-4, at close to identical positions, occupying the
site for a phospholipid substrate (Figure 7-16).
Figure 7-16 The polyethylene glycol
molecules in ACII-4.
Molecule A and B of ACII-4 superposed
onto each other. ACII-4 molecule A is
colored green with its polyethylene
glycol molecules as green spheres. ACII-
4 molecule B is colored blue with its
polyethylene glycol molecules as blue
spheres.
The polyethylene glycol molecule fits (situated furthest) inside a pocket lined by
Leu2, Phe5, Ile9, Phe99, and the hydrophobic part of the side-chains of Tyr22, Tyr52
(Figure 7-17). The hydrophobic side-chains of residue Leu2, Ile3, Leu20 and Ala23
guard the entrance of the hydrophobic channel and the side-chain of Trp31 is
shielding the Ca2+ ion (Figure 7-18). Earlier studies on PA11 showed that chemical
modification of tryptophan residues at positions 31 and 69 caused loss of all
activities (Takasaki et al., 1990a). This indicated an important role for either or both
of these two residues. As seen in the crystal structure Trp31 with its large bulky side-
chain is located close to the active site and it can be speculated that it can easily
move out into the solvent like a gate with the possibility to open and close.
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Figure 7-17 The hydrophobic channel
leads into the active site in ACII-4.
Molecule A of ACII-4 is green and the
Ca2+ ion is a yellow sphere. The
polyethylene glycol molecule located
inside the active site is represented as
spheres, with carbon atoms in white
and oxygen atoms in red.
Figure 7-18 Hydrophobic entrance to the active site of ACII-4.
Residues Leu2, Ile3, Phe5, Ile9, Ser19, Leu20, Ala23 and Trp31 guard the entrance of the
hydrophobic channel and the side-chain of Trp31 shields the Ca2+ ion. The Connolly surface
with the electrostatic surface potentials in molecule A of ACII-4 is displayed. Regions of
positive charge are colored blue, negative charges are colored red and neutral regions are
white. A polyethylene glycol molecule (PEG1) located deep inside the active site is
represented as a stick with green carbon and red oxygen atoms.
One end of the polyethylene glycol molecule is positioned close to the catalytic diad
(His48 and Asp92) and a water molecule (Figure 7-19; Figure 7-20; Figure 7-21).
His48Nį1 forms a hydrogen bond to this water molecule (2.94 Å and 2.99 Å) and the
His48Nİ2 atom forms a hydrogen bond to the Asp92Oį2 (2.93 Å and 2.87 Å) while
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Asp92 is stabilized by Tyr52 and Tyr67. Tyr52OȘ forms a hydrogen bond to
Aps92Oį1 (2.73 Å and 2.66 Å) and Tyr67OȘ forms a hydrogen bond to Asp92Oį2
(2.68 Å and 2.69 Å) (Figure 7-22).
Figure 7-19 The 2Fo-Fc electron density map contoured at 1ı for His48, Asp49 and Asp92,
two water molecules, one polyethylene glycol molecule and one Ca2+ ion for ACII-4.
The electron density map is displayed as a light grey mesh. Carbon, nitrogen and oxygen are
colored green, red and blue respectively. The polyethylene glycol molecule is displayed as a
balls and stick model with purple carbon and red oxygen atoms. Water molecules are
represented as red spheres and the Ca2+ ion as a yellow sphere.
Figure 7-20 The polyethylene glycol molecules and the catalytic diad.
Molecule A of ACII-4 is colored green with Ca2+ as a yellow sphere. The polyethylene
glycol molecules (PEG1 and PEG2) are represented as balls and stick with purple carbon
atoms and red oxygen atoms. The catalytic diad; Asp92 and His48 are represented as sticks
with green carbon atoms, red oxygen atoms and blue nitrogen atoms. Water molecules are
shown as red spheres. (a) With PEG molecules. (b) Without PEG molecules.
(a) (b)
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Figure 7-21 The catalytic diad and the catalytic water molecule.
Molecule A of ACII-4 colored green with Ca2+ as a yellow sphere. The catalytic diad; Asp92
and His48 are represented as sticks with green carbon atoms, red oxygen atoms and blue
nitrogen atoms. Water molecules are shown as red spheres.
Figure 7-22 Stereo view of the two tyrosine residues stabilizing Asp92.
Molecule A of ACII-4 is colored green. His48, Tyr52, Tyr67 and Asp92 are shown as sticks.
Carbon atoms are colored green, oxygen red and nitrogen blue. Distances are in Å.
Superimposing a PLA2 from porcine pancrease with a tetrahedral mimic bound in
the active site onto ACII-4 confirmed that the polyethylene glycol molecules are
overlapping with the tetrahedral mimic. The polyethylene glycol molecule furthest
inside the hydrophobic channel is situated close to the phosphate group of the
tetrahedral mimic which is coordinated to the calcium ion. The polyethylene glycol
molecule outside the active site touches the alkyl chain of the tetrahedral mimic
which extends out from the hydrophobic channel (Figure 7-23).
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(a)
(b)
(c)
Figure 7-23 Comparison of active sites of ACII-4 and PLA2 from porcine pancrease.
PLA2 from porcine pancrease (1FXF) and molecule A of ACII-4 are superimposed. Carbon
atoms are colored green for ACII-4 and pink for the PLA2 from porcine pancreas. The
tetrahedral mimic (salmon) and the polyethylene glycol (blue) in ACII-4 are shown as balls
and sticks. Residues His48 and Asp49 are shown as stick models. Oxygen is colored red,
nitrogen blue, phosphate orange and fluorine white. The Ca2+ ion is shown as a purple
sphere. The catalytic water is shown as a red sphere. (a) The polyethylene glycol molecules
and tetrahedral mimic in the active site. (b) Zoomed in on the active site. (c) Stereo view.
Superimposition of a PLA2 from Common Indian krait, Bungarus caeruleus, (Singh
et al., 2005a) with a fatty acid bound in the active site onto ACII-4 showed that the
226
side-chains of residues Asp48, His49 and Asp92 (ACII-4 numbering) aligned well.
Two carbon atoms of polyethylene glycol in the active site superposed onto two
carbon atoms of the fatty acid in the active site of the PLA2 from Common Indian
krait (Figure 7-24).
(a)
(b)
Figure 7-24 Comparison of active sites of ACII-4 and PLA2 from Common Indian krait
venom.
PLA2 from Common Indian krait venom (1TC8) and molecule A of ACII-4 (green) are
superimposed. The fatty acid (salmon) in the PLA2 from Common Indian krait and the
polyethylene glycol (blue) in ACII-4 are shown as balls and sticks. The catalytic diad is
shown with green carbon atoms for ACII-4 and yellow carbon atoms for the PLA2 from
Common Indian krait. Oxygen is colored red and nitrogen blue. The Ca2+ ion is shown as a
purple sphere. (a) The catalytic diad, catalytic water and polyethylene glycol molecules/fatty
acid shown in the active site. (b) Stereo view.
A change in the conformation of the side-chain of Trp19 PLA2 from Common Indian
krait venom, which is located at the entry of the substrate-binding site, is observed
when comparing a structure of the free PLA2 (1FE5) and complex (1TC8) (Singh et
al., 2005b). The side-chain of Trp19 in the free structure of the PLA2 from Common
Indian krait venom would have clashed with the fatty acid if it was not rotated. In the
complex, the side-chain of Trp19 is more rotated inwards towards the core of the
protein. The corresponding amino acid in ACII-4 is Ser19 and its side-chain does not
have the ability to obstruct the entrance to the active site. In a crystal structure of a
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PLA2 from the venom of Russell’s viper, Daboia russelli pulchella, showed a dimer
where a peptide inhibitor (FLSYK) had entered only one of the monomers. The
orientation of the Trp31 side-chain was suitable for the binding of the inhibitor in
that monomer and it was assumed that in a micellar environment the two monomers
would separate and each bind to the phospholipid interface and be catalytic effective
(Chandra et al., 2002). Superposing the PLA2 from Russell’s viper onto ACII-4
showed that the polyethylene glycol molecules in ACII-4 and the peptide inhibitor
were located in the catalytic active site of the PLA2s (Figure 7-25). The side-chain of
Trp31 in the inhibited monomer from Russell’s viper had the same rotation as the
side-chain of Trp31 in ACII-4. However, the side-chain of Trp31 in the uninhibited
monomer from Russell’s viper clashed with the polyethylene glycol molecules
(Figure 7-26). I speculate that rotation of the side-chain of Trp31 could regulate the
binding of molecules in the active site of the PLA2.
(a)
(b)
Figure 7-25 Comparison of bound molecules in the active site.
(a) The PLA2 from Russell’s viper venom (1JQ9) and molecule A of ACII-4 (green) are
superimposed. Only ACII-4 with its Ca2+ ion (purple sphere) and the polyethylene glycol
molecules (light blue carbon atoms) and the inhibitor (yellow carbon atoms) in the active site
of the PLA2 from Russell’s viper venom are shown. (c) Stereo view of the active site.
Oxygen is colored blue and oxygen is colored red.
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(a) (b)
Figure 7-26 Comparison of the active site entrance.
The PLA2 from Russell’s viper venom (1JQ9) (purple) and molecule A of ACII-4 (green) are
superimposed. (a) The location of the inhibitor and polyethylene glycol molecules in the
active site. (b) Trp31 in PLA2 from Russell’s viper is shown as sticks with carbon atoms
colored purple and Trp31 in ACII-4 is shown as a stick with carbon atoms colored green.
The polyethylene glycol molecules are shown as spheres with white carbon atoms. Oxygen
atoms are colored red. The side-chain of Trp31 in the uninhibited monomer of PLA2 from
Russell’s viper venom clashes with the polyethylene glycol molecules in ACII-4. The side-
chain of Trp31 in the uninhibited monomer of the PLA2 from Russell’s viper venom is in a
position not observed in ACII-4.
The activity of secreted PLA2s towards lipid micelles, membranes, and vesicles is
several times higher than that on molecular dispersed substrates (Yuan et al., 1990).
It has been established that the PLA2s bind to the substrate interface via an interfacial
binding surface which is different from the site where the phospholipase activity
occurs (Verger and de Haas, 1976; Dennis, 1983). The area referred to as the
interfacial binding surface have been proposed to consists of a ring of positively
charged side-chains surrounding a hydrophobic channel that leads to the centrally
located active site (Scott et al., 1990; Scott et al., 1994). Twelve lysine residues and
two arginine residues (Lys14, Arg17, Lys57, Lys58, Lys63, Lys70, Lys81, Lys85,
Lys105, Lys106, Lys114, Lys115, Arg116 and Lys118) form a ring of positively
charged side-chains which surrounds the active site (Figure 7-27; Figure 7-28).
Figure 7-27 The amino acid sequence of ACII-4
The positively charged (blue) residues and hydrophobic residues (orange) labeled in Figure
7-28 are highlighted.
1 5 10 15 20 25 30 35 40 45 50 55 60 65 70
| | | | | | | | | | | | | | |
ACII-4 NLIQFGNMIQCANKGSRPSLDYADYGCYCGWGGSGTPVDELDRCCQVHDNCYEQAGKKGCFPKLTLYSWKCTGN
75 80 85 90 95 100 105 110 115118
| | | | | | | | | |
VPTCNSKPGCKSFVCACDAAAAKCFAKAPYKKENYNIDTKKRCK
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Figure 7-28 Interfacial binding surface.
The Connolly surface with the electrostatic surface potentials in molecule A of ACII-4.
Positive charges are colored blue, negative charges are colored red and neutral regions are
white. The positively charged residues are labeled and form a loop marked in blue.
7.8 Comparison of ACII-4 with other PLA2 molecules
Division of PLA2s into several sub-classes of PLA2s have been carried out based on
phospholytic activity, Ca2+ dependency and structural features that include the
number of disulfide bonds and the number of loop extensions (Dennis, 1994; Arni
and Ward, 1996; Dennis, 1997; Six and Dennis, 2000). PLA2s from snake venoms
can be classified into two main groups, I and II (Davidson and Dennis, 1990; Dennis,
1994; Six and Dennis, 2000). Group I includes PLA2s from venoms of elapid snakes,
sea snakes and from mammalian pancreas (Heinrikson et al., 1977; Davidson and
Dennis, 1990; Dennis, 2000). The PLA2s in group I are cross-linked by seven
disulfide bridges which stabilize the globular fold. The group is characterized by a
disulfide bridge between residues 11 and 77 which secure the ȕ-wing to the N-
terminal major Į–helix.
ACII-4 belongs to IA. This subgroup is characterized by a surface loop connecting
the second major Į-helix to the ȕ-wing. This surface loop is between the second
major Į-helix and the first ȕ-strand (residues Lys58-Trp69 in ACII-4). The loop is
located near the entrance of the hydrophobic channel in the active site and is referred
to as the “elapid loop” (Figure 7-29; Figure 7-30). In subgroup IB where the PLA2’s
from mammalian pancreas is found, this loop is defined by the presence of a few
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extra residues to the elapid loop and is referred to as the “pancreatic loop” (Fremont
et al., 1993; Carredano et al., 1998; Alape-Girón et al., 1999; S. Xu et al., 2003).
Figure 7-29 Sequence alignment of PLA2 to show the elapid loop.
Alignment carried out with BLAST and adjusted by manual tracing the superposition of the
structures. The elapid loop region is marked with an orange bar underlining residues 56-62
which is also marked in Figure 7-30.
Figure 7-30 Comparison of group IA and group II PLA2.
The elapid loop and disulfide bridge Cys11-Cys71 in group IA is missing in
group II. Molecule A of ACII-4 (green), notechis II-5 from Australian Tiger snake venom
(2NOT) (blue) and a PLA2 from Russell’s viper venom (1VIP) (pink) are superimposed.
ACII-4 and notechis II-5 belong to the subgroup IA of group I and the PLA2 from Russell’s
viper belong to group II. All PLA2 in group I has a Cys11-Cys77 disulfide bridge. Subgroup
IA has an elapid loop. Labeled and marked out in orange. Group II does not have an elapid
loop and not a disulfide bridge between residues 11 and 77. The disulfide bridge is labeled.
The C-terminus of PLA2s from group II is a few residues longer than PLA2s from group I.
1 5 10 15 20 25 30 35 40 45 50 55 60
| | | | | | | | | | | | |
ACII-4 NLIQFGNMIQCANKGSRPSL-DYADYGCYCGWGGSGTPVDELDRCCQVHDNCYEQAGKKGCFPKL
2NOT NLVQFSYLIQCANHGRRPTR-HYMDYGCYCGWGGSGTPVDELDRCCKIHDDCYSDAEKKGCSPKM
1VIP NLFQFAEMIVKMT-G-KNPLSSYSDYGCYCGWGGKGKPQDATDRCCFVHDCCYEKVK--SCKPKL
65 70 75 80 85 90 95 100 105 110 115 120
| | | | | | | | | | | |
TLYSWKCTGNVPTCN-SKPGCKSFVCACDAAAAKCFAKA--PYKKENYNIDTKKRCK---
SAYDYYCGENGPYCRNIKKKCLRFVCDCDVEAAFCFAKA--PYNNANWNIDTKKRCQ
SLYSYSFQNGGIVCGD-NHSCKRAVCECDRVAATCFRDNLNTYDKKYHNYPP-SQCTGTEQC
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A search for proteins with similar fold and sequence to ACII-4 in the PDB was
performed using the program BLAST (Schäffer et al., 2001). The six top hits are
shown in Table 7-6. Their overall structure are similar (Figure 7-32).
Table 7-6 Hits from BLAST search versus the PDB
PDB entry Amino acid
sequence identity
(%)
Name
1AE7 65 Notexin from Australian Tiger snake,
Notechis scuatus scutatus venom
2NOT 64 Notechis II-5 from Australian Tiger snake,
Notechis scuatus scutatus venom
5P2P 59 Porcine pancreatic PLA2 mutant, residues
62-66 deleted, Trp3Phe and Leu31Trp
1GP7 56 PLA2 from King cobra, Ophiophagus Hanna
venom
3P2P 58 Porcine pancreatic PLA2 mutant, residues
62-66 deleted
1YXH 58 PLA2 from Indian cobra, Naja naja
sagittifera venom
1 5 10 15 20 25 30 35 40 45 50
| | | | | | | | | | |
ACII-4 NLIQFGNMIQCANKGSRPSLDYADYGCYCGWGGSGTPVDELDRCCQVHDNCYEQ
1AE7 NLVQFSYLIQCANHGKRPTWHYMDYGCYCGAGGSGTPVDELDRCCKIHDDCYDE
2NOT NLVQFSYLIQCANHGRRPTRHYMDYGCYCGWGGSGTPVDELDRCCKIHDDCYSD
5P2P ALFQFRSMIKCAIPGSHPLMDFNNYGCYCGWGGSGTPVDELDRCCETHDNCYRD
1GP7 HLIQFGNMIQCTVPGFLSWIKYADYGCYCGAGGSGTPVDKLDRCCQVHDNCYTQ
3P2P ALWQFRSMIKCAIPGSHPLMDFNNYGCYCGLGGSGTPVDELDRCCETHDNCYRD
1YXH NIYQFKNMIQCTVP-SRSWWDFADYGCYCGRGGSGTPVDDLDRCCQVHDNCYNQ
55 60 65 70 75 80 85 90 95 100
| | | | | | | | | |
ACII-4 AGKK-GCF-----PKLTLYSWKCTGNVPTCN-SKPGCKSFVCACDAAAAKCFAK
1AE7 AGKK-GCF-----PKMSAYDYYCGENGPYCRNIKKKCLRFVCDCDVEAAFCFAK
2NOT AEKK-GCS-----PKMSAYDYYCGENGPYCRNIKKKCLRFVCDCDVEAAFCFAK
5P2P AKNLSGCY-----PYTESYSYSCSNTEITCNSKNNACEAFICNCDRNAAICFSK
1GP7 AQKLPACSSIMDSPYVKIYSYDCSERTVTCKADNDECAAFICNCDRVAAHCFAA
3P2P AKNLSGCY-----PYTESYSYSCSNTEITCNSKNNACEAFICNCDRNAAICFSK
1YXH AQEITGCR-----PKWKTYTYECSQGTLTCKGRNNACAATVCDCDRLAAICFAG
105 110 115118
| | | |
ACII-4 APYKKENYNIDTKKRCK
1AE7 APYNNANWNIDTKKRCQ
2NOT APYNNANWNIDTKKRCQ
5P2P APYNKEHKNLDTKKYC-
1GP7 SPYNNNNYNIDTTTRC-
3P2P APYNKEHKNLDTKKYC-
1YXH APYNDNNYNIDLKARCQ
Figure 7-31 Sequence alignment of PLA2 proteins homologous to ACII-4.
Alignment carried out with BLAST and adjusted by manual tracing the superposition of the
structures. The elapid/pancreatic loop region is marked with an orange bar underlining
residues 56-67 (ACII-4 numbering). The green bar underlines a loop region between the
second ȕ-strand and the third major Į-helix consisting of residues 79-83 (ACII-4
numbering).
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Figure 7-32 Comparison of
the structures of ACII-4 and
the six top hits from a
BLAST search.
Superposition of molecule A
of ACII-4 (green), notexin
from Australian Tiger snake
(1AE7) (white), notechis II-
5 from Australian Tiger
snake venom (1NOT) (blue),
porcine pancreatic PLA2
mutant (5P2P) (orange),
PLA2 from King cobra
venom (1GP7) (yellow),
porcine pancreatic PLA2
mutant, with residues 62-66
deleted (3P2P) (steel blue)
and PLA2 from Indian cobra
venom (1YXH) (cerise).
The two PLA2 from the Australian Tiger snake, Notechis scuatus scutatus, venom,
notexin (1AE7) (Westerlund et al., 1992) and notechis II-5 (2NOT) (Carredano et
al., 1998) and the PLA2 from Indian cobra, Naja naja sagittifera, venom (1YXH)
(Jabeen et al., 2005) belong to subgroup IA. Notexin is presynaptic neurotoxic and
myotoxic and notechis II-5 is presynaptic neurotoxic (Halpert and Eaker, 1975).
Notexin is three times as lethal as its relative notechis II-5 (Halpert and Eaker, 1975).
The structure of the PLA2 from Indian cobra is the first structure of a PLA2 from
group I with strong anticoagulant activity (Jabeen et al., 2005). ACII-4, notexin,
notechis II-5 and the PLA2 from Indian cobra all have an elapid loop. However, the
PLA2 from Indian cobra has one more residue inserted in this region which makes its
loop more protruding and exposed (Figure 7-31).
Interestingly, the structure that differes the most from ACII-4 is notexin which has
the highest amino acid identity. The largest variation between the structures of ACII-
4 and notexin are situated in two areas (Figure 7-31; Figure 7-35). One is the loop
region after the second major Į-helix (residues Gly56-Tyr67 in ACII-4). The other is
the loop region after the second ȕ-strand (residues Asn79-Gly83). Cys60Į in ACII-4
and Cys61Į in notexin differ 1.93 Å in position. This difference misalign the
sequences and instead of Phe61-Pro62 in ACII-4 and Phe67-Pro68 in notexin
superimposing onto each other, the hydrophobic side-chain of Phe67 in notexin is in
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the same position as the side-chain of Pro62 in ACII-4. The difference in the position
of the Pro62 in ACII-4 and Pro68 in notexin steer the loops in different directions
and the loops does not align again until Tyr67 in ACII-4 and Tyr73 in notexin. One
reason for the difference in structure in this region could be due to binding of a
sulfate ion in the notexin structure. Instead of the side-chain of Lys69 pointing out to
the solvent as the side-chain of Lys69 in the notechis II-5 structure, the side-chain of
Lys69 in notexin points inwards the molecule and form a bond to the sulfate ion
(Figure 7-33). This indicates that the loop between the second major Į-helix and the
first ȕ-strand in this group of PLA2 molecules can have different conformations.
(a)
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Figure 7-33 Differences between ACII-4 and notexin.
Molecule A of ACII-4 (green) and notexin (blue). Sulfate ion is shown as balls. Oxygen is
colored red, nitrogen blue and sulfur is yellow. (a) Residues mentioned in the text are
labeled. Distance is in Å. (b) Stereo view.
A single amino acid insertion in the region after the second ȕ-strand and a change
from Pro82 in ACII-4 to Lys88 in notexin have given notexin a loop structure in this
region which is more protruding compared to ACII-4. However, the Cys60-Cys84
disulfide bridge (ACII-4 numbering) anchors the loop to the core of the structure
(Figure 7-34).
(b)
(a)
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Figure 7-34 Differences between ACII-4 and notexin.
Molecule A of ACII-4 (green) and notexin (blue). Oxygen is colored red, nitrogen blue and
sulfur is yellow. (a) Residues mentioned in the text are labeled. Distance is in Å. (b) Stereo
view.
The structures of ACII-4 and notechis II-5 follow the same path after the second
major Į-helix. Notechin II-5, like notexin, has an insertion of one residue in this
region and a lysine residue replacing Pro82 in ACII-4. Thus, after the second ȕ-
strand the structure of notechin II-5 and notexin follow the same trail.
Figure 7-35 Structural differences between ACII-4 and the BLAST top hits belonging to
group IA.
Molecule A of ACII-4, notexin from Australian Tiger snake venom (1AE7) (white), notechis
II-5 from Australian Tiger snake venom (1NOT) (blue) and PLA2 from Indian cobra venom
(1YXH) (cerise) are superimposed. The regions with the largest variations between the
structures are marked with orange bars. These regions are the elapid/pancreatic loop region
residues 56-67 in ACII-4 and a loop region between residues 79-83 in ACII-4.
(a)
(b)
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The pancreatic loop of the mutants of the PLA2 from porcine pancrease (5P2P and
3P2P) (Kuipers et al., 1989; Thunnissen et al., 1990a) have been shortened to the
same size as the elapid loop of the PLA2 from the Indian cobra venom. Thus the
elapid loop in the two mutants of the PLA2 from porcine pancrease and the PLA2
from the Indian cobra differ with one amino acid to the elapid loop in ACII-4. The
PLA2 from King cobra, Ophiophagus Hannah, venom (1GP7) (Zhang et al., 2002) is
the first crystal structure of a PLA2 from venom with a pancreatic loop and differ
with six residues to the elapid loop in ACII-4, notexin and notechis II-5 (Figure 7-31;
Figure 7-36). The elapid loop in the two mutants of the PLA2 from porcine
pancrease, the PLA2 from Indian cobra and the pancreatic loop in the PLA2 from
King cobra are therefore more protruding and exposed compared to ACII-4 (Figure
7-32). The loop region after the second ȕ-strand in the ȕ-wing in the two mutants of
the PLA2 from porcine pancreas, the PLA2 from Indian cobra and the PLA2 from
King cobra venom follow the same path which differs from ACII-4 (Figure 7-32;
Figure 7-37).
Figure 7-36 The elapid loop in PLA2 belonging to group IA and the pancreatic loop in
PLA2 belonging to group IB.
Molecule A of ACII-4 (green), the PLA2 from Australian Tiger snake venom referred to as
notechis II-5 (2NOT) (blue) and the PLA2 from King cobra venom (1GP7) (yellow) are
superimposed.
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Figure 7-37 Structural differences between ACII-4 and the BLAST top hits belonging to
PLA2s from group II.
Molecule A of ACII-4, porcine pancreatic PLA2 mutant (5P2P) (orange), PLA2 from King
cobra, Ophiophagus Hanna venom (1GP7) (yellow) and porcine pancreatic PLA2 mutant
(3P2P) (blue steel) are superimposed. The regions with the largest variations between the
structures are marked with orange bars. These regions are the elapid/pancreatic loop region
residues 56-67 in ACII-4 and a loop region between residues 79-83 in ACII-4.
7.9 Crystal contacts and electrostatic surface
The crystal packing is very tight with only 43% solvent content (Chapter 3). Analysis
revealed that there are about the same number of surrounding atoms within a distance
of 5 Å in both molecule A and B of ACII-4. These contacts are distributed over
similar areas. The crystal contacts are around the N-terminal Į-helix, the catalytic
site of the phospholipase activity, the loop region Thr36-Glu41 prior to the N-
terminal side of the second major Į-helix, the C-terminal side of the second major Į-
helix, the first ȕ-strand of the ȕ-wing, the minor 310-helix consisting of residues 106-
108 and the C-terminal minor Į-helix (Figure 7-38). It is likely that these regions that
form crystal contacts are also important for biological activity. The most clear cut
example of this is that the PEG molecules in the active site mimic the phospholipase
substrate (Section 7.7) (Volwerk et al., 1974; Scott et al., 1990; Thunnissen et al.,
1990a).
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Figure 7-38 Contacts between the surrounding atoms and molecule A of ACII-4.
Connolly surface of molecule A of ACII-4 is green. Atom within 5 Å are shown. Carbon
atoms are green from molecule A and blue from molecule B. Carbons atoms from
polyethylene glycol molecules are white, yellow and salmon. Sulfur atoms from sulfate ions
are yellow. Nitrogen is blue and oxygen is red. Figures are rotated 90o around the vertical
axis.
The crystal contacts are similar in both molecule A and B of ACII-4 (Figure 7-45;
Figure 7-46). The region corresponding to residues 53-70 in ACII-4 (Figure 7-39)
contain positively charged residues and is the most likely source of the anticoagulant
activity (Kini and Evans, 1987; Carredano et al., 1998; Jabeen et al., 2005; Prijatelj
et al., 2006). The crystal contacts that are made by residues 53-70 in ACII-4 are
marked out and are discussed below (Figure 7-41; Figure 7-42; Figure 7-43; Figure
7-44).
Figure 7-39 The amino acid sequence of ACII-4.
The region corresponding to residues 53-70 in ACII-4 which is suggested to contain the
anticoagulant activity are highlighted.
In both molecule A and B of ACII-4 a polyethylene glycol molecule forms a
semicircle around the Lys63Nȗ at a distance of ~3 Å and this polyethylene glycol
molecule is also in hydrophobic contact to Trp31 (~3.5 Å) in both molecules. This
molecule is also close to Phe61 (~4 Å) from an adjacent molecule (Figure 7-41;
Figure 7-42). Leu64 and Phe61 from both molecules form a hydrophobic cluster and
sandwich the polyethylene glycol molecules, together with the side-chain of Trp31
which is in hydrophobic contact (~4 Å) to the side-chain of Lys57, in both molecule
A and B (Figure 7-40; Figure 7-41; Figure 7-42).
1 5 10 15 20 25 30 35 40 45 50 55 60 65 70
| | | | | | | | | | | | | | |
ACII-4 NLIQFGNMIQCANKGSRPSLDYADYGCYCGWGGSGTPVDELDRCCQVHDNCYEQAGKKGCFPKLTLYSWKCTGN
75 80 85 90 95 100 105 110 115118
| | | | | | | | | |
VPTCNSKPGCKSFVCACDAAAAKCFAKAPYKKENYNIDTKKRCK
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Figure 7-40 Region 61-64 and Trp31 of ACII-4 participating in a hydrophobic interface.
Carbon atoms in molecule A of ACII-4 are colored green and molecule B is colored blue.
Oxygen atoms are colored red and nitrogen blue. Trp31, Lys57, Lys63, Leu64 and Phe61 are
shown as sticks. Polyethylene glycol is shown as a ball and stick model with carbon atoms
yellow (PEG2) or salmon (PEG2') are forming a semicircle around the Lys63Nȗ..
Trp69 and Lys70 are situated at the start of a ȕ-strand of the ȕ-wing, form crystal
contacts with the N-terminal Į-helix in both molecule A and B of ACII-4 (Figure
7-41). A sulfate ion (Figure 7-41 and) is close to the N-terminal Į-helix and bound to
Gln4Nİ2 (2.96 Å and 2.94 Å), Asn7Nį2 (2.94 Å and 2.89 Å) and Trp69Nİ1 (2.84 Å
and 2.92 Å). The second sulfate ion is bound to Lys115Nȗ(A) (3.01 Å) and
Arg17NȘ2(A) (2.41 Å) and Arg17Nİ(A) (2.80 Å). Arg17 and Lys115 are part of the
region with positively charged residues referred to as the interfacial binding surface
(Scott et al., 1990; Scott et al., 1994; Mounier et al., 2000) (Section 7.10). Gln54Oİ1
in both molecule A and B is forming hydrogen bonds to Gln54Nİ2 (3.13 Å in both
molecule A and B) and Lys58Nȗ from the adjacent molecule (2.93 Å in both
molecule A and B) (Figure 7-41). The ȕ-wing also forms crystal contacts. Asn74 is
situated in the short loop connecting the two antiparallel ȕ-strands, the wing-tip, and
its side-chain extends out from the molecule. In both molecule A and B of ACII-4,
the Asn74Nį2 atom forms a hydrogen bond to Gly15O in the adjacent molecule (2.98
Å and 2.96 Å in molecule A and B, respectively) (Figure 7-44; Figure 7-49;Figure
7-50).
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Figure 7-41 Crystal contacts for ACII-4.
Connolly surface of molecule A of ACII-4 is shown with electrostatic surface potentials
overlaid. Regions of positive potential are colored blue, negative potential are colored red
and neutral regions are white. Atom within 5 Å are shown. Carbon atoms are green from
molecule A and blue from molecule B. Carbons atoms from polyethylene glycol molecules
and are white (PEG1), yellow (PEG2) and pink (PEG2'). Sulfur atoms from sulfate ions are
yellow. Nitrogen is blue and oxygen is red. Atoms labeled in black or white are part of
molecule A. Atoms labeled in light blue are the residues 53-70 making crystal contacts to
molecule A.
Figure 7-42 Crystal contacts for
ACII-4.
Molecule A of ACII-4 is rotated
by 90° around the vertical axis
compared to Figure 7-41. The
same labeling system as in Figure
7-41 is used.
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Figure 7-43 Crystal contacts
for ACII-4.
Molecule A of ACII-4 is rotated
by 90° around the vertical axis
compared to Figure 7-42. The
same labeling system as in
Figure-41 is used.
Figure 7-44 Crystal contacts for ACII-
4.
Molecule A of ACII-4 is rotated by 90°
around the vertical axis compared to
Figure 7-43. The same labeling system
as in Figure 7-41 is used.
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Figure 7-45 Four views of molecule A of ACII-4.
Crystal contacts between the surrounding atoms and molecule A of ACII-4. Connolly surface
of molecule A of ACII-4 is shown with electrostatic surface potentials overlaid. Atoms
within 5 Å are shown. Carbon atoms are green from molecule A and blue from molecule B.
Carbons atoms from polyethylene glycol molecules are white, yellow and pink. Sulfur atoms
from sulfate ions are yellow. Nitrogen is blue and oxygen is red. Figures are rotated 90o
around the vertical axis.
Figure 7-46 Four views of molecule B of ACII-4.
Same description of molecule and atoms as in Figure 7-45.
7.10 Dimerization of ACII-4
Previous studies showed that ACII-4 could exist as a dimer (Masci, 2000). Two
possible dimers are shown, dimer AB and dimer AB', in Figure 7-47 and Figure
7-48. The buried surface of the AB dimer (1141 Å2) is larger then the AB' dimer (686
Å2) (AREAIMOL (B. Lee and Richards, 1971) which would suggest this is the most
likely dimer in solution. Further more, the AB dimers have both active sites exposed
to solvent, where as the AB' dimer has the active site located close to the buried
surface. The electrostatic areas are differently distributed in the two dimers AB and
AB' of ACII-4 (Figure 7-47; Figure 7-48). The AB interface is more hydrophilic than
the AB' interface. One of the sulfate ions is important for mediating the major
intermolecular contacts in the AB interface. Except for the contacts mediated by the
sulfate ion and the contacts formed by the Asn74 residue situated in the wing-tip, two
more hydrogen bonds are formed between Asn7Oį1 and Cys71N (2.90 Å and 2.75 Å
in molecule A and B, respectively), and Asn7Nį2 and Trp69O (3.27 Å and 3.07 Å in
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molecule A and B, respectively) (Figure 7-49; Figure 7-50). The interactions in the
AB' interface are the hydrophobic contacts formed by the polyethylene glycol
molecules, residues 61-64 and Trp31 (Figure 7-51).
(a) (b)
Figure 7-47 AB dimer formation.
(a) Showing the two ACII-4 molecules in the asymmetric unit. The Ca2+ ions are shown as
yellow spheres. A sulphate ion is located in between the two molecules represented as
spheres and sulfur atoms are yellow and oxygen red. The two polyethylene glycol molecules
are visible close to the active site as spheres with carbon atoms colored pink and oxygen
atoms colored red. (b) Connolly surface with the electrostatic surface potentials mapped out.
Positive charge is colored blue, negative charge is colored red and neutral is white. The
polyethylene glycol molecules located close to the active site are represented as green
spheres.
Figure 7-48 AB' dimer formation.
(a) Showing molecule A from the asymmetric unit and a symmetry related molecule B. The
Ca2+ ions are shown as yellow spheres. (b) The two polyethylene glycol molecules are
visible close to the active site as spheres with carbon atoms colored pink and oxygen atoms
colored red. (c) Connolly surface with the electrostatic surface potentials mapped out.
Positive charge is colored blue, negative charge is colored read and neutral is white. The
polyethylene glycol molecules located close to the active site are represented as green
spheres.
(a) (b) (c)
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Figure 7-49 Interactions in the AB interface
Molecule A (green) and molecule B (blue) of ACII-4 pack together with a sulfate ion shown
as balls and stick mediating the major intermolecular contacts. The residues Asn7, Gly15,
Trp69, Cys71 and Asn74 form contacts in the interface. Oxygen atoms are colored red and
nitrogen blue. Distances are in Å.
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Figure 7-50 Stereo view of the interactions in the AB interface.
Description of the picture is given in Figure 7-49
Figure 7-51 Stereo view of the interactions in the AB' interface.
Molecule A (green) and molecule B (blue) of ACII-4 pack together with two polyethylene
glycol molecules shown as balls and stick in the D interface. The carbon atoms in PEG2 are
colored yellow and in PEG2' salmon. Trp31, Lys57, Lys63, Leu64 and Phe61 are shown as
sticks. Oxygen atoms are colored red and nitrogen blue.
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Oligomerization of PLA2 has been stated to affect the pharmacological activities
(Soares et al., 2000) and affect the phospholytic activity (Rigden et al., 2003).
Superposing the crystal structure of the PLA2 from Common Indian Krait, Bungarus
caeruleus, venom with a fatty acid bound to the active site (Singh et al., 2005a) onto
each monomer of ACII-4 in the different dimer formations showed that the fatty acid
fits into both dimer constellations (Figure 7-52).
(a) (b)
Figure 7-52 Superposing the PLA2 from Common Indian krait (1TC8) onto each monomer
of the two ACII-4 dimer formations shows the fitting of the fatty acid.
Molecule A (green) and molecule B (blue) of ACII-4. The fatty acid represented as spheres
with purple carbon atoms and red oxygen atoms. (a) The fatty acid can bind in the AB dimer
formation. (b) The fatty acid can bind in the AB' dimer formation.
Superposing the crystal structure of the PLA2 from Russell’s viper, Daboia russelli
pulchella, venom with a peptide inhibitor (FLSYK) in the active site (Chandra et al.,
2002) on each of the monomers in the two ACII-4 dimer formations showed that the
inhibitor clashes with the facing monomer in the AB dimer formation but fits in the
AB' dimer formation. This indicates that the active site is more restricted in the AB
dimer than the AB' dimer.
(a) (b)
Figure 7-53 Superposing the PLA2 from Russell’s viper (1JQ9) onto each monomer of the
two ACII-4 dimer formations shows the fitting of the protein inhibitor.
The two ACII-4 molecule in the asymmetric unit are green and blue. The protein inhibitor
represented as spheres with yellow carbon atoms and red oxygen atoms. (a) The protein
inhibitor clashed with the facing monomer in the AB dimer formation. (b) The protein
inhibitor can bind in the AB' dimer formation.
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7.11 Pharmacological activities
It has previously been shown that ACII-4 has Ca2+ dependent anticoagulant activity
and phospholipase activity (Masci, 2000). However, the individual activities are not
dependent on each other (Masci, 2000). The observation suggests that the different
activities are located in separate regions of the molecule.
A comparison of sequences of PLA2s from the genus Naja (group I) with different
grades of anticoagulant potency has shown that the region corresponding to residues
53-70 in ACII-4 is strongly anticoagulant when positively charged but weakly or
non-anticoagulant when negatively charged (Kini and Evans, 1987). A comparison
of the sequences of a PLA2 from Black-necked Spitting cobra, Naja nigricollis,
venom (group I) and a PLA2 from Russell’s viper, Vipera russelli russelli, venom
(group II) suggested their strong anticoagulant activity is due to a positively charged
ridge of lysine residues situated in this region (marked with blue in the amino acid
sequence of the PLA2 from Black-necked Spitting cobra venom and Russell’s viper
venom; Figure 7-54), together with a negatively charged residue (marked with red in
the amino acid sequence of the PLA2 from Black-necked Spitting cobra venom and
Russell’s viper venom; Figure 7-54) (Figure 7-55) (Kini and Evans, 1987; Carredano
et al., 1998). ACII-4 contains four positively charged residues in this region (Lys57,
Lys58, Lys63 and Lys70) and a negatively charged glutamate at position Glu53.
The strong anticoagulant property from Indian cobra, Naja naja sagittifera, venom
(group I) (Section 7.8) is suggested to be in the region from Glu57 to Glu71 the
PLA2 (marked with red in the amino acid sequence of the PLA2 from Indian cobra
venom; Figure 7-54). This sequence includes three charged residues (marked with
blue in the amino acid sequence of the PLA2 from Indian cobra venom; Figure 7-54)
(Figure 7-55) (Jabeen et al., 2005).
Studies on an anticoagulant PLA2 from the venom of Agkistrodon halys Pallas
(group II) suggested that the residues Glu53 and Trp70 in this PLA2 (Figure 7-54),
might play an important role in the anticoagulant activity (Zhao et al., 2000) (marked
with red in the amino acid sequence of the PLA2 from Agkistrodon halys Pallas
venom; Figure 7-54) (Figure 7-55). These residues also correspond to a negatively
charged and a hydrophobic residue, Glu53 and Leu64, in ACII-4.
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Figure 7-54 Sequence alignment of PLA2 with anticoagulant activity.
The alignment was carried out using BLAST and adjusted by manually tracing the
superposition of the structures (1VIP, 1YXH, 1JIA and ACII-4). Reference for the amino
acid sequences for Naja nigricollis not found at the PDB is (Kini and Evans, 1987;
Carredano et al., 1998). Residues mentioned in the text are marked.
Superimposition of the structures of the PLA2 from Russell’s viper (Carredano et al.,
1998), Indian cobra (Jabeen et al., 2005) and Agkistrodon halys Pallas (Zhao et al.,
2000) venom onto molecule A of ACII-4 and comparing the region between residue
53-70 (ACII-4 numbering) shows the conserved residues at equivalent positions in
the structures. Tyr67 (ACII-4 numbering) is conserved and its side-chain has the
same conformation in all four structures. In ACII-4, and in the three other structures,
the side-chain of Tyr67 is buried in the core and confirms that this residue is not
significantly important for interface interactions but does provide structural support
and aids in the catalytic activity by stabilizing the carboxylate group of the catalytic
Asp92 (ACII-4 numbering). All four PLA2s have an aromatic side-chain, either a
tryptophan or a tyrosine, at position 69 (ACII-4 numbering). This aromatic side-
chain creates a hydrophobic environment for the side-chain of Tyr67 and Tyr67
which in turn stabilizes the catalytic Asp92 (ACII-4 numbering).
The Cys60–Cys84 disulfide bridge and the Pro62 are also conserved in all four
structures (ACII-4 numbering). The conservation of these residues indicates that they
have important structural roles. The Cys60–Cys84 disulfide bridge stabilizes the loop
region between residues 53-70 and the Pro62 produces a kink in the loop. All four
PLA2s have a hydrophobic residue, either an alanine or a valine residue, at position
1 5 10 15 20 25 30 35 40 45
| | | | | | | | | |
ACII-4 NLIQFGNMIQCANKGSRPSL-DYADYGCYCGWGGSGTPVDELDRCCQVHD
Naja nigricollis NLYQFKNMIHCTVP-SRPWW-HFADYGCYCGRGGKGTPVDDLDRCCQVHD
1VIP Russell’s vipera NLFQFAEMIVKMTG--KNPLSSYSDYGCYCGWGGKGKPQDATDRCCFVHD
1YXH Naja naja sagittifera NIYQFKNMIQCTVP-SRSWW-DFADYGCYCGRGGSGTPVDDLDRCCQVHD
1JIA Agkistrodon halys Pallas HLLQFRKMIKKMTG--KEPVVSYAFYGCYCGSGGRGKPKDATDRCCFVHD
50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 124
| | | | | | | | | | | | | | | |
NCYEQAGKKG-CFPKLTLYSWKCT-GNVPTCNS-KPGCKSFVCACDAAAAKCFAKA--PYKKENYNI-DTKKRCK---
NCYEKAGKMG-CWPYLTLYKYKCSQG-KLTCSGGNSKCGAAVCNCDLVAANCFAGA--RYIDANYNI-NFKKRCQ---
CCYEKVK-S--CKPKLSLYSYSFQNGG-IVCGD-NHSCKRAVCECDRVAATCFRDNLNTYDKKYHNYP-P-SQCTG-TEQC
NCYNQAQEITGCRPKWKTYTYECSQG-TLTCKGRNNACAATVCDCDRLAAICFAGA--PYNDNNYNI-DLKARCQ---
CCYEKV--T-GCDPKWDDYTYSWKNG-TIVCGG-DDPCKKEVCECDKAAAICFRDNLKTYKKRYMAYP-D-ILCSSKSEKC
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55 (ACII-4 numbering). This residue is situated in between the two major Į-helices
which run antiparallel and is not exposed to solvent.
Of the positively charged residues in the region between residue 53-70 (ACII-4
numbering) only one (Lys63, ACII-4 numbering) is conserved in all four structures.
Importantly, its side-chain is exposed and free for molecular interaction. In addition,
all four PLA2s have a hydrophobic residue, either a leucine or a tryptophan, at
position 64 (ACII-4 numbering) and a polar residue, either a serine or a threonine, at
position 68 (ACII-4 numbering) exposed and free for molecular interaction. Three of
the PLA2s (ACII-4, PLA2 from Russell’s viper and PLA2 from Agkistrodon halys
Pallas venom) have a glutamate at position 53 (ACII-4 numbering). Suggesting this
residue may also be important for the anticoagulant activity. The PLA2 from
Russell’s viper and Agkistrodon halys Pallas venom do not have a residue which
aligns with Lys57 in ACII-4 while the PLA2 from Indian cobra venom has a
negatively charged residue in this location. Lys58 in ACII-4 is a polar or aliphatic
residue in the other three PLA2’s. Lys70 in ACII-4 has changed into a polar or
negatively charged residue, in the other three PLA2s (PLA2 from Russell’s viper,
Indian cobra and Agkistrodon halys Pallas venom). This also suggests that out of the
positively charged residues in the region between residue 50-73 in ACII-4, only
Lys63 in ACII-4 may have the same role in anticoagulant activity as the PLA2 from
Russell’s viper, Indian cobra and Agkistrodon halys Pallas venom.
However, Lys57 and Lys58 are conserved in ACII-4, notexin and notechis II-5.
ACII-4, notexin and notechis II-5 have presynaptic neurotoxic and myotoxic
activities (Rowan et al., 1989; Westerlund et al., 1992; Carredano et al., 1998). This
indicates that Lys57 and Lys58 may be significant in these pharmacological
activities.
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(a)
(b)
251
(c)
Figure 7-55 Comparison of residues with possible anticoagulant effect.
Residues 53-76 (ACII-4 numbering) are shown as sticks models. ACII-4 colored green with
side-chains yellow. (a) PLA2 from Russell’s viper (1VIP) and molecule A of ACII-4 are
superimposed. PLA2 from Russell’s viper colored purple with side-chains blue. (b) The
PLA2 from Indian cobra (1YXH) and ACII-4 are superimposed. PLA2 from Indian cobra
colored pink with side-chains blue. (c) The PLA2 from Agkistrodon halys Pallas (1JIA) and
ACII-4 are superimposed. PLA2 from Agkistrodon halys Pallas colored purple with side-
chains light blue. Oxygen atoms are colored red and nitrogen atoms are blue.
The anticoagulant activity of PLA2s arises from different mechanisms. It has been
suggested that enzymatic activity is essential for the anticoagulant properties in some
cases e.g. by hydrolyzing procoagulant phospholipids (Verheij et al., 1980a; Evans
and Kini, 1997; Andrião-Escarsoa et al., 2000). Other investigations have proposed
that some PLA2s compete with clotting proteins for the lipid surface by interacting
with phospholipids and thus inhibit coagulation (Prigent-Dachary et al., 1980). On
the other hand, a study on three anticoagulant PLA2 from Black-necked spitting
cobra, Naja nigricollis, venom (group I) showed that the extrinsic tenase (tissue
factor-factor VIIa)) complex was inhibited by all three PLA2s but the prothrombinase
complex was inhibited by only one of the PLA2 (Stefansson et al., 1989; Kini and
Evans, 1995; Kini, 2006). Another study showed that secreted PLA2s from human
(group II) bind to coagulation factor Xa thus inhibiting formation of the
prothrombinase complex and inhibiting coagulation (Mounier et al., 2000). Two
regions of the secreted PLA2s from human (group II) have been proposed to exert the
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anticoagulant effect. One corresponds to residues 51-75 in ACII-4 (marked with blue
in the amino acid sequence of the secreted PLA2 from human; Figure 7-56) (Mounier
et al., 1998). The other region reported to bind to factor Xa and inhibit
prothrombinase activity are made up by residues in the putative interfacial binding
surface; Arg7, Lys10, Lys16, Lys38, Lys74, Lys87, Arg92, Lys110, Lys115,
Lys116, Lys124 and Lys127 in the secreted PLA2 from human (marked with red in
the amino acid sequence of the secreted PLA2 from human; Figure 7-56) (Snitko et
al., 1997; Mounier et al., 2000).
Figure 7-56 Sequence alignment of PLA2 with anticoagulant activity.
Alignment carried out with BLAST and adjusted by manual tracing the superposition of the
structures (1POE and ACII-4).
Superimposing the structure of the secreted PLA2 from human (1POE) and ACII-4
showed that there are three conserved positively charged residues in the region that
corresponds to residues 51-75 in ACII-4. These are Lys57, Lys58 and Lys63 in
ACII-4 (Figure 7-56; Figure 7-57). Three positively charged residues in the secreted
PLA2 from human have changed in ACII-4. Glu53, Gln54 and Ser68 have become
Lys53, Arg54 and Lys68 in human PLA2. On the other hand Lys70 in ACII-4 is
Ser69 in the secreted PLA2 from human. In the putative interfacial binding surface,
five positively charged residues are conserved; Arg17, Lys85, Lys106, Lys114 and
Lys118 in ACII-4 (Figure 7-57). A substantial number of residues have change from
a positive charge; one from positive to negative (Glu107 in ACII-4), four have
changed from positive to polar (Asn7, Gln10, Ser80 and Ser68 in ACII-4), one has
changed from positive to neutral (Val38 in ACII-4) and one is an insertion in the
secreted PLA2 from human (Lys102 in the secreted PLA2 from human is an
insertion) (Figure 7-57). The lack of many conserved residues and difference in the
charge distribution between ACII-4 and the secreted PLA2 from human, in the region
corresponding to residues 51-75 in ACII-4 and the putative interfacial binding
1 5 10 15 20 25 30 35 40 45 50 55
| | | | | | | | | | | |
ACII-4 NLIQFGNMIQCANKGSRPSL-DYADYGCYCGWGGSGTPVDELDRCCQVHDNCYEQAGKKG-
1POE Human NLVNFHRMIKLTTG--KEAALSYGFYGCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRG-
60 65 70 75 80 85 90 95 100 105 110 115 120
| | | | | | | | | | | | |
CFPKLTLYSWKCT-GNVPTCNS-KPGCKSFVCACDAAAAKCFAKA--PYKKENYNI-DTKKRCK---
CGTKFLSYKFSN-SGSRITCAK-QDSCRSQLCECDKAAATCFARNKTTYNKKYQYY-SNKH-CRGSTPRC
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surface, indicate that these areas are likely to have different specificities in these two
PLA2s. Overall, this supposes that the anticoagulant activity of ACII-4 arises from
the same mechanism as the closely related PLA2 from the Black-necked Spitting
cobra, and target the extrinsic coagulation cascade, e.g the extrinsic tenase (tissue
factor-factor VIIa)) complex (Stefansson et al., 1989; Kini and Evans, 1995).
(a)
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(b)
Figure 7-57 Comparison of residues with possible anticoagulant effect.
The human secreted PLA2 (1POE) and molecule A of ACII-4 are superimposed. ACII-4
colored green with side-chains yellow. Oxygen atoms are colored red and nitrogen atoms are
blue. (a) Residues 51-75 (ACII-4 numbering) are shown as sticks. Human secreted PLA2
colored purple with side-chains blue. (b) The side-chains in the interfacial binding surface
are shown as sticks. ACII-4 colored green with side-chains yellow. Human secreted PLA2
colored purple with side-chains pink.
A study on an anticoagulant PLA2 from the venom of Vipera ammodytes ammodytes
(group II) showed that four positively charged residues Arg72, Lys74, His76 and
Arg77 (marked with blue in the amino acid sequence of the PLA2 Vipera ammodytes
ammodytes venom; Figure 7-58) bind directly to human coagulation factor Xa and
are involved in inhibition of prothrombinase complex formation and are therefore
critical for the anticoagulant effect (Prijatelj et al., 2006). However, only His76 in
this PLA2 aligns with a positively charged residue in ACII-4 (Lys70). Basic residues
located at the C-terminus, Arg118, Lys128 and Lys132 in the PLA2 from the Vipera
ammodytes ammodytes venom have also been proposed to bind to factor Xa (Prijatelj
et al., 2006). Arg118 is the only one of these residues that can be aligned with ACII-
4 (marked with blue in the amino acid sequence of the PLA2 Vipera ammodytes
ammodytes venom; Figure 7-58)(correspond to Tyr109 in ACII-4 from the sequence
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alignment) the other (Lys128 and Lys132) are part of the extra residues in the C-
terminus which exist in the PLA2s from group II but not group I. This further
suggests that the anticoagulant activity of ACII-4 does not arise from interaction with
factor Xa but has a similar mechanism to the closely related PLA2 from the Black-
necked Spitting cobra, thereby targeting the extrinsic coagulation cascade
(Stefansson et al., 1989; Kini and Evans, 1995).
The crystal structure of the anticoagulant PLA2 from the venom of Agkistrodon halys
Pallas (group II) showed that the molecule contains a positively charged face at the
C-terminus. It is suggested that this region might be involved in hemolytic activity
(Zhao et al., 2000). There are four residues contributing to a positively charge area in
the C-terminus in ACII-4 (Lys114, Lys115, Arg116 and Lys118), however, only
Lys118 aligns with a positively charged residue from the PLA2 from the Vipera
ammodytes ammodytes venom (Figure 7-58).
Lys114, Lys115 and Arg116 (ACII-4 numbering) are conserved in ACII-4, notexin
and notechis II-5, thus it is possible that this region is important for presynaptic
neurotoxic and myotoxic activity.
Figure 7-58 Sequence alignment of PLA2s with anticoagulant activity.
The amino acid sequences for Vipera ammodytes ammodytes is taken from (Prijatelj et al.,
2006).
A study on three PLA2s from Small-eye snake, Micropechis ikaheka, venom (group
I) showed an increasing number of positive charges on the surface of the C-terminal
face and higher levels of oligomerization, correlated with higher anticoagulant
potency (Lok et al., 2005) (Figure 7-59). The C-terminal face of ACII-4 has several
areas with positive charge (Figure 7-59 (a)). Comparing the charge distribution over
the C-terminal face of ACII-4 and the PLA2s form Small-eye snake shows that ACII-
1 5 10 15 20 25 30 35 40 45
| | | | | | | | | |
ACII-4 NLIQFGNMIQCANKGSRPSL-DYADYGCYCGWGGSGTPVDELDRCCQVHD
Vipera ammodytes ammodytes SLLEFGMMILGETG--KNPLTSYSFYGCYCGVGGKGTPKDATDRCCFVHD
1JIA Agkistrodon halys Pallas HLLQFRKMIKKMTG--KEPVVSYAFYGCYCGSGGRGKPKDATDRCCFVHD
50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 124
| | | | | | | | | | | | | | | |
NCYEQAGKKG-CFPKLTLYSWKCT-GNVPTCNS-KPGCKSFVCACDAAAAKCFAKA--PYKKENYNI-DTKKRCK---
CCYG---NLPDCSPKTDRYKYHRENGA-IVCG-KGTSCENRICECDRAAAICFRKNLKTYNYIYRNYP-D-FLCKKESEKC
CCYEKV--T-GCDPKWDDYTYSWKNG-TIVCGG-DDPCKKEVCECDKAAAICFRDNLKTYKKRYMAYP-D-ILCSSKSEKC
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4 is more similar to the C-terminal face of the PLA2 with the strongest anticoagulant
strength than the PLA2 with the lowest anticoagulant strength (Figure 7-59).
Figure 7-59 Comparison of the electrostatic surface potentials.
The C-terminal face of ACII-4 and two PLA2 from Small-eye snake venom. Connolly
surface with the electrostatic surface potentials mapped out. Positive charge is colored blue,
negative charge is colored read and neutral is white. (a) Molecule A of ACII-4. (b) The PLA2
from Small-eye snake venom with the strongest anticoagulant strength. (c) The PLA2 from
Small-eye snake venom with the lowest anticoagulant strength.
7.12 Summary
The structure of ACII-4 has been determined by molecular replacement to a
resolution of 1.56 Å after detwinning the reflection data. There are two ACII-4
molecules in the asymmetric unit. ACII-4 has a characteristic PLA2 fold stabilized by
seven disulfide bonds stabilizing the fold. One Ca2+ ion is bound by seven ligands,
which are the carbonyl oxygens of Tyr28O, Gly30O, Gly32O, the side-chain
oxygens of Asp49, and two water molecules, positioned at the edges of a distorted
pentagonal bipyramid. A PEG molecule is situated in the active site and appears to
mimic the binding of fatty acid substrate. The PEG molecule is close to a water
molecule and the catalytic His48 and Asp92. The carboxylate group of Asp92 is
stabilized by the hydroxyl group of Tyr52 and Tyr67.
Two possible dimer formations of ACII-4 can be deduced from the crystal lattice.
One is a hydrophilic interface with a buried surface of 1141 Å2 and the other is a
hydrophobic interface with a buried surface of 686 Å2.
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Chapter 8
Conclusions and Future Directions
This study has focused on structural investigations of two molecules isolated from
the venoms of Australian snakes. While the venom itself does provide a rich source
of a range of different compounds, the amounts that are produced for each
component is relatively minute, thus making it impossible to concentrate this sample
to the level needed for crystallization trials. If restricted to only working with protein
from the native source it is unlikely that the project would have been a success. For
this work, I was in the fortunate position to have recombinant protein available. Tens
of milligrams of rTxln-1 were required to initially crystallize the free molecule,
though lesser amounts were needed in crystallization trials of the complexes. For
rTxln-1, three crystal structures have been determined and the results of the structural
studies from this work are presented in Chapters 4, 5 and 6.
Nowadays, the availability of robots to pipette solutions, prepare crystallization
plates and monitor the results of experiments has meant that much smaller samples of
purified protein are required to carry out the crystallization process. It is therefore
conceivable that, in the future, there could be a return to structure determination of
proteins from their native sources. As an example of the efficiency of the robotics
approach, the “Mosquito” can dispense volumes as low as 100 nL for crystallization
trials. If three hundred crystallization trials were attempted on a sample concentrated
to 10 mg/mL only ~0.3 mg of protein would be required. Thus it is conceivable that
the structures of a large majority of venom proteins could now be determined in this
way.
My study on the crystallography of ACII-4 is an example where a protein from a
native source has been successfully crystallized. In this instance, a relatively small
sample of protein was provided, <5 mg in total, but I was able to produce crystals
that diffracted to better than 1.6 Å resolution. With the use of the new robotics
systems that are now available it is clear that I would have been able to determine the
structure with a sample of much less than 1 mg of total protein.
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In a recent proteomics study of 18 Australian snake venoms it has been shown that
there are of the order of 200 or more unique protein/peptide components per snake
(Birrell et al., 2007). With this number in mind, and given that this study is the first
of its kind, it is apparent that the field of “structural venomics” of Australian snakes
is wide-open. Of particular interest would be a complete analysis of the structure and
function of all of the different Kunitz type inhibitors from all of the venomous snakes
in Australia. In addition to the studies with Txtln-1, our group has recently identified
two new Kunitz-type molecules that are potent inhibitors of plasma kallikrein but are
only weak inhibitors for plasmin. Furthermore, using a genomics approach, five
other Textilinins and more than twenty other Kunitz-type inhibitors have been
identified from Australian snake venoms (Filippovich et al., 2002). It will therefore
be interesting to investigate the structure, specificity and inhibitory activities of each
of these.
As with the Kunitz-type inhibitors, there are also a large number of PLA2s present in
snake venoms. It is estimated that there are at least 15 different isoforms present in
each individual snake (Braganca and Sambray, 1967; Takasaki et al., 1990b). Once
the biological activities of all of these have been fully characterized it is certain that
very clearly defined locations on these proteins will be ascribed to specific biological
functions. My analysis has shown that some links between structure and function can
now be made, but they are by no means definitive (Chapter 8; Figure 8-1). Further
characterization of PLA2s form the venoms of Australian snakes is required if we are
to precisely identify the regions on these proteins that are responsible for their
activities that include anticoagulant, hemolytic and mytotoxic.
Another approach to deconvoluting the individual activities of each of the PLA2s is
by site-directed mutagenesis. Such studies require that recombinant forms of the
PLA2s become available. While the cloning and expression of these molecules has a
high guarantee of success, the production of fully folded/ fully active protein is not
assured. There is however reason to be optimistic that active recombinant versions of
PLA2s from Australian snake venoms can be produced using a systematic approach.
For example, it has recently been shown that a recombinant version of a PLA2, OS2,
from the Australian Taipan snake, Oxyuranus scutellatus scutellatus is active and
correctly folded (Rouault et al., 2006).
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Figure 8-1 Two orthogonal views of the surface of the putative ACII-4 dimer.
Molecule A of ACII-4 is colored green and molecule B is colored cyan, with the predicted
anticoagulant sites in red. The entrance to the active site is identified by the presence a balls
and stick model for a polyethylene glycol molecule, which was in the crystallization buffer.
The C-terminus region is highlighted in yellow. This region is predicted to be important for
presynaptic, neurotoxic and myotoxic activity.
8.1 How can we modify the potency and selectivity of
textilinin-1
Aprotinin (Trasylol®) has been in clinical use for over fifteen years as an anti-
bleeding agent during surgery. In the last year and half, a number of studies have
raised concerns that the use of this drug can lead to an increased risk of death, serious
kidney damage or stroke. Thus it is timely to consider if snake venom components
that are analogues of this molecule could be developed as safer alternatives. Now
that the structure of rTxln-1 has been determined as the free inhibitor and in complex
with microplasmin, the way is open for rational structure-based design of new
inhibitors. There are several approaches that could be undertaken to develop new
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plasmin inhibitors. For example, the structure of rTxln-1 inhibited microplasmin
could be used in virtual screening or docking simulations with other known protease
inhibitors to see if there is potential for complementarity of fit. If such molecules are
identified, they can be screened against the enzyme for inhibitory activity. Another
approach is to use the structure of rTxln-1 as bound to microplasmin as a template
for the synthesis of peptides or peptide mimetics. Such molecules would be expected
to form similar interactions as those observed for rTxln-1. While both of these
approaches are valid, the question that arises is, will they be able to lead to the
discovery of molecules that are highly potent, and highly specific for a given target
protease? A better, strategy may be to start with rTxln-1 or a similar Kunitz-type
inhibitor and, in a rational way, make changes to the amino acid sequence that will
modify its inhibitory activity. Clearly, alterations to residues that make direct contact
to plasmin are likely to have the greatest impact, though residues that are distal to the
canonical or secondary loops could also be modified to provide more subtle
variations.
The P1 residue, which protrudes into the specificity pocket of plasmin and other
proteases is the most logical place to start mutagenesis studies. In Txtln-1 this
residue is arginine, and in aprotinin it is lysine. An interesting comparison would
therefore be to mutate this residue to lysine in Txtln-1 and investigate its inhibitory
properties. This molecule would still be expected to inhibit proteases with trypsin
like activity but would it bind more or less tightly to plasmin? In rTxln-1, the P1'
position is occupied by valine, forcing the histidine in plasmin to rotate out of its
position in the catalytic triad. Would a change to a shorter hydrophobic residue such
as glycine or an alanine alter the inhibition mechanism, leaving the histidine in its
catalytically active orientation? In light of the fact that valine can have two different
side-chain conformations when rTxln-1 is in complex with microplasmin, a bulkier
side-chain such as leucine or isoleucine may also be accommodated in this site.
Modeling studies suggest that the binding affinity to plasmin would be either
unchanged or slightly enhanced, but how would this change affect the binding to
other proteases? It could at least be assumed that proteases that have a less flexible
active site than plasmin would become precluded from forming interactions with
such an inhibitor. Threonine has a similar shape to valine, but provides an hydroxyl
group which could form an hydrogen bond with Phe587O in the case of plasmin.
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However, the energy gained from the formation of the hydrogen bond may well be
offset by the loss of the energy due to a reduction in the hydrophobic effect. Residues
in the P2' and P3' sites and those in the secondary binding loop that interact with
plasmin are also prime candidates to consider for mutagenesis experiments.
Two crystal structures of human plasma kallikrein (pdb file 2ANW and 2ANY) are
available, therefore it is possible to make some suggests as to how to design an
inhibitor that might be selective for either of these two proteases. By comparison
with microplasmin, the S2' and S3' sites in plasma kallikrein are compact, precluding
a large aromatic side-chain such as phenylalanine, tyrosine, tryptophan or histidine
from binding. Thus the presence of a phenylalanine at P3' in microplasmin could be
an important arbiter in selectivity. Within the secondary binding loop, an Ile36Tyr
mutation could allow the formation of a hydrogen bond to Gln738O or the side-chain
of Glu687 in microplasmin, whereas such a large side-chain would make it difficult
for rTxln-1 to interact with plasma kallikrein.
In terms of X-ray crystallographic studies, a structure of aprotinin bound to plasmin
would be the next most interesting structure to determine. It would show us if
aprotinin also inhibits by the same mechanism forcing the histidine side-chain out of
its catalytically active site. My prediction is that this will not be the case and that the
catalytic triad will remain intact.
It was postulated that rTxln-1 could dimerize in solution. If this were to happen its
inhibitory activity might be decreased (Chapter 4). Further analysis of a dimerization
of rTxln-1 should be undertaken. Studies could include, dynamic light scattering,
circular dichroism, and NMR spectroscopy. Investigations at different pH values and
salt concentrations should also be undertaken.
8.2 Further investigations with ACII-4 and other
Australian snake phospholipases
The crystal structure of ACII-4 is a starting point to build a hypothesis around the
different activities of three phospholipases isolated from the Australian King Brown
snake. Strikingly, these molecules, although having very similar sequences but
exhibit different activities. The first has a strong anticoagulant activity and low
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phospholipase activity, the second has very strong phospholipase activity and the
third has strong haemolytic activity. Crystal structures, along with biological assay
data for each of these is therefore required if we are to rationally explain each of the
different activities.
The precise target or targets for ACII-4 in human plasma are unknown. It is
suggested that binding studies (i.e. surface plasmon resonance) with factor Va, Xa,
IXa, XIa and XIIa be undertaken to determine which of these are the binding partners
for ACII-4. Once these have been established X-ray crystallographic studies of the
complexes should be carried out to better define their binding sites.
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Appendix A
Common and Latin names of Australian
venomous snakes
Table A- 1 Family Elapidae
Genus Species Common Name
Acanthophis A. antarcticus Common Death Adder
Austrelaps A. superbus
A. ramsayi
Lowland Copperhead
Highland Copperhead
Cryptophis C. nigrescens Smalled-eyed Snake
Demansia D. vestigiata Black Whip Snake
Hoplocephalus H. stephensi Stephen’s Banded Snake
Notechis N. scutatus
N. ater niger
N. ater serventi
Mainland Tiger Snake
Island Tiger Snake
Island Tiger Snake
Oxyuranus O. scutellatus
O. microlepidotus
Taipan
Fierce Snake
Pseudechis P. porphyriacus
P. australis
P. guttatus
P. colletti
Red-bellied Black Snake
King Brown Snake
Blue-bellied Black Snake
Collett’s Snake
Pseudonaja P. textilis
P. nuchalis
P. affinis
P. inframacula
Common Brown Snake
Western Brown Snake
Dugite
Peninsula Brown Snake
Tropidechis P. carinatus Rough Scaled Snake
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Appendix B
Laboratory methods
B.1 Analytical ultracentrifugation
Analytical ultracentrifugation can be used to determine the molecular weight and
oligomeric state of proteins. The sample is monitored through either of two optical
detection systems, interference or absorption optics. This allows the operator to
observe the evolution of the sample concentration versus the axis of rotation profile
as a result of the applied centrifugal field. These observations are electronically
digitized and stored for further mathematical analysis. Two kinds of experiments can
be performed: sedimentation velocity or sedimentation equilibrium experiments.
Sedimentation velocity is a hydrodynamic technique and is sensitive to the mass and
shape of the macromolecular species. In sedimentation velocity, a moving boundary
is formed on application of a strong centrifugal field. A series of scans (i.e.
measurements of sample concentration, c, as a function of radial distance, r) are
recorded at regular intervals to determine the rate of movement of the boundary as a
function of time. Sedimentation velocity experiments aim to interpret the entire time-
course of sedimentation, and report on the shape and molar mass of the dissolved
macromolecules, as well as their size-distribution. In contrast, sedimentation
equilibrium is carried out at a lower speed for a longer time period until the solute is
in equilibrium with opposing forces operating. Thus sedimentation velocity and
equilibrium measurements provide complementary information, and it is often useful
to apply both techniques to a given problem. Computer programs such as Sedfit
(Schuck, 1998) then calculate the frictional coefficient to determine the principal
shape of a molecule.
In equilibrium sedimentation, the equilibrium (Tinoco et al., 1995; Hensley, 1996) is
given by
cr = cA exp (MA (1 – vƍȡ ) Ȧ2 (r2 – rm2) / 2RT) (B.1)
where cr and cA are the concentrations of macromolecule at a radial position r and the
meniscus, respectively. MA is the molecular mass of A. vƍ is the partial specific
volume of A, Ȧ is the angular velocity, ȡ is the solvent density, and r and rm are
radial positions at an arbitrary position and at the meniscus, respectively. R is the gas
constant and T is the absolute temperature. Parameter dimensions are; MA in
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kg mol-1, vƍ in m3 kg-1, ȡ in kg m-3, Ȧ in rad s-1, r in m, R = 8.314 kg m2 s-2 K-1 mol-1,
T in K and c arbitrary. By choosing the speed of rotation Ȧ, it is possible to sediment
molecules of any molecular weight.
The following equation is used to determine the molecular weight from the
sedimentation equilibrium experiment, which is the logarithm of Equation B.1.
ln(cr/cA) = MA (1 – vƍȡ ) Ȧ2 (r2 – rm2) / 2RT (B.2)
The equation shows that ln(cr/cA) as a function of r2 is a straight line with a slope Ȝ
Ȝ = MA (1 – vƍȡ ) Ȧ2 / 2RT (B.3)
and the absolute molecular weight becomes
MA = Ȝ 2RT / ((1 – vƍȡ ) Ȧ2) (B.4)
Hence, by measuring absorbance versus radial distance and plotting ln Abs as a
function of the square of radial distance the molecular weight can be obtained if the
plot is linear.
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Appendix C
Crystallization of protein
C.1 Introduction
The first step in structure determination is to obtain crystals of the protein of interest.
The quality of the crystal sets a limit on the maximal resolution to which data can be
measured. The amount of data collected determines the accuracy of the final model.
C.2 The process of crystal growth
There are two phases to the crystallization of molecules, nucleation and growth. In
the first phase, molecules must overcome an energy barrier to form a nucleus, a
microcrystal. In the second phase, growth can be accomplished if the solid state is
made more attractive to individual molecules than the free solution state.
For a protein to start crystallization it is necessary that it reaches a supersaturated
state in solution so that the growing of a three-dimensional periodic arrangement of
molecules is initiated. Formation of a crystal nucleus and the subsequent growth is
shown in the Figure C- 1.
The solubility curve divides the concentration space into two areas, the
undersaturated and the supersaturated. On this curve each point corresponds to
concentrations at which the solution is in equilibrium with the precipitating agent.
The curve represents a situation either at the end of the crystal growth process from
supersaturated solution or to a situation when crystal dissolution occurs in an
undersaturated solution. In the area under the solubility curve, the solution is
undersaturated and crystallization will never occur. Above the solubility curve is the
supersaturation zone. For a given concentration of precipitating agent in this zone,
the protein concentration is higher than that at the equilibrium. The supersaturated
area is subdivided into three zones, depending on the kinetics to reach equilibrium
and the level of supersaturation.
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They are:
x Precipitation zone: Excess of protein molecules immediately separates from
the solution to form amorphous aggregates.
x Nucleation zone: Excess of protein molecules aggregate in a crystalline form.
x Metastable zone: Spontaneous nucleation does not occur unless it is induced
by vibration or a seed is introduced that will promote heterogeneous
nucleation.
Figure C- 1 Phase diagram for protein solubility.
A favorable way to grow well-ordered crystals is to start with the formation of one or
more nuclei in the nucleation zone just above the metastable zone. When the crystals
grow the solution moves to the metastable zone and the creation of more should stop.
The existing nuclei continue to grow at a decreasing rate until equilibrium is attained.
C.3 Crystallization methods
C.3.1 Vapor diffusion
The vapor diffusion technique is by far the most used crystallization method for
protein (Bergfors, 1999) . A small drop of the order of 0.5 – 5 µL of the protein is
mixed with about the same volume of the crystallization reagent. The word reagent,
or agent, is a collective name for buffer, salt and precipitant. The drop is placed on a
SUPERSATURATION
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Nucleation
zone
Metastable
zone
UNDERSATURATION
Concentration of precipitating agent
Protein
molecules
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cover slip and placed over a reservoir of reagent. Vapor phase equilibration can then
occur.
The drop contains a lower concentration of reagents than the reservoir. To achieve
equilibrium, water leaves the drop and migrates to the reservoir. As water leaves, the
sample undergoes an increase in supersaturation. Both the sample and the reagent
increases in concentration as water leaves the drop for the reservoir. Equilibrium is
reached when the reagent concentration in the drop is approximately the same as that
in the reservoir. A schematic description of the process is shown in Figure C- 1.
The protein will start to concentrate from an undersaturated state, point A, and then
reaches a supersaturated state, point B. The first crystals take form and the
concentration of protein starts to decrease. The crystal then grows until the
concentration of the protein in the drop reaches the solubility curve, point C.
C.3.2 Crystallization vessels
In the hanging drop technique the precipitant solution is placed in a container. A
drop consisting of the protein and the same volume of the precipitant solution is
placed on a siliconized glass cover slip. The slip is placed on the container with the
drop facing the precipitant solution. The cover slip is sealed to the container using
grease. The set-up is shown schematically in Figure C- 2.
The sitting drop technique is similar to the hanging drop except that the sample sits
on a shelf, Figure C- 2.
Figure C- 2 Protein crystallization vessels.
Schematic representations of three frequently used apparatus; hanging drop and sitting drop.
Precipitant
Drop
Hanging drop Sitting drop
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C.4 Preparation for crystallization, screening, optimizing
There are many parameters that influence the crystallization process. Deciding upon
which conditions may lead to success is difficult to predict. Protein crystallization is
considered a trial-and-error experiment in which a wide range of conditions are
initially screened to yield promising lead conditions.
To find suitable conditions for crystallization, screening and optimization
experiments must be undertaken. Examples of initial grid screening and optimization
protocols have been published (Weber, 1990; Shaw and Khimasia, 1994) or an
alternative to a first attempt of screening is to use spare matrix screens from
Hampton Research (Jancarik and Kim, 1991). By far the most important factor in
crystallization is the purity of the protein sample. Screening is performed by varying
one or several of the parameters; protein concentration, precipitate concentration, pH,
temperature, method, protein. To refine the possible conditions that give crystals,
screening around conditions that give microcrystals is suggested.
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Appendix D
Molecular replacement and model refinement
D.1 Introduction
This appendix describes the phase problem in X-ray crystallography, molecular
replacement model refinement and reliability indices.
D.2 Structure factors and the phase problem
Diffracted rays are recorded as spots on an imaging plate. The diffracted X-rays are
the Fourier transforms of the molecular structure being analyzed. In the mathematical
theory of crystallography the diffracted X-rays are called structure factors and are
denoted by F. They can be derived (Drenth, 1999) by a three-dimensional Fourier
transform of the electron density distribution of the molecule and as a function of the
Miller indices.
(D.1)
Here F(h k l) is the structure factor, a complex number, with an absolute value equal
to the amplitude of the diffracted wave and the argument corresponding to the phase
of the wave. The Miller indices are denoted h, k and l. The integration is performed
over all electrons in the unit cell, ȡ(x y z) describing the electron density distribution
of the molecule, and x, y and z being the fractional coordinates of the unit cell. V is
the volume of the unit cell. The Equation D.1 illustrates that each structure factor
contains contributions from the electron density of the entire unit cell.
In protein X-ray crystallography the primary goal is not to calculate the diffraction
pattern but to be able to calculate the electron density ȡ at every position x,y,z in the
unit cell and hence make it possible to display the whole electron density map. This
can be accomplished by calculating the inverse Fourier transform. F(h k l) is the
transform of ȡ(x y z), but there is an inverse Fourier transform of F(h k l) that gives
ȡ(x y z). According to the Laue conditions diffraction occurs only in discrete
directions and the inverse Fourier integration can therefore be replaced by a
summation.
F(h k l) = V ȡ(x y z) exp[2ʌi(hx + ky + lz)]dx dy dz
1 1 1
  
x=0 y=0 z=0
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(D.2)
It should now be possible to calculate the electron density ȡ(x y z) at all positions
(x y z) in the unit cell if we know F(h k l). Unfortunately, the measured intensities, I,
carry no information about the phase angles as I is proportional to |F|2. Rewriting F
in the form F = |F| exp[iĮ] and introducing in Equation D.2 gives
(D.3)
This equation demonstrates the phase angle problem in crystallography. The absolute
values |F(h k l)| can be derived from the recorded intensities I(h k l) but the phase
angles Į(h k l) cannot. There are methods available to solve the phase problem.
D.3 Solving the phase problem
The X-ray diffraction pattern from a crystal contains no information about the
relative phase angles of the reflections. As seen from Equation D.3 the electron
density, ȡ(x y z), can therefore not be calculated due to the lack of phases. There
exist today three principal techniques (Drenth, 1999) for solving the phase problem
in protein X-ray crystallography; (i) the isomorphous replacement method which
requires the attachment of heavy atoms to the protein, (ii) the multiple wavelength
anomalous diffraction method, which depends on the presence of sufficiently strong
anomalous scattering atoms in the protein structure itself and (iii) molecular
replacement for which a similar structure to that of the unknown has to be available.
In this work the molecular replacement method has been used for structure
determination. A useful tool in this type of work is the Patterson function, which is
described in the below.
ȡ(x y z) =    F(h k l) exp [-2ʌi(hx + ky + lz)]
h k lV
1
ȡ(x y z) =    |F(h k l)| exp [-2ʌi(hx + ky + lz) + iĮ(h k l)]
h k lV
1
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D.4 The Patterson function
The Patterson function (Patterson, 1934) is a Fourier summation of the square of the
structure factor amplitudes and with no phases. The value of the three-dimensional
Patterson function at a position u,v,w is calculated as
(D.4)
where u,v and w are relative coordinates in the unit cell.
It can be shown that this is equivalent to
(D.5)
This expression means that the Patterson function is the product of the electron
density in two points in space related by the vector u,v,w summed over the whole
unit cell. The Patterson function calculated from the amplitudes of a diffraction
experiment will thus have large values for points u,v,w that represent vectors
between positions with high electron density. This is the reason for choosing the
coordinates u,v,w, which are coordinates in vector space, rather than x,y,z, which are
used in real space.
D.5 Molecular replacement
In the molecular replacement method a preliminary set of protein phases are derived
from a known structure, if there is sufficient structural similarity between the
unkown (observed) and the known structures. The known structure serves as a first
model that can subsequently be refined. This procedure is based on the observation
that proteins, homologous in their amino acid sequence, have a very similar folding
of their polypeptide chain. The structure factors F(h k l) of the model (amplitude and
phase), can be calculated using Equation D.1. The calculated phases and the
observed |F| values can then be applied to Equation D.3 to calculate a first electron
density of the observed structure, which later can be refined. Before the phases of the
model can be used for the observed structure the model has to be put in an
orientation in agreement with the observed structure. The above is the essence of the
macromolecular replacement technique (Rossmann and Blow, 1962). The known
structure is referred to with several names; search model, probe model or just model.
P(u v w) =    |F(h k l)|2 cos [2ʌ(hu + kv + lw)]
h k lV
1
P(u v w) = ȡ(x y z) ȡ(x+u, y+v, z+w) dV
unit cell
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The process of orienting the model in proper orientation and precise location within
the unit cell is performed using the Patterson function (Drenth, 1999; Liljas, 2003) .
This function can be calculated from experimental data and for the model using
Equations D.4 and D.5. The transformation of the model is performed in two steps.
First a rotation and then a translation.
It is important to distinguish between different types of vectors in the crystal. Vectors
between atoms within a molecule are called self-vectors, and vectors between
different molecules in the crystal are called cross-vectors. All the self-vectors will be
shorter than, or equal to, the longest dimension of the molecule, but the majority of
them will be relatively short. The cross-vectors can have any length. Most of the self-
vectors will be shorter than most of the cross-vectors, as long as the molecule does
not have a very peculiar shape.
The set of self-vectors of a molecule will be the same independent of the packing of
the molecule in the crystal. When molecules have different orientations in the crystal,
the self-vectors will differ only by a rotation around the origin. When a molecule is
present in different crystals, or in multiple copies in one crystal, the relative
orientation of the molecules can therefore be found by comparing the self-vectors.
One of the molecules is fixed and the other rotated in order to find a rotation that
gives the best overlap of the Patterson functions.
In the rotation function R below, the best overlap is found by locating the maximum
value of the product of a stationary Patterson function Pobs(u) and a rotated Patterson
function Pmodel(ur), intregrated over a suitable volume U. Here ur denotes the
coordinates of the rotated molecule and the Patterson function will be rotated in the
same way.
(D.6)
The volume U is chosen so that it contains most of the self-vectors, but few of the
cross-vectors. The R-function is calculated as a function of the orientation of the
rotated molecule.
R = Pobs(u) Pmodel(ur) du
U
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Once the orientation of the model is known, the model is put in the native unit cell
for the translation search (Crowther and Blow, 1967) to determine the absolute
position of the unknown molecule. The cross-vectors between the model and a
symmetry-related molecule of the space group are calculated as a function of its
position in the cell. A cross Patterson function P12 (the calculated cross-vectors
between symmetry-related molecules 1 and 2) is calculated as a function of the
position of the first molecule. When the relative position is correct, the observed
Patterson function, Pobs, will contain the same cross-vectors as the calculated
Patterson function. Calculating the product of the two Patterson functions as a
function of an intermolecular vector t gives the translation function (Giacovazzo et
al., 2002) .
(D.7)
This function can be expected to show large values for the t corresponding to the
correct translation, giving the position of the molecule.
D.6 Model refinement
The experimental phases will normally have significiant errors (Liljas, 2003) . The
‘observed’ electron density, the Fobs map, calculated from initial calculated phases,
Įcalc , and the amplitudes of the observed structure factors using Equation D.3 might
make the map (at least locally) difficult to interpret due to the errors. There might
even be other reasons for errors in the form of small inaccuracies or even mistakes in
model building. It is therefore necessary to refine the model coordinates to correct
these errors. There are various methods that can be applied to correct the errors.
These methods try to minimize the difference between experimental data for the
crystal, for example the amplitude of reflections Fobs, and the corresponding
quantities calculated from the current model Fcalc. Most refinement programs also try
to minimize deviations from standard geometry and to avoid collisions between the
atoms. The new refined coordinates are used to calculate improved phases and
electron density maps. The new maps make it possible to perform manual rebuilding
of regions of the model, where the refinement program did not succeeded to correct
the model. The refinement is an iterative process that gradually improves the model.
T(t) = P12(u,t) Pobs(u) du
V
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The validation step in the structure determination is where parameters such as rmsd
values for bond lengths and angles, Ramachandran plot and correspondence between
calculated and observed amplitudes are measured and compared with other models to
decide the quality of the model.
Manual refinement is performed using the Fobs–Fcalc electron density maps. Negative
densities in the Fobs–Fcalc tend to reveal mistakes in the model, such as misplaced
atoms or extraneous atoms that should not belong to the model, while positive
densities indicate the omissions in the model. The model is manually adjusted and
can be further improved by refining coordinates, B-factors (isotropic and
anisotropic), and adding solvent or other relevant molecules, see below. It is also
common to use 2Fobs–Fcalc density maps for model building to reduce the bias
towards the model (McRee, 1993). Improved models lead to better values of Įcalc and
subsequently a better observed electron density map.
Refinement of atomic parameters
The atomic model of a molecule obtained from building in the electron density map
will have small errors. The model can be improved by automatic refinement
methods. There is a major problem as in general the observed data-to-parameter ratio
is low. A ratio above 10 is generally required for accurate and independent
determination of each parameter (Giacovazzo et al., 2002). This is often the case for
small molecules, but for macromolecules the number of refined parameters (number
of atoms in the model x 4 (x,y,z and B-factors)) might be of the same order as the
number of observations (the number of reflections). The errors in the measurements
will then lead to incorrect models.
Rigid body refinement
Rigid body refinement is a useful method often applied in early stages to improve
positioning and orientation. A rigid group can be the entire molecule or domains of a
molecule. Each rigid group is moved as a whole to refine its position and orientation
in the asymmetric unit.
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Restrained refinement
The problem with the unfavorable ratio of observations to parameters is overcome by
adding information about the model that can be seen as extra “observations”. These
observations are derived from careful studies of small molecules as well as other
molecules, where the stereochemistry of the polypeptide has been well defined. The
known bond lengths and angles are added to the refinement as restraints of the
corresponding properties in the model. The restraints are mostly sufficient to guide
the refinement to better models. Besides bond lengths and angles the restrains can
include; planarity of groups (e.g. aromatic rings), non-bonded contacts (avoiding
collisions of atoms) and chirality.
Simulated annealing
A considerable problem with the refinement is that the minimization might stop at a
local minimum. Simulated annealing allows the structure to find new parts of the
conformational space and escape entrapment in a local energy minimum. This is
done by using molecular dynamics. The rearrangement of the atoms is made by
allowing the coordinates and velocities to change according to Newton’s Law of
motion. The movements of the atoms in the molecule are analyzed as a function of
the potential energy of the system. By computationally heating the molecule to a
very high temperature, typically 3000 to 4000K, the atom can pass energy barriers.
The potential energy of the molecule can be combined with a pseudo-energy based
on the similarity of Fobs and Fcalc using a least squares criteria of these entities. When
the system is “annealed” by cooling it down to normal temperatures, the model can
be refined even if it has relatively large errors from the beginning. The procedure can
increase the radius of convergence.
D.7 Reliability indices
In the course of obtaining a final model there are several causes of errors that have to
be controlled. This is commonly done by analysis of indices that can unveil if the
obtained results are acceptable. It starts with the measurement of diffraction
intensities and their errors which need to be evaluated in a reliable manner. In
molecular replacement the quality of the initial Fobs map is given by the initial phases
from the model. The improvement of the subsequent calculations of the electron
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density maps may be unduly biased towards the model at hand rather than the true
model due to the use of the Įcalc in the calculations. Manual intervention when fitting
the model to electron density may also introduce errors due to subjectivity.
Improvement in the model by adding more parameters may result in over-fitting
(Kleywegt and Jones, 1997). Objective measures of the quality during the
development process of a model are necessary. Commonly a number of reliability
indices are used for this purpose.
The quality of X-ray diffraction data is examined by several parameters, such as
completeness, intensity to noise ratio and an index called Rsym. The latter is a
measure of the agreement among the independent measures of symmetry related
reflections in a crystal data set.
(D.8)
where < I > is the mean of all the symmetry related reflections with indices (hkl) and
Ii is the intensity of each symmetry related reflection. Symmetry related reflections
should have identical intensities. If they do not, it suggests some type of
measurement error and may also be caused by morphology and absorption.
A variation of Rsym is the Rmerge. In this case it is a measure of agreement among
multiple measurements of the same reflections (not symmetry related), with the
different measurements being in different frames of data or different data sets.
Completeness is the number of unique reflections relative to the theoretical number
of unique reflections. The intensity to noise ratio is given by <I>/<ı(I)>, where < >
is the mean value. This ratio is sometimes written as I/ı. The ratio shows the quality
of the recorded measurements. These statistics can be calculated for the entire data
set or for subsets such as resolution shells. Using resolutions shells makes it possible
to set an upper resolution limit beyond which data is not useful. By choosing the
values of the criteria a balance can be achieved between maximizing the useful data
set and still keeping a high quality of the overall data. Choosing the following figures
  | Ii - < I > |
h k l iRsym =   | Ii |
h k l i
sym
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for the highest resolution shell is considered good practice; completeness at least
50%, I/ı above 2 and Rsym and Rmerge below 30%.
The agreement between the magnitudes of observed and calculated structure factors
are commonly used to obtain a measure of the quality of the model structure. The
measure is quantified by a residual index called R-factor
(D.9)
with summations over (hkl). It has been shown that the R-factor, or Rfactor , can reach
surprisingly low values in the refinement of protein structural models that appear
later to be incorrect, one reason being that the number of model parameters used is
too high. To avoid this situation Brünger (1992, 1993), suggested the introductiuon
of a free R-factor, which is unbiased by the refinement process. In this method 5-10
% of the reflections are randomly set aside as a test set and not used in the
refinement. The R-factor for the test set is called the free R-factor or Rfree and is
calculated using Equation D.9. If the refinement improves the model this is reflected
in the concurrent decrease in Rfactor (working set) and Rfree (test set). If errors in the
model occur, Rfree will increase or remain high (Kleywegt and Brünger, 1996). In
general an R-value ~20% and an Rfree not more than an additional 5% higher is
recommended.
In addition to R-factors a linear correlation coefficient between observed and
calculated structure factor amplitudes are used for a quality check of the structure.
The correlation coefficient is given by
(D.10)
The correlation coefficient has a value -1  C  1. The closer |C| is to 1 the greater is
the correlation between observed and calculated structure factors.
C =
 ( |Fobs| - <|Fobs|> ) x ( |Fcalc| - <|Fcalc|> )
(  ( |Fobs| - <|Fobs|> )2 x  ( |Fcalc| - <|Fcalc|> )2 )½
R =
 | |Fobs| - |Fcalc| |
 |Fobs|
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Appendix E
Computer programs
E.1 Introduction
This appendix describes computer programs that have been used in the thesis. The
major part of the programs belong to the Collaborate Computational Project, No.4
(CCP4) program suite (CCP4, 1994).
E.2 AMoRe
AMoRe (Navaza, 1994) consists of three core programs, (i) orientation of the model,
(ii) translation of the model, (iii) rigid-body refinement of the model (Navaza and
Vernoslova, 1995; Navaza and Soludjian, 1997).
Calculating the rotation function is computationally very time-consuming. One
approach to facilitating calculation times is to use the Fast Rotation Function
developed by (Crowther, 1972). In this method the Patterson function is calculated in
polar coordinates. A spherical volume in the Patterson function is assumed. The new
treatment with spherical harmonics has the advantage that Fast Fourier Transforms
(FFT) can be utilized thereby improving calculation times. However, it has a
limitation in that the maximal radius of integration is dependent on the resolution of
the diffraction. In AMoRe the rotation function is calculated using a variation of the
Fast Rotation Function that does not have the size/resolution limitations of the
original procedure.
A common problem in molecular replacement is that the correct solution to the
rotation function cannot be found in the background noise. To overcome this
problem all rotation function solutions are tested in translation function calculations.
The parameters for orientation are then improved by rigid body refinement. The
program then calculates the correlation coefficient between the calculated model data
and the observed data.
The model is placed in an orthogonal P1 unit cell, about four times the size of the
model molecule. The combination of integration sphere and unit cell size when
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computing the Patterson function is chosen so that it contains only self-vectors and
no cross-vectors between atoms. The next steps are the translation and the rigid body
refinement. There are several recommendations on how to choose the size of the
artificial P1 unit cell and the parameters for the computations (e.g. CCP4 AMoRe
Manual, (Navaza, 1994) ).
E.3 EPMR
EPMR an Evolutionary Program for Molecular Replacement (Kissinger et al., 1999)
applies an evolutionary search algorithm to find crystallographic molecular
replacement solutions. The program optimizes a target function for a search model
with respect to the three rotational and the three positional parameters. The
evolutionary nature of the program makes it significantly faster than the brute force
approach. The target function is the correlation coefficient between the observed and
calculated structure factors.
The program (Kissinger et al., 2001) uses the following steps:
- Generates a set of random solutions.
- The correlation coefficient is calculated for each orientation.
- A fraction of the highest scoring orientations are kept. These are used to
regenerate a complete set of new trial orientations. This is done by applying
random alterations to the orientation angles and translations for each
remaining solution.
- The correlation coefficients for the new population are calculated. A new
population is again regenerated from the top scoring solutions, and this
procedure is repeated for a number of cycles.
- A traditional conjugate gradient minimization is carried out. This is a local,
rigid-body refinement of the search molecule.
A correct solution on every run due to the stochastic nature of the optimization
process is not always possible. The success rate is normally high if you have a good
model. It is recommended to try 10 times in the case of a difficult problem. For a
single molecule in the asymmetric unit a correlation coefficient of 0.5 or more is
expected for a correct solution with a very good search model. For poor search
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models the efficiency can be low. If other molecular replacement methods have
failed to give a solution, it is a good idea to try an extensive run with EPMR.
E.4 PHASER
The maximum likelihood method Fisher (1912) was introduced 1992 by Bricogne
(1992) as a tool for solving molecular replacement optimization.
Earlier, the least squares refinement was the predominant method, but the conditions
for least squares refinement are not always fulfilled (de La Fortell and Bricogne,
1994; Pannu and Read, 1996; Tickle et al., 1998). The maximum likelihood is a
more general method and includes the least squares as a special case, where the
errors in the parameters are simple Gaussians, rather than more complex functions.
The maximum likelihood method is based on Bayesian statistics. A good
introduction to the subject is given in (McCoy, 2004) . The relationship between the
probabilities of the model and the data according to Bayes’ theorem is
(E.1)
where P is the probability and the semicolon “;” stands for “given the known values
of”. The data is the measured data and the model is the search model to be optimized.
Applying the theorem in crystallography (Drenth, 1999) the likelihood function Ltotal
for the joint probability for all reflections can be written as
(E.2)
where h = (h,k,l). Ltotal is a product of the many structure factors and it is easier to
compute and maximize a sum. Ltotal is therefore replaced by
(E.3)
which has its minimum at the same place as Ltotal has its maximum.
P(model; data) =
P(model)
P(data)
× P(data; model)
Ltotal = P [| Fh (obs)| ; Fh (calc)]
h
- log Ltotal = - log (P [| Fh (obs)| ; Fh (calc)])
h
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The aim of the maximum likelihood is to minimize the target function -log Ltotal with
respect to the parameters of the model structure.
Phaser is built around the log-likelihood function. The molecular replacement
process is a two step process aimed at maximizing the log-likelihood target function.
Firstly, the search model is rotated to find the orientation. Secondly, the oriented
search model is translated to find its position.
The program starts with a correction of anisotropy as the likelihood target assumes
that data are isotropic. Next a likelihood-enhanced fast rotation function (Storoni et
al., 2004) is performed. This rotation function is an effective approximation to the
full likelihood target but is several orders of magnitude faster. Translation is
calculated using a likelihood-enhanced fast translation function (McCoy et al., 2005).
Both the fast translation and the fast rotation functions are based on series
approximations to the full likelihood targets and FFT. The full likelihood target,
which is more computationally intensive, can be used for final optimization. The
program checks if the solutions pack into the unit cell without overlap.
The selection of good candidates in the different runs is done using Z-score and log-
likelihood gain (LLG) score. The Z-score is the number of standard deviations above
the mean value and should generally be greater than five. The LLG score is the
difference between the log-likelihood scores for a molecular replacement trial and
the log-likelihood calculated for a Wilson distribution. It measures how much better
the data can be predicted from the model than with a random distribution of the same
atoms. The LLG makes it possible to compare different models against the same data
set, but the LLG values for different data sets should not be compared with each
other.
E.5 ARP/wARP
The Automated Refinement Procedure, ARP/wARP, (Lamzin and Wilson, 1993)
(Lamzin and Wilson, 1997) (Morris et al., 2003) is a package of programs that are
used for automated model building and refinement of protein structures. When the
phase information is available for the measured structure factor amplitudes, a three-
dimensional electron density map can be computed. The task is then to derive an
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atomic model of the molecule. The solution process is a combination of electron
density interpretation using the concept of hybrid model, pattern recognition in the
electron density map and maximum likelihood model parameter refinement. If the
measured structure factor data has a resolution of at least 2.6 Å (ARP/wARP 6.1) and
the initial phase estimates are of reasonable quality, ARP/wARP is capable of
deriving a fairly complete and refined model.
The main chain of a protein molecule can to a high degree of accuracy be determined
by the positions of the CĮ atoms (Esnouf, 1997). If a correct main chain is at hand,
the side-chain placements can be performed as the side-chains are well defined by
the CĮ atoms. Therefore, the first step usually in the interpretation of a protein
electronic density map is to find the main chain of the protein. In the ARP/w/ARP
program suite the warpNtrace module is designed to perform such a task.
The basic idea of ARP/wARP is that the derived model consists only of what is
found in the electron density map. ARP/wARP starts to reproduce the given electron
density distribution by the placement of dummy atoms, usually oxygen, in regions of
significant electron density. In this concept atoms can be added or removed, which is
not possible in traditional refinement. The introduced dummy atoms are referred to
as “free atoms” (Isaacs and Agarwal, 1985) .
The model is expanded from random atoms by stepwise addition of atoms in
significant electro density and at bonding distances from existing atoms. The
geometrical criteria remain the same and all the atoms in the model are of the same
type. The density threshold is gradually reduced and new atoms are positioned in the
low density areas of the map.
Atoms placed by ARP/wARP are normally within 0.5 Å of the corresponding
position in the final structure (Lamzin and Wilson, 1997) but depend on the quality
of the data. It is the task of the model-building algorithms to identify their
connectivity. When the bonds and atom types are determined the stereochemical
restraints can be established and used in restrained refinement. The set of built
protein fragments with the remaining free atoms are referred to as a hybrid model.
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By iterating the interpretation of the map, the model building and refinement cycle
results in an improvement of the phase estimates and give the final protein model.
The wARP part of the name of the program suite ARP/wARP refers to a concept
(Perrakis et al., 1997) that improves crystallographic phases by weighted averaging
of multiple refined dummy atom models as an additional step after density
modification methods such as solvent flattening and averaging. The initial phase set
is used to generate a number of dummy atom models which are improved by
maximum likelihood refinement and the iterative model updating. The extra models
are built from intermediates that gave the first model or created by random positional
shifts of 0.5 Å. A weighted combination of the individual phases of the models
improves the quality of the maps compared to maps for the individual models.
The default refinement procedure is the REFMAC program using maximum
likelihood optimization.
The progress of the refinement is reflected in the value of a connectivity index that
should increase if the tracing is successful (see ARP/wARP Manual). A value below
0.6 is not promising. A value around 0.8 indicates good progress. A value above 0.95
indicates an essentially complete tracing. The R-factor from ARP/REFMAC is not a
good indicator as it varies with the ARP/REFMAC refinement cycles. Sequence
coverage is defined as the ratio between the number of docked residues and the total
number of traced residues. A value higher than 0.8 is considered as good
convergence.
E.6 COOT
Coot is a new program package (Emsley and Cowtan, 2004) that is a stand alone
portion of the CCP4’s Molecular Graphics project. Coot, abbreviation for
Crystallographic Object Oriented Toolkit, is for crystallographic model building and
manipulation. Coot is a completely independent system that has some features that
resemble program O (Jones and Kjeldgaard, 1998) .
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A molecular graphics program is a useful tool when it comes to functions of the type;
side-chain placement, loop, ligand and fragment fitting, structure comparison,
analysis and validation.
The program functions of Coot are primarily built around two major libraries; mmdb
(E. B. Krissinel et al., 2004) which is a library for the handling of macromolecular
coordinates, and Clipper (Cowtan, 2003) which is a library for crystallographic
objects and their computation.
The generation of the electron density maps is based on the Clipper libraries. After
reading a file of structure factors including phase information a map can be
generated. The Coot program can read mtz, mmCIF and phs files, the output from
refinement programs, and display electron density maps. To start model building a
pdb-file is input and there are functions available to analyze the structure and to
manipulate, extend and build a molecule. There is also a possibility to run REFMAC
(Section E.7) from Coot. The user can decide to use REFMAC to refine the current
coordinates after having done some interactive model building.
The rigid body refinement makes use of the Clipper library that provides functions
for map gradients. After the selection of a coordinate set the map gradients at atomic
centers are averaged. The next computation applies a small shift that is some fraction
of the average gradient. The transformations continue until the average shift length is
less than 0.0005 Å.
Coot can auto-fit rotamers using the backbone independent library of Dunbrack &
Cohen (1997). The library is built from a large sample set of 850 chains. Coot picks a
set of most likely rotamers, makes rigid body refinement, including backbone, and
accepts the rotamer that best fits the density.
A useful feature is the possibility to regularize and refine the coordinates of the
model. This can be applied to fragments which are chosen by clicking on two atoms
defining a zone of interest. Coot reads from REFMAC the mmCIF dictionaries which
contain ideal values and estimated standard deviations for bond lengths, angles,
torsion planes and chiral centers. The target function for the optimization of the
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coordinates is a sum of squared differences of the parameters. The optimization is
performed using Polak-Ribiere variant of the BFGS (Brogden, Fletcher, Goldfarb,
Shanno) conjugate-gradient multi-variable function minimizer to optimize the model
coordinates. In another function, fitting to the map, which is called ‘Refinement’ in
Coot, the map gradients are just multiplied by a scaling factor determined by the user
and added to the geometric terms in the target function.
Further, Coot has functions for finding ligands and to add terminal residues.
Skeletonization and CĮ building is also available.
E.7 REFMAC
The REFMAC program package (Murshudov et al., 1997; Murshudov et al., 1999)
is a macromolecular program that is part of the CCP4 program suite. The program
can perform rigid-body, restrained or unrestrained refinement against X-ray data.
The optimization is carried out by adjusting the coordinate parameters to minimize
either a maximum likelihood (Section E.4) or a least squares (Glusker et al., 1994)
crystallographic residual. If the user does not input experimental phases, REFMAC
can run to generate phases. Anisotropic refinement is performed using TLS
parameterization (Winn et al., 2001) .
E.8 MrBUMP
MrBUMP is a new automated procedure for macromolecular structure solution by
molecular replacement (Keegan and Winn, 2007). The aim of MrBUMP is to start
from native structure factors and a target sequence and to deliver a positional and
partly refined model suitable for further model rebuilding, model completion and/or
refinement.
MrBUMP takes advantage of the increasing number of models of macromolecular
structures deposited in the Protein Data Bank (Berman et al., 2000) that continues to
grow fast, supporting further structure determination through the use of molecular
replacement. On the highest level the process consists of three stages; (i) discovery
of search model templates, (ii) construction of search models from these templates,
(iii) molecular replacement itself.
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In the first stage, the target sequence is used to search for related proteins in the
PDB, using a simple pairwise alignment as implemented in the FASTA package
(Pearson and Lipman, 1988) . The user can manually add models from local PDB
files if such exists. Optionally the FASTA search can be complemented by search in
the SSM service (E. Krissinel and Henrick, 2004) , SCOP database (Murzin et al.,
1995; Lo Conte et al., 2002) and the PQS database (Henrick and Thornton, 1998) .
The set of sequences of the template chains and domains are aligned using a multiple
alignment program. From this multiple alignment, pairwise alignments between the
target and each of the templates are extracted and are used in the model building
step. The multiple alignment is also used to score the template models.
A subset of the top ranked template models is passed to the search model preparation
stage of MrBUMP, which generates an actual MR search model from the template
structure. The most sophisticated methods used for this are CHAINSAW (Stein,
2007) and MOLREP (Vagin and Teplyakov, 1997) .
The list of search models is passed to the MR stage, which uses MOLREP or Phaser
(McCoy et al., 2005) or both. If the program finds a solution, then the positioned
model is passed to REFMAC for 30 cycles of refinement. A criterion based on the
behaviour of the free R-factor is used to inform the user about a possible successful
structure solution.
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